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The	 overarching	 aim	 of	 this	 PhD	 thesis	 is	 to	 develop	 methods,	 which	 will	
ultimately	improve	the	management	of	patients	with	acute	kidney	injury	(AKI).	
Over	 the	 years	 one	 inherent	 problem	 in	 both	 diagnosing	 AKI	 clinically	 and	
reviewing	 and	 comparing	 studies	 published	 in	 the	 literature	 has	 been	 the	





A	 retrospective	 observational	 database	 study	 was	 performed	 from	 secondary	
care	in	East	Kent	(adult	catchment	population	of	582,300).	All	adult	patients	(18	
years	 or	 over)	 admitted	 between	 1st	February	 2009	 and	 31st	July	 2009,	 were	
included.	Patients	receiving	chronic	renal	replacement	therapy	(RRT),	maternity	
and	 day	 case	 admissions	were	 excluded.	 AKI	was	 defined	 by	 the	 acute	 kidney	




The	 incidence	of	AKI	 in	 the	6	month	period	was	15,325	pmp/yr	(adults)	 (69%	
AKIN1,	 18%	AKIN2	 and	 13%	AKIN3).	 In-hospital	mortality,	 length	 of	 stay	 and	




the	 intensive	 therapy	unit	 (ITU),	a	39%	 longer	 ITU	stay	 (in	 those	who	went	 to	
ITU),	and	a	2.4-fold	greater	in-hospital	mortality.	Furthermore,	patients	with	AKI	
stage	 1	 had	 twice	 the	 long-term	 risk	 of	 death,	 a	 33%	 higher	 likelihood	 of	 an	
increase	in	care,	and	a	42%	higher	risk	of	re-admission	within	30	days.	In	those	
patients	with	AKI	 stage	 3	 (the	 subject	 of	 the	NCEPOD	 report)	 100	 hospital	 LOS	
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doubled,	there	was	a	22	times	higher	risk	of	admission	to	ITU	and	ITU	LOS	was	
also	 doubled,	 consistent	 with	 national	 data	 from	 the	 Intensive	 Care	 National	
Audit	and	Research	Centre.	
	
A	 further	 study	 using	 this	 data	 in	 collaboration	 with	 Marion	 Kerr	 (health	
economist)	at	the	Department	of	Health,	suggested	the	annual	number	of	excess	




With	the	problem	now	evident	and	clearly	defined,	 the	 first	stage	 in	 improving	
management	was	to	alert	clinicians	to	the	presence	of	AKI	as	soon	as	possible	to	




A	 qualitative	 analysis	 was	 then	 used	 to	 explore	 the	 effect	 of	 professional	
interactions,	 information	sharing,	and	personal	and	professional	characteristics	
on	 the	 use	 of	 electronic	 clinical	 information	 and	 clinical	 decision	 support.	 Key	
areas	 highlighted	 in	 the	 qualitative	 analysis	 included	 real-time	 delivery	 of	 AKI	
alerts,	clear	responsibility	of	care	to	be	with	the	clinical	teams	with	advice	from	
the	 critical	 care	 outreach	 nurses	 and	 renal	 consultants	 as	 required,	 and	
improved	communication	with	the	clinical	teams	looking	after	the	patients.	This	












where	 significant	 clinical	 decision	making	 takes	 place	 and	 at	which	 points	 the	
use	 of	 risk	 models	 would	 have	 greatest	 impact	 on	 clinical	 care	 and	 patient	
management.	 These	 were	 the	 point	 of	 admission	 to	 hospital	 to	 guide	 renal	
function	testing	and	inform	admission	planning,	and	secondly,	at	24	hours	after	
admission,	often	on	the	post-take	ward	round	to	highlight	patients	who	are	likely	
to	 develop	 new	 or	 worsening	 AKI	 if	 already	 present,	 in	 the	 first	 72	 hours	 of	
hospital	 admission	 so	 that	 appropriate	management	decisions	 can	be	made	on	
the	ward	round.	
	
The	study	population	 included	hospital	admissions	 to	 the	 three	acute	hospitals	
of	 East	 Kent	 Hospitals	 University	 NHS	 Foundation	 Trust	 (EKHUFT)	 in	 2011,	
excluding	 maternity	 and	 elective	 admissions.	 For	 validation	 in	 a	 second	
population	 the	study	 included	hospital	admissions	 to	Medway	NHS	Foundation	
Trust.	
	
The	 study	 developed	 and	 assessed	 traditional	methods	 to	 provide	 risk	models	
for	the	prediction	of	new	or	worsening	AKI	in	patients	presenting	to	hospital	and	
in	 their	 management	 within	 the	 first	 24	 hours	 of	 admission.	 Ordinal	 logistic	
regression	with	uni-variable	 analyses	were	used	 to	 inform	 the	development	of	
multi-variable	analyses.	Backward	selection	was	used	to	retain	only	statistically	
significant	variables	in	the	final	models.	The	models	were	validated	using	actual	











The	 work	 reported	 here	 has	 demonstrated	 the	 significant	 morbidity	 and	
mortality	 both	 long	 and	 short	 term	 of	 patients	 who	 experience	 acute	 kidney	
injury	managed	in	hospital	and	has	developed	methods	of	alerting	the	presence	
of	AKI	 to	 the	point	of	 care	 in	 real-time	 to	ensure	efficient	 intervention	with	an	
aim	 to	 improve	 these	 outcomes.	 Qualitative	 work	 has	 also	 highlighted	 the	
complexity	regarding	the	implementation	and	delivery	of	alerting	systems	to	the	





























































































































































































































































































































































































































































A&E		 	 	 accident	and	emergency	
ACKD		 	 	 acute-on-chronic	kidney	disease		
AKD		 	 	 acute	kidney	diseases	and	disorders		
AKI		 	 	 acute	kidney	injury	
AKIN		 	 	 Acute	Kidney	Injury	Network	
ALT		 	 	 alanine	transaminase	
AMY		 	 	 amylase	
ATN		 	 	 acute	tubular	necrosis	
AUC		 	 	 area	under	the	curve	
AUROC		 	 area	under	the	receiver	operating	characteristic	
BNP		 	 	 brain	natriuretic	peptide		
CDSS		 	 	 clinical	decision	support	system		
CI		 	 	 confidence	interval	
CKD		 	 	 chronic	kidney	disease	
CRP		 	 	 C-reactive	protein		
CSU		 	 	 catheter	specimen	urine	
eGFR		 	 	 estimated	glomerular	filtration	rate		
EKHUFT		 	 East	Kent	Hospitals	University	NHS	Foundation	Trust		
ESRD		 	 	 end-stage	renal	disease		
HbA1c		 	 	 glycated	haemoglobin		
ICD-10		 	 International	Classification	of	Diseases,	Tenth	Edition		
ICU		 	 	 intensive	care	unit	




MSU		 	 	 mid-stream	specimen	urine		
NCEPOD		 National	Confidential	Enquiry	into	Patient	Outcome	and	
Death		
PLT		 	 	 platelets		
RIFLE			 	 Risk,	Injury,	Failure,	Loss	of	function,	and	End-stage	renal		
failure	classification	
ROC		 	 	 receiver	operating	characteristic		
RRT		 	 	 renal	replacement	therapy	

























I	 am	 grateful	 to	 the	 Department	 of	 Renal	 Medicine,	 East	 Kent	 Hospitals	
University	NHS	Foundation	Trust	(EKHUFT)	where	this	work	was	performed.	
	











support	 and	 advice	 in	 design	 and	 delivery	 of	 these	 studies.	 In	 particular,	 the	

















This	 work	 has	 led	 to	 the	 publication	 of	 4	 peer	 reviewed	 journal	 article	
publications	with	myself	as	the	first	author	in	three	of	these	(see	Appendices	1-
4),	 and	 the	 publication	 of	 the	 National	 Institute	 for	 Health	 Research	 (NIHR)	 –	












was	 cleaned	 by	myself	 and	 anonymised.	 The	 algorithm	 for	 detecting	 AKI	 was	
defined	by	myself	and	programmed	and	run	on	the	dataset	by	Mr	Toby	Wheeler.		
Stata	 (verion	 12.1)	 was	 used	 for	 statistical	 analysis.	 The	 use	 of	 Stata	 was	







Health,	 the	 data	 sources	 and	 analyses	 here	 were	 used	 to	 inform	 a	 health	




was	 cleaned	 and	 anonymised	 by	myself.	 The	Markov	model	was	 developed	by	
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Mrs	 Marion	 Kerr	 with	 clinical	 advice	 and	 critique	 by	 myself,	 Professor	 Donal	
O’Donoghue	 (Consultant	 Renal	 Physician	 and	 honorary	 Professor	 of	 Renal	
Medicine	at	the	University	of	Manchester)	and	Mrs	Beverley	Matthews	(Director	
of	NHS	Kidney	Care).	The	peer	reviewed	publication	(Appendix	3)	was	written	
by	Mrs	Marion	Kerr	 (as	 first	author)	with	clinical	advice	and	critical	 review	by	
myself	and	Professor	Donal	O’Donoghue.	
	
The	 development	 of	 static	 AKI	 alerting	 was	 designed	 and	 implemented	
(including	training	of	critical	care	outreach	nurses	in	the	use	of	the	system	and	
management	 of	 AKI)	 by	myself.	 The	 AKI	 detection	 algorithm	was	 designed	 by	
myself.	 The	 automated	 software	 to	 detect	 AKI	 in	 the	 inpatient	 population	was	





and	 Critical	 Care	 Outreach	 Nurses	 was	 conceived	 and	 designed	 by	 myself	 in	
collaboration	 with	 Professor	 Jenny	 Billings	 (Professor	 of	 Applied	 Health	
Research,	 Centre	 for	 Health	 Services	 Studies	 (CHSS),	 University	 of	 Kent).	 The	
focus	group	and	interviews	were	conducted	by	Professor	Jenny	Billings	and	the	
analysis	 performed	 by	 Professor	 Jenny	Billings	with	 advice	 from	myself.	 I	was	
not	 directly	 involved	 in	 conducting	 the	 focus	 groups	 and	 interviews	 as	 we	
believed	 this	may	 bias	 the	 results.	 As	 above,	 I	 had	 implemented	 the	 AKI	 alert	
system,	and	trained	the	Renal	Consultants	and	Critical	Care	Outreach	Nurses	in	





In	 the	 next	 stage	 of	 development	 I,	 on	 behalf	 of	 EKHUFT,	 entered	 into	 a	
development	partnership	with	Dr	 Jon	Shaw	and	Dr	 Jonathan	Bloor	at	Careflow	
Connect	 Limited,	 along	 with	 Professor	 Chris	 Farmer	 and	Mr	 Toby	Wheeler	 to	




application	 in	 terms	 of	 clinical	 alerting,	 patient	 list	 functionality	 and	 SBAR	
handover	and	referral	processes.	This	led	to	the	Enhancing	Innovation	Through	
Collaboration	Award	 from	 the	Kent,	 Surrey	 and	 Sussex	 (KSS)	Academic	Health	
Science	Network	at	their	Expo	and	Awards	2016.	
	
In	 the	 study	 to	 develop	 risk	models	 for	 the	 prediction	 of	 AKI,	 the	 design	 and	
theoretical	framework	for	the	study,	including	obtaining	funding	from	the	NIHR	
HS&DR	 and	 project	 management	 of	 the	 study	 was	 performed	 by	 myself.	
Definition	of	the	dataset	including	variable	selection	(with	expert	clinical	advice	
from	Professor	Chris	Farmer	and	Dr	Paul	Stevens)	and	data	point	determination	
from	 the	 databases	 was	 performed	 by	 myself.	 The	 data	 was	 extracted	 by	 Mr	
Toby	Wheeler	at	EKHUFT	and	Mr	Brian	Hughes	(Business	Intelligence	Manager)	
at	Medway	NHS	Foundation	Trust.	The	algorithm	for	detecting	AKI	was	designed	





NIHR	 HS&DR	 programme	 was	 published	 in	 the	 peer	 reviewed	 NIHR	 Journals	
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The	 overarching	 aim	 of	 this	 PhD	 thesis	 is	 to	 develop	 methods,	 which	 will	
ultimately	improve	the	management	of	patients	with	acute	kidney	injury	(AKI).	
	
Following	 introduction	 (Chapter	 1)	 of	 what	 defines	 AKI	 and	 what	 is	 already	
known	about	AKI	from	the	literature,	Chapter	2	will	define	the	‘true’	problem	of	
AKI	 and	 set	 the	 scene	 as	 to	why	 action	 is	 needed.	 Chapter	 3	will	 develop	 and	
assess	methods	 to	provide	AKI	alerts	 to	 clinicians	at	 the	point	of	 care	 to	allow	
early	 recognition	and	early	effective	 intervention	 in	patients	with	AKI.	As	with	
any	 disease	 process	 however	 the	 ultimate	 form	 of	 treatment	 is	 prevention.	
Chapter	4	will	introduce	what	is	available	in	the	literature	in	terms	of	known	risk	
factors	 for	 AKI,	 and	 define	 the	 need	 for	 risk	models	 to	 predict	 AKI	 in	 clinical	
practice.	 Chapter	 5	 will	 provide	 data	 on	 relationships	 between	 available	
variables	/	risk	 factors	and	AKI,	and	then	modelling	 techniques	will	be	used	to	



















































































The	 aim	 of	 this	 chapter	 is	 to	 set	 the	 scene	 of	 acute	 kidney	 injury	 (AKI)	 to	






result	 of	 which	 ranges	 from	minimal	 alteration	 in	 serum	 creatinine	 to	 anuric	
renal	 failure	 requiring	 renal	 replacement	 therapy	 (RRT).	 This	 abrupt	 rise	 in	
serum	 creatinine	 results	 from	 an	 insult	 or	 injury	 that	 causes	 a	 functional	 or	
structural	 change	 in	 the	 kidney.	 The	 aetiologies	 and	 risk	 factors	 for	 AKI	 are	
numerous,	 but	 now	well	 defined.	 1-4	 Even	 without	 the	 need	 for	 RRT	 AKI	may	
impact	on	a	patient’s	 clinical	 course	with	 complications	 such	as	 fluid	overload,	
acidosis	and	hyperkalaemia,	 all	 of	which	may	 lead	 to	an	 increase	 in	morbidity,	
length	of	stay	and	ultimately	mortality	both	long	and	short	term.	Renal	outcomes	
include:	 full	 renal	 recovery,	 no	 renal	 recovery,	 development	 of	 chronic	 kidney	
disease	(CKD)	or	progression	of	pre-existing	CKD.5-9	
	












diseases	 and	 disorders	 (AKD)	 is	 relatively	 new	 and	 attempts	 to	 map	 to	 the	
widely	accepted	CKD	concept.	The	definition	of	AKI,	in	contradistinction	to	CKD,	















changes	 eventually	 cause	 cortical	 glomerulosclerosis,	 interstitial	 fibrosis	 and	
tubular	atrophy,	and	compensatory	hypertrophy	and	hyperfiltration	of	glomeruli	
in	 the	medulla,	 contributing	 to	development	of	CKD.18	With	 increasing	age	and	
CKD,	 function	 in	 both	 proximal	 and	 distal	 tubules	 is	 compromised,	 hampering	
the	ability	to	control	fluid	and	electrolyte	balance	and	affecting	tubuloglomerular	
feedback.	 17,19	 These	 changes,	 related	 to	 age	 and	 CKD,	may	 exacerbate	 clinical	
events	such	as	dehydration	and	drug	toxicity,	which	carry	a	high	risk	of	AKI.	18	
	
Contrary	 to	 the	 idea	 that	 the	diseased	kidney	 is	at	 increased	risk	of	AKI,	 is	 the	
“intact	 nephron”	 hypothesis.	 20,21	 In	 surviving	 nephrons	 of	 a	 kidney	with	 CKD,	
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there	 remains	 homogeneity	 of	 function	 and	 regulatory	 capacity.	 The	 kidney	
responds	in	a	predictable	and	organised	manner	to	maintain	homeostasis	in	the	
face	of	a	number	of	challenges.	There	may	be	less	functional	nephrons	available,	
and	 reduced	 reserve,	 but	 available	 nephrons	 are	 functionally	 intact.	 This	 is	
evident	 until	 the	 late	 stages	 of	 disease	 and	 should	 therefore	 not	 produce	 an	
increased	 risk	 of	 AKI,	 but	may	 impart	 an	 increased	 severity	when	 it	 develops,	
which	is	therefore	more	likely	to	be	clinically	evident.	There	is	also	the	concept	





that	 less	 of	 a	 vascular	 insult	 is	 required	 to	 provoke	AKI.	 There	 are	 supportive	
data	 from	 animal	 models	 of	 AKI,	 which	 suggest	 AKI	 as	 a	 “vasomotor	
nephropathy”	 22,23.	 People	 with	 CKD	 and	 a	 greater	 burden	 of	 vascular	 disease	
may	have	increased	severity	of	AKI	when	it	develops,	which	is	more	likely	to	be	
clinically	 apparent	 and	 require	 hospitalisation,	 and	 thus	 be	 captured	 in	
epidemiological	 studies.	 Patients	 without	 CKD,	 and	with	 less	 vascular	 disease,	
may	 have	 less	 severe	 AKI,	 manifest	 as	 ‘silent	 and	 discrete’	 episodes	 in	 the	
community,	 and	 may	 not	 be	 captured	 in	 existing	 epidemiological	 studies	
suggesting	an	increased	incidence	of	AKI	in	CKD.	
Further	prospective	studies	are	 required	 to	assess	 the	 true	 incidence	of	AKI	 in	
patients	 with	 CKD,	 and	 correct	 more	 accurately	 for	 co-morbidity	 and	
hospitalisation.	
	
But	what	 happens	 following	 AKI?	 Renal	 tissue	 has	 the	 ability	 to	 recover	 from	
sub-lethal	 or	 lethal	 cellular	 damage.	 24-27	 However,	 function	 may	 not	 be	 fully	
restored,	 with	 development	 of	 CKD.	 25	 It	 is	 suggested	 kidney	 function	 can	 be	
directly	related	to	a	cycle	of	cell	injury	and	recovery	following	AKI	(Figure	1a).	28	
This	 involves	 renal	 tubular	 epithelial	 cells,	 damage	 to	 which,	 is	 thought	 to	 be	
extended	by	renal	vascular	endothelial	injury	and	dysfunction.	It	is	believed	that	
endothelial	 repair	 is	 important	 to	 overall	 renal	 recovery,	 and	 may	 impact	 on	
long-term	 function.	 29	 This	 model	 however	 considers	 acute	 tubular	 necrosis	
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(ATN)	as	the	cause	of	AKI.	What	happens	most	frequently	is	limited	to	the	very	
early	part	of	 this	process.	 In	patients	developing	CKD	(Figure	1b)	 the	 initiating	
insult	 leading	 to	 damage,	 inflammation	 and	 repair	 (initiation)	 may	 result	 in	
fibrosis	 (extension)	 and	 then	 further	 damage	 in	 a	 self-perpetuating	 cycle	 of	
progression	(maintenance)	to	end	stage	renal	disease	(ESRD).	Early	intervention	
at	the	stages	of	initiation	and	extension	may	prevent	CKD	and	ESRD,	whilst	later	




Okusa	 et	 al	 (pathophysiological	 concepts	 from	 Sutton	 et	 al),	 suggest	 that	
following	AKI,	there	are	four	possible	outcomes:	(1)	full	recovery,	(2)	incomplete	
recovery	 resulting	 in	 CKD,	 (3)	 exacerbation	 of	 pre-existing	 CKD	 accelerating	




develop	 AKI	 already	 have	 unrecognised	 renal	 disease	 and	 reduced	 functional	





A	 key	 question	 is	whether	 the	 ‘I’	 in	 AKI	 truly	 stands	 for	 injury	 or	 actually	 for	
impairment	and/or	injury?	Is	it	under-pinned	by	histo-pathological	damage,	and	
if	 so,	 when	 does	 this	 become	 relevant	 in	 terms	 of	 future	 CKD	 or	 CKD	
progression?	 Do	 undetected	 episodes	 of	 AKI	 in	 the	 community	 lead	 to	 CKD?	

















1b:	The	phases	of	cellular	 injury	in	chronic	kidney	disease.	Following	an	initial	 insult	there	is	 initiation	of	
the	inflammatory	response	with	repair.	This	may	then	lead	to	the	extension	phase	with	added	fibrosis.	Past	
a	 point	 of	 no	 return	 the	 disease	 process	 embarks	 upon	 a	 self-perpetuating	 cycle	 of	 cellular	 damage	 and	
fibrosis	 (maintenance	phase)	 leading	 to	deterioration	 in	GFR,	 and	progression	 to	 end-stage	 renal	disease	
(ESRD).	The	figure	also	shows	the	effect	of	intervention	on	the	disease	process.	
1c:	 The	 effect	 of	 episodes	 of	 acute	 kidney	 injury	 on	 the	 progression	 of	 chronic	 kidney	 disease,	 with	 3	
possible	outcomes;	complete	recovery,	stepwise	progression	and	inexorable	decline.	
 
In	 an	 ischaemia-reperfusion	 injury	 model	 of	 AKI	 in	 rats	 Basile	 et	 al	 found	





cellular	matrix,	contributing	 to development	of	 interstitial	 fibrosis,	29	 leading	 to	
development	 of	 CKD.	 They	 hypothesise	 that	 as	 long	 as	 there	 is	 adequate	
functional	 reserve	 the	 single-nephron	 GFR	 of	 surviving	 nephrons	 increases	 to	
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maintain	 a	 constant	 total	 GFR.	 29	 This	 suggests	 that	 even	 in	 patients	 in	whom	
creatinine	 and	 GFR	 return	 to	 baseline,	 there	 may	 be	 underlying	 permanent	
damage,	 masked	 by	 compensatory	 mechanisms.	 These	 patients	 may	










(ATN))	31),	 is	an	 independent	risk	 factor	 for	graft	survival.	31-33	The	kidney	has	
the	 ability	 to	 restore	 structure	 and	 function	 following	AKI,	 but	 there	 are	 some	
changes	 and	 damage,	 which	 are	 permanent.	 This	may	 lead	 to	 development	 of	
CKD	(or	progression	of	existing	CKD)	if	there	is	not	sufficient	functional	reserve	
to	compensate.	In	cases	where	compensation	maintains	baseline	GFR,	there	may	













38,39	 in	 developed	 countries	 it	 is	 a	 disease	 of	 the	 elderly.40,41	 With	 overall	




medications,	 radio-contrast	agents	and	surgery,	will	 lead	 to	a	continued	rise	 in	
the	incidence	of	AKI.	It	had	been	suggested	that	the	incidence	will	nearly	double	
in	 the	 next	 decade.40,42	 Reported	 incidences	 will	 also	 rise	 as	 with	 increased	
understanding	 in	 the	medical	 community	 there	will	 be	 greater	 awareness	 and	





region	 of	 Scotland,	 conducted	 a	 population	 based	 study	 of	 AKI,	 reporting	 an	
incidence	of	1811	cases	of	AKI	and	336	of	acute-on-chronic	renal	failure	(ACRF)	





in	 this	 chapter	 and	 also	 in	 Chapter	 2	 (‘Define	 the	 Epidemiology	 of	 AKI’).	With	
increased	 recognition	 of	 AKI	 over	 the	 last	 decade,	 and	 the	 low	 cost	 of	 renal	
Michael	Bedford	 11905027	 35	





outcome	 from	AKI	 is	 poor.	 From	historic	 local	 data,	 only	 56%	of	 patients	who	
experienced	severe	AKI	in	hospital	survived	to	discharge;	only	28%	survived	to	3	
years	 post	 discharge.	 43	 Most	 studies	 of	 AKI	 in	 the	 intensive	 care	 unit	 (ICU)	




associated	 increase	 in	 short-term	morbidity	 and	mortality	 and	 in	 longer-term	
outcomes	 including	 1	 year	 mortality;	 39,49,61,68-72	 even	 more	 so	 when	 renal	
replacement	 therapy	 (RRT)	 is	 required.	 5,6,13,34,57	 A	 study	 from	 the	 Medicare	
Sample	Beneficiary	Analytical	File	 from	1992	 to	2001	 found	 that	patients	with	
AKI	who	required	RRT	had	an	in	hospital	mortality	of	32.9%,	compared	to	27.5%	
in	patients	with	AKI	without	 requiring	RRT,	 and	4.6%	 in	patients	without	AKI.	
Importantly	they	found	the	mortality	rate	was	32.6%	in	patients	with	AKI	coded	
as	 a	 secondary	 diagnosis,	 and	 15.2%	 in	 patients	with	 AKI	 coded	 as	 a	 primary	
diagnosis.	 40	 This	 suggests,	 as	 is	 known,	 that	 isolated	AKI	without	 other	 organ	
involvement	 has	 a	 better	 prognosis	 than	 AKI	 in	 the	 context	 of	 multi-organ	
failure.	
	
Chronic	 Kidney	 Disease	 (CKD)	 is	 an	 independent	 predictor	 of	 morbidity	 and	
mortality.	58,59	Hence	we	would	assume	that	AKI	in	CKD	has	a	summative	effect	
on	 outcome,	 raising	 the	 question	 of	 whether	 outcome	 of	 AKI	 differs	 with	
presence	 of	 background	 CKD.	 Studies	 actually	 demonstrate	 lower	 in-hospital	
mortality	in	patients	with	AKI	on	a	background	of	CKD,	compared	with	patients	








in	mortality	 statistics.	Conversely	 those	with	CKD	may	have	more	 resilience	 to	
acute	insults	secondary	to	conditioning	or	priming,	and	tolerate	AKI	better.	It	is	
also	 possible	 that	 those	 with	 CKD	 receive	 better/different	 care	 than	 non-CKD	
counterparts	when	AKI	 is	 identified,	 thus	 impacting	outcomes.	 It	has	also	been	




short-term	 morbidity	 and	 mortality	 and	 in	 longer-term	 outcomes	 including	 1	
year	mortality.	1,2,4,47,65-68	 ‘Silent	and	discrete’	episodes	of	AKI	in	the	community	
therefore	 require	 further	 research	 directed	 at	 recognition	 and	 early	
indentification	 as	 intervention	 in	 this	 group	 may	 have	 a	 significant	 effect	 on	
outcomes.	
	




hospitalised	 patients	 who	 had	 AKI	 and	 progressed	 to	 ESRD,	 had	 background	
CKD.	69	CKD	or	co-morbid	conditions	leading	to	CKD	are	risk	factors	that	predict	
dialysis	dependence	following	AKI.	70,71	Wald	et	al	looked	at	outcomes	of	chronic	
dialysis	 and	 death	 in	 AKI	 patients	 requiring	 in-hospital	 dialysis	 who	 survived	
free	of	dialysis	 for	at	 least	30	days	after	discharge,	 from	a	10-year	cohort	of	all	
adult	patients	in	Ontario	Canada.	Patients	with	AKI	were	3	times	more	likely	to	







leads	 to	 ESRD	 at	 a	 higher	 frequency	 than	 does	 AKI	 alone.	 12,40,46	 Ishani	 et	 al	
assessed	 a	 random	 cohort	 of	 233,803	hospitalised	 patients	 based	 on	Medicare	
claims,	 aged	 ≥	 67	 years	 on	 discharge	 and	 without	 previous	 ESRD	 or	 AKI.	 12	






Importantly,	 as	 already	 suggested	 (and	 to	 be	 discussed	 later	 in	 this	 chapter)	
these	 studies	 all	 depend	on	definition	of	both	CKD	and	AKI,	which	may	not	be	
accurate	 or	 comparable.	 For	 example,	 definition	 of	 CKD	 based	 on	 diagnostic	






There	 is	mounting	evidence	 that	AKI	 contributes	 significantly	 to	CKD	and	CKD	




and	 (4)	non-recovery	of	 function	 leading	 to	ESRD,	 28,30	 (Figure	2).	There	 could	









experiencing	 AKI	 are	 likely	 to	 also	 have	 risk	 factors	 for	 CKD.	 It	 may	 be	 that	
patients	 without	 known	 background	 CKD	 who	 develop	 AKI	 already	 have	
unrecognised	renal	disease	and	reduced	functional	reserve,	not	yet	manifest	as	






et	 al	 demonstrated,	 following	 AKI	 50%	 of	 patients	 without	 background	 CKD	
progressed	 to	 CKD	within	 3	 years.	 79	 Hsu	 et	al	 suggested	 the	 growth	 of	 ESRD	
incidence	 (United	 States)	 could	 not	 be	 accounted	 for	 solely	 by	 rise	 in	 CKD	
incidence.	Growth	in	ESRD	incidence	may	partly	be	attributable	to	AKI.	80		
There	 are	 further	 studies	 suggesting	 development	 of	 CKD,	 and	 dialysis	
dependency	following	AKI.	1,2,7,9,62,81	Amdur	et	al	 tested	the	hypothesis	 that	AKI	
and	 specifically	 acute	 tubular	 necrosis	 (ATN),	 causes	 CKD.	 5,404	 of	 113,272	
patients	(United	States	Department	of	Veterans	Affairs	database,	1999	to	2005)	
had	 diagnostic	 codes	 indicating	 AKI	 or	 ATN	 without	 background	 CKD.	 82	 A	








If	 AKI	 is	 a	 cause	 of	 CKD,	 it	 seems	 logical	 AKI	may	 progress	 pre-existing	 CKD.	
There	are	however	difficulties	in	testing	this	hypothesis.	A	large	number	of	risk	










to	 development	 and/or	 progression	 of	 CKD?	 The	 effect	 of	 ‘silent	 and	 discrete’	








episode	 demonstrates	 ‘susceptibility’	 and	 qualifies	 a	 high-risk	 population.	
Further	research	is	warranted	to	inform	the	optimal	follow	up	period	and	better	
understand	 the	 clinical	 consequences	 of	 AKI	 in	 patients	 with	 and	 without	
underlying	CKD.	83	
	
Again,	 as	 previously	 suggested,	 the	 above	 reported	 studies	 depend	 on	 the	




The	 concept	 of	 acute	 kidney	 injury	 (AKI)	 or	 as	 it	 was	 previously	 acute	 renal	
failure	is	not	new.	There	was	renewed	interest	in	acute	renal	failure	dating	from	
the	 now	 classical	 description	 of	 tubular	 degeneration	 and	 tubular	 pigmented	
casts,	 together	 with	 intact	 glomeruli,	 in	 patients	 crushed	 by	 fallen	 masonry	
during	 the	 London	 blitz.	 84	 However	 in	 the	 last	 5-10	 years	 there	 has	 been	 a	





the	 AKI	 Delivery	 Group.	 This	 has	 led	 to	 an	 AKI	 National	 programme,	 which	
includes	the	workstreams:	education,	risk,	detection,	measurement,	intervention	
and	implementation.	There	has	also	been	the	development	and	promotion	of	the	




the	 development	 of	 guidelines;	 the	 KDIGO	 (Kidney	 Disease:	 Improving	 Global	
Outcomes)	 AKI	 guideline,83	 the	 recent	 NICE	 (National	 Institute	 for	 Health	 and	
Care	 Excellence)	 guidance	 on	 AKI	 (‘Acute	 kidney	 injury:	 prevention,	 detection	
and	 management’,	 NICE	 CG	 169),85	 and	 the	 updated	 Renal	 Association	
Guidelines.	 86	AKI	has	 also	now	been	 incorporated	as	 a	 clinical	pathway	 in	 the	
Enhancing	Quality	Initiative.	
	







As	 suggested	 previously,	 the	 first	 debate	 in	 acute	 kidney	 injury	 was	 and	 is	
definition.	Over	the	years	one	inherent	problem	in	both	diagnosing	AKI	clinically	











to	 define	 AKI	 as	 either	 a	 1.5-fold	 increase	 in	 serum	 creatinine,	 a	 decrease	 in	




1.5-2.0-fold	 increase,	 injury	as	a	2.0-3.0-fold	 increase,	and	failure	as	a	>3.0-fold	
increase	 in	 serum	creatinine.	 67	 Loss	was	defined	 as	 a	 complete	 loss	 of	 kidney	
function	requiring	renal	replacement	therapy	(RRT)	for	>	4	weeks	and	ESRF	as	



















In	 2007	 the	 Acute	 Kidney	 Injury	 Network	 (AKIN)	modified	 the	 RIFLE	 criteria,	





The	 addition	 of	 a	 rise	 in	 26.4µmol/l	 to	 define	 AKIN	 1	 was	 based	 on	 2	 large	
studies,	which	demonstrated	an	independent	association	between	an	increase	in	












































In	 the	 recent	 KDIGO	 AKI	 guideline	 (2012),	 AKI	 is	 defined	 as	 a	 syndrome,	
including	direct	injury	to	the	kidney	as	well	as	acute	impairment	of	function.	83		
The	guideline	defines	AKI	as:	













and	CKD	may	 lead	 to	 changes	 in	 serum	creatinine	and	GFR	over	a	 time	period	
outside	 those	currently	specified,	precluding	definition.	These	cases	should	not	
be	neglected,	 as	 intervention	may	be	 required.	 For	 this	 reason,	 the	KDIGO	AKI	
Work	 Group	 proposed	 an	 operational	 definition	 for	 acute	 kidney	 diseases	 and	
disorders	 (AKD),	 to	 provide	 an	 integrated	 clinical	 approach	 to	 patients	 with	




























































It	 is	 important	 to	 note	 that	 in	 the	majority	 of	 clinical	 practice	 and	 in	 research	
using	 retrospective	 database	 analyses	 as	 described	 here,	 solely	 the	 serum	






AKI	 and	 AKD	 often	 occur	 in	 patients	 with	 CKD.	 What	 previously	 made	 the	
determination	of	 the	 epidemiology	of	AKI	 and	CKD,	 and	 the	 interplay	between	
the	 two,	 more	 difficult	 was	 the	 variation	 in	 definitions	 used	 and	 populations	



















A	 retrospective	 cohort	 study	 by	 LaFrance	 and	 Miller	 assessed	 1,126,636	
veterans	 (US	 Department	 of	 Veterans	 Affairs	 healthcare	 system),	 who	 were	
hospitalised	 at	 least	 once	 between	 2000	 and	 2005.95	 The	 highest	 serum	
creatinine	during	hospitalisation	was	compared	with	the	lowest	using	4	different	




baseline	 period	 to	 at	 least	 3	 months	 they	 found	 the	 discriminative	 power	
increased	 slightly	 (C	 statistic	 increased	 from	 0.846	 to	 0.855;	 p	 =	 0.001).	 They	
suggested	 the	need	 for	 consensus	on	how	baseline	 serum	creatinine	 should	be	
determined	in	database	studies.		
 
Previously,	 when	 a	 clinician	 defined	 baseline	 kidney	 function	 this	 was	 often	
achieved	 through	 the	 visualization	 of	 serum	 creatinine	 results	 graphically	
represented,	 and	 providing	 a	 subjective	 assessment	 of	 baseline	 visually.	
However,	 to	 objectively	 quantify	 and	 standardise	 the	 definition	 strict	
mathematical	parameters,	however	simplified	must	be	employed.	One	solution,	
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as	reported	by	LaFrance	and	Miller	 is	 to	define	the	baseline	kidney	 function	as	





fluid	 loading	 and	 hence	 dilution	 during	 a	 previous	 hospital	 admission,	 will	 be	
taken	 as	 the	 baseline	 kidney	 function	 (Figure	 3a).	 This	 could	 in	 fact	 be	
significantly	lower	than	the	patient’s	true	baseline	kidney	function,	leading	to	an	
incorrect	trigger	of	a	diagnosis	of	AKI	on	a	new	blood	test.		
There	 is	 also	 the	possibility	 that	 a	patient	with	progressive	CKD	may	 trigger	 a	
diagnosis	of	AKI	based	on	a	baseline	defined	as	 the	 lowest	serum	creatinine	 in	
the	 preceding	 12	 months,	 when	 actually	 the	 kidney	 function	 has	 slowly	
deteriorated	over	the	12-month	period,	but	comparison	of	the	present	creatinine	
and	that	of	12-months	prior	triggers	a	diagnosis	of	AKI	(Figure	3b).	In	the	same	
way,	 within	 a	 12-month	 period	 a	 patient	 may	 have	 a	 stepwise	 reduction	 in	
kidney	function	(likely	due	to	an	AKI)	and	hence	increase	in	creatinine	that	then	
remains	stable.	However,	a	new	serum	creatinine	test,	although	at	the	same	level	
as	 the	 previous	 number	 of	 months	 may	 be	 higher	 than	 the	 previously	 lower	





























































































b) A	 progressive	 decline	 in	 CKD	 over	 the	 course	 of	 12	months.	 Using	 the	 lowest	 creatinine	 in	 12	
months	as	the	baseline	will	trigger	a	definition	of	AKI.	
c) Here	 there	 has	 been	 a	 stepwise	 deterioration	 in	 kidney	 function	 around	 4	 months	 previously	
(likely	 to	have	been	 an	AKI	 at	 that	point	 in	 time),	 and	 since	 then	 the	kidney	 function	has	been	
stable.	However,	using	a	12-month	baseline	will	continue	define	this	as	an	acute	event.  
 
In	 an	 attempt	 to	 tackle	 some	 of	 these	 issues,	 other	 strategies	 have	 been	
suggested	 including	 taking	 the	 average	 of	 values	 between	 7-365	 days	 prior	 to	
admission,96	back	calculating	reference	serum	creatinine	(SCr)	for	missing	values	
from	 an	 assumed	 MDRD	 (Modification	 of	 Diet	 in	 Renal	 Disease)	 defined	
glomerular	filtration	rate	of	75	ml/min/1.73m2	97	and	(more	recently)	a	method	




KDIGO	 AKI	 guideline	 suggests	 an	 estimated	 creatinine	 can	 be	 used,	 provided	
there	 is	 no	 evidence	 of	 CKD.83	 However	 there	 remain	 cases	 of	 CKD	 in	 the	
community	 that	 have	 not	 been	 previously	 appreciated,	 and	 hence	 estimating	
baseline	creatinine	may	lead	to	diagnosis	of	AKI	in	patients	with	previously	un-





the	 need	 for	 new	 biomarkers	 and	 point	 of	 care	 devices	 to	 allow	 early	
identification	 of	 patients,	 aiding	 early	 intervention,	 and	 indeed	more	 accurate	











alerting	 to	 AKI	 (by	 9th	 March	 2015)	 and	 that	 there	 is	 standardization	 in	 the	
identification	 of	 AKI	 using	 a	 single	 algorithm99	 (Figure	 4).	 This	will	 also	 allow	
(through	the	Renal	Registry)	collection	of	standardised	epidemiological	data	on	
the	 incidence	 and	 outcomes	 of	 AKI	 from	 across	 England.	 The	 studies	 reported	
here	(epidemiology	in	Chapter	2	and	risk	modelling	in	Chapter	5)	do	not	use	the	
NHS	 England	 algorithm,	 as	 these	 studies	 were	 designed	 and	 the	 analysis	









Previous result  
Within 0 ± 365 days? 
Index creatinine value 
Defined as 
C1 
If Result within 
0 ± 7 days 
Then: 
If Result within 






Calculate RV ratio 





Calculate RV ratio 
C1 / RV2 
Is higher RV ratio 
" 
Is higher RV ratio 
DQG" 








Is higher RV ratio 
" 
Has change occurred 
Within 48hrs? 
,V'!ȝPRO/" Report without 
alert 
Report without alert. 
Send to authorisation Q 
If creatinine has  
,QFUHDVHG!ȝPRO/ 
In < 7 days. 
Consider requesting 
 repeat If CKD 
 unlikely. 
< RI? Flag low 





Algorithm for detecting Acute 
Kidney Injury (AKI) based on 
serum creatinine changes with 
time  
 
This algorithm relates to the 





(Age and sex 
related if available) 
RV = Reference value. Defined as:  
the creatinine value with which an index 
creatinine value is compared 
D = difference between 
current and lowest 




















Is age < 18 years? 
Serum creatinine 
















in	 the	 Renal	 National	 Service	 Framework.	 However,	 the	 2009	 National	
Confidential	Enquiry	into	Patient	Outcome	and	Death	(NCEPOD)	in	the	setting	of	
AKI,	 highlighted	 systematic	 failings	 in	 identification	 and	 subsequent	
management.	100		
The	 aim	 of	 the	 NCEPOD	 study	was	 to	 assess	 the	 care	 of	 patients	who	 died	 in	
hospital	with	 acute	 kidney	 injury,	 to	 highlight	 deficiencies	 in	 care	 and	provide	
recommendations	 to	 improve	 clinical	 management	 in	 the	 future.	 An	 advisory	
group	 consisting	 of	 nephrologists,	 anaesthetists,	 intensivists,	 and	 general	









All	 NHS	 hospitals	 in	 England,	 Wales	 and	 Northern	 Ireland	 were	 expected	 to	
participate.	Hospitals	in	the	independent	sector	and	public	hospitals	in	the	Isle	of	
Man,	Guernsey	and	Jersey,	also	participated.	The	inclusion	criteria	was	set	as	any	
patient	 16	 years	 or	 older	who	 died	 in	 hospital	 between	 January	 1st	 2007	 and	
March	 31st	 2007	 inclusive,	 and	 who	 had	 a	 coded	 diagnosis	 of	 acute	 kidney	
injury.	Patients	were	excluded	if	they	were	already	receiving	renal	replacement	
therapy,	 or	 their	 admission	 was	 for	 palliative	 care	 from	 the	 outset.	 At	 each	
hospital	 the	NCEPOD	Local	 Reporter,	who	 acted	 as	 a	 liaison	 between	NCEPOD	
and	 the	 hospital	 staff,	 facilitated	 the	 identification	 of	 these	 cases	 within	 the	
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inclusion	criteria,	and	then	facilitated	dissemination	of	questionnaires	and	data	
collation	 for	 these	 patients.	 For	 each	 patient	 identified	 there	 was	 a	 clinical	
questionnaire	sent	to	the	clinician	responsible	for	the	patient’s	care	at	the	time	of	
death,	and	an	organizational	questionnaire	for	each	hospital.	Photocopies	of	the	




subsequently	 excluded	 for	 either	 not	 being	 indicative	 of	 AKI,	 or	 because	 the	
admission,	 at	 the	 outset,	was	 for	 palliative	 care.	 In	 a	 further	69	 cases	 the	 case	
notes	were	reported	as	being	 lost	or	 the	consultant	 in	charge	of	 the	patient͒ at	
the	 time	 of	 their	 death	 had	 left	 the	 Trust.	 This	 left	 976	 patients.	 A	 clinical	







care	 was	 considered	 less	 than	 good,	 they	 were	 judged	 to	 have	 room	 for	
improvement	 in	 their	 clinical	 care,	 rather	 than	 at	 an	 organizational	 level.	 This	
suggests	inadequacies	in	the	clinician’s	recognition	of	AKI,	and	of	its	subsequent	
management.	In	the	assessment	of	complications	of	AKI,	in	13%	of	patients	these	
were	 missed,	 and	 importantly	 in	 17%	 the	 advisors	 assessed	 that	 the	
complications	of	AKI	were	avoidable.	 In	22%	the	complications	were	managed	
badly.	 In	 relation	 to	 the	 assessment	 and	 management	 of	 AKI,	 the	 advisors	
assessed	that	in	only	67%	of	patients	there	was	an	adequacy	of	investigation	of	
AKI.	 The	 advisors	 also	 assessed	 that	 in	 1	 in	 6	 cases	 there	 was	 a	 failure	 to	
recognize	the	severity	of	the	illness.	In	patients	developing	AKI	post	admission,	a	





clinical	 coding	 and	 its	 inherent	 inaccuracies	 to	 define	 AKI,	 and	 a	 patient	
population	 in	 which	 the	 outcome	 in	 each	 case	was	 death,	 the	 conclusions	 are	
very	 clear;	 there	 are	 currently	 significant	 deficiencies	 in	 the	 recognition	 and	
clinical	management	 of	 patients	with	 acute	 kidney	 injury.	 The	NCEPOD	 report	
recommends	 risk	 assessment	 for	 AKI	 in	 all	 emergency	 admissions	 to	 hospital,	
and	suggests	that	predictable	and	avoidable	AKI	should	never	occur.	100	
 











kidney	 injury	 (AKI)	 on	 both	 the	 patient	 and	 the	 health	 care	 economy	must	 be	
defined.	From	the	defined	outcomes	of	AKI	work	should	then	move	backwards	in	
the	 disease	 process	 to	 first	 alert	 to	 the	 presence	 of	 AKI,	 and	 ultimately	 then	 a	









(a) What is the true epidemiology of AKI? 
	
As	 the	 political	 recognition	 of	 AKI	 gathers	 pace	 it	 is	 important	 now	 with	 the	






“grass	 roots”	 epidemiology	 of	 AKI.	 This	 then	 provides	 a	 clinical	 context	 and	
definition	of	the	problem	to	be	addressed.	
(b) How can we intervene early in AKI? 
	




























¥ ‘Patient	Event’	–	for	example	a	presenting	illness	(such	as	chest	 infection,	urinary	tract	 infection,	
myocardial	infarction)	or	iatrogenic	risk	such	as	contrast	media	for	radiological	imaging.	
¥ ‘Harm	to	Kidneys’	–	the	development	of	overt	AKI	as	defined	by	creatinine	testing	described	above.	















The	 first	 stage	 in	 improving	 the	management	of	 acute	kidney	 injury	 is	 to	 alert	
clinicians	 to	 its	 presence	 as	 soon	 as	 possible.	 This	 early	 recognition	will	 allow	
optimum	management	 and	 effective	 intervention	 to	 be	 instigated	 early	 in	 the	
disease	 process	 in	 order	 to	 improve	 outcomes	 in	 terms	 of	 morbidity	 and	
mortality.	This	aids	the	“early	management”	documented	in	Figure	6.	
(c) Can we predict AKI? 
	
Although	by	providing	effective	alerting	to	the	presence	of	patients	with	AKI	and	
intervening	 at	 this	 stage	 should	 improve	 outcomes	 in	 AKI,	 the	 next	 step	 in	
improving	the	overall	management	of	AKI	would	be	to	intervene	one	step	earlier	
in	 the	 disease	 process;	 to	 prevent	 AKI	 in	 the	 first	 place.	 This	 is	 particularly	
important,	as	 the	creatinine	 from	which	AKI	 is	defined	takes	up	to	48	hours	 to	






If	 each	 patient’s	 risk	 of	 AKI,	 or	 of	 worsening	 AKI	 if	 already	 present,	 can	 be	
defined,	 then	 clinicians	 can	 be	 alerted	 to	 these	 patients	 and	 management	














in	 a	 variety	 of	 populations	 34-41,43-46	 often	 in	 a	 teaching	 hospital	 or	 solely	
intensive	care	setting,	but	to	date	the	real	 incidence	of	AKI	 in	a	district	general	
hospital	 setting	 has	 not	 been	 accurately	 documented.	 Before	 developing	
strategies	to	improve	clinical	management,	first	the	problem	must	be	defined.	
Aims	
The	aims	of	 this	study	are	 therefore	 to	(i)	use	 the	acute	kidney	 injury	network	
(AKIN)	 definition	 to	 describe	 the	 real	 incidence	 of	 AKI	 in	 a	 typical	 general	
hospital	setting	in	an	unselected	patient	population,	(ii)	describe	the	associated	





Ethical	 approval	 for	 this	 study	 was	 obtained	 from	 Kent	 Research	 Ethics	
Committee	(ref	10/H1101/89).	All	adult	patients	(18	years	or	over)	admitted	to	
East	 Kent	 Hospitals	 University	 NHS	 Foundation	 Trust	 (EKHUFT)	 between	 1st	
February	and	31st	July	2009	were	included.	Time	of	entry	to	the	cohort	was	the	
date	of	admission	for	each	patient.	EKHUFT	comprises	3	general	hospitals	with	a	
total	 of	 1250	 inpatients	 beds	 serving	 a	 defined	 population	 of	 approximately	
744,400	 people	 (582,300	 adults)	 in	 the	 geographical	 area	 of	 East	 Kent	 in	 the	





31st	 March	 2011.	 Patients	 receiving	 chronic	 renal	 replacement	 therapy	 (RRT)	




Data	 were	 extracted	 from	 the	 EKHUFT	 data	 warehouse.	 This	 data	 warehouse	
stores	 patient	 demographics	 and	 details	 of	 all	 patient	 episodes,	 including	
primary	diagnosis	and	co-morbidity	for	each	episode.	Unique	patient	identifiers	
were	used	 to	 link	 the	data	warehouse	with	 the	pathology	database,	 to	provide	
creatinine	 blood	 test	 results	 during	 the	 inpatient	 stay,	 and	 for	 the	 prior	 12-




Further	 documentation	 on	 data	 extraction	 is	 provided	 in	 Chapter	 5.	 The	 data	
linking	 in	 this	 study	 however	 differs	 from	 that	 in	 Chapter	 5	 (where	 the	 basic		











last	name,	 ‘F’	 their	 first,	 ‘S’	 their	 sex	 and	 ‘D’	 their	date	of	 birth	 in	 an	 ISO-8601	
format.	 Sylvester	 J.	 Pussycat,	 Sr	
Michael	Bedford	 11905027	 59	






to	 be	 used	 to	 automatically	 match	 records	 used	 for	 patient	 care,	 but	 limited	
testing	 found	 no	 false	 positive	 results.	 The	 collisions	 produced	 where,	 for	
example,	 longer	 names	 are	 misspelled	 after	 six	 characters,	 and	 the	 lack	 of	
reliance	 on	 an	 assigned	 number,	 such	 as	 the	 NHS	 number,	 allowed	 for	 a	 high	




























Patient	 demographics	 (to	 determine	 age	 and	 eGFR	 calculations),	 postcode	 (to	
determine	deprivation	score),	co-morbidity	(secondary	diagnoses),	and	primary	
diagnosis	were	extracted.	Both	co-morbidity	and	primary	diagnosis	were	coded	
for	 each	 hospital	 episode	 on	 the	 data	 warehouse	 using	 ICD-10	 (International	
Classification	of	Diseases	–	10th	Edition)	codes.	For	primary	diagnoses	the	ICD-10	
group	 was	 extracted	 for	 each	 admission.	 For	 co-morbidity	 (secondary	
diagnoses),	 validated	 coding	 algorithms	 from	 Quan	 et	 al,101	 with	 further	
validated	algorithms	for	diabetes	102	and	hypertension,	were	used	to	determine	a	
modified	 Charlson	 co-morbidity	 score	 for	 each	 patient.	 The	 number	 of	
admissions	 and	 outpatient	 appointments	 in	 the	 12	 months	 prior	 to	 a	 patient	
admission	 were	 also	 recorded.	 From	 the	 baseline	 pathology	 data	 (creatinine	




Mortality,	 hospital	 length	 of	 stay	 (LOS),	 intensive	 therapy	 unit	 (ITU)	 LOS,	 and	
change	in	residence	resulting	from	admission	were	recorded.	Date	of	death	and	
30-day	 re-admission	 rates	were	 also	 recorded	wherever	 relevant.	 The	 date	 of	
death	was	obtained	from	the	Patient	Master	Index	(PMI)	on	the	hospital	patient	





for	 any	 patient	 recently	 deceased.103	 Data	 on	 LOS,	 intensive	 care	 LOS,	 re-
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the	 intensive	 care	 database	 to	 determine	 whether	 patients	 in	 this	 cohort	
received	renal	replacement	therapy	(RRT)	during	admission,	and	whether	they	
were	 still	dependent	on	RRT	90	days	post	discharge	 (defined	as	 chronic	RRT).	
Patients	who	received	RRT	(often	in	ITU)	but	did	not	meet	the	creatinine	criteria	




Patient	 level	 demographic	 summaries	 were	 performed,	 considering	 a	 single	
observation	 per	 patient.	 For	 patients	with	more	 than	 one	 admission	with	 AKI	
during	 the	 recruitment	 period,	 data	 were	 summarised	 at	 the	 time	 of	 the	
admission	 with	 their	 highest	 stage	 of	 AKI	 where	 there	 was	 a	 valid	 reference	




Normally	 distributed	 data	 were	 summarised	 as	 the	 mean	 and	 standard	
deviation.	Normally	distributed	data	is	symmetrical	about	the	mean.	Continuous	
data	 not	 normally	 distributed	 were	 summarised	 by	median	 and	 inter-quartile	
range,	 or	 the	 percentage	 of	 values	 in	 each	 category	 for	 categorical	 variables.	
Three	 of	 the	 continuous	 variables,	 modified	 Charlson	 co-morbidity	 score,	
number	 of	 admissions	 in	 the	 previous	 12	 months,	 and	 number	 of	 outpatient	
appointments	 in	 the	 previous	 12	 months	 all	 had	 a	 very	 highly	 skewed	




So	 that	 outlying	 values	were	 not	 overly	 influential,	 these	 three	 variables	were	
categorised	for	analysis.	
	
Chosen	 outcomes	 of	 interest	 were	 mortality,	 length	 of	 stay	 (LOS),	 intensive	
therapy	 unit	 (ITU)	 utilisation,	 and	 increase	 in	 care	 following	 discharge.	
Regression	 analyses	 were	 performed	 to	 determine	 the	 impact	 of	 AKI	 on	 each	
outcome.	Regression	analysis	is	a	technique	to	determine	relationships	between	
variables	and	importantly	between	predictor	variables	and	the	outcome	variable	
of	 interest.	 Variables	 used	 in	 the	 regression	 model,	 and	 thought	 to	 be	
confounders	 were:	 age,	 gender,	 primary	 diagnosis,	 modified	 Charlson	 co-
morbidity	 score,	 stage	 of	 chronic	 kidney	 disease	 (CKD),	 admission	 from	
residential	 or	 nursing	 care,	 deprivation	 index,	 and	 hospital	 admissions	 and	
outpatient	appointments	in	the	last	12	months.	The	analyses	were	performed	in	
three	 stages.	 In	 the	 first	 analysis,	 the	 effect	 of	 AKI	 upon	 each	 outcome	 was	
examined	 (an	 unadjusted	 analysis).	 The	 second	 analysis	 was	 age	 and	 gender	
adjusted	and	the	final	analysis	was	multiply	adjusted	for	the	above	variables.	
	
For	 primary	 diagnosis	 in	 the	 regression	 model,	 specifically	 for	 elective	
admissions	there	were	diagnosis	groups	with	too	few	events,	which	would	have	
led	to	small	sample	bias.	Therefore,	elective	admissions	were	set	as	the	reference	
and	emergency	admissions	 split	 by	 ICD-10	group	 for	primary	diagnosis,	 under	
the	 assumption	 that	 a	 patient	 being	 admitted	 electively	 for	 a	 procedure	 or	
investigation,	should	not	be	unwell	and	present	with	an	event	precipitating	AKI.	
However,	 this	 assumption	 may	 not	 be	 valid	 in	 the	 case	 of	 elective	 major	
operations	 for	 example	 abdominal	 or	 vascular	 surgery,	 which	 although	 the	
patient	 presents	 to	 hospital	 clinically	well,	 has	 a	 significant	 risk	 of	 developing	
AKI	during	their	hospital	stay	as	a	result	of	the	operative	procedure	or	resultant	


















relates	 the	 time	 until	 an	 event	 occurs	 (in	 this	 case	 death)	 with	 predictor	
variables	which	are	associated	with	this	time.	Hence	the	length	of	time	until	the	
outcome	 (death)	 occurs	 is	 related	 to	 the	 predictor	 variables	 (for	 example	 age,	
gender,	co-morbidity).	Cox	regression	estimates	the	effects	of	these	variables	on	
the	time	to	the	event.	The	regression	model	has	two	constituent	parts,	firstly	the	
baseline	 hazard	 function	 which	 describes	 how	 (at	 baseline	 of	 the	 predictor	
variables)	 the	 risk	 of	 the	 outcome	 (death)	 occurring	 changes	 over	 time,	 and	
secondly	 the	 effect	 parameters	 which	 describes	 how	 this	 risk	 changes	 with	
respect	 to	 changes	 in	 the	 predictor	 variables	 (for	 example	 age,	 gender,	 co-
morbidity).	
	




acute	 kidney	 injury.	 These	 further	 admissions	 could	 significantly	 impact	 on	 a	
patient’s	survival	during	follow-up	irrespective	of	the	index	definition	of	AKI.	For	
example,	 if	 a	 patient	 experienced	 AKI	 stage	 1	 during	 the	 recruitment	 period,	
however	 subsequently	 during	 the	 follow-up	 period	 they	 experienced	 an	
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admission	 with	 AKI	 stage	 3,	 it	 is	 more	 likely	 that	 the	 AKI	 stage	 3	 will	 have	
defined	 their	 survival	 in	 follow-up	 than	 the	 AKI	 stage	 1.	 Therefore,	 the	 time	




negative	 binomial	 regression.	 Skewed	 data	 is	 that	 in	 which	 there	 is	 not	 a	
symmetry	 in	 the	probability	 distribution	 about	 the	mean.	Variables	with	 these	
distributions	must	be	 treated	differently	 to	ensure	 that	outlying	values	are	not	
overly	influential.	In	the	case	of	length	of	stay	(LOS)	the	majority	of	patients	have	
a	low	length	of	stay	of	0-4	days,	however	there	are	then	outliers	with	lengths	of	
stay	 significantly	 higher	 for	 example	 50-100	 days.	 This	 is	 a	 positively	 skewed	
distribution	of	values	for	length	of	stay.	These	skewed	datasets	must	be	treated	
differently	 in	 terms	 of	 regression	methods.	 In	 a	 skewed	 dataset	 the	mean	 and	
variance	are	not	the	same	and	therefore	we	cannot	use	regression	methods	that	
assume	a	Poisson	distribution	as	we	will	get	a	poor	fit	of	the	model	produced.	In	
this	 case	 we	 can	 use	 negative	 binomial	 regression	 which	 utilises	 a	 negative	
binomial	 distribution	 in	 which	 the	 variance	 and	 mean	 are	 not	 equal.	 In	 this	
distribution	 the	 variance	 is	 a	 function	 of	 the	 mean	 with	 the	 inclusion	 of	 a	
dispersion	 parameter.	 With	 increase	 in	 the	 dispersion	 parameter	 there	 is	
convergence	of	the	variance	to	the	same	value	as	the	mean.	
	
The	 analysis	 of	 LOS	 was	 performed	 at	 the	 admission	 level	 in	 the	 recruitment	
period,	 and	hence	patients	may	have	 contributed	 to	 the	 analysis	 several	 times	
during	 the	 recruitment	 period	 by	 having	 a	 number	 of	 admissions	 during	 this	
time.	 Admissions	 from	 a	 single	 patient	 are	 more	 likely	 to	 be	 similar	 than	
admissions	from	different	patients.	To	allow	for	the	correlation	between	repeat	
LOS	 values	 from	 the	 same	 patients	 (grouped	 or	 clustered	 data)	 a	 multilevel	






















































month	 recruitment,	 14.6%	 had	 2	 admissions,	 4.1%	 had	 3	 and	 2.2%	 had	 4	 or	
more).	Overall,	there	were	10,030	admissions	in	7,496	patients	with	insufficient	
SCr	data	to	define	AKI.	Of	these	42.9%	were	elective	admissions	and	57.1%	were	
non-elective,	 the	 majority	 had	 a	 LOS	 of	 0-2	 days	 (see	 below).	 Of	 the	 25,985	




















reported	 in	 the	results	but	only	 those	patients	with	valid	SCr	data	sufficient	 to	
define	AKI	were	 included	 in	 the	 regression	 analyses.	 Patients	with	 insufficient	

























Age	-	Mean	(SD)	 62.0	(20.3)	 74.2	(16.3)	 76.1	(14.7)	 72.5	(15.7)	 54.2	(21.0)	
Age:	18-39	 17.1%	 5.1%	 3.6%	 4.4%	 29.0%	
									40-59	 23.7%	 11.3%	 8.9%	 16.0%	 28.3%	
									60-79	 36.9%	 38.2%	 37.3%	 40.7%	 29.5%	
									80+	 22.3%	 45.5%	 50.2%	 39.0%	 13.2%	













AIDS	-	%	 0.1%	 0.1%	 0.1%	 0.0%	 0.0%	
Malignancy	-	%	 6.2%	 11.5%	 14.0%	 16.7%	 4.8%	
CHF	-	%	 2.6%	 10.4%	 13.9%	 11.6%	 1.0%	
CPD	-	%	 12.8%	 17.0%	 16.1%	 17.4%	 8.5%	
Cerebrovascular	
disease	-%	
7.3%	 13.5%	 12.3%	 11.2%	 3.4%	
Dementia	-	%	 3.2%	 6.7%	 8.2%	 7.0%	 1.9%	
Diabetes	-	%	 10.3%	 20.2%	 18.7%	 23.8%	 6.0%	
Hemiplegia.	-	%	 1.3%	 1.8%	 1.4%	 1.5%	 0.5%	
Hypertension	-	%	 27.2%	 39.%	 39.3%	 39.0%	 15.5%	
MI	-	%	 3.0%	 5.0%	 6.0%	 3.9%	 0.7%	
Solid	tumour	-	%	 2.0%	 3.2%	 4.8%	 4.4%	 0.9%	
Liver	disease	-	%	 0.9%	 1.8%	 3.0%	 6.1%	 0.5%	
PVD	-	%	 2.1%	 5.4%	 6.2%	 4.6%	 1.0%	
Peptic	ulcer	-	%	 0.6%	 1.2%	 1.7%	 1.9%	 0.4%	
Renal	disease	-	%	 1.7%	 11.2%	 16.4%	 22.3%	 1.1%	
Rheumatic	
disease	-	%	
2.3%	 3.9%	 3.1%	 4.1%	 1.1%	
CKD	-	no	data	 0%	 0%	 0%	 0.7%	 34.4%	
no	CKD	 84.8%	 61.9%	 62.1%	 68.2%	 58.0%	
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CKD	Stage	3a	 10.0%	 19.1%	 20.1%	 15.0%	 5.0%	
CKD	Stage	3b	 4.0%	 13.1%	 12.1%	 10.2%	 2.0%	
CKD	Stage	4	 1.0%	 5.3%	 5.5%	 2.6%	 0.5%	
CKD	Stage	5	 0.2%	 0.5%	 0.2%	 3.4%	 0.1%	
Charlson	≤0	-	%	 58.0%	 31.9%	 25.8%	 23.3%	 74.5%	
															1-10	-%	 25.9%	 29.4%	 30.5%	 30.1%	 17.4%	
															11+	=	%	 16.2%	 38.8%	 43.7%	 46.6%	 8.2%	
	






The	crude	 incidence	of	AKI	 in	 the	6-month	period	was	3,067	patients	with	AKI	






Co-morbidity	 as	 evidenced	 by	 the	 Charlson	 co-morbidity	 score	 was	 over	
represented	 in	 patients	 with	 AKI,	 and	 increased	 with	 AKI	 stage	 (Table	 4).	
Deprivation	was	not	related	to	AKI	stage.	
	
Renal Replacement Therapy (RRT) 
	
Only	 77	 patients	 of	 the	 588	 patients	with	 AKI	 stage	 3	 (13.1%)	 received	 renal	
replacement	 therapy	(RRT).	Of	 these,	16	remained	on	RRT	90	days	(defined	as	
chronic	RRT)	following	discharge	(2.7%	of	AKI	stage	3).	A	further	4	patients	who	
experienced	AKI	 stage	 3	 in	 their	 index	 admission	 (admission	with	 highest	AKI	
stage	 during	 the	 recruitment	 period)	 who	 did	 not	 require	 RRT	 during	 that	
admission,	 subsequently	 required	 chronic	 RRT	 within	 90	 days	 of	 discharge.	
There	were	also	2	patients	with	AKI	stage	1,	2	patients	with	AKI	stage	2	and	1	
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patient	with	 no	 AKI	 info	who	 did	 not	 require	 RRT	 in	 the	 index	 admission	 but	




Throughout	 follow	up	survival	was	related	 to	AKI	stage,	 (Table	5,	Figure	8).	 In	




for	 a	 certain	 quantity	 of	 time	 (survival	 time)	 following	 a	 given	 occurrence	 /	
event.	 In	 this	 case	 the	 occurrence	 /	 event	 is	 an	 episode	 of	 acute	 kidney	 injury	
(AKI).	 The	 graphical	 representation	 of	 the	 Kaplan	Meier	 survival	 curve	 allows	
visual	comparison	of	 the	survival	of	different	groups	of	patients,	 in	 this	case	of	
the	categorical	variable	of	AKI,	with	the	groups;	‘no	AKI’,	‘AKI	stage	1’,	‘AKI	stage	
































































































	 	 	 	 	 	 	 	 	
























































































































	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	






























































































	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	



























































































































Length of Stay (LOS) 
	



















	 	 	 	 	 	
All	patients	 	 	 	 	 	
	 	 	 	 	 	
Mean	(SD)	 4.5	(10.5)	 9.7	(14.6)	 12.3	(16.0)	 14.9	(18.5)	 2.3	(9.8)	
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Median	(IQR)	 2	(0,	5)	 5	(1,	12)	 7	(3,	15)	 9	(4,	20)	 1	(0,	2)	
	 	 	 	 	 	
0	days	 28.6%	 12.1%	 6.5%	 5.1%	 37.3%	
1	-	2	days	 31.2%	 22.3%	 15.3%	 13.0%	 46.1%	
3	-	5	days	 19.0%	 18.5%	 18.6%	 17.2%	 9.9%	
6	-	10	days	 11.2%	 19.4%	 23.3%	 20.2%	 2.8%	
11	-	20	days	 5.8%	 14.4%	 19.5%	 20.9%	 1.8%	
21	-	50	days	 3.4%	 11.0%	 13.5%	 18.6%	 1.6%	
51+	days	 0.8%	 2.3%	 3.3%	 5.1%	 0.4%	
	 	 	 	 	 	
Hosp	mortality	 	 	 	 	 	
	 	 	 	 	 	
Mean	(SD)	 11.1	(14.4)	 11.8	(16.3)	 10.0	(11.9)	 10.3	(12.2)	 13.5	(29.1)	
Median	(IQR)	 6	(2,	14)	 6	(2,	15)	 6	(2,	14)	 6	(2,	14)	 5	(1,	15)	
	 	 	 	 	 	
Survived	disch.	 	 	 	 	 	
	 	 	 	 	 	
Mean	(SD)	 4.4	(10.4)	 9.5	(14.5)	 13.0	(17.1)	 17.2	(120.5)	 2.1	(8.8)	
Median	(IQR)	 1	(0,	5)	 5	(1,	11)	 8	(3,	15)	 11	(5,	22)	 1	(0,	2)	
	 	 	 	 	 	
	




with	 1.8%	 of	 patients	 without	 AKI.	 Intensive	 care	 LOS	 also	 increased	 with	
severity	of	AKI	from	a	mean	of	3.0	(SD	7.0)	days	in	patients	without	AKI,	to	4.4	





longer	 in	 patients	with	 AKI	 stage	 1,2	 and	 3	 respectively	 compared	 to	 patients	
without	AKI.	
Increase in Care 
	
A	greater	proportion	of	patients	with	AKI	(4.5%	AKI	stage	1,	5.7%	AKI	stage	2	
and	 3.7%	AKI	 stage	 3)	 had	 an	 increase	 in	 care	 on	 discharge	 in	 comparison	 to	










Summary of main findings 
	
The	 incidence	 of	 AKI	 in	 an	 adult	 population	 reported	 here,	 15,325	 pmp/yr	
(10,534	 pmp/yr	 with	 AKI	 stage	 1,	 2,772	 pmp/yr	 with	 AKI	 stage	 2	 and	 2,020	
pmp/yr	 with	 AKI	 stage	 3),	 is	 significantly	 higher	 than	 previous	 estimates	
reported	in	the	literature,46	and	is	likely	to	be	closer	to	the	real	incidence	in	the	
population.	The	reasons	for	the	higher	incidence	reported	here	are	several.	This	
is	 an	unselected	 in-hospital	 population;	 there	 is	 increased	 testing	of	 creatinine	
due	 to	 heightened	 awareness;	 the	 laboratory	 service	 in	 East	 Kent	
comprehensively	covers	the	catchment	population;	because	of	the	geography	of	
the	 catchment	 area	 all	 patients	 in	 the	 area	 are	 admitted	 to	 one	 of	 the	 three	
hospital	sites	of	East	Kent	Hospitals	University	NHS	Foundation	Trust	(EKHUFT);	
the	 population	 in	 East	 Kent	 is	 older	 in	 comparison	 to	 the	 United	 Kingdom	
average;	 and	 finally,	 use	 of	 the	 LaFrance	 methodology	 will	 also	 increase	 the	
reported	incidence.		
	







In	 comparison	 with	 patients	 with	 no	 AKI	 those	 with	 AKI	 stage	 1	 had	 a	 52%	
longer	hospital	stay	(length	of	stay	(LOS)),	a	2.8-fold	increased	risk	of	admission	
to	the	intensive	therapy	unit	(ITU),	a	39%	longer	ITU	stay	(in	those	who	went	to	
ITU),	 and	 a	 2.4-fold	 greater	 in-hospital	 mortality.	 Furthermore,	 patients	 with	
AKIN	 1	 had	 twice	 the	 long-term	 risk	 of	 death,	 a	 33%	 higher	 likelihood	 of	 an	





ITU	 length	 of	 stay	 was	 also	 doubled,	 consistent	 with	 national	 data	 from	 the	
Intensive	Care	National	Audit	and	Research	Centre.104	Acute	renal	 replacement	
therapy	 (RRT)	 support	 was	 required	 in	 13.1%	 of	 patients	 with	 AKI	 stage	 3.	







In	 terms	of	 length	of	 stay,	 as	 the	 time	of	 entry	 into	 the	 cohort	was	 the	date	of	
admission	 for	 each	 patient	 there	 is	 the	 possibility	 of	 reverse	 causality,	 for	
example	 a	 patient	 who	 has	 a	 longer	 length	 of	 stay	 may	 have	 a	 greater	 risk	
exposure	 to	 the	 development	 of	 AKI.	 However,	 in	 this	 cohort,	 of	 the	 5,521	
admissions	with	AKI,	4,064	(73.6%)	already	had	AKI	on	admission.	
Strengths and weaknesses of study 
	
The	population-based	analysis	reported	here	considers	all	patients	admitted	in	a	
general	 hospital	 setting	 in	 the	 United	 Kingdom	 during	 a	 6-month	 period.	 The	
catchment	population	for	this	cohort	is	from	East	Kent	in	the	South	East	Coast	of	




with	 14.6%	 nationally).105	 Nevertheless,	 data	 linkages	 between	 the	 pathology,	
hospital	data	warehouse,	renal	and	intensive	therapy	unit	systems	have	enabled	
the	 study	described	here	 to	 come	closer	 to	 the	 real	 incidence	and	outcomes	of	
AKI	managed	in-hospital	than	any	study	published	in	the	literature	to	date.		
However,	this	study	is	a	retrospective	database	study	and	clearly	has	limitations	




value	 should	 be	 based	 on	 SCr	 values	 available	 >	 3	 months	 prior	 to	 the	 index	
event.	The	reference	SCr	should	be	ideally	be	the	lowest	SCr	recorded	within	90	
days	 of	 the	 event	 to	 distinguish	 this	 value	 from	 the	 baseline	 SCr.	 However,	
practically	in	many	cases	there	may	be	either	few	or	no	pre-hospitalisation	SCr	
values	making	distinction	between	baseline	and	reference	SCr	impossible.	This	is	
an	 area	 that	 requires	 further	 guidance	 and	 consensus	 from	 the	 international	
community	 and	 various	 strategies	 have	 been	 suggested	 including	 varying	 the	
baseline/reference	 creatinine	 from	 admission	 to	 365	 days	 prior,	 95	 taking	 the	





months	 prior	 to	 hospital	 admission	 to	 define	 AKI,	 and	 expressed	 this	 as	 the	
baseline	serum	creatinine.	It	may	be	that	by	employing	this	method	the	study	has	
included	 patients	 with	 progressive	 CKD	 and	 defined	 them	 as	 AKI	 stage	 1.	
However,	 as	 LaFrance	 et	 al	 demonstrated	 and	 the	 data	 in	 this	 study	 confirms,	
patients	 with	 AKI	 stage	 1	 using	 this	 methodology	 still	 have	 a	 significantly	




to	 categorise	 AKI	 (for	 those	without	 pre-hospitalisation	 creatinine)	 in	 8.2%	 of	
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admissions	with	 AKI.	 It	 has	 to	 be	 acknowledged	 that	 the	 assumption	 that	 AKI	
was	present	 if	 serum	creatinine	 improved	 following	admission	by	greater	 than	
26.4	 µmol/l	may	 not	 always	 be	 correct	 but	 use	 of	 this	methodology	was	 only	
necessary	 in	 8%	 of	 those	 categorised	 as	 having	 AKI.	 The	 incidence	 of	 AKI	 in	








degree	of	AKI.	The	200	patients	 in	 this	group	who	did	not	survive	 the	hospital	
admission	 had	 a	 mean	 LOS	 of	 13.5	 days,	 lack	 of	 baseline	 SCr	 data	 precluded	
derivation	 of	 AKI	 status	 in	 these	 patients.	 AKI	 will	 therefore	 have	 been	
underestimated.	 This	 also	 raises	 the	 issue	 of	 possible	 ascertainment	 bias,	 that	
sicker	 patients	 may	 have	 more	 creatinine	 tests,	 increasing	 the	 probability	 of	
detecting	AKI.		
	
Co-morbidity	 data	 was	 extracted	 from	 the	 hospital	 data	 warehouse	 using	
validated	algorithms,	however	this	still	relies	on	the	accuracy	of	coding	of	clinical	
episodes	 (a	well	 recognised	 problem	of	 retrospective	 database	 studies),	which	
may	not	 necessarily	 be	 correct.	 This	 also	 applies	 to	 the	 analysis	 of	 increase	 in	
care	 on	 discharge,	 which	 relies	 on	 the	 accurate	 coding	 on	 the	 patient	
administration	system	(PAS)	at	time	of	discharge.		
	
While	 the	 statistical	 models	 used	 in	 this	 analysis	 have	 accounted	 for	multiple	
confounders	 identified	 in	 the	 literature	 to	 date	 there	 is	 always	 the	 possibility	
that	there	may	be	other	confounders	hitherto	unknown.	
	
Finally,	 despite	 the	 estimates	 here	 of	 the	 incidence	 of	 AKI	 in	 a	 typical	 general	








cent	 of	 all	 admissions	 and	 15	 per	 cent	 of	 non-maternity	 and	 non-day	 case	
admissions	 to	 hospital	 sustained	 an	 episode	 of	AKI	with	 increased	 subsequent	
short	 and	 long	 term	morbidity	 and	mortality,	 even	 in	 those	with	 AKI	 stage	 1.	
What	 this	 study	 adds	 to	 existing	 knowledge	 is	 data	 enabling	 a	 much	 more	
accurate	 assessment	 of	 the	 overall	 impact	 of	 AKI	 on	 the	 healthcare	 economy.	
This	 study	 provides	 data	 concerning	 hospital	 and	 intensive	 therapy	 unit	
mortality,	 length	 of	 stay	 (LOS),	 re-admission	 and	 renal	 replacement	 therapy	
(RRT)	usage.	The	study	also	details	the	rate	of	RRT	after	longer-term	follow-up	
and	the	social	care	impact	in	terms	of	increased	level	of	care	in	those	surviving	
an	 episode	 of	 AKI.	 These	 increased	 adverse	 outcomes	 from	 AKI	 confer	 an	
increased	burden	and	cost	to	the	healthcare	economy.	The	data	presented	here	
enables	 this	 cost	 to	 be	 quantified	 (see	 below)	 and	 will	 furnish	 a	 baseline	 for	





simply	 represent	 a	 marker	 of	 general	 system	 pathology	 and	 multi	 organ	
dysfunction,	not	specifically	related	to	kidney	injury	per	se.	Whether	this	is	true	




With	 the	 international	 agreement	on	 the	definition	of	AKI	 and	 its	 validation	 in	
clinical	research,	it	has	become	clearer	how	important	the	effective	management	











warehouse	 and	 laboratory	 data	 from	 East	 Kent	 Hospitals	 University	 NHS	
Foundation	 Trust	 (EKHUFT)	were	 used	 in	 regression	 analyses	 to	 estimate	 the	























real	 incidence	 and	 outcomes	 of	 AKI	 managed	 in-hospital	 than	 any	 study	
published	in	the	literature	to	date.	Fifteen	percent	of	all	admissions	sustained	an	




kidney	 injury	 in	 England).	 These	 results	 will	 furnish	 a	 baseline	 for	 quality	
improvement	projects	aimed	at	early	identification,	improved	management	and	
where	 possible	 prevention	 of	 AKI.	 The	 publication	 of	 these	 papers	 led	 to	
considerable	 debate	 within	 the	 media,	 the	 medical	 community,	 and	 at	 a	 high	















subsequently	 managed	 by	 clinicians.	 Now	 the	 problem	 is	 evident	 and	 clearly	
defined,	the	first	stage	therefore	in	improving	the	management	of	AKI	is	to	alert	
clinicians	 to	 its	 presence	 as	 soon	 as	 possible.	 This	 early	 recognition	will	 allow	
optimum	management	 and	 effective	 intervention	 to	 be	 instigated	 early	 in	 the	




In	 terms	 of	 diagnosis	 of	 AKI,	 as	 previously	 discussed,	 this	 involves	 the	
comparison	of	the	present	laboratory	serum	creatinine	(SCr)	to	a	baseline	result	
for	a	given	patient.	This	 is	 therefore	the	comparison	of	one	numerical	result	 to	
another,	 a	 process	 which	 does	 not	 require	 human	 intervention	 and	 can	 be	
automated	 by	 a	 computer.	 In	 this	 way	 AKI	 lends	 itself	 to	 automated	 clinical	




to	 provide	 early	 recognition	 and	 support	 early	 effective	 management	
interventions	in	these	patients.	
Daily	AKI	report	–	Static	Alert	-	Methods	
With	 this	 in	 mind	 a	 daily	 report	 of	 patients	 with	 AKI	 at	 East	 Kent	 Hospitals	
University	NHS	Foundation	Trust	(EKHUFT),	a	system	named	SAKI	(Stop	Acute	
Kidney	Injury)	was	developed.	Each	morning	all	creatinine	tests	performed	and	
recorded	 on	 the	 East	 Kent	 pathology	 database	 from	 the	 previous	 day	 are	
downloaded	 from	 the	 pathology	 server	 to	 the	 secure	 ‘AKI	 Database’.	 The	
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database	 already	 contains	 all	 creatinine	 results	 from	 the	 last	 12	 months.	 The	
alert	 program	 defines	 acute	 kidney	 injury	 (as	 described	 in	 Chapter	 2)	 by	
comparing	 the	 creatinine	 result	 from	 the	 previous	 day,	 with	 the	 lowest	
creatinine	 in	 the	 database	 for	 that	 patient	 in	 the	 last	 12	months	 (taken	 as	 the	




accessible	 to	 business	 intelligence	 software	 (a	 product	 called	 Qlikview,	
(Qlik.com)	 was	 used)	 for	 reporting.	 Qlikview	 is	 business	 intelligence	 software	






University	 NHS	 Foundation	 Trust	 (EKHUFT)	 who	 have	 acute	 kidney	 injury,	
defined	 from	 the	 previous	 day’s	 bloods	 results.	 This	 provides	 the	 first	 step	 of	




The	 next	 step	 is	 therefore	 to	 provide	 standardized	 investigation	 and	




standardised	 effective	 assessment,	 investigation	 and	 management	 of	 AKI)	
(Figures	 9,10,11),	 an	 AKI	 referral	 protocol	 (to	 ensure	 timely	 referral	 to	 renal,	
urological	 and	 intensive	 care	 services)	 (Figure	 12),	 and	 an	AKI	 transfer	 policy	
(ensuring	safe	 inter-hospital	patient	transfer	 in	a	patient	with	AKI)	(Figure	13)	
were	 developed	 based	 on	 and	 modified	 from	 policies	 from	 the	 London	 Acute	
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Kidney	 Injury	Network	 (LAKIN;	 http://www.londonaki.net)	 and	 posted	 on	 the	
website	 alongside	 the	 AKI	 report.	 The	 LAKIN	 treatment	 pathways	 were	










AKIN 3  -  discuss 
with renal registrar 
(see referral 
protocol) 
Note patientÕs usual 





Assess fluid balance 
and look for signs of 
shock or 
hypoperfusion 
Check for signs 
of sepsis 
Initially 30 minute 
observations, moving to 
hourly then 2 hourly and 4 






Stop NSAID / ACEi / ARB / 
metformin / K-sparing 
diuretic. 
Modify drug doses 
dependent on renal 
function 
Assess BP, P, JVP, 
capillary refill, GCS, urine 
output 
Consider antibiotics 





If hypovolaemia, give 
250mls fluid bolus and 
observe response 
If volume replete and 
remains hypotensive, 
consider ITU referral for 
inotropic support 
If response, continue fluid 
replacement until volume 
replete 
AKI Treatment Pathway - 
Assessment 
SAKI 









referral to Renal / 
ITU / Urology is 
appropriate 
Bloods Consider Acute 
Renal Screen 
Within 24 hours of AKI 
recognition to rule out 
obstruction 
See Referral Protocol 
Ensure all bloods taken 
including: 
FBC, CRP, CK, LFTs, Ur, 
Cr, Na, K, Ca, Mg, 
bicarbonate 
Correct electrolytes (see 
management of 
complications) 
If electrolyte disturbance 
consider twice daily 
repeats or after treatment 
Ensure renal function 
checked daily 







Bence Jones + 
Serum 
Electrophoresis if: 
¥  Raised calcium or 
globulin fraction 
¥  Known MGUS / 
myeloma 
¥  Short prodrome 
¥  Rapid rise in 
creatinine 
¥  No signs of sepsis 
¥  +/- haemoptysis 
¥  Raised CRP 
¥  Without signs of 
sepsis 









Assess and Treat 
Complications of 
AKI 
Fluid assessment, BP, P, 
JVP, capillary refill, GCS, 
urine output, daily weight 
Minimum 4 hourly 
observations 
Hyperkalaemia 
K > 6.5 
Reverse Hypovolaemia 
When fluid replete give 
maintenance fluids 
(estimated output plus 
500mls) 




¥  10mls of 10% calcium 
gluconate 
¥  Insulin / dextrose (10-15 IU 
in 50mls of 20% dextrose 
over 30 minutes) 
¥  Salbutamol 2.5mg 
nebulisers 6 hourly 
Repeat K post 
treatment 
If K remains >6.5 after 
3 treatments consider 
renal / ITU referral for 
RRT  
Note insulin / dextrose and 
salbutamol reduce ECF 
potassium for < 4 hours 
If bicarbonate <22 and no fluid 
overload consider 500mls of 
1.26% sodium bicarbonate 
over 2hrs (consider repeat 
dependent on level of 
acidosis) 
Oxygen therapy and 
consider CPAP for 
pulmonary oedema 
Give Frusemide 80mg IV 
If no response consider 
frusemide infusion (10mg/hr 
If no response, anuria or 
oliguria, consider referral to 
Renal Physician / ITU to 
consider RRT Regular assessment of 
fluid status 
SAKI 














¥  All AKI with confirmed 
obstruction on imaging 
¥  If K > 6.0 also discuss with 
Renal Registrar as may 
require renal replacement 
prior to intervention 
¥  All AKIN 3 
¥  AKIN 1/2/3 if blood and 
protein on urine dip 
¥  AKIN 1/2/3 if known 
myeloma or BJP positive 
¥  AKIN 1/2/3 if possible 
HUS / TTP 
¥  AKIN 1/2/3 with 
hyperkalaemia resistant 
to medical treatment 
¥  AKIN 1/2/3 with anuria 
despite adequate volume 
replacement / fluid 
overload 






¥  AKIN 1/2/3 with 
hyperkalaemia / fluid 
overload resistant to 
medical treatment and 
not safe for transfer to 
Renal Unit (see 
Transfer Policy) 
SAKI 
Stop Acute Kidney Injury 
AKI Transfer Policy 
¥  Patients must meet the 
following criteria to be deemed 
safe for inter-hospital transfer 
to the Renal Unit at Kent and 
Canterbury Hospital 
¥  All patients must be assessed 
as safe for transfer by a doctor 
prior to transfer 
¥  If patients do not meet these 
criteria, discuss with local 
intensive care for treatment in 
ITU until stable for transfer  
Hyperkalaemia: 
¥  No ECG changes 
¥  K < 6.0 
¥  If K lowered to < 6.0, this must be sustained on repeat testing 
 
Renal Acidosis: 
¥  pH > 7.2 
¥  Bicarbonate >12 
¥  Lactate < 4 
¥  Respiratory rate < 24 
Respiratory: 
¥  Respiratory rate < 24 
¥  Saturations > 94% on not more than 35% oxygen 
¥  If patient required acute CPAP, must have been independent of 
CPAP for > 24 hours 
Circulatory: 
¥  Heart rate < 120 
¥  Blood pressure > 100 mmHg systolic, mean arterial pressure > 65 
mmHg (lower values acceptable if evidence these are usual for the 
patient) 
¥  Lactate < 4 
 
Neurological: 
¥  GCS > 12 
SAKI 







at	 the	 3	 hospitals	 of	 EKHUFT,	 who	 have	 acute	 kidney	 injury.	 This	 provides	


















calculates	 the	 stage	 of	 AKI	 (using	 the	 AKIN	 criteria	 described	 previously)	 by	
comparing	the	creatinine	result	from	the	previous	day	with	the	lowest	creatinine	
in	 the	 prior	 12-month	 period.	 The	 table	 shows	 the	 patient’s	 demographics	
followed	by	 their	 stage	 of	 AKI	 and	 the	 current	 and	 baseline	 creatinine	 results.	
For	each	patient	there	is	also	the	consultant	responsible	for	the	patient’s	care.	
The	modality	 column	 documents	whether	 the	 patient	 is	 already	 known	 to	 the	
renal	 service,	 and	 what	 renal	 clinic	 they	 attend,	 for	 example	 the	 general	
nephrology	clinic,	or	the	transplant	clinic.	
	
By	 clicking	 on	 the	 filter	 tables	 at	 the	 top	 left	 of	 the	 screen,	 the	 lower	 table	 of	
patients	 can	 be	 filtered	 by	 specific	 groups	 for	 example	 by;	 hospital,	 AKI	 stage,	
ward	or	consultant.	It	is	possible	to	search	for	a	specific	patient	using	the	search	










the	 “Test	 Results”	 page	 (Figure	 16)	 the	 results	 specific	 to	 that	 patient	 are	
displayed.	At	 the	 top	of	 the	page	 are	 the	demographics	 for	 that	patient.	Below	
this	 is	 a	 graphical	 representation	 of	 the	patient’s	 results	 over	 time,	 along	with	






















AKI by Ward 
	
The	 “AKI	by	Ward”	 report	 (Figure	18)	documents	 the	number	of	AKIs	on	each	
ward	at	EKHUFT.	The	patients	with	AKI	stage	1	are	shown	in	yellow,	AKI	stage	2	
in	orange	and	AKI	stage	3	in	red.	By	clicking	on	a	specific	ward	and	then	on	the	








With	 the	 developed	AKI	 report	 and	 agreed	management	 protocols	 for	 AKI	 the	
next	 question	 is	 who	 to	 deliver	 the	 information	 to,	 in	 order	 to	 efficiently	





and	 they	 moved	 from	 one	 rotational	 job	 to	 the	 next	 every	 3-4	 months.	 The	
decision	was	therefore	made	to	provide	education	sessions	to	the	junior	doctors	
in	order	to	begin	to	raise	awareness	of	acute	kidney	injury,	but	deliver	the	AKI	
report	 to	 the	critical	care	outreach	nurses	and	 the	renal	consultants.	Figure	19	
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shows	 a	 pictorial	 representation	 of	 how	 the	 SAKI	 AKI	 alert	 system	worked	 in	
terms	of	data	flow	and	clinical	intervention.	
	
Small	 focused	educational	 sessions	were	delivered	 to	 the	critical	 care	outreach	
nurses	 at	 each	 of	 the	 3	 hospital	 sites	 of	 EKHUFT,	 both	 to	 educate	 on	 the	
assessment,	 investigation	and	management	of	 acute	kidney	 injury,	but	also	 the	
use	 of	 the	 SAKI	 AKI	 reporting	 system.	 The	 critical	 care	 outreach	 nurses	 were	
thought	 to	 be	 ideal	 to	 both	 assess	 and	 provide	 management	 advice	 for	 the	
patient	with	AKI,	but	also	in	doing	so	deliver	education	at	the	point	of	care	to	the	
nursing	 and	 medical	 staff	 looking	 after	 the	 patient.	 In	 the	 year	 2000	 the	
Department	 of	 Health	 published	 the	 report	 ‘Comprehensive	 Critical	 Care’	 107	
which	was	a	catalyst	for	the	development	of	the	role	of	the	critical	care	outreach	
nurse	 to	 support	 the	 nursing	 and	 medical	 staff	 on	 the	 wards	 to	 ensure	
recognition	 and	 optimum	 management	 of	 the	 unwell	 patient,	 with	 early	
escalation	 to	 intensive	care	as	necessary.	This	role	 therefore	 fits	 in	neatly	with	
the	 management	 of	 acute	 kidney	 injury,	 for	 a	 number	 of	 reasons.	 Firstly,	 as	
discussed	at	the	end	of	the	last	chapter	it	has	been	postulated	that	especially	in	
the	 milder	 forms	 of	 acute	 kidney	 injury,	 AKI	 is	 a	 marker	 of	 general	 system	
pathology	and	multi	organ	dysfunction	rather	 than	being	specifically	related	 to	
kidney	injury.	Therefore,	AKI	in	this	respect	could	be	seen	as	an	alert	system	in	























review.	 The	 patients	 are	 reviewed	 as	 deemed	 necessary	 with	 all	 interactions	
documented	in	both	the	medical	notes	and	the	AKI	audit	form	online.	The	critical	
care	 outreach	 nurse	 contacts	 the	 renal	 registrar	 for	 advice	 as	 necessary,	 and	
following	discussion	the	decision	is	made	regarding	appropriate	transfer	to	the	
Kent	Kidney	Care	Centre	at	Kent	and	Canterbury	Hospital,	 in	 line	with	 the	AKI	
Referral	 Protocol	 (Figure	 12)	 and	AKI	 Transfer	 Policy	 (Figure	 13).	 The	 critical	






¥ Alerting	 the	clinical	 team	when	reviewing	 the	notes	 that	 the	patient	has	
AKI	
¥ Providing	 generic	 advice	 for	 the	 investigation	 and	 management	 of	
patients	with	AKI	









is	 arranged.	 Patients	 with	 AKI	 stage	 3	 are	 the	 most	 likely	 to	 need	 specialist	
intervention	 in	 terms	 of	 invasive	 investigations	 such	 as	 renal	 biopsy,	 and	
specialist	management	in	terms	of	renal	replacement	therapy	(RRT).	Hence	the	
intervention	 of	 the	 renal	 specialist	 in	 all	 cases	 of	AKI	 stage	3	 to	 ensure	 timely	
specialist	 intervention,	 investigation	 and	 management.	 Again	 the	 renal	













(KCH, WHH, QEQM) 
Renal Consultant 
Telephone Call to 
clinical team 
(KCH Ð Acute ward 
consultant, WHH and 
QEQM Ð covering 
consultants) 
 
Review if necessary 
AKI Treatment Plan 
Documented in 
Medical Notes (see 
AKI Treatment 
Pathway) (if reviewed) 




For Renal specialist 
advice discuss with Renal 
Registrar: 
Bleep 7151 (KCH) 
Bleep 7150 (QEQM, WHH) 
Transfer to Renal 
Unit if appropriate 




Stop Acute Kidney Injury 
Daily Review 
of AKI Alert 
Report 
http:// 
Data stored on ÒAKI Audit 
DatabaseÓ and reported 
on AKI Alert Report 
All creatinines 
performed at 
EKHUFT previous day 
Compared with 
lowest creatinine in 
previous 12 months 




















Stop Acute Kidney Injury
The AKI alert system
This paƟ ent has Acute Kidney Injury Stage 2
For further informaƟ on regarding assessment, invesƟ gaƟ on and management of AKI 
including referral and transfer protocols please see: hƩ p://aki.kentrenal.org/stage2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• Test renal funcƟ on daily
Outreach notes or suggesƟ ons:
Pharmacy notes or suggesƟ ons:
	ǣ
Bleep 7151 (KCH)
Bleep 7150 (QEQM, WHH)
Ɵ
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With	 development	 of	 Information	 Technology	 (IT)	 and	 greater	 access	 to	
electronic	data	within	healthcare,	there	is	a	great	opportunity	to	deliver	data	in	
the	 form	 of	 clinical	 information	 both	 efficiently	 and	 effectively	 to	 the	 clinical	
team.	 This	 can	 be	 taken	 one	 step	 further	 with	 the	 use	 of	 a	 clinical	 decision	
support	system	(CDSS)	as	with	the	SAKI	AKI	alert	system	above,	which	can	use	
clinical	 data	 to	 provide	 advice	 on	 clinical	 management,	 using	 and	 ensuring	
compliance	 with	 locally	 or	 nationally	 agreed	 clinical	 guidelines.	 As	 well	 as	
effective	intervention	in	clinical	care,	this	also	allows	the	standardization	of	care.		
	
However,	 the	 key	 to	 success	 of	 an	 alert	 system	 or	 clinical	 decision	 support	
system	 is	 the	 effective	 integration	 into	 clinical	 care,	 with	 user	 adoption	 and	
active	use	of	the	system.	Although	there	has	been	work	to	predict	whether	users	
will	embrace	a	new	IT	system,	this	has	mainly	assessed	communication	between	
clinicians,	 result	 reporting,	 clinical	 documentation	 and	 ordering	 of	
investigations.	There	has	been	 less	 evaluation	of	 the	delivery	of	 a	 clinical	 alert	









and	 alerting	 to	 the	 renal	 consultants	 of	 patients	 with	 AKI	 stage	 3,	 to	 provide	
early	 intervention	in	AKI.	The	next	stage	of	this	project	was	then,	 following	the	
development	 of	 accurate	 risk	models	 to	 predict	which	 patients	would	 develop	
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new	 AKI	 (to	 allow	 earlier	 intervention	 in	 the	 disease	 process	 to	 ultimately	
prevent	AKI),	or	worsening	AKI	if	already	present	(Chapter	5),	to	add	alerting	to	
patients	 at	 risk	 of	 developing	AKI	 to	 the	 SAKI	 AKI	 alert	 system.	 The	 SAKI	 AKI	
alert	system	would	 then	encompass	AKI	and	AKI	risk	alerting.	However	before	
progressing	further	with	the	development	of	alerting	to	include	alerting	to	risk,	it	
was	 key	 to	 ensure	 that	 the	 correct	 method	 of	 alert	 delivery	 and	 clinical	
intervention	 was	 achieved.	 This	 would	 however	 only	 be	 the	 case	 if	 there	 is	
sufficient	user	acceptance	and	adoption.	Therefore,	the	next	step	here	focuses	on	
what	barriers	exist	to	the	introduction	and	integration	of	a	clinical	alert	system	
or	 CDSS	 into	 clinical	 care,	 and	 using	 qualitative	 research	 methods	 investigate	
how	this	can	be	successfully	achieved	in	the	setting	of	AKI,	initially	at	East	Kent	




With	 increasing	 processing	 power	 of	 computing	 devices,	 proliferation	 of	 the	
internet,	mobile	and	smartphone	devices,	and	our	ability	to	access	information	in	
real	 time,	 comes	 a	 change	 in	 our	 expectations	 of	 information	 delivery	 and	
communication	 in	healthcare.	With	access	 to	electronic	 information	 systems	at	
the	 point	 of	 care,	 we	 have	 the	 potential	 to	 inform	 clinical	 decision-making,	
improve	 efficiency,	 quality	 and	 standardisation	 of	 healthcare,	 and	 provide	 a	
patient-centred	approach.108,109	
	
The	 2009	 National	 Confidential	 Enquiry	 into	 Patient	 Outcome	 and	 Death	
(NCEPOD)	 in	 the	 setting	 of	 acute	 kidney	 injury	 (AKI)	 highlighted	 systematic	
failing	 of	 identification	 and	 subsequent	management	 of	 AKI	 in	 hospital.	 100	 As	












patient	 safety,	 an	 IT	 solution	 must	 be	 delivered	 to	 the	 correct	 person	 at	 the	
correct	time.	Picot	et	al	116	suggest	that	value	to	patients	is	not	created	directly	
by	 the	 IT	 solution,	 however	 it	 allows	 effective	 integration	 of	 a	 process	 into	
clinical	 care,	 which	 then	 provides	 value.	 Within	 all	 specialities	 in	 healthcare	
there	 are	 clinical	 practice	 guidelines	 (CPGs)	 to	 assist	 physician	 and	 patient	
decisions	along	appropriate	management	pathways.	117	We	know	however	that	
these	 are	 not	 followed	 effectively	 in	 clinical	 practice.	 118,119	 With	 the	
development	 in	 technology,	 the	computerization	of	CPGs	has	 taken	 the	 form	of	
computer	 interpretable	 guidelines	 (CIG),	 120	 computer	 executable	 guidelines	
(CEG),	121	and	integration	within	an	electronic	health	record.	122	Clinical	decision	
support	systems	(CDSSs),	through	patient	specific	advice,	can	be	used	to	inform	
and	 enforce	 management	 pathway	 guidelines.	 Previously,	 computerisation	 of	
CPGs	 have	 been	 technology	 driven.	 121	 However	 there	 is	 the	 need	 to	 actively	
involve	the	user	in	design	and	delivery	of	the	system.					
	
Although	 benefits	 of	 electronic	 alert	 and	 CDSSs	 may	 be	 apparent,	 there	 have	
been	 barriers	 to	 their	 introduction	 and	 utilization	 within	 healthcare.	 One	 of	





Keys	 to	 successful	 integration	 of	 an	 IT	 solution	 into	 routine	 use	 are	 user	
acceptance,	124,125	 and	 often	 a	 determinant	 of	 this,	 hospital	 information	 system	
design.	 126-128	Yarborough	 and	 Smith	 suggest	 there	 are	 three	 main	 barriers	 to	
acceptance	by	physicians:	organizational,	 information	system	(technology),	and	
personal	(human).	129	Van	der	Meijden	et	al	suggest	that	satisfaction	with	the	use	
of	 an	 IT	 system	 leads	 to	 acceptance.	 130	 Chen	 and	 Hsiao	 suggest	 that	 top	










In	 Germany	 there	 has	 been	 extensive	 work	 to	 develop	 a	 nation-wide	
telemedicine	 infrastructure	 to	 enable	 electronic	 healthcare.	 136	 Although	
physicians	may	 agree	 on	 its	 advantages,	 137	 the	 programme	 has	 been	 delayed,	
primarily	due	to	physician	resistance.	135,137-139	This	position	is	echoed	across	the	
European	 Union.	 110	 Reasons	 thought	 to	 underlie	 resistance	 are:	 the	 scale	 of	
work	 required	 for	 delivery	 and	 implementation,	 a	 disappointment	 with	
performance,	and	importantly	concerns	regarding	privacy.	139		
	
Spil	 et	 al.	 suggest	 that	 user	 characteristics	 determine	 adoption	 of	 the	 system.	
These	characteristics	are	determined	by:	relevance,	resources,	requirements	and	
resistance.	 140	 Margreet	 Michel-Verkerke	 suggests	 that	 adoption	 is	 not	 a	
dichotomous	 phenomenon.	 141	When	 clinicians	 are	mandated	 to	 use	 a	 system,	
this	 does	 not	 ensure	 satisfaction	 and	 effective	 use.	 141	 This	 may	 lead	 to	
inaccuracies	in	data	recording	and	data	quality.	Quality	of	the	system	and	quality	





that	a	 system	performs	 its	 tasks	well.	 143	Spil,	 Schuring	and	Michel-Verkerke	as	
part	of	 the	USE	IT	 framework,	describe	the	quality	criteria	of	an	 innovation	as:	
timeliness	(accessibility),	accuracy	(informativeness)	and	ability	to	integrate.	140	
Delen	 and	 Rijsenbrij	 suggest	 that	 quality	 is	 related	 to:	 correctness,	 up-to-











support	 collaboration	 between	 physicians	 and	 nurses,	 physicians	 develop	
workarounds	 to	 the	 system.	 146	 These	 workarounds	 create	 inconsistencies	 in	
information,	 affecting	 data	 quality,	 reliability,	 and	 adversely	 affecting	 patient	
safety.	146	
	
Quantity	 is	 linked	 to	 quality	 of	 data.	 “Drowning	 in	 information,	 but	 thirsty	 for	
knowledge”	 suggests	on	one	hand	 there	 is	 too	much	 information,	while	on	 the	
other	people	complain	of	too	little.	They	suggest	the	solution	lies	in	information	
structuring.	113	
Information	 quality	 is	 also	 linked	 to	 its	 communication.	 Failure	 in	







Davis	 proposed	 a	 theoretical	 model	 to	 predict	 whether	 a	 user	 will	 accept	 the	
development	 and	 use	 of	 a	 new	 IT	 system,	 the	 technology	 acceptance	 model	
(TAM).	153	Perceived	usefulness	and	perceived	ease	of	use	are	two	key	factors	in	
this	 model	 in	 relation	 to	 user	 acceptance.	 153	 TAM	 has	 been	 used	 to	 assess	









adoption	 of	 the	 system,	 and	 that	 these	 characteristics	 are	 determined	 by:	
relevance,	resources,	requirements	and	resistance.	140	
	






there	 is	 the	 opportunity	 to	 deliver	 clinical	 information	 systems	 and	 clinical	
decision	 support	 systems	 (CDSSs)	 to	 the	 point	 of	 care,	 to	 improve	 clinical	
practice	 and	 patient	 safety.	 However,	 the	 key	 to	 success	 of	 these	 systems	 is	
effective	integration	into	clinical	care,	with	physician	adoption	and	active	use.	
Although	there	has	been	extensive	work	to	predict	whether	users	will	embrace	a	
new	 IT	 system,	 this	 has	 mainly	 assessed	 communication	 between	 clinicians,	
result	 reporting,	 clinical	 documentation	 and	 ordering	 of	 investigations.	 There	
has	been	less	evaluation	of	the	delivery	of	a	clinical	alert	system	or	CDSS.		
	
The	 work	 here	 (using	 qualitative	 methodology)	 will	 explore	 the	 effect	 of	






The	 qualitative	 analysis	 here,	 was	 designed	 by	 both	 Dr	 Michael	 Bedford	 and	
Professor	 Jenny	 Billings	 (Professor	 of	 Applied	 Health	 Research,	 University	 of	
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Kent).	 The	 focus	 group	 and	 interviews	 were	 conducted	 by	 Professor	 Jenny	
Billings	and	the	analysis	was	performed	by	Professor	Jenny	Billings,	with	advice	
from	Dr	Michael	Bedford.	While	the	qualitative	analysis	process	was	designed	by	
Dr	 Michael	 Bedford	 in	 collaboration	 with	 Professor	 Jenny	 Billings,	 and	
appropriate	training	undertaken	by	Dr	Michael	Bedford	within	the	Certificate	of	
Social	Research	Methods	at	the	University	of	Kent,	the	decision	was	made	for	Dr	
Michael	 Bedford	 not	 to	 conduct	 the	 focus	 group	 and	 interviews	 or	 primarily	
analyse	the	resultant	content.	The	reasoning	behind	this	decision	was	so	as	not	
to	 introduce	bias	 into	 the	 results,	 and	ensure	an	objective	and	 truthful	view	of	
the	 use	 of	 the	 AKI	 alert	 system	 in	 clinical	 practice	 at	 EKHUFT.	 I	 myself	 had	
implemented	 the	 AKI	 alert	 system	 at	 EKHUFT	 and	 both	 trained	 the	 Renal	
Consultants	and	Critical	Care	Outreach	Nurses	 in	the	clinical	use	of	 the	system,	
and	provided	education	to	the	Critical	Care	Outreach	Nurses	in	the	investigation	
and	 management	 of	 AKI.	 Therefore	 if	 I	 was	 present	 at	 the	 focus	 groups	 or	
interviews	 the	 participants	 may	 not	 have	 felt	 able	 to	 speak	 openly	 about	 the	




This	 qualitative	 study	 employed	 both	 focus	 group	 and	 individual	 interview	
design.	 Focus	 group	 method	 was	 used	 in	 this	 healthcare	 setting	 not	 only	 to	
expand	ideas,	but	to	gain	consensus	on	views	and	promote	good	practice.	175	This	
particular	 research	 study	promotes	new	and	 innovative	 ideas	 that	may	benefit	
from	being	explored	within	a	group,	particularly	within	a	longitudinal	approach.	
Variations	 in	 perception	 and	 experience	will	 encourage	 deeper	 discussion	 and	
illuminate	impacts,	as	well	as	reveal	the	nature	and	cause	of	practice	changes	in	
relation	 to	 the	 intervention.	 Individual	 semi-structured	 interview	 method,	
adapted	for	the	Renal	Consultant	participants	(as	described	in	Chapter	3)	allows	





As	 above,	 the	 purpose	 of	 this	 was	 to	 inform	 and	 plan	 developments	 to	 the	
alerting	 system,	 adopting	 a	 user-involvement	 approach,	 using	 qualitative	
methodology	 to	 identify	 perceptions	 of	 the	 SAKI	AKI	 alert	 system	presently	 in	
place	 at	 EKHUFT	 and	 explore	 best	 communication	 and	 information	 pathways	
that	 will	 permit	 an	 alert	 system	 to	 both	 alert	 and	 provide	 actionable	
recommendations	 to	 clinicians	 for	 decision-making.	 This	would	 allow	 accurate	
planning	of	a	new	/	modified	alerting	system	to	include	AKI	and	AKI	risk	alerting	




The	sample	consisted	of	six	renal	consultants	 for	 the	 individual	 interviews	and	
six	outreach	nurses	who	attended	the	focus	group.	All	consultants	worked	across	
the	 three	hospital	 sites	within	EKHUFT,	 and	 there	was	 representation	 from	all	
hospital	 sites	 from	 the	 outreach	 nurses.	 Consultants	 used	 the	 alert	 system	 to	
identify	patients	with	 the	more	serious	AKI	stage	3	and	alert	medical	 teams	 to	
offer	advice	and	review	 if	 required,	and	outreach	nurses	 identified	AKI	stage	2	
patients	and	provided	clinical	review	of	the	patient	on	the	ward.	
 
In	 terms	of	 accessibility	 of	 the	 consultant	 and	nurse	 groups	 it	was	 established	
early	on	that	different	qualitative	approaches	would	need	to	be	used	given	their	
individual	availability	and	potential	 to	meet	 together.	Consultants	had	 to	cover	
three	 sites	 and	 group	meetings	were	 difficult	 to	 convene,	 therefore	 interviews	
were	the	method	of	choice.	Conversely,	outreach	nurses	were	difficult	to	capture	
individually	 but	 held	 a	 training	 session	 as	 a	 group	 once	 a	 month,	 and	 this	
provided	 an	 opportunity	 for	 a	 focus	 group.	 Tuning	 different	 methods	 to	 the	






recommendations.	 This	 covered	 aspects	 such	 as	 accessibility	 of	 information,	
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hardware,	who	the	recipient	should	be	(junior	doctor,	consultant),	what	form	the	
alert	 should	 take	 (additional	 email,	 text),	 how	 to	 avoid	 alert	 fatigue	 and	 alerts	
being	ignored.	The	focus	group	lasted	one	hour	and	was	facilitated	by	Professor	
Jenny	Billings	an	experienced	researcher	external	to	the	clinical	team.	Interviews	







Data	 consisted	 of	 six	 30-minute	 interviews	 and	 a	 one-hour	 focus	 group.	 These	
data	were	transcribed	verbatim	and	subjected	to	a	thematic	analysis,	using	a	pre-
determined	theme	as	an	initial	template	for	analysis	derived	from	the	interview	
schedule.	 Clinical	 team	 members	 were	 not	 involved	 in	 the	 data	 collection	 or	
analysis	 of	 the	 data;	 this	 was	 undertaken	 by	 Professor	 Jenny	 Billings,	 a	
researcher	external	to	the	clinical	team.	Regarding	the	interview	and	focus	group	
schedules,	 sections	 1,	 2,	 and	 4	were	 identical,	 however	 section	 3	 (‘impacts	 on	
clinical	 practice	 and	 patients’)	was	 altered	 to	 account	 for	 the	 differing	 clinical	
roles	in	the	project	and	communication	experiences	(i.e.	with	different	people	at	




approaches	 can	be	blended	and	contrasted,	provided	 they	are	at	 first	 analysed	




The	analytical	 approach	 taken	was	Flick’s	 content	 analysis,169	whereby	 themes	
and	 subthemes	 were	 categorised	 within	 a	 pre-existing	 template	 (within	 the	




was	 conducted	 within	 the	 research	 team.	 	 The	 analysis	 from	 the	 focus	 group	
concentrated	on	the	identification	of	best	methods	for	delivering	the	alerts	and	
recommendations	 in	 order	 to	 inform	 the	 AKI	 and	 AKI	 risk	 alert	 system	
development	and	implementation.	The	aim	was	for	this	qualitative	analysis	to	be	
part	of	a	 larger	 longitudinal	qualitative	research	design,	with	two	further	 focus	
group	 waves	 with	 implementation	 of	 the	 AKI	 risk	 alerting	 within	 the	 clinical	
decision	support	system.	Longitudinal	qualitative	research	(LQR)	involves	repeat	
interviews	or	observations	of,	 ideally,	 the	same	research	subjects	over	time.	170	
In	 recent	 years,	 LQR	 has	 been	 used	 in	 a	 number	 of	 health-related	 areas	 to	
generate	rich	data	and	a	deeper	understanding	regarding	people’s	perspectives	
and	 experiences	 and	 how	 and	 why	 these	 may	 change	 over	 time	 in	 order	 to	
improve	practice.	171-174	Rather	than	comparing	findings	at	a	number	of	distinct	
moments,	 LQR	 is	 concerned	 with	 the	 comparison	 of	 different,	 continuous	
processes	of	 change.	The	benefits	 of	 the	 longitudinal	design	will	 be	 that	 it	will	
permit	 the	 same	 participants	 to	 be	 involved	 in	 identifying	 practice	 challenges	
and	solutions,	 in	developing	methods	 for	how	alerts	and	recommendations	can	
be	best	delivered	for	action,	and	for	examining	and	reflecting	on	the	effects	with	
regard	 to	practice	change	as	well	as	 system	evaluation	and	 improvement.	 	The	
qualitative	 aspect	 of	 both	 this	 and	 the	 further	 study	 will	 strengthen	 the	













management	 of	 these	 often	 complex	 patients,	 and	 an	 understanding	 of	 the	
potential	benefit	of	use	of	the	system	in	the	management	of	these	patients.	At	the	
time	 of	 study,	 the	 SAKI	 AKI	 alert	 system	 had	 been	 in	 use	 by	 the	 critical	 care	





very	 apparent	 that	 while	 both	 the	 critical	 care	 outreach	 nurses	 and	 the	 renal	
consultants	 saw	 their	 role	 as	 firstly	 alerting	 the	medical	 teams	 to	 the	 fact	 that	
their	patient	had	AKI,	and	then	to	provide	clinical	assessment	and	advice	(critical	
care	 outreach	 nurse),	 or	 advice	 over	 the	 phone	 (renal	 consultant),	 that	 both	
groups	were	then	worried	as	to	when	their	responsibility	for	the	patient	ended.	
Particularly	 for	 the	 critical	 care	 outreach	 nurses	 there	 was	 the	 worry	 that,	
especially	 on	 surgical	 wards,	 they	 were	 believed	 to	 have	 taken	 over	
responsibility	 for	 the	clinical	management	of	AKI	 from	that	point	on.	They	also	
found	it	harder	to	communicate	the	alert	to	the	surgical	and	orthopaedic	teams,	
and	also	reported	a	lack	of	recognition	of	AKI	and	how	to	manage	these	patients	
by	 these	 teams.	 They	 also	 experienced	 a	 lack	 of	 understanding	 by	 the	 clinical	
teams	as	 to	why	they	were	being	contacted.	 In	 terms	of	 follow-up	of	cases,	 the	
majority	 of	 the	 consultants	 interviewed	 did	 not	 follow-up	 cases	 and	 some	 felt	




















a	 day	 after	 the	 diagnosis	 of	 acute	 kidney	 injury	 (AKI)	was	 evident	 from	blood	





were	 often	 not	 based	 at	 the	 site	 of	 the	 patient	 and	 so	 used	 bleeping	 of	 junior	
doctors	 to	make	 contact,	 and	 less	 so	 for	 the	 critical	 care	 outreach	 nurses	who	
physically	 reviewed	 the	patient	on	 the	ward.	This	 took	a	 significant	 amount	of	
time.	For	the	renal	consultants,	strategies	such	as	calling	the	ward	and	speaking	
to	 the	 nursing	 staff	 looking	 after	 the	 patient	 had	 been	 developed	 to	 overcome	
this	problem.	In	the	most	part,	when	contact	was	made	with	the	clinical	teams,	
most	users	 found	 that	 they	were	already	aware	of	 the	presence	of	AKI	 in	 their	
patient.	
 
The	 critical	 care	 outreach	 nurses	 thought	 that	 the	 AKI	 stickers	 as	 described	
above,	(placed	by	them	in	the	medical	notes	of	the	patients	at	the	time	of	review)	









renal	 consultants	 who	 in	 the	 most	 part	 found	 that	 the	 clinical	 teams	 when	
contacted	 were	 already	 aware	 of	 the	 AKI	 and	 had	 instigated	 management	
changes	in	response	to	this.	This	could	however,	after	two	years	of	the	alerting	
system,	 and	 clinician	 education	 sessions,	 be	 a	 result	 of	 a	 better	 understanding	







team	 looking	 after	 the	 patient,	 and	 along	 with	 this	 ensuring	 that	 the	 clinical	





of	 clinical	 intervention	 in	 acute	 kidney	 injury,	 and	 importantly	 the	 concept	 of	
education	 at	 the	 point	 of	 care,	 this	 study	 highlighted	 a	 number	 of	 key	 areas	
requiring	 improvement.	 The	 key	 areas	 highlighted	 in	 the	 qualitative	 analysis	
included	real-time	delivery	of	AKI	alerts,	clear	responsibility	of	care	 to	be	with	
the	 clinical	 teams	with	 advice	 from	 the	 critical	 care	outreach	nurses	 and	 renal	




With	 the	 above	 qualitative	 study	 in	 mind	 the	 next	 step,	 (in	 parallel	 with	 the	
development	of	 risk	modelling	 to	determine	patients	 at	 risk	of	 developing	AKI	
that	 can	 then	be	 alerted	 alongside	 the	patients	who	 already	have	AKI),	was	 to	
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improve	 the	 usability	 and	 functionality	 of	 the	 alerting	 system	 to	 deliver	 these	
alerts	 to	 the	point	 of	 care.	 In	 clinical	medicine	 communication	 often	has	 a	 key	
role	 in	medical	 errors,	 and	 also	 is	 of	 key	 importance	 when	 trying	 to	 improve	
clinical	 management	 procedures.	 With	 communication	 as	 the	 focus	 of	
improvements	 of	 the	 alerting	 system,	 a	 development	 partnership	was	 entered	
into	 with	 a	 commercial	 company	 (Doctor	 Communications	 Limited	 later	
changing	their	name	to	Careflow	Connect	Limited)	whose	key	aim	was	to	bring	
social	 media	 technology	 securely	 into	 healthcare	 to	 improve	 clinical	






computers	 and	 also	 on	 mobile	 devices.	 The	 data	 is	 encrypted	 at	 rest	 and	 in	
transit,	and	no	data	 is	stored	on	the	devices	on	which	it	 is	viewed,	maintaining	
data	 security	 and	 complying	 with	 strict	 NHS	 information	 governance.	 This	
mobile	 technology	 allows	 clinicians	 to	 access	 patient	 data	 and	 receive	 clinical	
alerts	 about	 their	 patients	 in	 real	 time	 to	 the	 point	 of	 care,	 and	 the	 social	




was	 delivered	 to	 the	 clinical	 team	 looking	 after	 the	 patient,	 and	 that	 they	
retained	clinical	responsibility	for	the	patient	and	the	management	of	the	acute	
kidney	 injury	 (as	 suggested	 by	 the	 qualitative	 analysis),	 there	 needed	 to	 be	 a	
realigning	of	 the	alert	delivery	strategy.	The	old	static	 system	of	AKI	alerting	/	
reporting	 as	 described	 above,	 involved	 alerts	 being	 delivered	 via	 an	 intranet	
portal	 to	 the	 renal	 consultants	 and	 critical	 care	outreach	nurses,	 and	 then	 this	
information	being	conveyed	to	the	clinical	teams	looking	after	the	patients,	with	
the	addition	of	advice	and	guidance	on	management.	The	aim	of	the	new	alerting	
system	was	 to	 reverse	 this	 by	 delivering	 the	 AKI	 alerts	 directly	 to	 the	 clinical	
teams	 at	 the	 point	 of	 care,	 but	 also	 to	 the	 specialist	 renal	 and	 critical	 care	
Michael	Bedford	 11905027	 111	
outreach	teams	at	the	same	time	to	allow	collaboration	and	advice	in	real	time.	
This	 therefore	 required	 the	 clinical	 teams	 to	 take	 ownership	 for	 their	 patients	
that	they	would	then	receive	alerts	for.	While	it	is	possible	to	determine	from	the	
hospital	 electronic	 patient	 administration	 system	 (PAS)	 which	 consultant	 is	
responsible	for	a	given	patient’s	care,	and	from	this	try	and	determine	the	junior	
doctors	to	deliver	the	clinical	alerts	to,	this	is	often	not	successful	or	robust	for	a	








given	 point	 in	 time	 which	 doctors	 are	 responsible	 for	 which	 patients.	 This	
therefore	posed	 the	 first	problem	 in	 the	 reversal	of	 the	alert	delivery	 strategy,	
but	was	also	the	core	of	the	problem	experienced	with	the	SAKI	AKI	alert	system,	
of	the	renal	consultants	being	unable	to	find	and	communicate	with	the	clinical	






‘patient	 list’.	 In	general,	 (although	variable	between	 teams)	 this	 list	documents	
each	of	the	patients	under	the	care	of	a	given	team,	their	demographics,	hospital	
and	 NHS	 number,	 past	 medical	 history,	 reason	 for	 admission,	 results	 and	
investigations	so	far,	and	the	medical	plan	for	the	patient’s	care.	These	lists	are	
often	 created	on	a	word	processing	document	or	 spreadsheet,	 and	 stored	on	a	






clinical	record	and	results	 in	no	action	being	taken.	 In	 terms	of	patient	specific	
information	being	held	on	these	‘patient	lists’	it	is	also	vital	that	confidentiality	is	
maintained.	 The	 terminology	 and	 clarity	 used	 in	 these	 lists	 is	 also	 often	 very	
different	 to	 how	 a	 healthcare	 professional	would	 document	within	 the	 clinical	
notes	 and	 patient	 record.	Within	 the	NHS	 there	 is	 a	 legal	 requirement	 that	 all	
clinical	 information	 is	 recorded	 in	 clinical	 notes	 as	 part	 of	 formal	 information	
governance	 procedures.	 Yet	 the	 recording	 of	 some	 patient	 information	 in	
everyday	clinical	practice	remains	outside	the	domain	of	 ‘formal’	and	takes	the	
form	 of	 more	 ‘informal’	 recording,	 manifested	 through	 the	 documentation	 of	
information	 within	 these	 so-called	 ‘handover	 lists’	 or	 ‘patient	 lists’	 for	 shift	
changes.	This	 therefore	proved	an	opportunity	 to	both	 formalise	 these	 ‘patient	
lists’	to	comply	with	information	governance	and	data	security,	but	also	provide	
a	 clear	 record	 of	 which	 clinical	 teams	 and	 importantly	 junior	 doctors	 were	
responsible	for	a	given	patient	to	allow	AKI	alerting	to	the	clinical	teams	at	the	




to	 replicate	 the	 ‘handover	 list’	 or	 ‘patient	 list’	used	by	 the	 clinical	 teams,	using	
the	 Situation	 Background	 Assessment	 Response	 /	 Recommendations	 (SBAR)	
format	 to	 document	 patient	 information.	 This	 provided	 the	 benefits	 of	
standardisation	 of	 practice	 across	 the	 organisation,	 transparency	 and	 audit	 of	
data	(all	data	entry	is	recorded	with	the	user	details	and	the	date	and	time	of	the	
entry),	data	security,	the	ability	of	other	members	of	the	team	to	see	updates	to	
the	 list	 in	 real-time,	 viewing	 of	 the	 list	 on	 any	 desktop	 computer	 or	 mobile	











With	 the	definition	of	 the	clinical	 team	responsible	 for	a	given	patient,	 the	AKI	
alert	 could	 then	 be	 developed.	 The	 clinical	 team	 would	 automatically	 be	
subscribed	 to	 the	AKI	alerts	 for	 their	patients.	The	AKI	alerts	would	be	sent	 to	
and	received	by	the	clinical	teams	in	real-time	as	soon	as	the	information	(in	the	
form	of	a	creatinine	blood	test	result	defining	acute	kidney	injury)	was	available.	
In	 this	 way	 mobile	 IT	 technology	 is	 being	 used	 to	 create	 a	 shift	 change	 in	
healthcare	delivery.		
	
Traditionally	 information	 flow	 in	 healthcare	 involves	 sequential	 processing	














care	 in	 real-time	 to	 the	 clinical	 team	 looking	 after	 the	 patient,	 and	 the	
management	of	the	patient	can	then	be	changed,	reducing	treatment	delay.		
	
AKI	alerts	were	developed	with	a	 separate	alert	 for	each	stage	of	 acute	kidney	
injury	(Figure	27).	The	alerts	are	received	in	real-time	to	users’	mobile	devices	
and	stored	in	a	feed	in	chronological	order	(Figure	27).	If	the	user	puts	themself	
‘on	 duty’	 (Figure	 27),	 an	 additional	 push	 notification	 is	 sent	 to	 their	 mobile	

















































































































































































an	 alert	was	 viewed	 and	 by	whom	 in	 the	 clinical	 team.	 It	 also	 enables	 clinical	
comments	 to	 be	 placed	 directly	 on	 the	 alert	 to	 allow	 collaboration	within	 the	
clinical	 team	 in	 real-time	 as	 all	 members	 of	 the	 clinical	 team	 can	 see	 these	
comments	as	soon	as	they	are	entered	onto	the	system.	This	does	not	however	
remove	 the	 specialist	 renal	 and	 critical	 care	 outreach	 teams	 from	 the	 clinical	
collaboration	as	they	can	also	view	the	alerts	and	see	who	from	the	clinical	team	
has	seen	the	alerts	and	also	view	and	if	necessary	add	to	the	clinical	comments	
on	 the	 alerts.	 This	 allows	 the	 specialist	 teams	 to	 collaborate	 with	 the	 clinical	
team	 looking	 after	 the	 patient,	 and	 give	 advice	 and	 support	 as	 and	 when	
required.	If	the	clinical	team	wishes	to	actively	ask	for	advice	and	support,	then	
the	 referral	 functionality	 can	 be	 employed.	 This	 setup	 removes	 the	
communication	challenges	reported	in	the	qualitative	analysis,	and	ensures	that	




The	 Careflow	 system	 to	 deliver	 patient	 lists,	 acute	 kidney	 injury	 alerting	 and	










time	 alerting	 of	 patients	 with	 acute	 kidney	 injury	 to	 the	 point	 of	 care,	 this	
satisfies	the	third	aim	of	this	thesis.	
Chapter Summary 
The	 work	 reported	 here	 has	 developed	 a	 simple	 reporting	 /	 alerting	 tool	 to	
define	all	patients	within	a	hospital	trust	who	have	acute	kidney	injury	(AKI),	to	
allow	 focused	 and	 standardised	 clinical	 intervention	 by	 Critical	 Care	 Outreach	
Nurses	 and	 specialist	 Renal	 Consultants.	 Importantly	 the	 use	 of	 Critical	 Care	
Outreach	 Nurses	 to	 support	 the	 management	 of	 AKI	 has	 been	 replicated	 in	





care	 was	 assessed,	 in	 particular	 the	 effect	 of	 professional	 interactions,	
information	sharing,	and	personal	and	professional	characteristics	on	the	use	of	
electronic	clinical	information	and	clinical	decision	support.	The	study	concluded	
that	 while	 the	 alert	 system	 had	 significant	 benefits	 in	 terms	 of	 clinical	
intervention	 in	AKI,	and	also	 the	realisation	of	unexpected	benefits	such	as	 the	
concept	of	education	at	the	point	of	care,	the	study	recognised	a	number	of	key	
areas	 that	 required	 improvement.	 The	 key	 outcomes	 from	 the	 qualitative	
analysis	 included	 the	 need	 for	 real-time	delivery	 of	 alerts	 to	 the	 point	 of	 care,	
clear	responsibility	of	care	to	be	with	the	clinical	teams	with	advice	from	Critical	
Care	 Outreach	 Nurses	 and	 Renal	 Consultants,	 collaborating	 in	 real-time	 with	
improved	 communication.	 This	 work	 has	 informed	 further	 developments	 in	
alerting	 reported	 here	 and	 future	 work	 as	 electronic	 alerting	 and	 real-time	




The	 second	 stage	 of	 the	 work	 in	 this	 chapter,	 as	 part	 of	 a	 development	
partnership	 with	 a	 commercial	 company,	 developed	 a	 new	 alert	 system	 to	
provide	 real-time	 alerting	 of	 patients	 with	 AKI	 to	 the	 point	 of	 care,	 utilising	
mobile	 device	 technology,	 and	 allowing	 collaboration	 with	 specialist	 teams	 in	
real-time.	This	successful	system	has	now	been	implemented	in	a	number	of	NHS	
trusts	 in	 England	 to	 provide	AKI	 alerting	 as	well	 as	 other	 patient	 safety	 alerts	
and	 for	 clinical	 communication	 and	 collaboration	 in	 real-time.	 Since	 this	








With	 these	 improvements	 in	management	 of	AKI,	 the	 next	 stage	 in	 the	 quality	
improvement	process	 is	 to	move	 further	back	 in	 the	disease	process	 to	before	
acute	kidney	injury	develops	and	aim	at	preventing	AKI	by	determining	risk.	The	



















Death	 (NCEPOD)	 in	 the	 setting	 of	 AKI,	 highlighted	 systematic	 failings	 in	
identification	 and	 subsequent	 management.	 100	 One	 of	 the	 reports	 key	
recommendations	was	that	risk	assessment	for	AKI	should	be	carried	out	for	all	
emergency	admissions.		Following	on	from	this	report,	the	2010	NCEPOD	report	
‘An	 Age	 Old	 Problem;	 A	 review	 of	 the	 care	 received	 by	 elderly	 patients	
undergoing	 surgery’	 suggested	 that	 “Risk	 assessment	 [for	 surgery]	 must	 take	
into	 account	 all	 information	 strands,	 including	 risk	 factors	 for	 acute	 kidney	
injury.”176	 	 The	 report	 also	 suggested	 “a	 need	 for	 continuous	 post	 graduate	







can	assess	 their	risk	of	AKI	as	 they	enter	 the	emergency	department	 to	ensure	
that	 patients	 at	 high	 risk	 have	 their	 kidney	 function	 checked,	 to	 reveal	 their	





Following	 the	 determination	 of	 which	 risk	 factors	 are	 important	 in	 the	
development	of	AKI,	or	of	worsening	AKI,	as	there	are	a	large	number	of	factors	
involved,	 these	 can	 then	 be	 employed	 in	 risk	 models	 and	 risk	 scores	 to	





In	 the	 disease	 process	 of	 acute	 kidney	 injury,	 a	 patient	 experiences	 an	 event	
(Figure	32).	This	event	may	be	an	 illness	 for	example	a	chest	 infection,	urinary	
tract	 infection,	 or	myocardial	 infarction,	 which	 carry	 a	 risk	 of	 AKI.	 This	 event	




fluid	 overload,	 the	 need	 for	 renal	 replacement	 therapy,	 and	 the	 resultant	









At	 these	 points	 of	 clinical	 intervention,	we	 can	 then	 provide	 an	 assessment	 of	
risk	 factors	 in	 order	 to	 guide	 clinical	 intervention	 and	 provide	 management	
changes	in	high-risk	patients.		
 
The	 Kidney	 Disease	 Improving	 Global	 Outcomes	 (KDIGO)	 clinical	 practice	








In	 clinical	 medicine	 there	 are	 certain	 procedures	 or	 treatments	 that	 a	 patient	
may	experience	as	part	of	 their	 clinical	management	 that	 are	essential	 in	 their	
care,	 but	 carry	 an	 inherent	 risk	 of	 precipitating	 AKI.	 Some	 insults	may	 not	 be	













outweigh	 the	 benefit	 of	 the	 procedure	 or	 treatment.	 In	 other	 cases,	 while	 the	





Risk	assessing	 the	patient	 in	 the	context	of	 the	expected	exposure	 to	 the	 insult	
can	allow	appropriate	decisions	then	to	be	made	regarding	the	risk	benefit	of	the	
procedure	 or	 treatment,	 modifications	 in	 dosing	 and	 exposure,	 and	 clinical	
optimization	prior	to	the	procedure.	  
After	exposure	to	an	insult	





to	make	management	changes	 (Table	8)	 to	aid	prevention	of	AKI	 following	 the	

















end	 of	 the	 story.	 At	 this	 point	 we	 have	 the	 opportunity	 to	 intervene	 early	 at	
recognition	 to	 make	 management	 changes	 (often	 the	 same	 as	 prior	 to	 the	
development	of	AKI	(Table	8)),	 to	effectively	manage	the	AKI	and	both	prevent	
worsening	 of	 AKI	 and	 the	 development	 of	 sequelae	 including	 the	 significant	
morbidity	and	mortality	demonstrated	in	Chapter	2.		
	
By	 risk	 assessing	 patients	 at	 this	 point	 and	 defining	 patients	 at	 high	 risk	 of	
worsening	AKI	 or	 resultant	morbidity	 and	mortality,	we	 can	 focus	 clinical	 and	
specialist	care	to	these	patients.	
After	recovery	from	AKI	
As	described	 in	 Chapter	 1	 there	 is	 a	 complex	 interplay	 between	AKI	 and	CKD.	
Following	 an	 episode	 of	 acute	 kidney	 injury,	 a	 patient	 may	 have	 complete	
recovery	of	their	kidney	function,	this	recovery	may	not	be	complete,	resulting	in	






















factors	 that	 are	 common	 (‘generic’)	 to	 all	 settings.	 177-179	 One	 of	 the	 most	
important	 and	 indeed	 modifiable	 risk	 factors	 for	 AKI	 is	 in	 regard	 to	 volume	






In	 the	majority	of	disease	processes	older	age	 is	 found	 to	be	a	risk	 factor.	This	
may	 be	 related	 to	 the	 increasing	 co-morbidity	 burden	 (either	 overt	 or	 as	 yet	
unknown)	 with	 advancing	 age,	 or	 in	 relation	 to	 vascular	 changes	 with	 age	
described	in	Chapter	1.	In	most	cases,	irrespective	of	the	insult	precipitating	AKI,	
there	 is	 evidence	 that	 with	 increasing	 age	 there	 is	 an	 increasing	 risk	 of	 both	
community-acquired	and	hospital-acquired	AKI.	70,180-184	
	
As	with	other	disease	processes	 there	 is	a	reported	gender	discordance	 in	AKI,	
however	unlike	with	most	chronic	kidney	diseases,	in	AKI	a	female	gender	has	a	












AKI	 in	 CKD.	 At	 present	 however	 the	 epidemiological	 data	 available	 suggests	 a	
significantly	 higher	 risk	 of	 AKI	 in	 patients	 with	 CKD,	 in	 both	 community	 or	
hospital-acquired	AKI.	180-183,186-192		
	
Another	risk	 factor,	again	 in	relation	to	vascular	disease	 is	cardiac	disease,	and	
this	increased	risk	of	AKI	is	commonly	reported	with	cardiac	intervention	either	









Other	 co-morbidity	 including;	 chronic	 lung	 disease,	 183	 chronic	 liver	 disease,	
182,190	myeloma,	202,203	and	malignant	disease	in	general.	204	
	








the	 time	 of	 exposure	 to	 another	 risk	 factor	 for	 AKI	 (for	 example	 operative	
intervention,	contrast	administration,	presenting	disease	process	such	as	sepsis).	
An	 increased	 medication	 burden	 may	 increase	 susceptibility	 to	 AKI	 in	 these	
situations,	 but	 may	 also	 be	 simply	 a	 reflection	 of	 underlying	 co-morbidity.	 In	
Michael	Bedford	 11905027	 131	
relation	 to	 renin-angiotensin	 system	 blockade	 as	 a	 risk	 factor	 for	 AKI	 there	 is	





care?’).	 210	 This	 study	 demonstrated	 that	 the	 use	 of	 RAS	 antagonists	 increased	
the	 risk	 of	 AKI	 in	 general,	 independent	 of	 common	 confounding	 variables,	
however	 after	 correction	 for	 confounders	 the	 risk	 fell	 away	 and	 became	 non-





define	a	patient’s	risk,	 in	 the	 literature	the	majority	of	 the	reports	 focus	on	the	
need	for	renal	replacement	therapy	(RRT)	after	cardiac	surgery.	One	of	the	first	
of	these	was	by	Chertow	et	al	who	produced	a	risk	model	for	predicting	AKI	after	
cardiac	 surgery,	 based	 on	 a	 population	 of	 40,000	 patients	 from	 43	 Veterans	
Administration	Hospitals	 in	Virginia	who	underwent	cardiac	bypass	or	valvular	
surgery.	211	From	this	study	the	described	interactions	between	risk	factors	for	
AKI	 were	 used	 to	 develop	 a	 risk	 stratification	 algorithm.	 211	 Despite	 its	
widespread	 use	 this	 study	 did	 however	 have	 a	 number	 of	 key	 limitations,	

























































prediction	 of	 AKI	 in	 unselected	 emergency	 admissions	 to	 a	 district	 general	
hospital.	 Finlay	 et	 al	 published	 a	 recent	 study	 of	 AKI	 risk	 factors	 (Table	 10)	
associated	 with	 AKI	 in	 patients	 admitted	 to	 acute	 medical	 units	 (AMUs)	 in	 a	
study	 conducted	 over	 two	 separate	 24-hour	 periods	 at	 a	 total	 of	 10	 AMUs.	 212	
Forni	and	colleagues	have	developed	a	model	for	predicting	acute	kidney	injury	
in	 a	 subset	 of	 medical	 patients	 admitted	 to	 a	 UK	 hospital.	 213	 Their	 model	
included	some	physiological	markers.	
	
The	 literature	 here	 and	 suggested	 risk	 factors	 for	 the	 development	 of	 AKI	
provide	a	basis	and	guidance	 for	 the	development	of	 risk	models	 in	 this	 thesis	
(Chapter	 5).	 As	 reported,	 the	 above	 risk	 analyses	 so	 far	 described	 in	 the	
literature	 are	 mainly	 restricted	 to	 defined	 populations,	 importantly	 following	
cardiac	 surgery	 or	 following	 the	 administration	 of	 contrast	 for	 radiological	




As	 discussed	 previously,	 the	 ultimate	 form	 of	 treatment	 is	 prevention	 of	 a	
disease	process,	and	 in	 the	same	way	 that	we	can	use	computing	 to	effectively	
alert	 to	 the	 presence	 of	 acute	 kidney	 injury	 (AKI),	 can	 we	 use	 computing	 to	
determine	a	patient’s	risk	of	AKI,	and	then	alert	 the	clinician	 to	 this	risk	at	 the	













(for	 example	 home	 or	 residential	 care),	 consultant	 responsible	 for	 care,	 GP	
details,	primary	(often	the	reason	for	admission	or	primary	diagnosis	during	the	
admission)	 and	 secondary	 (often	 past	 medical	 history)	 medical	 problems	
(standardised	 in	 the	 ICD-10	definition	of	diseases),	 type	of	admission	(elective,	
emergency),	 and	 length	 of	 stay.	All	 blood	 test	 results	 and	microbiology	 testing	
and	results	are	clearly	stored	in	the	pathology	database.	Discharge	notifications,	
which	are	sent	to	primary	care	on	discharge	of	a	patient	from	hospital,	including	
coding	 of	 the	 reason	 for	 admission,	 past	medical	 history,	 and	 importantly	 the	
medications	 that	 the	patient	was	discharged	on,	 are	 all	 clearly	 recorded	 in	 the	
Trust	Data	Warehouse.	All	operations	(standardised	using	the	OPCS	definition	of	
procedures),	the	surgeon	carrying	out	the	procedure,	the	anaesthetist	delivering	
the	 anaesthetic,	 the	 timing	 of	 the	 procedure	 and	 anaesthetic	 are	 all	 stored	
electronically.	See	appendix	7	for	further	details	of	the	data	sources	used	in	the	
study	here	(Chapter	5).	In	some	Trusts	vital	signs	observations	(blood	pressure,	
pulse,	 temperature,	 oxygen	 saturations)	 of	 patients	 are	 now	 stored	
electronically.	
	
All	 of	 these	 data	 sources	 can	 be	 used	 in	 real-time	 to	 determine	 the	 risk	 of	 a	
patient	without	 the	 need	 to	 clinically	 assess	 the	 patient.	 For	 example,	 when	 a	
patient	 is	 admitted	 to	 A&E,	 without	 a	 doctor	 even	 reviewing	 the	 patient	 it	 is	
possible	 to	 extract	 electronically	 from	 previous	 hospital	 admission	 records	 as	
described	above,	the	patient’s	age	and	gender,	past	medical	history,	medications	
on	last	discharge,	all	blood	results	and	microbiology	testing	and	results	over	the	
last	year.	This	data	can	 then	be	used	 instantly	 to	determine	risk,	even	more	so	
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when	 combined	with	 the	 reason	 for	 admission	 in	 this	 instance.	 As	 the	 patient	
moves	 through	 the	 pathway	 of	 admission,	 further	 data	 including	 acute	 blood	
testing,	 radiology	 investigations,	 operative	 procedures	 and	 vital	 signs	





AKI,	 which	 could	 be	 used	 to	 determine	 a	 patient’s	 risk	 of	 developing	 AKI	 and	
hence	 predict	 which	 patients	 to	 focus	 management	 strategies	 to	 attempt	 to	
reduce	/	mitigate	tis	risk.	
	
Key	potential	 risk	 factors	 include;	age,	gender,	 level	of	care	prior	 to	admission,	
co-morbidity	 (importantly	 congestive	 cardiac	 failure,	 chronic	 obstructive	
pulmonary	 disease	 (COPD),	 diabetes,	 chronic	 kidney	 disease	 (CKD),	 vascular	
disease,	 liver	disease),	potentially	nephrotoxic	medication,	sepsis,	blood	results	
as	 markers	 of	 infection	 /	 sepsis	 including	 white	 blood	 cell	 (WBC),	 c-reactive	
protein	(CRP),	positive	microbiology	results	indicating	infection	/	sepsis,	surgical	




AKI,	 or	 if	 patients	 already	 have	AKI,	which	 of	 them	will	 experience	worsening	
AKI,	 in	 order	 for	management	 changes	 to	be	 instigated	 early	 to	 either	prevent	
AKI	or	prevent	worsening	AKI?		The	answer	is	in	risk	modelling.	
	
This	 literature	 provides	 a	 basis	 for	 variable	 selection	 for	 the	 risk	modelling	 in	
Chapter	 5.	 Table	 11	 documents	 the	 variables	 chosen	 for	 risk	 modelling,	 the	







Variable	Name	 Variable	Description	 Scientific	Justification	 References	




































































































































































































































































































































































































































































































































































































































































































Quantitative	methodology	 in	 the	 form	 of	 traditional	 risk	modelling	 techniques	









The	risk	analysis	study	here	was	 funded	by	a	grant	 from	the	National	 Institute	
for	 Health	 Research	 (NIHR)	 Health	 Services	 and	 Delivery	 Research	 (HS&DR)	
Researcher-Led	work-stream	(11/2004/28:	Development	of	risk	models	for	the	





For	 risk	 model	 development	 and	 validation	 in	 the	 first	 population	 the	 study	
population	 included	all	patients	presenting	 to	 the	 three	acute	hospitals	of	East	
Kent	 Hospitals	 University	 NHS	 Foundation	 Trust	 (EKHUFT);	 Kent	 and	
Canterbury	 Hospital	 in	 Canterbury,	 William	 Harvey	 Hospital	 in	 Ashford,	 and	
Queen	Elizabeth	the	Queen	Mother	Hospital	 in	Margate,	 in	the	calendar	year	of	
2011.	 Maternity	 admissions	 and	 elective	 admissions	 were	 excluded.	 While	
elective	 admissions	 to	 hospital	 should	 by	 their	 very	 nature	 (clinically	 more	
stable	patients)	have	a	significantly	lower	risk	of	developing	acute	kidney	injury	
(AKI)	 during	 admission,	 or	 even	 less	 so	 having	 AKI	 at	 the	 point	 of	 admission,	
there	 is	 still	 a	 risk	 present.	 For	 example,	 a	 patient	 undergoing	 elective	 major	
abdominal	or	cardiac	surgery,	which	carry	a	significant	risk	of	AKI.	However,	the	
analysis	here	was	 focused	on	emergency	admissions	to	hospital.	 It	may	be	that	








The	 project	 received	 full	 ethical	 approval	 from	 the	 Kent	 Research	 Ethics	
Committee	 (reference	10/H1101/89)	 on	 20/12/2010.	 This	 approval	was	 for	
patients	in	East	Kent.	Subsequently	a	substantial	amendment	was	submitted	on	
16/06/2011	 to	 the	 research	 ethics	 committee	 to	 include	 validation	 of	 the	 risk	
model	in	the	Medway	(Medway	NHS	Foundation	Trust)	population,	and	this	was	





patient	 data	 of	 all	 admissions	 to	 hospital	 over	 a	 12-month	 period.	 For	 a	
retrospective	 analysis	 of	 this	 type,	 it	 would	 not	 have	 been	 appropriate	 or	
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practical	 to	 seek	 consent	 from	 all	 patients	 previously	 admitted	 to	 hospital.	
The	 study	 had	 the	 support	 and	 endorsement	 of	 the	 Medical	 Director	 and	
Chief	 Executive	 of	 the	 EKHUFT	 and	 the	 Primary	 Care	 Trust	 (PCT)	 and	 the	
Trust	Patient	Safety	Board.	 	
	
¥ Confidentiality:	 Patient	 information	 was	 extracted	 and	 stored	
anonymously	 under	 a	 unique	 identification	 number	 on	 a	 secure	 server.	
Confirmation	 was	 obtained	 from	 the	 Caldicott	 Guardian	 that	 the	 study	
satisfied	 the	 Information	 Governance	 issues	 of	 confidentiality	 and	 data	
security.	
	
















a	 relational	 database	 structure	 and	 managed	 with	 the	 ‘Structured	 Query	




1. An	 identifier	 in	order	 to	define	data	unique	 to	a	given	patient.	 It	was	determined	
that	 the	 best	 identifier	 to	 utilise	 would	 be	 the	 NHS	 number.	 The	 NHS	 number	 is	
unique	 to	 a	 patient	 and	 allowed	 linkage	 of	 datasets.	One	 limitation	 of	 the	 use	 of	
NHS	number	 is	when	a	patient	 is	admitted	to	the	hospital	and	the	NHS	number	 is	
not	known	to	the	Patient	Administration	System	(PAS).	This	may	be	for	a	number	of	
reasons;	1)	 the	patient	has	not	been	 seen	 /	had	an	episode	of	 care	before	at	 the	
hospital,	in	which	case	a	request	is	put	through	to	Open	Exeter	and	the	data	held	on	
the	National	Health	Application	and	Infrastructure	Services	(NHAIS,	as	part	of	NHS	
Digital)	 to	 look	 up	 the	 patient	 and	 their	 demographic	 data	 and	 linking	 this	 to	
provide	 their	 NHS	 number.	 This	 would	 usually	 be	 achieved	 during	 the	 patient’s	
inpatient	 stay	or	 shortly	afterward	during	clinical	 coding	and	so	 in	a	 retrospective	
database	study	such	as	this,	the	NHS	number	in	these	patients	should	be	available	







robustness	 of	 this	 approach,	 the	 occurrence	 of	 this	 identifier	 in	 each	 database	 in	
order	 to	 allow	 linking	 of	 the	 datasets	 into	 one	 unique	 record	 for	 a	 patient	 in	 the	
study	database.	In	each	database	the	NHS	number	was	the	most	robust	and	unique	
identifier	to	utilise.	For	this	analysis	data	was	extracted	for	the	calendar	year	2011.	
Following	 analysis	 of	 the	 pathology	 database	 which	 included	 both	 blood	 testing	




date,	and	 the	earliest	admission	 in	 the	dataset	would	be	01/01/2011,	 the	earliest	
data	required	would	be	01/01/2010	and	therefore	after	the	change	in	requesting	in	
2009.	The	NHS	number	could	therefore	again	in	this	instance	be	used	as	the	unique	




2. Coding.	Within	each	database	a	number	of	 fields	were	populated	with	 codes	 that	








diagnoses	 predictor	 variables	 in	 the	 regression	 analyses.	 Statistically	 there	 would	
have	 been	 too	 few	 values	 for	 each	 category	 of	 the	 variable	 to	 develop	 a	 model	
from.	 In	 order	 to	 narrow	 the	 categorisations	 of	 co-morbidity,	 validated	 coding	
algorithms	from	Quan	et	al,101	with	further	validated	algorithms	for	diabetes	102	and	
hypertension,	 were	 used	 to	 create	 lookup	 tables	 which	 allowed	 translation	 of	 a	
specific	 ICD-10	 code	 into	 a	 higher	 level	 co-morbidity	 descriptive	 and	 also	 a	 score.	
The	 score	 could	 then	 be	 summated	 to	 determine	 the	 modified	 Charlson	 co-
morbidity	 score	 for	 each	 patient.	Within	 the	 hospital	 episode	 data	 tables	 lookup	
tables	were	 also	 required	 to	 translate	 codes,	 for	 example	 admission	 location	 and	
discharge	location	(for	example	home,	residential	care,	nursing	care).	
	
3. The	 required	 variables	 from	 each	 database	 and	 the	 source	 tables	 where	 these	
variables	were	located.	
	
4. Data	 linkage	 between	 tables.	 In	 order	 to	 collate	 variables	 across	 multiple	 tables	
within	 the	 databases,	 time	was	 taken	 to	 understand	 data	 linkage	 between	 tables	





Wheeler	 (IT	 Application	 Manager,	 EKHUFT)	 in	 collaboration	 with	 myself	 to	
extract	the	required	variables	in	the	context	of	each	patient.	Data	was	extracted	





variables	 such	 as	 blood	 results	 (for	 example	 c-reactive	 protein	 (CRP),	
haemoglobin	(Hb))	the	variables	were	extracted	by	coding	/	programming	which	
included	 time	 constraints	 to	 determine	 the	 values	 to	 extract	 and	 place	 in	 the	
research	database	 for	 that	episode	of	 care.	For	example	 the	most	 recent	 result	
being	 the	 result	within	 the	 last	 30	 days	 prior	 to	 hospital	 admission,	 or	 the	 12	




provided	 by	 myself	 to	 Mr	 Toby	 Wheeler	 for	 coding	 /	 programming	 for	 data	
extraction.	As	described	in	the	methods,	the	analysis	in	Chapter	2	and	the	initial	
analysis	 in	Chapter	5	used	 an	 algorithm	comparing	 the	 index	 creatinine	under	
assessment	 to	 the	 baseline	 creatinine	 (which	 was	 determined	 as	 the	 lowest	




into	memory	 to	 allow	definition	of	AKI	with	 the	 above	 algorithms	which	were	
coded	into	computer	programming	by	Mr	Toby	Wheeler.	The	values	for	AKI	(‘no	
AKI’,	 ‘AKI	stage	1’,	 ‘AKI	stage	2’,	 ‘AKI	stage	3’,	 ‘missing	data’)	were	 then	placed	




example	 the	 NHS	 number	 and	 date	 of	 birth,	 and	 a	 unique	 study	 number	 was	
inserted,	in	order	to	pseudoanonymise	the	dataset	in	compliance	with	the	ethical	
approvals,	 and	 also	 allow	 linkage	 to	 the	 original	 source	 datasets	 by	 the	 data	
custodian	 if	 required	 to	 ensure	 data	 integrity,	 again	 in	 compliance	 with	 the	
ethical	 approvals.	 The	 dataset	 was	 then	 frozen	 in	 this	 state	 for	 statistical	
analysis.	
	






data	 the	 Hospital	 Episode	 Statistics	 (HES),	 and	 the	 Secondary	 Uses	 Services	
(SUS)	 data	 that	 are	 collected	 nationally	 are	 derived.	 Importantly	 this	 dataset	
includes	patient	demographics	(date	of	birth,	age,	gender,	postcode),	admission	
and	 discharge	 dates	 and	 times	 (from	 this	 calculated	 length	 of	 stay),	 and	 co-
morbidity	defined	in	terms	of	primary	diagnoses	(reason	for	hospital	admission)	
and	secondary	diagnoses	(representing	either	past	medical	problems	or	further	





A	 full	 list	 of	 variables	 available	 from	 this	 dataset	 are	 described	 in	 Appendix	 7	
(Table	44).	
	
Pathology:	 The	 pathology	 database	 holds	 records	 of	 all	 blood	 tests	 in	 East	
Kent	requested	in	primary	care	and	in	secondary	care	both	in	the	outpatient	and	
inpatient	 setting.	All	NHS	blood	 testing	 results	 in	 the	East	Kent	population	are	
recorded	on	 this	 database.	 This	 dataset	 therefore	 includes	 blood	 tests	 prior	 to	
and	 during	 a	 patient’s	 admission,	 and	 importantly	 includes	 creatinine	 testing	
from	which	to	define	AKI.		
	







method	 of	 LaFrance	 et	 al.95	 Of	 note	 the	 analysis	 here	 used	 serum	 creatinine	
criteria	to	define	acute	kidney	injury.	As	described	in	Chapter	1	the	urine	output	
Michael	Bedford	 11905027	 151	




Foundation	 Trust	 (EKHUFT)	 all	 discharges	 from	 hospital	 are	 recorded	 on	 an	
electronic	 discharge	 notification	 (EDN)	 which	 includes	 a	 summary	 of	 the	
admission	and	the	medications	the	patient	is	taking	on	discharge.	This	summary	
is	 sent	 to	 the	General	 Practitioner	 (GP)	 in	 primary	 care	 at	 discharge	 to	 enable	
continuity	 of	 care.	 Therefore,	 at	 the	 point	 of	 hospital	 admission	 by	 reviewing	
previous	 EDNs,	 assumptions	 can	 be	 made	 as	 to	 the	 medications	 a	 patient	 is	
taking	prior	to	admission.	
	
The	 variables	 available	 from	 this	 database	 are	described	 in	Appendix	7	 (Table	
46).	
 
Operation	 Data:	 Every	 operation	 performed	 in	 theatres	 at	 EKHUFT	 is	
recorded	in	an	electronic	operation	database.	The	system	records	date	and	time	
of	 procedure,	 length	 of	 procedure,	 length	 of	 anaesthetic,	 surgeon	 and	
anaesthetist,	 name	 of	 procedure,	 and	 the	 ICD-10	 and	 READ	 code	 for	 the	
procedure,	 and	 the	 subjective	 ASA	 score,	 for	 the	 patient	 determined	 by	 the	
anaesthetist	(Appendix	7).		
	
Two	 clinicians;	Dr	Michael	 Bedford	 and	Professor	 Chris	 Farmer	 independently	
coded	each	procedure	in	the	database	with	a	severity	score	ranging	from	1	(least	
severe)	 to	 5	 (most	 severe),	 informed	 by	 the	 National	 Institute	 for	 Health	 and	
Care	 Excellence	 (NICE)	 guidance;	 Pre-operative	 tests:	 The	 use	 of	 routine	 pre-
operative	tests	for	elective	surgery.	215	Where	differing	opinions	of	severity	for	a	








The	main	 aim	 of	 the	 study	 presented	 in	 this	 chapter	 was	 the	 development	 of	
predictive	models	 for	 identifying	 and	 stratifying	 the	 risk	of	AKI	 at	 the	point	of	
and	 during	 hospital	 admission.	 These	models	 included	 a	 large	 set	 of	 potential	








from	the	qualitative	analysis	presented	 in	Chapter	3,	 it	 is	key	that	such	alert	of	
risk	 is	 delivered	 to	 the	 right	 person	 at	 the	 right	 time	 in	 order	 to	 inform	 and	
influence	 clinical	 decision	 making	 and	 add	 value	 to	 the	 patient’s	 care.	 It	 was	
determined	 therefore	 that	 there	 were	 three	 time	 points	 during	 a	 patient’s	
hospital	 admission	 where	 significant	 clinical	 decision	 making	 takes	 place	 at	




The	 model	 applied	 in	 this	 case	 (referred	 to	 as	 Model	 1)	 	 uses	 all	
electronic	 data	 up	 until	 the	 point	 of	 admission	 (and	 the	 reason	 for	
admission	to	hospital),	to	determine	the	risk	of	a	patient	already	having	










as	Model	3)	 in	 the	 first	72	hours	of	admission.	At	 this	point	 (24	hours)	
patients	 are	 likely	 to	 be	 admitted	 to	 a	 ward	 or	 clinical	 decision	 unit	 /	
medical	 admissions	 unit	 and	 are	 likely	 to	 then	 be	 reviewed	 by	 the	
admitting	clinical	team	on	the	post	take	ward	round,	or	by	the	ward	team	
on	 their	 ward	 round	 of	 new	 patients,	 providing	 another	 clear	 point	 of	
intervention.	 This	 will	 then	 guide	 clinical	 management	 at	 this	 point	 to	
define	patients	at	risk	of	AKI	that	require:	
 
1. management	 changes	 to	 include	 the	 stopping	 of	 nephrotoxic	
medication,	 fluid	 assessment	 and	 ensuring	 fluid	 repletion,	










3. After	 72	 hours	 of	 admission:	 The	 purpose	 of	 this	 model	 was	 to	








1. The	 risk	 models	 at	 this	 point	 were	 not	 sufficiently	 accurate	 to	
determine	risk	and	guide	clinical	management,	 in	part	 related	 to	
and	a	consequence	of	the	fact	that:	
	
2. Most	patients	remain	 in	hospital	 for	 less	 than	3	days	(72	hours).	
For	 those	who	do	 stay	 in	hospital	 over	72	hours	 this	may	 range	
from	3	days	up	to	as	high	as	90	–	365	days.	In	this	case	it	is	very	
difficult	 to	 determine	 risk	 of	 developing	AKI	 in	 a	widely	 varying	
time	period,	most	importantly	because	these	patients	will	develop	
new	conditions	and	changes	in	blood	results	(variables	in	the	risk	








AKI,	 but	 will	 also	 alert	 to	 patients	 with	 established	 AKI	 and	 provide	 clinical	
guidance	 to	 improve	 the	 management	 of	 these	 patients	 and	 reduce	 both	 the	





Alerting	 at	 the	 point	 of	 admission	 (Figure	 33):	 Initial	 risk	 model	
development	for	the	point	of	admission	included	pre-admission	AKI	as	a	variable	
in	 the	model.	As	would	be	expected	clinically,	 if	 a	patient	has	AKI	 just	prior	 to	
admission	then	they	have	a	high	risk	that	they	will	still	have	AKI	at	the	point	of	
admission.	 Initial	models	developed	confirmed	that	 the	variable	 ‘pre-admission	





patients,	 renal	 function	 testing	 should	 always	 occur	 on	 admission,	 and	 the	
management	 changes	 above	 should	 be	 implemented.	 Patients	 with	 pre-
admission	 AKI	were	 therefore	 removed	 from	 the	 admission	models	 to	 predict	
AKI	and	hence	 the	population	of	assessment	 for	 the	point	of	admission	models	
included	only	patients	either	without	pre-admission	AKI	or	patients	who	did	not	
have	pre-admission	AKI	 status	determined	as	 they	did	not	have	 renal	 function	
testing	in	the	pre-admission	period.		
 
Alerting	after	24	hours	 of	 admission	 (Figure	33):	 For	patients	who	
have	 AKI	 apparent	 on	 admission	 renal	 function	 testing,	 the	 clinical	 alerting	
system	will	 alert	 to	 the	presence	of	AKI,	 and	 suggest	 appropriate	management	
interventions	as	described	above,	including	daily	renal	function	testing.	Again	as	
part	 of	 the	 clinical	 practice	 algorithm,	 patients	 with	 AKI	 on	 admission	 were	
therefore	removed	from	the	risk	models	at	24	hours	to	predict	AKI	at	72	hours,	







































































of	 Stata	 was	 performed	 by	 Mr	 Paul	 Bassett	 (Stats	 Consultancy	 Limited),	 with	









The	 first	 stage	 of	 risk	modelling	was	 to	 determine	 relationships	 between	 risk	
factors	 and	 the	 outcome	 variable	 acute	 kidney	 injury	 (AKI).	 This	 was	 of	 key	





variables	 were	 converted	 into	 categorical	 variables	 with	 the	 categories:	 ‘not	
tested’,	 ‘normal’,	 ‘abnormal’.	While	each	blood	test	has	a	 ‘normal	range’	defined	






of	 admission	 to	 hospital.	 The	 risk	 model	 development	 included	 emergency	




Non-emergency	 admissions	 (i.e.	 elective	 admissions),	 admissions	 associated	
with	 pregnancy	 and	 childbirth,	 patient	 admissions	 without	 a	 creatinine	 blood	
test	on	admission	 (i.e.	 therefore	unable	 to	define	 the	outcome	variable,	AKI	on	
admission),	and	patient	admissions	with	pre-admission	AKI	(as	described	above)	





The	 included	patient	admissions	 in	 the	analysis	were	randomly	(using	pseudo-
random	numbers)	allocated	to	either	a	‘development’	dataset	which	was	used	to	
construct	 the	 model,	 and	 a	 ‘validation’	 dataset	 which	 was	 used	 to	 test	 and	









was	 therefore	 performed	 using	 ordinal	 logistic	 regression.	 Ordinal	 logistic	
regression	is	as	the	name	suggests	a	form	of	logistic	regression	that	deals	with	an	
outcome	 /	 dependent	 variable	 which	 is	 ordinal	 in	 nature.	 Hence	 the	 outcome	
variable	 has	 ordered	 categories,	 in	 this	 case	 the	 stages	 of	AKI.	 As	 discussed	 in	
Chapter	2,	 logistic	regression	utilises	a	 logistic	function	(the	cumulative	logistic	
distribution)	 to	 estimate	probabilities	 and	determine	 the	 relationship	between	









standard	 errors.	 The	 purpose	 of	 robust	 standard	 errors	 and	 robust	 regression	
methods	is	to	allow	estimate	adjustments	that	account	for	biases	in	the	dataset.	
In	 this	 case	 the	 fact	 that	 a	 single	 patient	may	have	 a	 number	 of	 admissions	 to	
hospital	during	the	one	year	study	period	and	hence	contribute	to	the	dataset	a	












be	 either	 at	 random	 or	 not	 at	 random.	 In	 medicine	 this	 can	 often	 be	 further	
complicated	by	being	a	known,	or	unknown,	combination	of	the	two.	In	this	data	
set	 /	 analysis	 some	variables	 such	as	 the	key	demographics	of	 age	and	gender	
were	complete	with	no	missing	data.	The	variable	 ‘primary	diagnosis’	 included	
missing	 data	 and	 the	 decision	was	made	 to	 exclude	 patients	 from	 the	 analysis	
who	 did	 not	 have	 a	 coded	 ‘primary	 diagnosis’.	 For	 the	 blood	 test	 variables	
missingness	 is	 less	 clear.	 In	 some	cases,	 it	may	be	 that	a	patient	has	not	had	a	
specific	 blood	 test	 performed,	 which	 would	 have	 been	 abnormal	 had	 it	 been	
tested.	This	may	be	due	to	error	on	the	part	of	the	clinician,	or	sometimes	failure	
of	 the	 test	 in	 the	 laboratory.	This	 could	be	assumed	as	missing	at	 random.	For	
most	 blood	 tests	 however	 the	 missingness	 is	 a	 combination	 of	 missing	 at	
random,	 and	 more	 importantly	 the	 fact	 that	 a	 result	 is	 missing	 may	 be	
informative.	For	example,	an	amylase	blood	test	(a	pancreatic	enzyme	often	used	
to	 define	 pancreatitis)	 is	 usually	 only	 tested	 in	 patients	 presenting	 with	
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abdominal	pain,	which	could	be	a	patient	group	with	an	increased	risk	of	acute	
kidney	 injury	 (AKI),	 even	more	 so	 if	 the	 amylase	 value	 is	 raised	 (‘abnormal’).	
This	 would	 therefore	 suggest	 differing	 risks	 for	 the	 categories:	 ‘not	 tested’,	




variables	 in	 the	 regression	 analysis	 /	 model	 are	 highly	 correlated,	 suggesting	
that	one	can	be	predicted	from	the	others.	For	example	the	testing	(or	presence	
of	 a	 test	 for)	 white	 blood	 cells	 (WBC)	 and	 haemoglobin	 (Hb)	 are	 likely	 to	 be	
correlated	 as	 these	 tests	 are	 usually	 if	 not	 always	 ordered	 together	 in	 clinical	
practice	as	part	of	a	full	blood	count	(FBC).	This	collinearity	does	not	affect	the	
overall	 predictive	 ability	 of	 the	 model,	 but	 does	 affect	 results	 for	 individual	
predictors	and	so	cannot	accurately	determine	the	effect	of	a	given	predictor.	
	









backwards	 selection	 procedure	 was	 employed.	 The	 process	 of	 backwards	
selection	involves	starting	with	all	potential	predictor	variables	in	the	model	and	
then	 systematically	 removing	 each	 predictor	 variable	 in	 turn	 and	 assessing	
whether	 the	predictive	ability	of	 the	model	 is	 improved	by	 the	absence	of	 that	
variable	in	the	model.	The	predictor	variable	that	improves	the	model	the	most	
when	 deleted	 is	 then	 excluded	 from	 the	 model	 permanently.	 This	 process	 is	















is	 an	 estimation	 of	 the	 increase	 in	 log	 odds	 of	 the	 outcome	 variable,	 per	 unit	
increase	 in	 the	 exposure	 /	 predictor	 variable.	 Hence	 the	 exponential	 of	 the	
regression	 coefficient	 describes	 the	 odds	 ratio	 (OR)	 related	 to	 a	 one-unit	
increase	 in	 the	 predictor	 variable.	 An	 odds	 ratio	 equal	 to	 1	 suggests	 that	
exposure	 to	 a	 given	 predictor	 variable	 (for	 example	 a	 given	 co-morbidity	 or	
operation)	 does	 not	 affect	 the	 odds	 of	 the	 outcome	 (in	 this	 case	 acute	 kidney	
injury	(AKI)).	An	odds	ratio	of	greater	 than	1	suggests	 that	a	given	exposure	 is	
associated	with	a	greater	odds	of	a	given	outcome.	An	odds	ratio	of	 less	than	1	






level	 (of	 whether	 a	 result	 (or	 difference	 between	 outcomes)	 is	 defined	 as	









in	 the	 first	 72	 hours	 of	 admission	 to	 hospital.	 The	 data	 used	 for	 the	 analysis	
includes	all	available	variables	pre-admission	and	up	to	the	end	of	24	hours	into	
the	admission,	with	the	outcome	variable	being	AKI	at	72	hours.	AKI	at	72	hours	
was	 defined	 from	 the	 peak	 creatinine	 within	 the	 time	 period	 12	 hours	 post	
admission	to	72	hours	post	admission	time	(see	Appendix	7).	
 
Non-emergency	 admissions	 (i.e.	 elective	 admissions),	 admissions	 associated	
with	 pregnancy	 and	 childbirth,	 patient	 admissions	 without	 a	 creatinine	 blood	
test	 within	 12-72	 hours	 post	 admission	 (i.e.	 therefore	 unable	 to	 define	 the	
outcome	variable	of	AKI	at	72	hours),	patient	admissions	with	pre-admission	AKI	
as	described	above,	and	in	this	model	patient	admissions	with	AKI	at	admission,	














stage	 2	 on	 admission	 to	 hospital.	 Although	 patients	 with	 AKI	 stage	 3	 on	
admission	could	experience	a	worsening	AKI	with	a	 rising	creatinine	 following	
admission,	 in	 terms	 of	 the	 ordinal	 definition	 of	 AKI	 they	 cannot	 experience	 a
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worsening	 AKI	 from	 a	 start	 point	 of	 AKI	 stage	 3	 and	 so	 these	 patients	 were	
excluded	from	this	analysis.	
	
For	 this	 analysis	 non-emergency	 admissions	 (i.e.	 elective	 admissions),	
admissions	 associated	 with	 pregnancy	 and	 childbirth,	 patient	 admissions	
without	 a	 creatinine	 blood	 test	 within	 12-72	 hours	 (i.e.	 therefore	 unable	 to	
define	the	outcome	variable	of	AKI	at	72	hours),	patient	admissions	with	‘no-AKI’	
on	 admission,	 and	 patient	 admissions	 with	 AKI	 stage	 3	 on	 admission	 were	
excluded	from	the	analysis	in	risk	Model	3.	
	









In	 this	model	 in	 contrast	with	Models	1	and	2,	due	 to	 the	binary	nature	of	 the	
outcome	variable,	 analysis	was	performed	using	multi-level	 logistic	 regression.	
Multi-level	statistical	methods	(two-level	models	with	admissions	nested	within	
patients)	were	employed	to	address	the	issue	that	a	patient	may	have	a	number	
of	 admissions	 to	 hospital	 during	 the	 one-year	 study	 period	 as	 described	
previously.		
	
















terms	of	a	comparison	of	 the	risk	of	AKI	 from	the	 fitted	model	with	that	 in	 the	
observed	data.	
	
















Three	methods	were	 employed	 for	 validation.	 Firstly,	 the	 categories:	 ‘any	 AKI	
and	 ‘AKI	 stage	 2	 or	 3’	 were	 split	 into	 four	 risk	 groups	 based	 on	 predicted	

















The	 receiver	 operating	 characteristic	 (ROC)	 curve	 is	 a	 graphical	 illustration	 /	
representation	 of	 the	 performance	 of	 the	 model	 to	 predict	 /	 discriminate	
between	 high	 and	 low	 risk	 cases	 (in	 this	 case	 the	 risk	 of	 acute	 kidney	 injury	
(AKI)),	and	the	change	in	this	performance	with	variation	of	the	discrimination	
threshold.	 In	 other	 words	 this	 process	 assesses	 the	 ability	 of	 the	 model	 to	
classify	/	predict	a	patient	as	high	or	low	risk	of	developing	AKI.	On	the	graph,	at	
each	 discrimination	 threshold	 the	 sensitivity	 (true	 positive	 rate)	 is	 plotted	
against	 1-specificity	 (false	 positive	 rate).	 In	 order	 to	 summarise	 the	 visual	
representation	 of	 the	 ROC	 curve,	 the	 area	 under	 the	 receiver	 operating	
characteristic	 (AUROC)	 curve	 is	 used.	 This	 is	 equivalent	 to	 the	 c-statistic.	 The	
AUROC	 is	 the	 probability	 that	 the	model	 being	 assessed	will	 rank	 a	 randomly	
chosen	 positive	 instance	 (to	 develop	 AKI)	 higher	 than	 a	 randomly	 chosen	
negative	one	(not	to	develop	AKI).	
	
Thirdly,	 the	 Hosmer-Lemeshow	 test	 was	 employed	 to	 assess	 the	 difference	
between	the	outcome	predicted	by	the	model	and	the	actual	observed	outcome,	
and	hence	 an	 assessment	 of	 goodness	 of	 fit	 of	 the	 regression	 /	 risk	prediction	




















Medway	 NHS	 Foundation	 Trust	 over	 the	 same	 time	 period	 as	 the	 East	 Kent	
population,	 the	 calendar	 year	 of	 2011.	 Medway	 has	 a	 significantly	 younger	
population	 with	 greater	 ethnic	 minorities	 in	 comparison	 to	 the	 East	 Kent	
population.	The	same	exclusions	applied	to	the	Medway	population	as	to	the	East	
Kent	population	 for	 the	model	development,	with	one	variance	 in	 the	data	 set.	







The	 first	 stage	 of	 risk	modelling	was	 to	 determine	 relationships	 between	 risk	
factors	 and	 acute	 kidney	 injury	 (AKI).	 This	 was	 carried	 out	 following	 the	
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definition	 and	 extraction	 of	 appropriate	 variables	 for	 the	 model.	 Of	 key	
importance	was	assessing	the	relationship	between	pathology	blood	test	results	
and	 AKI.	 A	 univariable	 analysis	 was	 performed	 to	 create	 a	 plot	 (see	 results	
below)	of	the	blood	test	value	on	the	x-axis	against	risk	of	AKI	on	the	y-axis.	Once	
a	normal	range	had	been	established	for	each	variable,	these	variables	could	be	
converted	 from	 continuous	 to	 categorical	 with	 the	 categories	 ‘not	 tested’,	
‘normal’	and	 ‘abnormal’.	Rather	than	simply	using	the	 laboratory	normal	range	
the	point	at	which	each	variable	became	associated	with	AKI	was	used	(based	on	










determine	 liver	 function.	 In	 the	 event	 of	 acute	 hepatocellular	 injury,	 the	 ALT	
level	rises.	Causes	of	hepatocellular	injury	such	as	ischaemia	in	a	hypovolaemic,	

















AMY	 (Amylase)	 is	 an	 enzyme	 produced	 in	 the	 pancreas	 that	 aids	 with	 the	
digestion	of	carbohydrates.	A	raised	level	of	amylase	can	signify	the	presence	of	
pancreatitis,	which	clinically	would	be	expected	to	carry	a	risk	of	AKI.	However,	














































































BNP	 (Brain	 Natriuretic	 Peptide)	 is	 an	 amino	 acid	 produced	 by	 the	 cardiac	
myocytes,	when	they	are	under	strain,	and	in	this	way	the	BNP	is	associated	with	
heart	 failure.	Heart	 failure,	may	result	 in	 reduced	perfusion	of	 the	kidneys	and	
thus	carry	a	risk	of	AKI.	The	relationship	between	BNP	and	AKI	 in	 this	dataset	












albumin	 level	 in	 the	 blood.	 Raised	 calcium	 can	 lead	 to	 dehydration	which	 can	
result	 in	 AKI.	 Low	 calcium	 can	 also	 signify	 acute	 disease,	 which	may	 have	 an	
increased	risk	of	AKI.	The	relationship	between	Ca	and	AKI	 in	this	dataset	(see	








































































































































an	 increased	 risk	 of	 AKI	 and	 that	 risk	 increases	 the	 further	 away	 the	 value	 is	
from	the	normal	range.	The	normal	range	of	haemoglobin	differs	between	men	












HbA1c	 (Glycated	Haemoglobin)	 gives	 an	 average	 of	 blood	 sugar	 readings	 over	
the	 last	 120	 days.	 A	 value	 greater	 than	 6.5	 indicates	 a	 patient	 with	 diabetes.	
Patients	with	 diabetes	 have	 an	 increased	 risk	 of	 AKI.	 A	 value	 greater	 than	 7.5	
indicates	that	the	diabetes	is	not	well	controlled,	and	it	would	be	expected	that	




















































K	(Potassium)	 is	an	electrolyte	which	 is	essential	 for	 the	normal	 functioning	of	
cells,	 importantly	 cardiac	 cells.	 Maintaining	 the	 gradient	 across	 the	 cellular	
membrane	is	essential,	and	changes	in	this	can	lead	to	cardiac	arrhythmias.	The	
K	level	itself	in	blood	would	not	be	thought	to	have	a	causal	relationship	with	the	
development	of	AKI,	however	a	 low	or	high	serum	 level	may	be	a	 reflection	of	
acute	 illness	 and	 changes	 in	 electrolyte	 and	 fluid	 balance.	 The	 relationship	
between	K	and	AKI	in	this	dataset	(see	below	graph),	suggests	that	both	a	low	K	














































cells.	 The	 Mg	 level	 itself	 in	 blood	 would	 not	 be	 thought	 to	 have	 a	 causal	
relationship	with	 the	development	of	AKI,	 but	 again	 a	 low	or	high	 serum	 level	
may	be	a	reflection	of	acute	illness	and	changes	in	electrolyte	and	fluid	balance.	
The	relationship	between	Mg	and	AKI	in	this	dataset	(see	below	graph),	suggests	
















































































Na	 (Sodium)	 is	 an	 electrolyte	which	 is	 essential	 for	 the	 normal	 functioning	 of	
cells.	 The	 Na	 level	 itself	 in	 blood	 would	 not	 be	 thought	 to	 have	 a	 causal	
relationship	with	 the	development	of	AKI,	 but	 again	 a	 low	or	high	 serum	 level	
may	be	a	reflection	of	acute	illness	and	changes	in	electrolyte	and	fluid	balance.	A	
low	Na	may	 also	 signify	 diuretic	medication	 use.	 The	 relationship	 between	Na	
and	AKI	in	this	dataset	(see	below	graph),	suggests	that	both	a	low	Na	and	a	high	














illness,	 and	 a	 high	platelet	 count	may	 also	 signify	 acute	 illness	 and	 specifically	
inflammation	 /	 infection.	 In	 both	 of	 these	 instances	 an	 increased	 risk	 of	 AKI	

















































(>11)	 WBC	 can	 signify	 infection	 and	 an	 infection	 carries	 a	 risk	 of	 AKI.	 The	














































































CK	 (Creatine	 Kinase)	 is	 a	 breakdown	 product	 of	 muscle.	When	 excess	muscle	
breakdown	occurs,	high	levels	of	CK	can	cause	damage	to	the	kidneys	and	result	


























































The	 development	 dataset	 included	 a	 total	 of	 27,532	 admissions	 from	 20,330	
patients.	 The	 outcome	 variable	 of	 interest	 in	 this	 model	 was	 the	 presence	 of	
acute	 kidney	 injury	 (AKI)	 on	 admission	 to	 hospital.	 In	 order	 to	 assess	 which	
variables	 in	 the	 dataset	 were	 associated	with	 the	 outcome	 variable,	 initially	 a	
series	 of	 univariable	 ordinal	 logistic	 regression	 analyses	were	 performed.	 The	
results	of	this	univariable	analysis	are	reported	in	Table	12.	In	this	analysis	the	
odds	ratios	(calculated	as	the	exponential	of	the	parameter	estimates	(beta))	are	
reported	 to	 demonstrate	 the	 sizes	 of	 the	 effects,	 with	 p-values	 to	 define	 the	
significance	of	each	variable	 in	 terms	of	 the	outcome.	This	univariable	analysis	
includes	both	 categorical	 variables	 in	which	 the	odds	 ratio	defines	 the	odds	of	
being	in	the	next	highest	outcome	category	(for	example	‘AKI	stage	1’	compared	
to	‘no	AKI’),	for	each	category	relative	to	a	baseline	category	(see	Table	12)	and	
continuous	variables	 in	which	 the	odds	ratio	defines	 the	relative	change	 in	 the	





Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 0.85	(0.51,	1.41)	 <0.001	
	 Quadratic	term	 1.08	(0.99,	1.18)	 	
	 Cubic	term	 0.996	(0.991,	1.000)	 	
	 	 	 	
Sex	 Male	 					1	 <0.001	
	 Female	 0.78	(0.73,	0.84)	 	




	 Yes	 1.13	(1.05,	1.21)	 	
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	 1	-	2	 1.64	(1.52,	1.77)	 	
	 3	-	5	 2.24	(2.03.	2.46)	 	
	 6+	 2.80	(2.43,	3.22)	 	




last	12	months	 1	-	2	 1.10	(1.01,	1.20)	 	
	 3	-	5	 1.29	(1.17.	1.41)	 	
	 6+	 1.67	(1.52,	1.84)	 	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 1.47	(1.13,	1.90)	 	
	 Blood	diseases	 0.62	(0.43.	0.87)	 	
	 Circulatory	system	 0.71	(0.59,	0.86)	 	
	 Digestive	system	 0.66	(0.55,	0.80)	 	
	 Diseases	 of	 the	
head/neck	
0.19	(0.09,	0.40)	 	
	 Genitourinary	system	 1.57	(1.30,	1.91)	 	
	 Musculoskeletal	 0.33	(0.26,	0.41)	 	
	 Nervous	system	 0.44	(0.33,	0.60)	 	
	 Respiratory	system	 1.02	(0.85,	1.23)	 	
	 Skin	 0.84	(0.65,	1.08)	 	
	 Endocrine/metabolic	 1.74	(1.47,	2.23)	 	
	 Injury/Poisoning	 0.47	(0.38,	0.57)	 	
	 Mental	disorders	 0.59	(0.42,	0.83)	 	
	 Symptoms/signs	 0.44	(0.37,	0.53)	 	
	 Other	 0.35	(0.16,	0.73)	 	






	 Normal	(2.2	-	2.6)	 1.24	(1.13,	1.36)	 	
	 Abnormal	 1.89	(1.34,	2.66)	 	






	 Normal	(≤10)	 0.86	(0.78,	0.96)	 	
	 Abnormal	 1.49	(1.36,	1.62)	 	
	 	 	 	
Hb	 (Haemoglobin)	
-	 most	 recent	
result	 in	 last	 30	
days	
Not	measured	 					1	 <0.001	
	 Normal	(f:	11	-	15)	(†)	 0.77	(0.71,	0.84)	 	
	 Abnormal	 1.76	(1.62,	1.91)	 	




12-month	average	 Normal	(≤	7.5)	 1.43	(1.31,	1.56)	 	
	 Abnormal	 1.93	(1.71,	2.17)	 	





	 Normal	(3.5	-	5.3)	 1.17	(1.09,	1.25)	 	
	 Abnormal	 1.79	(1.52,	2.10)	 	





	 Normal	(136	-	145)	 1.11	(1.04,	1.20)	 	
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	 Abnormal	 1.50	(1.36,	1.65)	 	






	 Both	normal	 1.07	(1.00,	1.16)	 	
	 Na	only	abnormal	 1.44	(1.31,	1.60)	 	
	 K	only	abnormal	 1.66	(1.35,	2.05)	 	
	 Both	abnormal	 1.96	(1.50,	2.55)	 	





	 Normal	(150	-	400)	 1.08	(1.01,	1.16)	 	
	 Abnormal	 1.44	(1.28,	1.62)	 	




	 1	 2.33	(2.07,	2.62)	 	
	 2+	 3.38	(2.72,	4.19)	 	






	 Normal	(1	-	11)	 1.13	(1.05,	1.21)	 	
	 Abnormal	 1.26	(1.12,	1.41)	 	





	 Not	significant	 1.95	(1.70,	2.22)	 	
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	 Significant	 4.67	(3.61,	6.04)	 	





	 1	-	10	 1.55	(1.40,	1.72)	 	
	 11+	 3.11	(2.84,	3.41)	 	
	 Not	recorded	 1.04	(0.91,	1.19)	 	







	 Quadratic	term	 0.93	(0.84,	1.03)	 	
	 Cubic	term	 1.01	(1.00,	1.02)	 	
	 	 	 	
Drugs	taken	(+)	 0	 					1	 <0.001	
	 1	 1.30	(1.18,	1.43)	 	
	 2	or	3	 1.93	(1.71,	2.18)	 	
	 Not	recorded	 0.62	(0.57,	0.67)	 	





	 Taken	 1.74	(1.32,	2.30)	 	










	 Not	significant	 1.20	(0.95,	1.52)	 	
	 Significant	 1.75	(1.54,	2.00)	 	
	 	 	 	
Proteinuria		 Not	done	 					1	 <0.001	
(worst	result)	 1		 1.39	(1.27,	1.53)	 	
	 2	or	3	 2.66	(2.42,	2.91)	 	





	 Taken	 1.02	(0.71,	1.48)	 	
	 	 	 	
Wound	 Swab	 /	
Fluid	 Aspirate	




	 Not	significant	 0.62	(0.39,	0.99)	 	
	 Significant	 1.14	(0.91,	1.44)	 	





(+)	 Total	 number	 of	 the	 following	 drugs	 taken:	 angiotensin	 converting	 enzyme	 inhibitors	 (ACEi),	
angiotensin	receptor	blockers	(ARBs),	non-steroidal	anti-inflammatory	drugs	(NSAID),	diuretics	
	
The	 results	 reported	 in	 terms	 of	 odds	 ratios	 in	 Table	 12	 are	 clearly	
understandable	 for	 the	 categorical	 variables,	 however	 for	 the	 continuous	
variables	the	associations	between	these	variables	and	the	outcome	variable	of	
AKI	 are	 less	 clear.	 These	 associations	 are	 most	 effectively	 demonstrated	
graphically.	 The	 relationship	 between	 these	 continuous	 variables	 (age	 and	
baseline	estimated	glomerular	filtration	rate	(eGFR))	and	the	probability	of	acute	
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for	 collinearity	 suggested	 this	 existed	 between	haemoglobin	 (Hb),	white	 blood	
cell	 count	 (WBC)	 and	 platelets	 (PLT),	 and	 also	 between	 sodium	 (Na)	 and	
potassium	 (K).	What	was	 apparent	was	 that	 these	 pathology	 blood	 tests	were	




a	clinician	orders	an	Hb	test,	 this	 is	ordered	as	part	of	a	 full	blood	count	(FBC)	












































results	and	 the	stage	of	AKI	was	assessed.	This	demonstrated	 that	only	 the	Hb	
was	statistically	significant	with	respect	to	the	outcome	of	AKI,	as	WBC	and	PLT	




assessed.	 In	 this	 analysis	 it	 appeared	 that	 both	 tests	 were	 independently	
associated	with	the	outcome	variable	of	AKI.	The	decision	was	therefore	made	to	
derive	a	 combined	variable	of	 the	 following	 categories:	 ‘not	measured’	 (one	or	
both	tests),	 ‘both	normal’,	 ‘Na	only	abnormal’,	 ‘K	only	abnormal’	and	‘both	tests	
abnormal’.		
	
To	 determine	 the	 final	 model,	 a	 backwards	 selection	 method	 was	 employed	
which	 retained	 only	 the	 statistically	 significant	 variables	 (in	 relation	 to	 the	
outcome	variable	of	AKI).	This	resulted	in	the	removal,	in	the	following	order	of	
the	variables:	wound	swab/fluid	aspirate	culture,	combined	sodium/potassium,	
calcium,	 gender,	 faeces	 culture,	 sputum	 culture,	 and	 number	 of	 outpatient	
attendances	in	the	last	12	months.		
	
It	 is	 likely	 that	 the	 culture	 variables	 were	 removed	 from	 the	 analysis	 in	
backwards	 selection	 as	 they	 are	 defining	 the	 presence	 of	 infection	 and	 in	 this	
case	the	c-reactive	protein	(CRP)	is	a	better	predictor	of	this	as	it	provides	both	
detection	of	infection	but	also	the	degree	of	severity	(which	along	with	this	one	
would	 expect	 the	 risk	 of	 AKI),	 with	 the	 higher	 the	 CRP	 the	 more	 severe	 the	
infection	 and	 the	 greater	 the	 risk	 of	 AKI.	 The	 outpatient	 attendances	 in	 12	
months	 likely	 fell	 out	 of	 the	 model	 as	 this	 is	 a	 marker	 of	 co-morbidity.	 The	









Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 3.35	(1.82,	6.16)	 <0.001	
	 Quadratic	term	 0.89	(0.81,	0.98)	 	
	 Cubic	term	 1.003	(0.998,	1.009)	 	




	 Yes	 0.82	(0.74,	0.91)	 	




	 1	-	2	 1.28	(1.16,	1.42)	 	
	 3	-	5	 1.54	(1.36.	1.75)	 	
	 6+	 2.01	(1.70,	3.80)	 	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 1.37	(1.05,	1.80)	 	
	 Blood	diseases	 0.50	(0.35.	0.72)	 	
	 Circulatory	system	 0.66	(0.55,	0.80)	 	
	 Digestive	system	 0.83	(0.68,	1.02)	 	
	 Diseases	head/neck	 0.30	(0.15,	0.63)	 	
	 Genitourinary	system	 1.76	(1.43,	2.15)	 	
	 Musculoskeletal	 0.39	(0.30,	0.49)	 	
	 Nervous	system	 0.53	(0.39,	0.72)	 	
	 Respiratory	system	 0.90	(0.75,	1.09)	 	
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	 Skin	 0.87	(0.68,	1.16)	 	
	 Endocrine/metabolic	 1.64	(1.26,	2.13)	 	
	 Injury/Poisoning	 0.55	(0.45,	0.67)	 	
	 Mental	disorders	 0.79	(0.55,	1.12)	 	
	 Symptoms/signs	 0.53	(0.44,	0.64)	 	
	 Other	 0.36	(0.16,	0.79)	 	






	 Normal	(≤10)	 0.99	(0.86,	1.14)	 	
	 Abnormal	 1.19	(1.04,	1.35)	 	
	 	 	 	
Hb	 (Haemoglobin)	
-	 most	 recent	
result	 in	 last	 30	
days	
Not	measured	 					1	 <0.001	
	 Normal	(f:	11	-	15)	(†)	 0.79	(0.70,	0.89)	 	
	 Abnormal	 1.10	(0.98,	1.24)	 	




12-month	average	 Normal	(≤	7.5)	 1.06	(0.96,	1.17)	 	
	 Abnormal	 1.24	(1.08,	1.43)	 	




	 1	 1.27	(1.11,	1.45)	 	
	 2+	 1.46	(1.15,	1.85)	 	






	 Not	significant	 1.49	(1.29,	1.73)	 	
	 Significant	 3.12	(2.36,	4.12)	 	





	 1	-	10	 1.08	(0.97,	1.21)	 	
	 11+	 1.37	(1.23,	1.53)	 	
	 Not	recorded	 1.11	(0.96,	1.29)	 	







	 Quadratic	term	 0.83	(0.74,	0.93)	 	
	 Cubic	term	 1.03	(1.02,	1.04)	 	
	 	 	 	
Drugs	taken	(+)	 0	 					1	 <0.001	
	 1	 1.15	(1.04,	1.27)	 	
	 2	or	3	 1.38	(1.20,	1.58)	 	
	 Not	recorded	 0.86	(0.77,	0.95)	 	









	 Not	significant	 1.05	(0.80,	1.36)	 	
	 Significant	 1.37	(1.19,	1.59)	 	
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Proteinuria		 Not	done	 					1	 <0.001	
(worst	result)	 1		 1.07	(0.96,	1.19)	 	
	 2	or	3	 1.38	(1.23,	1.54)	 	




(+)	 Total	 number	 of	 the	 following	 drugs	 taken:	 angiotensin	 converting	 enzyme	 inhibitors	 (ACEi),	
angiotensin	receptor	blockers	(ARBs),	non-steroidal	anti-inflammatory	drugs	(NSAID),	diuretics	
	
In	 this	 multivariable	 analysis,	 as	 would	 be	 expected	 following	 adjustment	 for	
other	variables	in	the	model,	the	effect	of	each	variable	on	the	outcome	variable	
of	 acute	 kidney	 injury	 (AKI)	was	 reduced,	 however	 the	 effects	were	 similar	 to	
those	 demonstrated	 in	 the	 univariable	 analyses.	 An	 exception	 to	 this	 in	 the	
model	 was	 the	 variable	 ‘admission	 in	 the	 last	 30	 days’	 (this	 variable	







admitted	 in	 the	 previous	 30	 days	 was	 0.82,	 suggesting	 the	 opposite	 effect,	 a	
lower	AKI	stage	in	these	patients.	
	
As	 with	 the	 univariable	 analyses	 the	 continuous	 variables,	 age	 and	 baseline	
estimated	 glomerular	 filtration	 rate	 (eGFR),	 are	 difficult	 to	 interpret	 from	 the	
odds	ratios.	To	demonstrate	the	relationship	between	these	continuous	variables	
and	 the	outcome	variable	of	 acute	kidney	 injury	 (AKI),	 ‘average’	 values	 for	 the	







75.	 However,	 for	 baseline	 estimated	 glomerular	 filtration	 rate	 (eGFR)	 after	









































































To	 firstly	 assess	 validity,	 the	 patient	 hospital	 admissions/episodes	 were	

































































	 	 	 	 	
Any	AKI	 ≤	10%	 3325	 6.2%	 5.0%	
	 10%	-	20%	 3057	 14.3%	 14.8%	
	 20%	-	40%		 2178	 27.5%	 28.4%	
	 >	40%	 597	 51.7%	 51.6%	
	 	 	 	 	
AKI	Stage	2	or	3	 ≤	2%	 3962	 1.2%	 0.8%	
	 2%	-	5%	 3358	 3.2%	 3.8%	
	 5%	-	10%		 1294	 6.9%	 7.2%	
	 >	10%	 543	 15.8%	 11.4%	




groups,	 suggesting	 good	 calibration.	 Table	 14	 also	 demonstrates	 a	 good	
agreement	 between	 the	 predicted/expected	 percentages	 and	 those	 that	 were	
observed	by	the	data,	with	a	slight	exception	in	the	second	analysis	(outcome	of	
‘AKI	stage	2	or	3’),	where	the	observed	percentage	of	patient	admissions	in	the	
high-risk	 group	 (>10%)	was	 less	 than	 that	 predicted	 by	 the	model.	 Following	
this,	 based	 on	 the	 predicted	 probabilities,	 Receiver	 Operating	 Characteristic	
(ROC)	 curves	 were	 plotted	 and	 the	 Area	 Under	 the	 Receiver	 Operating	
Characteristic	(AUROC)	curves	calculated,	for	both	‘any	AKI’	and	‘AKI	stage	2	or	
3’	as	outcomes.	The	ROC	curve	for	‘any	AKI’	is	demonstrated	in	Figure	51	and	for	
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An	 AUROC	 of	 0.75	 would	 suggest	 fair	 discriminatory	 power	 of	 risk	 Model	 1	
(predicting	AKI	on	admission)	being	validated	here.		
	
Finally,	 a	 Hosmer-Lemeshow	 test	 was	 performed	 to	 compare	 the	 numbers	 of	




















	 	 	 	 	 	
Any	AKI	 ≤	10%	 3158	(3119)	 167	(206)	 9.4	 0.009	
	 10%	-	20%	 2606	(2619)	 451	(438)	 	 	
	 20%	-	40%		 1559	(1580)	 619	(598)	 	 	
	 >	40%	 289	(289)	 308	(308)	 	 	
	 	 	 	 	 	
AKI	Stage	2	or	3	 ≤	2%	 3931	(3916)	 31	(46)	 16.4	 0.0003	
	 2%	-	5%	 3232	(3250)	 126	(108)	 	 	
	 5%	-	10%		 1201	(1205)	 93	(89)	 	 	
	 >	10%	 481	(457)	 62	(86)	 	 	





This	 test	 suggests	a	 lack	of	 fit	both	 for	 the	prediction	of	 the	outcome	 ‘any	AKI’	
and	also,	and	slightly	more	so,	for	‘AKI	stage	2	or	3’	as	evidenced	by	a	statistically	
significant	 difference	 between	 the	 numbers	 predicted	 by	 the	model	 and	 those	
observed	in	the	data.	The	Hosmer-Lemeshow	test	is	however	sensitive	to	slight	
differences	 between	 predicted	 and	 observed	 frequencies.	 As	 in	 the	 first	
validation	 analysis	 (Table	 14),	 there	 is	 an	 over-prediction	 by	 the	 model	 of	







As	 described	 in	 the	 methods	 the	 calibration	 and	 discriminative	 ability	 of	 risk	
Model	 1	 (predicting	 AKI	 on	 admission)	 was	 then	 assessed	 in	 the	 Medway	
(patients	 presenting	 to	Medway	NHS	 Foundation	 Trust)	 population	 to	 provide	
validation	 in	 a	 second	 demographically	 different	 population.	 Following	




as	 a	 second	 validation	 population)	 in	 terms	 of	 demographics	 and	 also	 of	
occurrence	of	AKI.	AKI	was	experienced	in	17%	of	patient	hospital	admissions	in	
the	 EKHUFT	 dataset	 in	 comparison	 to	 23%	 in	 the	 Medway	 dataset.	 As	 with	
validation	in	the	EKHUFT	dataset,	the	patient	hospital	admissions/episodes	were	













	 	 	 	 	
Any	AKI	 ≤	10%	 1961	 6.1%	 10.7%	
	 10%	-	20%	 1597	 14.1%	 23.0%	
	 20%	-	40%		 960	 27.1%	 39.8%	
	 >	40%	 208	 51.1%	 63.0%	
	 	 	 	 	
AKI	Stage	2	or	3	 ≤	2%	 2329	 1.1%	 2.1%	
	 2%	-	5%	 1657	 3.2%	 5.9%	
	 5%	-	10%		 552	 6.8%	 9.6%	
	 >	10%	 188	 15.3%	 18.6%	
	 	 	 	 	
	 	
Table	 17	 summarises	 these	 results	 and	 suggests	 good	 discrimination	 between	
risk	groups	for	both	the	outcome	‘any	AKI’	and	 ‘AKI	stage	2	or	3’,	however,	the	










These	 results	 demonstrate	 fair	 discriminatory	 power	 of	 risk	 Model	 1	 in	 the	
second	population,	although	slightly	poorer	 than	that	observed	 for	 the	 internal	
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Finally,	 the	 Hosmer-Lemeshow	 test	 was	 performed	 in	 this	 second	 population	
(Medway),	 as	 in	 the	 internal	 validation	 (EKHUFT).	 The	 results	 are	 reported	 in	

















	 	 	 	 	 	
Any	AKI	 ≤	10%	 1752	(1842)	 209	(119)	 269.6	 <0.0001	
	 10%	-	20%	 1229	(1372)	 368	(225)	 	 	
	 20%	-	40%		 578	(700)	 382	(260)	 	 	
	 >	40%	 77	(119)	 131	(106)	 	 	
	 	 	 	 	 	
AKI	Stage	2	or	3	 ≤	2%	 2280	(2302)	 49	(27)	 66.9	 <0.0001	
	 2%	-	5%	 1560	(1604)	 97	(52)	 	 	
	 5%	-	10%		 499	(515)	 53	(37)	 	 	
	 >	10%	 153	(159)	 35	(29)	 	 	





As	 previously	 demonstrated	 in	 comparison	 of	 expected	 and	 observed	
probabilities	(Table	17),	the	Hosmer-Lemeshow	test	again	demonstrates	that	the	












model	 produces	 values	 of	 0.75	 (‘any	AKI’)	 in	 the	 primary	 population	 and	 0.72	
(‘any	AKI’)	in	the	secondary	population.	The	calibration	of	the	model	is	good	in	
the	primary	 (EKHUFT)	population	with	good	agreement	of	 expected/predicted	
AKI	 and	 that	 observed	 in	 the	 data.	 This	 is	 less	 so	 on	 validation	 in	 the	 second	











The	 development	 dataset	 included	 a	 total	 of	 7,556	 admissions	 from	 6,626	
patients.	The	outcome	variable	of	interest	in	this	model	was	the	presence	of	new	
acute	kidney	injury	(AKI)	at	72	hours	into	hospital	admission.	In	order	to	assess	
which	 variables	 in	 the	 dataset	 were	 associated	 with	 the	 outcome	 variable,	
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initially	 a	 series	 of	 univariable	 ordinal	 logistic	 regression	 analyses	 were	
performed.	The	results	of	 this	univariable	analysis	are	reported	 in	Table	20.	 In	
this	 analysis	 the	 odds	 ratios	 (calculated	 as	 the	 exponential	 of	 the	 parameter	
estimates	 (beta))	 are	 reported	 to	 demonstrate	 the	 sizes	 of	 the	 effects,	with	 p-










Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 1.28	(1.21,	1.35)	 <0.001	
	 	 	 	
Sex	 Male	 					1	 0.27	
	 Female	 0.91	(0.78,	1.07)	 	
	 	 	 	
Admission	 in	 last	 30	
days	
No	 					1	 0.56	
	 Yes	 0.95	(0.79,	1.14)	 	




	 1	-	2	 1.31	(1.09,	1.58)	 	
	 3	-	5	 1.55	(1.22.	1.97)	 	
	 6+	 1.88	(1.37,	2.58)	 	





in	last	12	months	 1	-	2	 1.03	(0.84,	1.28)	 	
	 3	-	5	 1.25	(1.00.	1.55)	 	
	 6+	 1.28	(1.02,	1.62)	 	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 1.80	(1.08,	3.00)	 	
	 Blood	diseases	 0.63	(0.28.	1.43)	 	
	 Circulatory	system	 1.09	(0.73,	1.62)	 	
	 Digestive	system	 0.71	(0.47,	1.08)	 	
	 Genitourinary	system	 1.54	(0.98,	2.42)	 	
	 Musculoskeletal	 0.74	(0.37,	1.47)	 	
	 Nervous	system	 0.53	(0.23,	1.22)	 	
	 Respiratory	system	 0.78	(0.52,	1.19)	 	
	 Skin	 0.89	(0.47,	1.69)	 	
	 Endocrine/metabolic	 0.70	(0.34,	1.43)	 	
	 Injury/Poisoning	 0.97	(0.64,	1.48)	 	
	 Mental	disorders	 0.14	(0.02,	1.04)	 	
	 Symptoms/signs	 0.72	(0.46,	1.14)	 	
	 Other	 1.02	(0.29,	3.65)	 	






	 Normal	(≤50)	 1.06	(0.86,	1.32)	 	
	 Abnormal	 1.08	(0.79,	1.48)	 	





	 Normal	(≤125)	 0.90	(0.73,	1.10)	 	
	 Abnormal	 1.05	(0.62,	1.79)	 	






	 Measured	 1.19	(0.73,	1.96)	 	




	 Normal	(2.2	-	2.6)	 1.09	(0.92,	1.30)	 	
	 Abnormal	 1.24	(0.75,	2.03)	 	





	 Normal	(≤10)	 0.81	(0.59,	1.10)	 	
	 Abnormal	 1.16	(0.87,	1.53)	 	
	 	 	 	
Hb	 (Haemoglobin)	 –	
most	 recent	 result	 in	
last	30	days	
Not	measured	 					1	 <0.001	
	 Normal	(f:	11	-	15)	(†)	 0.65	(0.41,	1.01)	 	
	 Abnormal	 0.94	(0.60,	1.47)	 	




12-month	average	 Normal	(≤	7.5)	 1.51	(1.24,	1.85)	 	
	 Abnormal	 1.52	(1.13,	2.02)	 	
	 	 	 	




	 Normal	(3.5	-	5.3)	 0.67	(0.50,	0.91)	 	
	 Abnormal	 0.94	(0.65,	1.37)	 	
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Mg	 (Magnesium)	 –	
most	 recent	 result	 in	
last	30	days	
Not	measured	 					1	 		0.008	
	 Normal	(0.7	-	1.0)	 0.87	(0.66,	1.15)	 	
	 Abnormal	 1.72	(1.19,	2.48)	 	
	 	 	 	






	 Abnormal	 1.06	(0.90,	1.25)	 	







	 Abnormal	 1.17	(0.97,	1.41)	 	
	 	 	 	
Troponin	 –	 tested	 in	
last	12	months	
0	 					1	 <0.001	
	 1	 1.35	(1.10,	1.66)	 	
	 2+	 2.33	(1.86,	2.93)	 	
	 	 	 	
WBC	 (White	 blood	





	 Abnormal	 1.20	(1.02,	1.40)	 	
	 	 	 	
CK.	(Creatine	Kinase)	-	
most	 recent	 result	 in	
last	30	days	
Not	measured	 					1	 0.67	
	 Normal	((≤	1000)	 0.96	(0.63,	1.47)	 	
	 Abnormal	 1.35	(0.68,	2.67)	 	
	 	 	 	
Blood	 culture	 –	 on	 Not	taken	 					1	 0.02	
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admission	
	 Taken	 1.28	(1.03,	1.59)	 	




	 1	-	10	 1.45	(1.12,	1.87)	 	
	 11+	 2.33	(1.86,	2.93)	 	
	 Not	recorded	 1.39	(1.03,	1.88)	 	
	 	 	 	
Number	of	contrast	 0	 					1	 0.82	
radiology	scans	 1+	 1.03	(0.78,	1.37)	 	
	 	 	 	





	 Quadratic	term	 1.03	(1.00,	1.08)	 	
	 	 	 	
Drugs	taken	(+)	 0	 					1	 <0.001	
	 1	 1.25	(1.00,	1.58)	 	
	 2	or	3	 1.92	(1.42,	2.59)	 	
	 Not	recorded	 0.85	(0.71,	1.03)	 	
	 	 	 	
Faeces	 Culture	 –	
within	 2	 weeks	 prior	
to	admission	
Not	taken	 					1	 0.30	
	 Taken	 1.36	(0.76,	2.43)	 	
	 	 	 	
Faeces	 Culture	 –	 on	
admission	
Not	taken	 					1	 0.42	
	 Taken	 0.78	(0.43,	1.42)	 	
	 	 	 	
Mid-stream	 specimen	 Not	taken	 					1	 0.07	
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of	 urine	 (MSU)	 or	
catheter	 specimen	 of	
urine	 (CSU)	 culture	 –	
within	 2	 weeks	 prior	
to	admission	
	 Not	significant	 0.63	(0.29,	1.36)	 	
	 Significant	 1.40	(1.00,	1.96)	 	
	 	 	 	
Mid-stream	 specimen	
of	 urine	 (MSU)	 or	
catheter	 specimen	 of	
urine	 (CSU)	 culture	 –	
on	admission	
Not	taken	 					1	 		0.001	
	 Taken	 1.43	(1.15,	1.78)	 	




	 Score	1-2	 0.99	(0.68,	1.44)	 	
	 Score	3-4	 1.47	(1.01,	2.13)	 	
	 	 	 	
Proteinuria		 Not	done	 					1	 <0.001	
(worst	result)	 1		 1.27	(1.01,	1.60)	 	
	 2	or	3	 2.56	(2.08,	3.15)	 	
	 	 	 	
Sputum	 Culture	 –	
within	 2	 weeks	 prior	
to	admission	
Not	taken	 					1	 0.73	
	 Taken	 1.14	(0.54,	2.42)	 	
	 	 	 	
Sputum	 Culture	 –	 on	
admission	
Not	taken	 					1	 0.12	
	 Taken	 0.54	(0.24,	1.17)	 	
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Wound	 Swab	 /	 Fluid	
Aspirate	Culture	
Not	taken	 					1	 0.55	
	-	on	admission	 Taken	 1.11	(0.80,	1.53)	 	







The	 results	 reported	 in	 terms	 of	 odds	 ratios	 in	 Table	 20	 are	 clearly	
understandable	 for	 the	 categorical	 variables,	 however	 for	 the	 continuous	
variables	the	associations	between	these	variables	and	the	outcome	variable	of	
AKI	 are	 less	 clear.	 These	 associations	 are	 most	 effectively	 demonstrated	
graphically.	 The	 relationship	 between	 these	 continuous	 variables	 (age	 and	
baseline	estimated	glomerular	filtration	rate	(eGFR))	and	the	probability	of	acute	
kidney	 injury	 (AKI)	are	 shown	 in	Figures	55	 (age)	and	56	 (eGFR)	 respectively.	
The	outcome	of	‘any	AKI’	is	plotted	here.	
	




In	 some	cases	 the	 results	 reported	here	may	seem	counter	 intuitive	where	 the	
confidence	 intervals(CIs)	 of	 the	 odds	 ratios	 cross	 1,	 however	 the	 differences	
between	 the	 categories	 remain	 statistically	 significant.	 An	 example	 is	 for	 ‘Hb	
(Haemoglobin)	 	 -	most	 recent	 result	 in	 last	 30	 days’	which	 has	 the	 categories:	
‘Not	Measured’,	 ‘Normal’	 and	 ‘Abnormal’,	with	 odds	 ratios	 (95%	CI)	 of	 1,	 0.65	
























































step	 in	 this	 multivariable	 analysis	 was	 to	 assess	 for	 collinearity,	 and	 in	 this	
analysis	 there	 was	 no	 strong	 evidence	 of	 collinearity	 between	 predictors,	 and	
hence	 all	 predictors	 could	 be	 considered	 as	 independent	 variables	 in	 the	
multivariable	analysis.	
	
From	 the	 univariable	 analyses	 it	was	 evident	 that	 in	 patients	who	 had	HbA1c	




‘not	 measured’	 could	 be	 understood	 as	 a	 patient	 not	 having	 diabetes,	 and	
‘measured’	as	having	diabetes.	
	
To	 determine	 the	 final	 model,	 a	 backwards	 selection	 method	 was	 employed	
which	 retained	 only	 the	 statistically	 significant	 variables	 (in	 relation	 to	 the	




































following	 order	 of	 the	 variables:	 calcium,	 gender,	 BNP	 (Brain	 Natriuretic	
Peptide),	 CK	 (Creatine	 Kinase),	 outpatient	 attendances	 in	 12	 months,	 sputum	
culture	within	2	weeks	prior	to	admission,	number	of	contrast	radiology	scans,	
wound	swab	/	fluid	aspirate	culture	within	2	weeks	prior	to	admission,	wound	
swab	 /	 fluid	 aspirate	 culture	 on	 admission,	 Na	 (sodium),	 ALT	 (alanine	
transaminase),	 mid-stream	 specimen	 of	 urine	 (MSU)	 or	 catheter	 specimen	 of	
urine	 (CSU)	 culture	 within	 2	 weeks	 prior	 to	 admission,	 faeces	 culture	 on	
admission,	 Hb	 (haemoglobin),	 sputum	 culture	 on	 admission,	 mid-stream	
specimen	 of	 urine	 (MSU)	 or	 catheter	 specimen	 of	 urine	 (CSU)	 culture	 on	
admission,	 faeces	culture	within	2	weeks	prior	to	admission,	operative	severity	
score	 at	 12	 hours,	 PLT	 (platelets),	 admissions	 in	 last	 30	 days,	 blood	 culture,	
drugs	taken,	AMY	(amylase).	
	
Again,	 as	 in	Model	 1	 the	 culture	 variables	were	 removed	 from	 the	 analysis	 in	
backwards	selection	which	is	likely	to	do	with	the	fact	that	they	are	defining	the	
presence	 of	 infection	 and	 in	 this	 case	 the	 c-reactive	 protein	 (CRP)	 is	 a	 better	
predictor	 of	 this.	 Also,	 the	 outpatient	 attendances	 again	 are	 a	 reflection	 of	 co-
morbidity,	 which	 is	 in	 itself	 (in	 the	 Charlson	 co-morbidity	 score)	 a	 better	
predictor	of	AKI	within	the	model.	Contrast	radiology	scans	may	have	fallen	out	
as	a	predictor	as	 it	may	be	too	early	 in	the	disease	process	of	contrast	 induced	
nephropathy	to	detect	an	acute	kidney	injury	secondary	to	contrast,	as	this	may	
be	 expected	 48	 -	 72	 hours	 after	 the	 insult.	 It	 is	 again	 also	 possible	 that	 the	
operative	 severity	 score	 fell	 out	 of	 the	model	 as	 the	 detection	 of	 AKI	was	 too	
early	in	the	disease	process	of	AKI	developing	after	an	operative	procedure,	and	







Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
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Age	(*)	 Linear	term		 1.78	(1.22,	2.60)	 <0.001	
	 Quadratic	term	 0.97	(0.95,	1.00)	 	
	 	 	 	
Admission	 in	 last	 2-
12	months	
0	 					1	 <0.001	
	 1	-	2	 1.41	(1.14,	1.75)	 	
	 3	-	5	 1.58	(1.20,	2.09)	 	
	 6+	 2.24	(1.57,	3.19)	 	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 1.53	(0.90,	2.61)	 	
	 Blood	diseases	 0.58	(0.25,	1.36)	 	
	 Circulatory	system	 0.77	(0.50,	1.20)	 	
	 Digestive	system	 0.84	(0.55,	1.30)	 	
	 Genitourinary	system	 1.52	(0.95,	2.43)	 	
	 Musculoskeletal	 0.79	(0.39,	1.58)	 	
	 Nervous	system	 0.57	(0.23,	1.38)	 	
	 Respiratory	system	 0.59	(0.38,	0.91)	 	
	 Skin	 0.88	(0.46,	1.72)	 	
	 Endocrine/metabolic	 0.71	(0.34,	1.46)	 	
	 Injury/Poisoning	 1.04	(0.67,	1.60)	 	
	 Mental	disorders	 0.18	(0.02,	1.32)	 	
	 Symptoms/signs	 0.78	(0.49,	1.26)	 	
	 Other	 1.33	(0.36,	4.85)	 	
	 	 	 	
CRP	 (C-Reactive	
Protein)	 -	 most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 0.05	
	 Normal	(≤10)	 0.89	(0.65,	1.22)	 	
	 Abnormal	 1.15	(0.85,	1.55)	 	
	 	 	 	
HbA1c	 (glycated	 Not	measured	 					1	 0.03	
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haemoglobin)	
	 Measured	 1.26	(1.03,	1.56)	 	
	 	 	 	
K	(Potassium)	 -	most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 0.02	
	 Normal	(3.5	-	5.3)	 0.69	(0.50,	0.94)	 	
	 Abnormal	 0.86	(0.58,	1.26)	 	
	 	 	 	
Mg	 (Magnesium)	 -	
most	 recent	 result	 in	
last	30	days	
Not	measured	 					1	 0.02	
	 Normal	(0.7	-	1.0)	 0.88	(0.65,	1.17)	 	
	 Abnormal	 1.69	(1.14,	2.50)	 	
	 	 	 	
Troponin	 –	 tested	 in	
last	12	months	
0	 					1	 <0.001	
	 1	 1.42	(1.15,	1.77)	 	
	 2+	 2.19	(1.67,	2.87)	 	
	 	 	 	
WBC	 (White	 blood	





	 Abnormal	 1.18	(1.00,	1.40)	 	




	 1	-	10	 1.14	(0.87,	1.49)	 	
	 11+	 1.35	(1.05,	1.75)	 	
	 Not	recorded	 1.41	(1.02,	1.95)	 	






	 Quadratic	term	 1.11	(1.06,	1.16)	 	
	 	 	 	
Proteinuria		 Not	done	 					1	 		0.001	
(worst	result)	 1		 0.95	(0.73,	1.22)	 	
	 2	or	3	 1.52	(1.19,	1.95)	 	





were	 of	 borderline	 significance,	 for	 example	 modified	 Charlson	 co-morbidity	
score	and	C-Reactive	Protein	(p-values	of	0.05).	In	total	the	final	model	retained	





with	 the	 inclusion	 of	 a	 quadratic	 term.	 Again,	 these	 results	 are	 difficult	 to	
interpret	 from	 odds	 ratios	 alone.	 Figure	 57	 demonstrates	 the	 relationship	
between	 age	and	the	adjusted	predicted	probability	of	AKI	 in	the	multivariable	
analysis	(assuming	‘average’	values	for	all	other	variables),	and	is	similar	to	the	














likely	 to	 reflect	 low	 muscle	 mass	 (eGFR	 is	 calculated	 from	 serum	 creatinine,	


































































To	 firstly	 assess	 validity,	 the	 patient	 hospital	 admissions/episodes	 were	






























































	 	 	 	 	
Any	AKI	 ≤	5%	 709	 3.3%	 4.5%	
	 5%	-	10%	 1023	 7.3%	 7.7%	
	 10%	-	20%		 633	 13.7%	 15.3%	
	 >	20%	 149	 26.9%	 22.1%	
	 	 	 	 	
AKI	Stage	2	or	3	 ≤	1%	 1441	 0.6%	 0.8%	
	 1%	-	2%	 737	 1.4%	 2.6%	
	 2%	-	3%		 210	 2.4%	 3.3%	
	 >	3%	 126	 4.3%	 2.4%	
	 	 	 	 	
	
For	 the	 outcome	 ‘any	 AKI’	 Table	 22	 demonstrates	 a	 reasonably	 good	
discrimination	 between	 risk	 groups,	 with	 observed	 results	 increasing	 with	
increased	risk,	and	the	categories	correctly	ordered.	For	the	outcome	‘AKI	stage	
2	or	3’,	the	discrimination	was	less	good.	The	outcome	in	this	patient	group	was	
relatively	 rare,	 with	 also	 relatively	 small	 group	 sizes.	 In	 terms	 of	 observed	
results	 the	 outcome	 (‘AKI	 stage	 2	 or	 3’)	 was	 least	 common	 in	 the	 lowest	 risk	






with	both	 a	 relatively	 good	agreement	between	 the	predicted	percentages	 and	
those	actually	observed	in	the	data,	and	all	observed	percentages	fell	within	the	
risk	boundaries.	However,	for	the	prediction	of	the	outcome	‘AKI	stage	2	or	3’	the	
calibration	 of	 the	 model	 was	 less	 good	 with	 both	 a	 disparity	 between	 the	
predicted	percentages	and	those	actually	observed	in	the	data,	and	for	the	three	
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higher	 risk	 groups	 (1%	 -	 2%,	 2%	 -	 3%,	 >	 3%)	 the	 observed	 percentages	 fell	
outside	 of	 the	 risk	 boundaries.	 However,	 for	 the	 prediction	 of	 this	 outcome	 it	
could	be	suggested	that	the	risk	boundaries	chosen	were	relatively	tight.	
	
Following	 this,	 based	 on	 the	 predicted	 probabilities,	 Receiver	 Operating	
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An	AUROC	of	 0.67	 (for	 the	 outcome	 ‘any	AKI’)	 and	0.68	 (for	 the	 outcome	 ‘AKI	
stage	 2	 or	 3’)	 would	 suggest	 poor	 discriminatory	 power	 of	 risk	 Model	 2	
(predicting	new	AKI	at	72	hours	 into	hospital	admission)	being	validated	here.	
However,	with	both	outcomes	the	lower	confidence	intervals	are	well	above	0.5	
and	 so	 could	 not	 be	 interpreted	 as	 a	 determination	 by	 chance	 and	 do	 suggest	
predictive	ability,	however	not	as	great	as	that	observed	in	risk	Model	1.		
	

























0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.6848
Michael	Bedford	 11905027	 218	
ability	in	risk	Model	2.	The	results	from	the	epidemiological	study	in	Chapter	1	
demonstrate	 that	73.6%	of	patients	with	AKI	managed	 in	hospital,	 had	AKI	on	
admission,	 as	 the	 presence	 of	 AKI	 in	 these	 cases	 is	 likely	 a	 reflection	 of	 the	
underlying	disease	process	 (for	example	 sepsis)	 that	precipitated	admission	 to	




The	 fact	 that	 new	 AKI	 in	 the	 first	 72	 hours	 of	 admission	 is	 more	 difficult	 to	
predict	 may	 also	 suggest	 we	 are	 missing	 a	 key	 variable	 for	 prediction.	 One	





Finally,	 a	 Hosmer-Lemeshow	 test	 was	 performed	 to	 compare	 the	 numbers	 of	


















	 	 	 	 	 	
Any	AKI	 ≤	5%	 677	(685)	 32	(24)	 6.4	 0.04	
	 5%	-	10%	 944	(949)	 79	(74)	 	 	
	 10%	-	20%		 536	(546)	 97	(87)	 	 	
	 >	20%	 116	(109)	 33	(40)	 	 	
	 	 	 	 	 	
AKI	Stage	2	or	3	 ≤	1%	 1430	(1432)	 11	(9)	 10.4	 0.005	
	 1%	-	2%	 718	(727)	 19	(10)	 	 	
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	 2%	-	3%		 203	(205)	 7	(5)	 	 	
	 >	3%	 123	(120)	 3	(5)	 	 	




This	 test	 suggests	a	 lack	of	 fit	both	 for	 the	prediction	of	 the	outcome	 ‘any	AKI’	
and	also,	and	even	more	so,	for	‘AKI	stage	2	or	3’	as	evidenced	by	a	statistically	
significant	 difference	 between	 the	 numbers	 predicted	 by	 the	model	 and	 those	
observed	in	the	data.	However,	for	the	outcome	‘any	AKI’	the	lack	of	fit	was	only	
just	statistically	significant	with	a	p-value	of	0.04.	The	Hosmer-Lemeshow	test	is	
known	 to	 be	 sensitive	 to	 slight	 differences	 between	 predicted	 and	 observed	
frequencies.		
	
For	 the	 outcome	 ‘any	 AKI’,	 in	 the	 three	 lowest	 risk	 groups	 the	 model	 under-





As	 described	 in	 the	 methods	 the	 calibration	 and	 discriminative	 ability	 of	 risk	
Model	 2	 (predicting	 new	 AKI	 at	 72	 hours	 into	 hospital	 admission)	 was	 then	
assessed	in	the	Medway	(patients	presenting	to	Medway	NHS	Foundation	Trust)	
population	 to	 provide	 validation	 in	 a	 second	 demographically	 different	
population.	 Following	 exclusions	 (as	 in	 the	 EKHUFT	 dataset)	 the	 Medway	
dataset	 included	 1,585	 patient	 hospital	 admissions.	 For	 each	 admission	 the	
predicted	probability	of	AKI	was	determined	from	the	risk	model.	In	comparison	
of	 the	 EKHUFT	 and	 Medway	 datasets,	 there	 were	 differences	 as	 would	 be	
expected	(hence	choice	of	Medway	as	a	second	validation	population)	in	terms	of	






As	 with	 validation	 in	 the	 EKHUFT	 dataset,	 the	 patient	 hospital	













	 	 	 	 	
Any	AKI	 ≤	5%	 760	 3.0%	 3.7%	
	 5%	-	10%	 563	 6.8%	 8.5%	
	 10%	-	20%		 214	 13.4%	 15.0%	
	 >	20%	 48	 26.5%	 25.0%	
	 	 	 	 	
AKI	Stage	2	or	3	 ≤	1%	 1218	 0.5%	 0.7%	
	 1%	-	2%	 262	 1.4%	 0.8%	
	 2%	-	3%		 69	 2.4%	 1.4%	
	 >	3%	 36	 4.3%	 0.0%	
	 	 	 	 	
	
For	 the	 outcome	 ‘any	 AKI’	 Table	 25	 demonstrates	 a	 reasonably	 good	
discrimination	 between	 risk	 groups,	 with	 observed	 results	 increasing	 with	
increased	risk,	and	the	categories	correctly	ordered.	For	the	outcome	‘AKI	stage	
2	or	3’,	the	discrimination	was	less	good,	with	the	outcome	being	least	common	
in	 the	 highest	 risk	 group	 (>3%).	 The	 first	 three	 risk	 groups	 were	 however	
correctly	 ordered,	 although	 little	 demonstrable	 difference	 between	 the	 lowest	





with	both	 a	 relatively	 good	agreement	between	 the	predicted	percentages	 and	
those	actually	observed	in	the	data,	and	all	observed	percentages	fell	within	the	
risk	boundaries.	However,	for	the	prediction	of	the	outcome	‘AKI	stage	2	or	3’	the	
calibration	 of	 the	 model	 was	 less	 good	 with	 both	 a	 disparity	 between	 the	
predicted	percentages	and	those	actually	observed	in	the	data,	and	for	the	three	
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An	AUROC	of	 0.71	 (for	 the	 outcome	 ‘any	AKI’)	 and	0.63	 (for	 the	 outcome	 ‘AKI	
stage	2	or	3’)	would	suggest	risk	Model	2	(predicting	new	AKI	at	72	hours	into	
hospital	admission)	being	validated	here	does	have	discriminatory	power,	more	
so	 for	 the	 prediction	 of	 ‘any	 AKI’	 (interpreted	 as	 ‘fair’)	 and	 less	 so	 for	 the	
prediction	of	the	more	severe	‘AKI	stage	2	or	3’	(interpreted	as	‘poor’).	However,	
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however	 for	 the	 outcome	 ‘AKI	 stage	 2	 or	 3’	 at	 0.52)	 and	 so	 could	 not	 be	
interpreted	as	a	determination	by	chance	and	do	suggest	predictive	ability.	



















	 	 	 	 	 	
Any	AKI	 ≤	5%	 732	(737)	 28	(23)	 4.3	 0.12	
	 5%	-	10%	 515	(525)	 48	(38)	 	 	
	 10%	-	20%		 182	(185)	 32	(29)	 	 	
	 >	20%	 36	(35)	 12	(13)	 	 	
	 	 	 	 	 	
AKI	Stage	2	or	3	 ≤	1%	 1209	(1211)	 9	(6.2)	 4.0	 0.14	
	 1%	-	2%	 260	(258)	 2	(3.6)	 	 	
	 2%	-	3%		 68	(67)	 1	(1.7)	 	 	
	 >	3%	 36	(34)	 0	(1.6)	 	 	












The	 results	 for	 risk	 Model	 2	 (predicting	 new	 AKI	 at	 72	 hours	 into	 hospital	
admission)	reported	here	suggest	the	model	is	better	at	predicting	the	outcome	
‘any	AKI’,	than	the	more	severe	‘AKI	stage	2	or	3’,	however	the	latter	outcome	is	






discrimination	 this	 was	 found	 to	 be	 even	 slightly	 better	 than	 in	 the	 primary	
(EKHUFT)	population.	For	the	more	severe	outcome	of	‘AKI	stage	2	or	3’	both	the	










The	 development	 dataset	 included	 a	 total	 of	 2,333	 admissions	 from	 2,159	
patients.	 The	 outcome	 variable	 of	 interest	 in	 this	 model	 was	 the	 presence	 of	
worsening	(as	described	in	the	methods)	acute	kidney	injury	(AKI)	at	72	hours	
into	hospital	admission.	 In	order	 to	assess	which	variables	 in	 the	dataset	were	
associated	 with	 the	 outcome	 variable,	 initially	 a	 series	 of	 univariable	 ordinal	




terms	 of	 the	 outcome.	 This	 univariable	 analysis	 includes	 both	 categorical	








Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 0.94	(0.86,	1.04)	 0.26	
	 	 	 	
Sex	 Male	 					1	 0.32	
	 Female	 1.18	(0.86,	1.61)	 	
	 	 	 	
Admission	 in	 last	 30	
days	
No	 					1	 0.53	
	 Yes	 0.89	(0.61,	1.129)	 	
	 	 	 	
Admissions	 in	 last	 2-
12	months	
0	 					1	 0.92	
	 1	-	2	 0.89	(0.61,	1.29)	 	
	 3	-	5	 0.88	(0.56.	1.38)	 	
	 6+	 0.98	(0.54,	1.78)	 	




in	last	12	months	 1	-	2	 0.86	(0.57,	1.33)	 	
	 3	-	5	 0.69	(0.42.	1.11)	 	
	 6+	 1.00	(0.66,	1.52)	 	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 6.39	(1.88,	21.7)	 	
	 Circulatory	system	 1.90	(0.63,	5.69)	 	
	 Digestive	system	 1.46	(0.47,	4.57)	 	
	 Genitourinary	system	 2.60	(0.85,	7.94)	 	
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	 Musculoskeletal	 1.67	(0.27,	10.3)	 	
	 Nervous	system	 0.82	(0.08,	8.08)	 	
	 Respiratory	system	 1.46	(0.48,	4.42)	 	
	 Skin	 1.15	(0.27,	4.99)	 	
	 Endocrine/metabolic	 1.06	(0.28,	4.02)	 	
	 Injury/Poisoning	 2.70	(0.84,	8.66)	 	
	 Symptoms/signs	 0.92	(0.26,	3.29)	 	
	 Other	 0.43	(0.04,	4.12)	 	




	 Normal	(≤50)	 1.05	(0.69,	1.63)	 	
	 Abnormal	 1.73	(0.98,	3.05)	 	
	 	 	 	
AMY	(amylase)	 Not	measured	 					1	 0.24	
	 Measured	 1.25	(0.86,	1.82)	 	




12-month	average	 Measured	 1.09	(0.45,	2.62)	 	
	 	 	 	
Ca	(calcium)	 Not	measured	 					1	 0.92	
	 Normal	(2.2	-	2.6)	 0.93	(0.66,	1.32)	 	
	 Abnormal	 1.01	(0.47,	2.19)	 	




	 Normal	(≤10)	 0.80	(0.32,	1.96)	 	
	 Abnormal	 1.40	(0.62,	3.17)	 	
	 	 	 	
Hb	(Haemoglobin)	 Not	measured	 					1	 0.73	
	 Normal	(f:	11	-	15)	(†)	 1.02	(0.38,	2.70)	 	
	 Abnormal	 0.89	(0.34,	2.37)	 	
Michael	Bedford	 11905027	 227	




12-month	average	 Normal	(≤	7.5)	 1.06	(0.72,	1.58)	 	
	 Abnormal	 1.14	(0.71,	1.83)	 	
	 	 	 	
K	(potassium)	 Not	measured	 					1	 0.76	
	 Normal	(3.5	-	5.3)	 0.89	(0.43,	1.86)	 	
	 Abnormal	 1.03	(0.47,	2.27)	 	
	 	 	 	
Mg	(magnesium)		 Not	measured	 					1	 <0.001	
	 Normal	(0.7	-	1.0)	 1.29	(0.80,	2.11)	 	
	 Abnormal	 2.92	(1.71,	4.98)	 	
	 	 	 	
Na	(sodium)	 Not	 measured	 /	
Normal	(136	–	145)	
					1	 0.55	
	 Abnormal	 1.10	(0.80,	1.52)	 	
	 	 	 	
PLT	(platelets)	 Not	 measured	 /	
Normal	(150	–	400)	
					1	 0.05	
	 Abnormal	 1.43	(1.00,	2.05)	 	
	 	 	 	
Troponin	 0	 					1	 0.66	
	 1	 0.90	(0.58,	1.39)	 	
	 2+	 1.16	(0.75,	1.78)	 	






	 Abnormal	 1.51	(1.08,	2.11)	 	
	 	 	 	
CK	(creatine	kinase)		 Not	measured	 					1	 		0.008	
	 Normal	(≤	1000)	 1.49	(0.73,	3.04)	 	
	 Abnormal	 4.90	(1.73,	13.9)	 	
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Blood	 culture	 –	 on	
admission	
Not	taken	 					1	 0.04	
	 Taken	 1.47	(1.03,	2.12)	 	




	 1	-	10	 1.40	(0.82,	2.39)	 	
	 11+	 1.10	(0.68,	1.78)	 	
	 Not	recorded	 1.45	(0.76,	2.79)	 	
	 	 	 	
Number	of	contrast	 0	 					1	 0.05	
radiology	scans	 1+	 1.77	(1.01,	3.09)	 	
	 	 	 	





	 	 	 	
Drugs	taken	(+)	 0	 					1	 0.23	
	 1	 1.09	(0.69,	1.72)	 	
	 2	or	3	 1.53	(0.90,	2.61)	 	
	 Not	recorded	 1.41	(0.96,	2.07)	 	
	 	 	 	
Faeces	 Culture	 –	
within	 2	 weeks	 prior	
to	admission	
Not	taken	 					1	 0.69	
	 Taken	 1.24	(0.42,	3.66)	 	
	 	 	 	
Faeces	 Culture	 –	 on	
admission	
Not	taken	 					1	 0.22	
	 Taken	 1.57	(0.78,	3.20)	 	









	 Taken	 1.20	(0.71,	2.04)	 	






	 Taken	 1.28	(0.88,	1.85)	 	




12	hours	 Score	1-2	 1.55	(0.68,	3.52)	 	
	 Score	3-4	 4.65	(2.24,	9.67)	 	
	 	 	 	
Proteinuria		 Not	done	 					1	 0.84	
(worst	result)	 1		 1.00	(0.65,	1.55)	 	
	 2	or	3	 1.12	(0.76,	1.65)	 	
	 	 	 	
Sputum	 culture	 –	
within	 2	 weeks	 prior	
to	admission	
Not	taken	 					1	 0.68	
	 Taken	 0.65	(0.08,	5.17)	 	




	 Taken	 2.95	(1.17,	7.42)	 	
	 	 	 	






	 	 	 	
Wound	 Swab	 /	 Fluid	
Aspirate	culture	
Not	taken	 					1	 <0.001	
	-	on	admission	 Taken	 3.16	(1.94,	5.13)	 	








step	 in	 this	 multivariable	 analysis	 was	 to	 assess	 for	 collinearity,	 and	 in	 this	
analysis	 there	 was	 no	 strong	 evidence	 of	 collinearity	 between	 predictors,	 and	
hence	 all	 predictors	 could	 be	 considered	 as	 independent	 variables	 in	 the	
multivariable	analysis.	
	
To	 determine	 the	 final	 model,	 a	 backwards	 selection	 method	 was	 employed	
which	 retained	 only	 the	 statistically	 significant	 variables	 (in	 relation	 to	 the	
outcome	variable	of	worsening	AKI	at	72	hours).	This	resulted	in	the	removal,	in	
the	 following	 order	 of	 the	 variables:	 admissions	 in	 last	 2	 -12	 months,	 faeces	
culture	 –	 on	 admission,	 troponin,	 number	 of	 contrast	 radiology	 scans,	 K	
(potassium),	 HbA1c,	 gender,	 AMY	 (amylase),	 BNP	 (Brain	 Natriuretic	 Peptide),	





stream	 specimen	 urine	 (MSU)	 or	 catheter	 specimen	 urine	 (CSU)	 culture	 on	
admission,	 blood	 culture,	 sputum	 culture	 on	 admission,	modified	 Charlson	 co-
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In	 this	case	 the	majority	of	variables	are	removed	 from	the	 final	model,	and	as	
will	 be	 demonstrated	 below,	 the	 model	 has	 poor	 performance	 in	 terms	 of	
calibration	 and	 discrimination,	 which	 suggests	 we	 do	 not	 have	 the	 correct	
predictors.	As	with	the	previous	model	it	may	be	that	one	predictor	of	worsening	
AKI	in	hospital	is	the	quality	of	care	or	management	path	of	the	patient	with	AKI	
which	 is	 not	 assessed	 or	 recorded	 in	 this	 database	 study.	 In	 this	 model,	 the	
operative	 severity	 score	 remains	 in	 the	 final	 model,	 which	 likely	 represents	
patients	 who	 have	 an	 acute	 admission	 with	 a	 surgical	 problem,	 have	 AKI	 on	
admission,	but	require	an	emergency	operation	which	further	worsens	the	AKI.	
In	 this	model,	 unlike	 previous	models,	 the	 c-reactive	 protein	 (CRP)	which	 is	 a	
good	marker	of	 infection	/	 inflammation,	and	a	good	marker	that	the	patient	 is	
systemically	unwell,	 is	 removed	 from	the	model.	However,	 the	CRP	often	has	a	
lag	phase	in	that	it	rises	after	the	peak	of	a	patient	being	systemically	unwell,	and	






Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 0.01	
	 Infectious	diseases	 7.91	(2.06,	30.3)	 	
	 Circulatory	system	 2.20	(0.67,	7.23)	 	
	 Digestive	system	 1.30	(0.38,	4.44)	 	
	 Genitourinary	system	 3.54	(1.04,	12.0)	 	
	 Musculoskeletal	 1.48	(0.20,	10.8)	 	
	 Nervous	system	 0.81	(0.07,	9.45)	 	
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	 Respiratory	system	 1.92	(0.58,	6.38)	 	
	 Skin	 1.27	(0.27,	6.12)	 	
	 Endocrine/metabolic	 1.03	(0.25,	4.32)	 	
	 Injury/Poisoning	 2.64	(0.74,	9.43)	 	
	 Symptoms/signs	 1.18	(0.31,	4.55)	 	
	 Other	 0.41	(0.04,	4.37)	 	
	 	 	 	
Mg	(magnesium)	 Not	measured	 					1	 0.03	
	 Normal	(0.7	-	1.0)	 1.10	(0.64,	1.90)	 	
	 Abnormal	 2.25	(1.23,	4.13)	 	
	 	 	 	
PLT	(platelets)	 Not	 measured	 /	
Normal	(150	–	400)	
					1	 0.06	
	 Abnormal	 1.48	(0.99,	2.12)	 	
	 	 	 	
CK	(creatine	kinase)	 Not	measured	 					1	 0.01	
	 Normal	(≤	1000)	 1.54	(0.70,	3.39)	 	
	 Abnormal	 5.44	(1.72,	17.2)	 	









	 Score	1-2	 1.16	(0.44,	3.03)	 	
	 Score	3-4	 4.68	(1.91,	11.5)	 	
	 	 	 	
Wound	 Swab	 /	 Fluid	
Aspirate	Culture	
Not	taken	 					1	 		0.001	
	-	on	admission	 Taken	 2.63	(1.49,	4.64)	 	





As	evident	 from	Table	29	 the	 final	model	consisted	of	7	variables	/	predictors.	






risk	 model.	 The	 validation	 dataset	 consisted	 of	 778	 patient	 hospital	
admissions/episodes.	Of	those,	3	admissions	were	removed	due	to	missing	data	




To	 firstly	 assess	 validity,	 the	 patient	 hospital	 admissions/episodes	 were	
separated	into	risk	groups	based	on	the	predicted	probability	of	worsening	AKI.	
Due	to	the	smaller	sample	size	and	low	occurrence	of	the	outcome	of	worsening	
AKI	 in	 this	 analysis,	 three	 risk	 groups	 were	 used	 (as	 opposed	 to	 four	 in	 risk	
Models	1	and	2).	These	groups	were:	≤	4%,	4%	-	10%,	and	>	10%,	(see	Table	30).		
For	each	of	the	risk	groups	the	‘expected’	risk	was	calculated	based	on	predicted	





Risk	Group	 N	 Mean	Expected	%		 Observed	%	
	 	 	 	
≤	4%	 445	 2.6%	 7.4%	
4%	-	10%	 244	 5.9%	 7.0%	
>	10%	 86	 19.7%	 11.6%	
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The	 results	 of	 this	 analysis	 (Table	 30)	 suggest	 that	 the	model	 developed	 here	




Following	 this,	 based	 on	 the	 predicted	 probabilities,	 a	 Receiver	 Operating	











Finally,	 a	 Hosmer-Lemeshow	 test	 was	 performed	 to	 compare	 the	 numbers	 of	
patients/	 admissions	 experiencing	worsening	AKI	predicted	by	 the	model,	 and	
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≤	4%	 412	(433)	 33	(40)	 44.8	 <0.001	
4%	-	10%	 227	(229)	 17	(15)	 	 	
>	10%	 76	(69)	 10	(17)	 	 	
	 	 	 	 	
(*)	With	1	degree	of	freedom	
	


















which	 is	 a	 step	 towards	 the	 standardisation	 of	 care	 in	AKI	 across	 the	 country,	
and	 also	 allows	 the	 collection	 of	 national	 epidemiological	 data	 in	 AKI.	 Future	
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studies	from	around	the	country	will	also	be	more	easily	comparable.	In	order	to	
ensure	 compliance,	 transferability	 and	 generalisability	 of	 the	 work	 performed	
here	 across	 the	 NHS,	 the	 risk	 analysis	 of	 risk	 Models	 1	 (predicting	 AKI	 on	
admission	 to	 hospital)	 and	 2	 (predicting	 new	 AKI	 in	 72	 hours	 of	 admission),	












The	 development	 dataset	 included	 a	 total	 of	 32,626	 admissions	 from	 23,659	
patients.	 The	 outcome	 variable	 of	 interest	 in	 this	 model	 was	 the	 presence	 of	
acute	 kidney	 injury	 (AKI)	 on	 admission	 to	 hospital.	 In	 order	 to	 assess	 which	
variables	 in	 the	 dataset	 were	 associated	with	 the	 outcome	 variable,	 initially	 a	
series	 of	 univariable	 ordinal	 logistic	 regression	 analyses	were	 performed.	 The	
results	of	this	univariable	analysis	are	reported	in	Table	32.	In	this	analysis	the	
odds	ratios	(calculated	as	the	exponential	of	the	parameter	estimates	(beta))	are	
reported	 to	 demonstrate	 the	 sizes	 of	 the	 effects,	 with	 p-values	 to	 define	 the	
significance	of	each	variable	 in	 terms	of	 the	outcome.	This	univariable	analysis	
includes	both	 categorical	 variables	 in	which	 the	odds	 ratio	defines	 the	odds	of	
being	in	the	next	highest	outcome	category	(for	example	‘AKI	stage	1’	compared	
to	‘no	AKI’),	for	each	category	relative	to	a	baseline	category	(see	Table	32)	and	
continuous	variables	 in	which	 the	odds	ratio	defines	 the	relative	change	 in	 the	







Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 1.21	(1.18,	1.24)	 <0.001	
	 	 	 	
Sex	 Male	 					1	 0.007	
	 Female	 0.88	(0.81,	0.97)	 	




	 Yes	 1.05	(0.95,	1.17)	 	




	 1	-	2	 1.12	(1.01,	1.24)	 	
	 3	-	5	 1.19	(1.04.	1.36)	 	
	 6+	 1.08	(0.89,	1.30)	 	




in	last	12	months	 1	-	2	 0.97	(0.86,	1.09)	 	
	 3	-	5	 0.86	(0.76.	0.98)	 	
	 6+	 0.97	(0.86,	1.09)	 	
	 	 	 	
Admission	source	 Home	 					1	 <0.001	
	 Not	home	 1.84	(1.40,	2.43)	 	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 1.88	(1.37,	2.56)	 	
	 Blood	diseases	 0.72	(0.44.	1.17)	 	
	 Circulatory	system	 0.54	(0.41,	0.69)	 	
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	 Digestive	system	 0.75	(0.59,	0.97)	 	
	 Diseases	 of	 the	
head/neck	
0.19	(0.06,	0.60)	 	
	 Genitourinary	system	 1.89	(1.48,	2.43)	 	
	 Musculoskeletal	 0.16	(0.11,	0.24)	 	
	 Nervous	system	 0.27	(0.17,	0.43)	 	
	 Respiratory	system	 0.88	(0.68,	1.19)	 	
	 Skin	 0.63	(0.44,	0.90)	 	
	 Endocrine/metabolic	 1.56	(1.16,	2.10)	 	
	 Injury/Poisoning	 0.31	(0.23,	0.41)	 	
	 Mental	disorders	 0.49	(0.30,	0.79)	 	
	 Symptoms/signs	 0.29	(0.23,	0.37)	 	
	 Other	 0.09	(0.01,	0.64)	 	





	 Normal	(2.2	-	2.6)	 1.06	(0.92,	1.17)	 	
	 Abnormal	 2.60	(1.99,	3.40)	 	






	 Normal	(≤10)	 0.71	(0.61,	0.83)	 	
	 Abnormal	 1.40	(1.25,	1.57)	 	
	 	 	 	
Hb	 (haemoglobin)	
–	 most	 recent	
result	 in	 last	 30	
days	
Not	measured	 					1	 <0.001	
	 Normal	(f:	11	-	15)	(†)	 0.85	(0.76,	0.95)	 	
	 Abnormal	 1.42	(1.27,	1.59)	 	
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	 Normal	(≤	7.5)	 1.26	(1.08,	1.46)	 	
	 Abnormal	 1.79	(1.49,	2.16)	 	





	 Normal	(3.5	-	5.3)	 1.04	(0.95,	1.14)	 	
	 Abnormal	 1.79	(1.46,	2.19)	 	





	 Normal	(136	-	145)	 0.93	(0.84,	1.03)	 	
	 Abnormal	 1.54	(1.37,	1.75)	 	








	 NA	only	abnormal	 1.41	(1.23,	1.61)	 	
	 K	only	abnormal	 1.36	(1.01,	1.82)	 	
	 Both	abnormal	 2.66	(2.00,	3.54)	 	





	 Normal	(150	-	400)	 1.01	(0.92,	1.11)	 	
	 Abnormal	 1.40	(1.21,	1.63)	 	
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	 1	 1.63	(1.38,	1.92)	 	
	 2+	 1.92	(1.36,	2.70)	 	






	 Normal	(1	-	11)	 0.97	(0.88,	1.07)	 	
	 Abnormal	 1.55	(1.34,	1.78)	 	





	 Not	significant	 2.16	(1.86,	2.51)	 	
	 Significant	 4.86	(3.83,	6.15)	 	




	 1	-	10	 1.34	(1.17,	1.54)	 	
	 11+	 1.96	(1.74,	2.21)	 	
	 Not	recorded	 1.30	(1.10,	1.54)	 	






	 Quadratic	term	 0.89	(0.76,	1.03)	 	
	 Cubic	term	 1.01	(1.00,	1.02)	 	
	 	 	 	




	 Taken	 2.24	(1.66,	3.02)	 	









	 Not	significant	 1.03	(0.71,	1.49)	 	
	 Significant	 1.95	(1.67,	2.29)	 	
	 	 	 	
Proteinuria		 Not	done	 					1	 <0.001	
(worst	result)	 1		 1.28	(1.13,	1.44)	 	
	 2	or	3	 1.64	(1.44,	1.86)	 	





	 Taken	 1.00	(0.61,	1.64)	 	
	 	 	 	
Wound	 swab	 /	
fluid	 aspirate	




	 Not	significant	 0.59	(0.27,	1.25)	 	
	 Significant	 1.59	(1.22,	2.07)	 	






(+)	 Total	 number	 of	 the	 following	 drugs	 taken:	 angiotensin	 converting	 enzyme	 inhibitors	 (ACEi),	
angiotensin	receptor	blockers	(ARBs),	non-steroidal	anti-inflammatory	drugs	(NSAID),	diuretics	
	
The	 results	 reported	 in	 terms	 of	 odds	 ratios	 in	 Table	 32	 are	 clearly	
understandable	 for	 the	 categorical	 variables,	 however	 for	 the	 continuous	
variables	the	associations	between	these	variables	and	the	outcome	variable	of	


























































lower	 the	 kidney	 function,	 the	 higher	 the	 probability	 of	 AKI,	which	 again	 is	 in	






for	 collinearity	 suggested	 this	 existed	 between	haemoglobin	 (Hb),	white	 blood	
cell	 count	 (WBC)	 and	 platelets	 (PLT),	 and	 also	 between	 sodium	 (Na)	 and	
potassium	 (K).	 As	 described	 in	 the	 initial	 analysis,	 it	 was	 apparent	 that	 these	
pathology	blood	tests	were	performed	in	the	same	patients.	Therefore,	for	both	






was	 statistically	 significant	with	 respect	 to	 the	outcome	of	AKI,	 as	Hb	and	PLT	




assessed.	 In	 this	 analysis	 it	 appeared	 that	 both	 tests	 were	 independently	
associated	with	the	outcome	variable	of	AKI.	The	decision	was	therefore	made	to	
derive	a	 combined	variable	of	 the	 following	 categories:	 ‘not	measured’	 (one	or	
both	tests),	 ‘both	normal’,	 ‘Na	only	abnormal’,	 ‘K	only	abnormal’	and	‘both	tests	
abnormal’.		
	
To	 determine	 the	 final	 model,	 a	 backwards	 selection	 method	 was	 employed	
which	 retained	 only	 the	 statistically	 significant	 variables	 (in	 relation	 to	 the	
outcome	variable	of	AKI).	This	resulted	in	the	removal,	in	the	following	order	of	






the	 systemic	 effects	 of	 the	 infection	which	may	 precipitate	 an	 episode	 of	 AKI.	
Admissions	in	the	last	30	days	and	also	in	the	last	2	–	12	months	may	be	markers	











Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 1.80	(1.45,	2.24)	 <0.001	
	 Quadratic	term	 0.97	(0.96,	0.99)	 	
	 	 	 	
Sex	 Male	 					1	 0.04	
	 Female	 0.89	(0.80,	0.99)	 	




in	last	12	months	 1	-	2	 0.90	(0.79,	1.02)	 	
	 3	-	5	 0.74	(0.64.	0.76)	 	
	 6+	 0.78	(0.68,	0.89)	 	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 1.84	(1.33,	2.53)	 	
	 Blood	diseases	 0.79	(0.48,	1.31)	 	
	 Circulatory	system	 0.54	(0.41,	0.71)	 	
	 Digestive	system	 0.86	(0.66,	1.13)	 	
	 Diseases	head/neck	 0.24	(0.07,	0.79)	 	
	 Genitourinary	system	 1.98	(1.52,	2.58)	 	
	 Musculoskeletal	 0.20	(0.14,	0.30)	 	
	 Nervous	system	 0.35	(0.21,	0.56)	 	
	 Respiratory	system	 0.80	(0.62,	1.04)	 	
	 Skin	 0.65	(0.45,	0.95)	 	
	 Endocrine/metabolic	 1.47	(1.08,	2.01)	 	
	 Injury/Poisoning	 0.36	(0.27,	0.48)	 	
	 Mental	disorders	 0.56	(0.34,	0.92)	 	
	 Symptoms/signs	 0.37	(0.28,	0.48)	 	
	 Other	 0.11	(0.01,	0.76)	 	
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	 Normal	(2.2	-	2.6)	 0.86	(0.73,	1.01)	 	
	 Abnormal	 1.59	(1.16,	2.17)	 	





	 Normal	(≤10)	 0.75	(0.61,	0.92)	 	
	 Abnormal	 0.94	(0.79,	1.13)	 	
	 	 	 	
WBC	(White	Blood	Cell	
count)	 –	 most	 recent	
result	in	last	30	days	
Not	measured	 					1	 		0.001	
	 Normal	(1	-	11)	 0.93	(0.74,	1.16)	 	
	 Abnormal	 1.28	(0.98,	1.67)	 	





	 Normal	(≤	7.5)	 1.12	(0.95,	1.31)	 	
	 Abnormal	 1.41	(1.16,	1.72)	 	
	 	 	 	
Potassium	/	sodium	 Not	measured	 					1	 0.01	
Combined	 –	 most	
recent	 results	 in	 last	
30	days	
Both	normal	 0.93	(0.79,	1.15)	 	
	 NA	only	abnormal	 1.09	(0.86,	1.37)	 	
	 K	only	abnormal	 1.04	(0.73,	1.48)	 	
	 Both	abnormal	 1.64	(1.15,	2.35)	 	
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Troponin	 –	 tested	 in	
last	12	months	
0	 					1	 <0.001	
	 1	 1.37	(1.15,	1.65)	 	
	 2+	 1.58	(1.10,	1.65)	 	
	 	 	 	
Blood	 culture	 –	within	
2	 weeks	 prior	 to	
admission	
Not	taken	 					1	 <0.001	
	 Not	significant	 1.59	(1.34,	1.90)	 	
	 Significant	 2.81	(2.16,	3.67)	 	




	 1	-	10	 1.07	(0.92,	1.25)	 	
	 11+	 1.21	(1.05,	1.39)	 	
	 Not	recorded	 1.16	(0.96,	1.40)	 	





	 Quadratic	term	 0.93	(0.80,	1.09)	 	
	 Cubic	term	 1.01	(1.00,	1.03)	 	
	 	 	 	
Faeces	culture	–	within	
2	 weeks	 prior	 to	
admission	
Not	taken	 					1	 0.05	
	 Taken	 1.44	(1.00,	2.09)	 	
	 	 	 	
Mid-stream	 specimen	
of	 urine	 (MSU)	 or	
catheter	 specimen	 of	
urine	 (CSU)	 culture	 –	




	 Not	significant	 0.79	(0.54,	1.16)	 	
	 Significant	 1.29	(1.07,	1.55)	 	




(+)	 Total	 number	 of	 the	 following	 drugs	 taken:	 angiotensin	 converting	 enzyme	 inhibitors	 (ACEi),	
angiotensin	receptor	blockers	(ARBs),	non-steroidal	anti-inflammatory	drugs	(NSAID),	diuretics	
	
In	 this	 multivariable	 analysis,	 as	 would	 be	 expected	 following	 adjustment	 for	
other	variables	in	the	model,	the	effect	of	each	variable	on	the	outcome	variable	
of	 acute	 kidney	 injury	 (AKI)	was	 reduced,	 however	 the	 effects	were	 similar	 to	
those	demonstrated	in	the	univariable	analyses.		
	
As	 with	 the	 univariable	 analyses	 the	 continuous	 variables,	 age	 and	 baseline	
estimated	 glomerular	 filtration	 rate	 (eGFR),	 are	 difficult	 to	 interpret	 from	 the	
odds	ratios.	To	demonstrate	the	relationship	between	these	continuous	variables	
and	 the	outcome	variable	of	 acute	kidney	 injury	 (AKI),	 ‘average’	 values	 for	 the	
other	 variables	 in	 the	 model	 were	 assumed.	 Figure	 65	 plots	 age	 (a	 quadratic	
term	was	required)	against	the	adjusted	predicted	probability	of	AKI	and	Figure	





90.	 However,	 for	 baseline	 estimated	 glomerular	 filtration	 rate	 (eGFR)	 after	
adjusting	 for	 other	 variables	 in	 the	 model,	 there	 appears	 to	 be	 an	 increased	
probability	of	AKI	in	patients	with	both	a	lower	than	normal	(assuming	a	normal	
eGFR	of	60-120)	and	a	higher	than	normal	eGFR	(kidney	function)	(Figure	66).	In	
comparison	 with	 the	 initial	 analysis	 the	 re-analysis	 using	 the	 NHS	 England	
























































































































risk	 model.	 The	 validation	 dataset	 consisted	 of	 10,876	 patient	 hospital	
admissions/episodes.	 Of	 those,	 569	 admissions	 were	 removed	 due	 to	 missing	




To	 firstly	 assess	 validity,	 the	 patient	 hospital	 admissions/episodes	 were	
separated	into	risk	groups	(slightly	different	risk	groups	were	chosen	compared	
to	 the	 initial	 analyses)	 based	 on	 the	 predicted	 probability	 of	 AKI.	 This	 was	
performed	in	two	analyses,	firstly,	for	the	probability	of	any	AKI	as	the	outcome,	










Categorisation	 Risk	Group	 N	 Mean	Expected	
%		
Observed	%	
	 	 	 	 	
Any	AKI	 ≤	5%	 4955	 2.9%	 2.8%	
	 5%	-	10%	 3263	 7.1%	 6.1%	
	 10%	-	15%		 1095	 12.1%	 12.4%	
	 >	15%	 994	 22.4%	 20.2%	
	 	 	 	 	
AKI	stage	2	or	3	 ≤	2%	 5110	 1.2%	 0.8%	
	 2%	-	5%	 3754	 3.1%	 2.4%	
	 5%	-	10%		 1105	 6.9%	 6.9%	
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	 >	10%	 338	 14.1%	 11.2%	
	 	 	 	 	
	
In	both	analyses	the	observed	percentages	fell	within	the	boundaries	of	the	risk	
groups,	 suggesting	 good	 calibration.	 Table	 34	 also	 demonstrates	 a	 good	
agreement	 between	 the	 predicted/expected	 percentages	 and	 those	 that	 were	
observed	by	the	data,	particularly	for	the	‘any	AKI’	analysis.	
	
Following	 this,	 based	 on	 the	 predicted	 probabilities,	 Receiver	 Operating	
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Finally,	 a	 Hosmer-Lemeshow	 test	 was	 performed	 to	 compare	 the	 numbers	 of	
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Any	AKI	 ≤	5%	 4815	(4809)	 140	(146)	 98.3	 0.02	
	 5%	-	10%	 3064	(3030)	 199	(233)	 	 	
	 10%	-	15%		 959	(962)	 136	(133)	 	 	
	 >	15%	 793	(771)	 201	(223)	 	 	
	 	 	 	 	 	
AKI	stage	2	or	3	 ≤	2%	 5069	(3916)	 41	(59)	 14.1	 0.0009	
	 2%	-	5%	 3664	(3637)	 90	(116)	 	 	
	 5%	-	10%		 1029	(1029)	 76	(76)	 	 	
	 >	10%	 300	(290)	 38	(48)	 	 	




This	 test	 suggests	a	 lack	of	 fit	both	 for	 the	prediction	of	 the	outcome	 ‘any	AKI’	
and	 also,	 and	 more	 so,	 for	 ‘AKI	 stage	 2	 or	 3’	 as	 evidenced	 by	 a	 statistically	
significant	 difference	 between	 the	 numbers	 predicted	 by	 the	model	 and	 those	
observed	 in	 the	 data.	 For	 both	 outcome	 analyses,	 the	 model	 slightly	 over-
predicts	the	number	of	cases	of	AKI.	












model	 produces	 a	 value	 of	 0.73	 for	 the	 outcome	 of	 ‘any	 AKI’	 and	 0.76	 for	 the	
outcome	of	‘AKI	stage	2	or	3’.		
	
These	 results	 using	 the	 NHS	 England	 standardised	 definition	 of	 AKI	 are	 very	
comparable	to	the	initial	results	reported	here	using	the	lowest	creatinine	in	the	













The	 development	 dataset	 included	 a	 total	 of	 11,213	 admissions	 from	 9,367	
patients.	The	outcome	variable	of	interest	in	this	model	was	the	presence	of	new	
acute	kidney	injury	(AKI)	at	72	hours	into	hospital	admission.	In	order	to	assess	
which	 variables	 in	 the	 dataset	 were	 associated	 with	 the	 outcome	 variable,	
initially	 a	 series	 of	 univariable	 ordinal	 logistic	 regression	 analyses	 were	
performed.	The	results	of	 this	univariable	analysis	are	reported	 in	Table	37.	 In	
this	 analysis	 the	 odds	 ratios	 (calculated	 as	 the	 exponential	 of	 the	 parameter	
estimates	 (beta))	 are	 reported	 to	 demonstrate	 the	 sizes	 of	 the	 effects,	with	 p-












Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 1.71	(1.24,	2.35)	 <0.001	
	 Quadratic	term	 0.98	(0.96,	1.00)	 	
	 	 	 	
Sex	 Male	 					1	 0.50	
	 Female	 0.95	(0.82,	1.10)	 	
	 	 	 	
Admission	 in	 last	 30	
days	
No	 					1	 0.66	
	 Yes	 0.96	(0.81,	1.14)	 	




	 1	-	2	 1.06	(0.89,	1.25)	 	
	 3	-	5	 1.15	(0.93.	1.42)	 	
	 6+	 0.91	(0.68,	1.23)	 	




in	last	12	months	 1	-	2	 1.02	(0.84,	1.25)	 	
	 3	-	5	 1.04	(0.84.	1.28)	 	
	 6+	 1.10	(0.90,	1.34)	 	
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Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 1.07	(0.61,	1.86)	 	
	 Circulatory	system	 1.66	(1.13,	2.45)	 	
	 Digestive	system	 0.94	(0.62,	142)	 	
	 Genitourinary	system	 1.70	(1.11,	2.62)	 	
	 Musculoskeletal	 0.93	(0.49,	1.78)	 	
	 Nervous	system	 1.02	(0.49,	2.13)	 	
	 Respiratory	system	 0.98	(0.66,	1.46)	 	
	 Skin	 1.00	(0.56,	1.77)	 	
	 Endocrine/metabolic	 0.81	(0.44,	1.47)	 	
	 Injury/Poisoning	 1.29	(0.85,	1.94)	 	
	 Symptoms/signs	 0.54	(0.34,	0.87)	 	
	 Other	 0.66	(0.33,	1.29)	 	
	 	 	 	
ALT	 (alanine	
transaminase)	–	most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 0.34	
	 Normal	(≤50)	 0.89	(0.72,	1.10)	 	
	 Abnormal	 1.02	(0.76,	1.37)	 	
	 	 	 	
AMY	 (amylase)	 –	
most	 recent	 result	 in	
last	30	days	
Not	measured	 					1	 0.43	
	 Normal	(≤125)	 0.89	(0.73,	1.08)	 	
	 Abnormal	 1.06	(0.65,	1.73)	 	





	 Measured	 1.05	(0.64,	1.72)	 	
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Ca	 (Calcium)	 –	 most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 0.15	
	 Normal	(2.2	-	2.6)	 1.04	(0.89,	1.23)	 	
	 Abnormal	 1.39	(0.99,	1.93)	 	
	 	 	 	
CRP	 (C-Reactive	
Protein)	 –	 most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 		0.002	
	 Normal	(≤10)	 0.97	(0.71,	1.32)	 	
	 Abnormal	 1.29	(0.97,	1.72)	 	
	 	 	 	
Hb	 (haemoglobin)	 –	
most	 recent	 result	 in	
last	30	days	
Not	measured	 					1	 <0.001	
	 Normal	(f:	11	-	15)	(†)	 0.95	(0.57,	1.60)	 	
	 Abnormal	 1.44	(0.85,	2.43)	 	




	 Normal	(≤	7.5)	 1.36	(1.07,	1.74)	 	
	 Abnormal	 1.97	(1.46,	2.65)	 	
	 	 	 	
K	(potassium)	–	most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 <0.001	
	 Normal	(3.5	-	5.3)	 0.66	(0.51,	0.87)	 	
	 Abnormal	 0.93	(0.67,	1.13)	 	
	 	 	 	
Mg	 (magnesium)	 –	




	 Normal	(0.7	-	1.0)	 1.18	(0.95,	1.47)	 	
	 Abnormal	 1.38	(0.97,	1.97)	 	
	 	 	 	
Na	 (sodium)	 –	 most	





	 Abnormal	 1.35	(1.16,	1.57)	 	
	 	 	 	
PLT	 (platelets)	 –	





	 Abnormal	 1.35	(1.13,	1.61)	 	
	 	 	 	
Troponin	 –	 tested	 in	
last	12	months	
0	 					1	 <0.001	
	 1	 1.04	(0.86,	1.27)	 	
	 2+	 1.69	(1.36,	2.09)	 	
	 	 	 	
WBC	 (White	 Blood	
Cell	 count)	 –	 most	





	 Abnormal	 1.32	(1.14,	1.54)	 	
	 	 	 	
CK	 (creatine	 kinase)	
–	 most	 recent	 result	
in	last	30	days	
Not	measured	 					1	 0.02	
	 Normal	((≤	1000)	 1.34	(0.98,	1.84)	 	
	 Abnormal	 1.79	(1.08,	2.97)	 	
	 	 	 	
Blood	 culture	 –	 on	
admission	
Not	taken	 					1	 		0.009	
	 Taken	 1.29	(1.07,	1.56)	 	
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	 1	-	10	 1.14	(0.90,	1.44)	 	
	 11+	 1.76	(1.44,	2.16)	 	
	 Not	recorded	 1.24	(0.92,	1.66)	 	
	 	 	 	





	 Quadratic	term	 1.31	(1.07,	1.59)	 	
	 Cubic	term	 0.98	(0.96,	1.00)	 	





	 Taken	 0.96	(0.53,	1.74)	 	
	 	 	 	
Faeces	 culture	 –	 on	
admission	
Not	taken	 					1	 0.73	
	 Taken	 1.10	(0.65,	1.86)	 	
	 	 	 	
Mid-stream	specimen	
of	 urine	 (MSU)	 or	
catheter	 specimen	 of	




	 Not	significant	 1.03	(0.60,	1.77)	 	
	 Significant	 1.17	(0.86,	1.59)	 	
	 	 	 	
Mid-stream	specimen	 Not	taken	 					1	 <0.001	
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of	 urine	 (MSU)	 or	
catheter	 specimen	 of	
urine	 (CSU)	 culture	 –	
on	admission	
	 Taken	 1.60	(1.29,	1.97)	 	




	 Score	1-2	 1.53	(1.08,	2.17)	 	
	 Score	3-4	 2.21	(1.53,	3.20)	 	
	 	 	 	
Proteinuria		 Not	done	 					1	 <0.001	
(worst	result)	 1		 1.32	(1.08,	1.63)	 	
	 2	or	3	 2.19	(1.80,	2.65)	 	





	 Taken	 0.79	(0.33,	1.88)	 	
	 	 	 	
Sputum	 culture	 –	 on	
admission	
Not	taken	 					1	 0.08	
	 Taken	 1.67	(0.95,	2.93)	 	
	 	 	 	
Wound	 swab	 /	 fluid	
aspirate	culture	
Not	taken	 					1	 0.01	
	-	 within	 2	 weeks	
prior	to	admission	
Taken	 1.61	(1.11,	2.33)	 	
	 	 	 	
Wound	 swab	 /	 fluid	
aspirate	culture	
Not	taken	 					1	 <0.001	
	-	on	admission	 Taken	 1.81	(1.38,	2.37)	 	








The	 results	 reported	 in	 terms	 of	 odds	 ratios	 in	 Table	 37	 are	 clearly	
understandable	 for	 the	 categorical	 variables,	 however	 for	 the	 continuous	
variables	the	associations	between	these	variables	and	the	outcome	variable	of	
AKI	 are	 less	 clear.	 These	 associations	 are	 most	 effectively	 demonstrated	
graphically.	 The	 relationship	 between	 these	 continuous	 variables	 (age	 and	
baseline	estimated	glomerular	filtration	rate	(eGFR))	and	the	probability	of	acute	






















































step	 in	 this	 multivariable	 analysis	 was	 to	 assess	 for	 collinearity,	 and	 in	 this	
analysis	 there	 was	 no	 strong	 evidence	 of	 collinearity	 between	 predictors,	 and	
hence	 all	 predictors	 could	 be	 considered	 as	 independent	 variables	 in	 the	
multivariable	analysis.	
	
To	 determine	 the	 final	 model,	 a	 backwards	 selection	 method	 was	 employed	
which	 retained	 only	 the	 statistically	 significant	 variables	 (in	 relation	 to	 the	
outcome	variable	of	new	AKI	at	72	hours).	This	 resulted	 in	 the	removal,	 in	 the	
following	 order	 of	 the	 variables:	 faeces	 culture	 –	 within	 2	 weeks	 prior	 to	
admission,	admissions	 in	 the	 last	2	–	12	months,	outpatient	attendances	 in	 the	
last	 12	months,	mid-stream	 specimen	 of	 urine	 (MSU)	 or	 catheter	 specimen	 of	
urine	(CSU)	culture	–	within	2	weeks	prior	to	admission,	sputum	culture	–	within	
2	weeks	prior	to	admission,	admission	in	the	last	30	days,	troponin,	wound	swab	












































an	 episode	 of	 acute	 kidney	 injury	 and	 so	 this	 situation	 may	 reflect	 a	 patient	





co-morbidity	and	c-reactive	protein	(CRP)	have	fallen	out	of	 the	 final	model.	 In	
the	 case	 of	 CRP,	 the	 cultures,	white	 blood	 cells	 (WBC)	 and	 platelets	 (PLT)	 for	
example	may	be	providing	markers	of	 infection	and	hence	risk	of	AKI	over	and	








Variable	 Category	/	term	 Odds	Ratio	(95%	CI)	 P-value	
	 	 	 	
Age	(*)	 Linear	term		 1.17	(1.08,	1.26)	 <0.001	
	 	 	 	
Primary	diagnosis	 Neoplasms	 					1	 <0.001	
	 Infectious	diseases	 0.95	(0.54,	1.68)	 	
	 Circulatory	system	 1.75	(1.17,	2.61)	 	
	 Digestive	system	 1.07	(0.70,	1.64)	 	
	 Genitourinary	system	 1.54	(0.99,	2.39)	 	
	 Musculoskeletal	 0.85	(0.43,	1.67)	 	
	 Nervous	system	 1.21	(0.58,	2.59)	 	
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	 Respiratory	system	 0.96	(0.64,	1.45)	 	
	 Skin	 0.80	(0.44,	1.45)	 	
	 Endocrine/metabolic	 0.71	(0.38,	1.32)	 	
	 Injury/Poisoning	 1.16	(0.75,	1.80)	 	
	 Symptoms/signs	 0.71	(0.44,	1.16)	 	
	 Other	 0.67	(0.33,	1.35)	 	
	 	 	 	
ALT	 (alanine	
transaminase)	–	most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 0.04	
	 Normal	(≤50)	 0.89	(0.71,	1.11)	 	
	 Abnormal	 1.21	(0.88,	1.67)	 	




	 Normal	(≤	7.5)	 1.09	(0.84,	1.41)	 	
	 Abnormal	 1.63	(1.17,	2.26)	 	
	 	 	 	
K	(potassium)	–	most	
recent	 result	 in	 last	
30	days	
Not	measured	 					1	 		0.004	
	 Normal	(3.5	-	5.3)	 0.66	(0.50,	0.87)	 	
	 Abnormal	 0.82	(0.59,	1.15)	 	
	 	 	 	
Na	 (sodium)	 –	 most	





	 Abnormal	 1.24	(1.05,	1.45)	 	
	 	 	 	
PLT	 (platelets)	 –	






	 Abnormal	 1.34	(1.12,	1.61)	 	
	 	 	 	
WBC	 (White	 Blood	





	 Abnormal	 1.33	(1.14,	1.56)	 	
	 	 	 	
Blood	 culture	 –	 on	
admission	
Not	taken	 					1	 0.05	
	 Taken	 1.24	(1.01,	1.53)	 	





	 Quadratic	term	 1.46	(1.17,	1.81)	 	
	 Cubic	term	 0.98	(0.96,	0.99)	 	
	 	 	 	
Mid-stream	specimen	
of	 urine	 (MSU)	 or	
catheter	 specimen	 of	
urine	 (CSU)	 culture	 –	
on	admission	
Not	taken	 					1	 0.02	
	 Taken	 1.31	(1.05,	1.64)	 	




	 Score	1-2	 1.76	(1.18,	2.61)	 	
	 Score	3-4	 2.20	(1.48,	3.29)	 	
	 	 	 	
Proteinuria		 Not	done	 					1	 		0.001	
(worst	result)	 1		 1.02	(0.82,	1.28)	 	
	 2	or	3	 1.35	(1.08,	1.68)	 	
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Wound	 swab	 /	 fluid	
aspirate	culture	
Not	taken	 					1	 <0.001	
	-	on	admission	 Taken	 1.77	(1.32,	2.38)	 	




As	 evident	 from	 Table	 38,	 the	 variable	 ‘blood	 culture	 –	 on	 admission’	 was	 of	
borderline	significance	(p-value	of	0.05),	however	the	decision	was	made	to	keep	
this	 variable	 in	 the	 final	 model.	 In	 total	 the	 final	 model	 retained	 fourteen	







































































filtration	 rate	 (eGFR)	 and	 the	 adjusted	 predicted	 probability	 of	 AKI	 in	 the	
multivariable	analysis	(assuming	‘average’	values	for	all	other	variables),	which	
















risk	 model.	 The	 validation	 dataset	 consisted	 of	 3,738	 patient	 hospital	

















































the	 validation	 and	 development	 datasets	 demonstrated	 good	 matching,	 which	
would	be	expected	following	random	selection	method.	
	
To	 firstly	 assess	 validity,	 the	 patient	 hospital	 admissions/episodes	 were	
separated	 into	 risk	 groups	 based	 on	 the	 predicted	 probability	 of	 AKI.	 In	 this	
analysis	 in	 comparison	 to	 the	 initial	 analyses	 performed	 slightly	 different	 risk	
groups	 were	 chosen,	 and	 only	 the	 outcome	 ‘any	 AKI’	 was	 analysed.	 The	 risk	
groups	were	<5%,	5-10%,	10-15%	and	>15%	(see	Table	39).	For	each	of	the	risk	









Risk	Group	 N	 Mean	 Expected	
%		
Observed	%	
	 	 	 	 	
Any	AKI	 ≤	5%	 1662	 3.3%	 4.2%	
	 5%	-	10%	 1271	 6.9%	 8.9%	
	 10%	-	15%		 389	 12.0%	 12.9%	
	 >	15%	 216	 21.3%	 20.8%	
	 	 	 	 	
	
For	 the	 outcome	 ‘any	 AKI’	 Table	 39	 demonstrates	 a	 reasonably	 good	









Following	 this,	 based	 on	 the	 predicted	 probabilities,	 a	 Receiver	 Operating	
Characteristic	 (ROC)	 curve	 was	 plotted	 and	 the	 Area	 Under	 the	 Receiver	
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interpreted	 as	 a	 determination	 by	 chance	 and	 do	 suggest	 predictive	 ability,	
however	 not	 as	 great	 as	 that	 observed	 in	 risk	 Model	 1.	 This	 does	 however	
compare	very	well	with	that	reported	in	the	initial	analysis.		
	
Finally,	 a	 Hosmer-Lemeshow	 test	 was	 performed	 to	 compare	 the	 numbers	 of	



















	 	 	 	 	 	
Any	AKI	 ≤	5%	 1593	(1607)	 69	(55)	 10.9	 0.004	
	 5%	-	10%	 1159	(1183)	 112	(88)	 	 	
	 10%	-	15%		 339	(342)	 50	(47)	 	 	
	 >	15%	 171	(170)	 45	(46)	 	 	




This	 test	 suggests	 a	 lack	 of	 fit	 for	 the	 prediction	 of	 the	 outcome	 ‘any	 AKI’	 as	
evidenced	by	a	statistically	significant	difference	between	the	numbers	predicted	
by	 the	 model	 and	 those	 observed	 in	 the	 data.	 The	 Hosmer-Lemeshow	 test	 is	
known	 to	 be	 sensitive	 to	 slight	 differences	 between	 predicted	 and	 observed	
frequencies.		
	






The	 results	 for	 risk	 Model	 2	 (predicting	 new	 AKI	 at	 72	 hours	 into	 hospital	
admission)	reported	here	suggest	that	risk	Model	2	is	relatively	well	calibrated,	
however	its	discriminatory	ability	is	less	so	than	that	demonstrated	in	risk	Model	
1	 (predicting	 AKI	 on	 admission	 to	 hospital),	 with	 an	 area	 under	 the	 receiver	
operating	 characteristic	 curve	 (AUROC)	 of	 0.67	 (interpreted	 as	 poor)	 for	 the	
outcome	of	‘any	AKI’.	
	
These	 results	 using	 the	 NHS	 England	 standardised	 definition	 of	 AKI	 are	 very	
comparable	to	the	initial	results	reported	here	using	the	lowest	creatinine	in	the	
12	months	 prior	 to	 admission	 as	 the	 baseline	 creatinine	 from	which	 to	 define	
AKI.	
Summary of Results 
Table	42	summarises	the	outcomes	in	terms	of	discriminatory	power	of	the	risk	
models	 developed	 in	 this	 study.	 Risk	Model	 1,	 predicting	 the	 risk	 of	 a	 patient	
already	 having	 acute	 kidney	 injury	 (AKI)	 on	 admission,	 demonstrates	 the	 best	
discriminatory	 ability	 with	 an	 AUROC	 of	 0.75	 to	 predict	 any	 AKI	 and	 0.75	 to	
predict	AKI	 stage	2	or	3	 in	 the	East	Kent	Hospitals	University	NHS	Foundation	
Trust	 (EKHUFT)	 dataset.	 This	 AUROC	 (between	 0.7	 -	 0.8)	 is	 interpreted	 as	
providing	 a	 ‘fair’	 discriminatory	 ability.	When	 the	 risk	model	 is	 validated	 in	 a	
second	 population,	 the	 Medway	 NHS	 Foundation	 Trust	 dataset,	 the	
discriminatory	ability	of	the	model	 falls	slightly	to	an	AUROC	of	0.72	to	predict	
any	 AKI	 and	 0.71	 to	 predict	 AKI	 stage	 2	 or	 3,	 as	 might	 be	 expected	 in	 a	
demographically	 very	 different	 population.	 This	 does	 however	 remain	 a	 very	
similar	outcome	and	interpreted	as	the	model	again	having	‘fair’	discriminatory	
ability	 in	 the	 second	 population.	 This	 demonstrates	 good	 transferability	 and	
generalizability	of	the	risk	model.	
	






NHS	 England	 algorithm	 in	 comparison	 to	 0.75	 in	 the	 initial	 analysis	 for	
predicting	any	AKI,	and	0.76	using	the	NHS	England	algorithm	in	comparison	to	
0.75	in	the	initial	analysis	for	predicting	AKI	stage	2	or	3.	
In	Risk	Model	2,	 to	predict	new	AKI	at	72	hours,	 in	each	validation	dataset	 the	
model	showed	less	discriminatory	ability	to	predict	either	any	AKI	or	AKI	stage	2	
or	3	than	in	Risk	Model	1.	Again	the	model	showed	similar	discriminatory	ability	
in	 all	 validation	 populations,	 however	 in	 this	 case	 the	 ability	 of	 the	 model	 to	
predict	any	AKI	was	greater	in	the	second	population	(Medway),	with	an	AUROC	
of	0.71	in	comparison	to	the	initial	population	(EKHUFT)	with	an	AUROC	of	0.67.	
The	 converse	 was	 true	 in	 predicting	 AKI	 stage	 2	 or	 3,	 with	 the	 ability	 of	 the	
model	 to	 predict	 AKI	 stage	 2	 or	 3	 being	 greater	 in	 the	 initial	 population	
(EKHUFT)	 with	 an	 AUROC	 of	 0.68,	 in	 comparison	 to	 the	 second	 population	
(Medway)	 of	 0.63.	 In	 this	 respect	 we	 can	 say	 that	 the	 model	 was	 better	 at	






This	 further	 validation	 using	 the	 NHS	 England	 algorithm	 to	 define	 AKI	 was	















































































risk	 assessment	 within	 the	 first	 24	 hours	 of	 hospital	 admission.	 Traditional	
regression	 methods	 identified	 key	 variables	 which	 predict	 AKI	 both	 on	
admission	and	at	72	hours	post	admission.	Validation	demonstrated	an	AUROC	
of	 0.75	 and	0.68	 respectively.	 Predicting	worsening	AKI	 during	 admission	was	









at	 risk	 of	 AKI,	 in	 real-time	 to	 the	 point	 of	 care.	 Ultimately	 then	 a	 health	











in	morbidity,	 length	of	 stay	and	ultimately	mortality	both	 long	and	short	 term.	
With	growing	 literature	and	a	now	standardised	definition,	AKI	has	become	an	
increasingly	recognised	public	health	 issue	with	a	growing	 impetus	 to	 improve	
management.		
	
The	 overarching	 aim	 of	 this	 PhD	 thesis	 was	 to	 begin	 down	 a	 path	 of	 quality	
improvement	measures	to	improve	patient	safety	in	AKI.	Firstly,	by	defining	and	
highlighting	the	real	impact	of	AKI	(Chapter	2),	secondly,	developing	methods	to	





With	 the	 accepted	 and	 validated	 definitions	 of	 AKI	 reported	 in	 the	 literature	
(Chapter	1),	the	first	stage	of	the	work	here	was	to	assess	the	‘true’	impact	of	this	
disease.	 Previous	 work	 reported	 in	 the	 literature	 (Chapter	 1)	 had	 employed	
varying	 definitions	 and	 often	 in	 the	 setting	 of	 a	 large	 teaching	 hospital,	 not	
providing	sufficient	insight	into	the	incidence	and	outcomes	of	AKI	in	a	‘typical’	
general	 hospital	 setting.	 The	 epidemiological	 study	 reported	 in	 Chapter	 2	
(published	form	in	Appendix	2)	comes	closer	to	the	real	incidence	and	outcomes	
of	 AKI	 managed	 in-hospital.	 In	 this	 study	 fifteen	 per	 cent	 of	 all	 admissions	
sustained	 an	 episode	 of	 AKI	 with	 increased	 subsequent	 short	 and	 long	 term	
morbidity	 and	 mortality,	 even	 in	 those	 with	 AKI	 stage	 1.	 In	 comparison	 with	
patients	with	 no	 AKI	 those	with	 AKI	 stage	 1	 had	 a	 52%	 longer	 length	 of	 stay	
Michael	Bedford	 11905027	 275	
(LOS)	in	hospital,	a	2.8-fold	increased	risk	of	admission	to	the	intensive	therapy	

























step	 was	 to	 begin	 to	 improve	 its	 recognition	 and	 management.	 The	 NCEPOD	
report	100	(see	Chapter	1),	suggested	that	in	14%	of	patients	who	die	from	acute	





The	 management	 of	 AKI	 is	 not	 complex	 and	 involves	 simple	 assessment	 and	
interventions,	 such	 as	 fluid	 assessment	 and	 correction	 of	 hypovolaemia	 and	
hypotension,	 withholding	 nephrotoxic	 medications,	 assess	 drug	 dosages	 in	
respect	 to	 level	 of	 kidney	 function,	 looking	 for	 and	 treating	 infection	 early,	




Chapter	 3	 documents	 the	 development	 of	 a	 simple	 reporting/alerting	 tool	 to	
define	all	patients	within	a	hospital	trust	who	have	acute	kidney	injury,	the	stage	
of	 their	 disease,	 demographic	 details,	 clinical	 team	 and	 location	 within	 the	
hospital,	 to	 allow	 focused	 intervention	 by	 critical	 care	 outreach	 nurses	 and	
specialist	 renal	 consultants.	 The	 intervention	 also	 included	 the	 placing	 of	 a	
sticker	into	the	clinical	notes	of	a	patient	with	AKI	to	firstly	alert	to	the	presence	
of	AKI	 to	 all	members	of	 the	healthcare	professional	 team,	but	 also	 to	provide	
clear	 both	 generic	 and	 patient	 specific	 advice	 on	 the	 assessment	 and	
management	 of	 AKI,	with	 links	 to	 local	 guidance	 and	 points	 of	 specialist	 renal	
contact	for	advice.	The	AKI	alert	system	developed	here	was	named	SAKI	(Stop	
Acute	Kidney	Injury).	As	with	any	 information	technology	(IT)	solution	though,	
the	 potential	 value	 of	 the	 clinical	 system	 will	 not	 be	 realised	 without	 use	
acceptance	and	adoption.	In	order	to	address	this,	a	formal	qualitative	analysis	of	
the	 use	 of	 the	 SAKI	 alert	 system	 at	 East	 Kent	 Hospitals	 University	 NHS	
Foundation	 Trust	 (EKHUFT)	 was	 performed	 to	 provide	 insight	 into	 and	
explanation	 of	 the	 processes	 involved	 in	 using	 an	 alert	 system	 in	 clinical	 care	
(Chapter	 3).	 The	 study	 concluded	 that	 while	 the	 SAKI	 AKI	 alert	 system	 had	
significant	benefits	 in	 terms	of	 clinical	 intervention	 in	acute	kidney	 injury,	 and	
also	 the	 realisation	of	 unexpected	benefits	 such	 as	 the	 concept	 of	 education	 at	
the	 point	 of	 care,	 the	 study	 recognised	 a	 number	 of	 key	 areas	 that	 required	
improvement.	 The	 key	 areas	 included	 real-time	 delivery	 of	 AKI	 alerts,	 clear	
responsibility	of	care	to	be	with	the	clinical	 teams	with	advice	from	the	critical	
care	 outreach	 nurses	 and	 renal	 consultants	 as	 required,	 and	 improved	







the	 qualitative	 analysis	 and	 importantly	 to	 deliver	 these	 alerts	 to	 the	 point	 of	
care	 in	 real-time	and	 to	 the	 correct	health	 care	professional.	 In	a	development	
partnership	 with	 the	 company	 Doctor	 Communications	 Limited,	 the	 alerting	
platform	 “Careflow”	 was	 developed	 to	 provide	 real-time	 acute	 kidney	 injury	
(AKI)	 alerts	 to	 the	 clinical	 teams	 looking	 after	 the	 patients	 on	 their	 mobile	
devices,	accessible	anywhere.	The	system	also	re-aligns	the	clinical	responsibility	
for	 acting	 upon	 the	 alert,	 ensuring	 the	 responsibility	 remains	with	 the	 clinical	
team,	a	key	requirement	highlighted	in	the	qualitative	analysis	of	the	use	of	the	
previous	SAKI	 reporting	 system.	Unlike	other	alerting	and	clinical	 systems,	 the	
“Careflow”	platform	also	allows	a	clear	transparency	as	to	the	viewing	of	alerts	
(with	recorded	and	visible	user	views),	with	the	additional	ability	to	add	clinical	
comments/communication	 directly	 to	 alerts,	 and	 in	 this	 way	 allow	 real-time	
clinical	 communication/collaboration	around	an	alert,	 including	with	members	
of	the	specialist	critical	care	outreach	and	renal	teams.	With	an	improved	system	
in	place,	based	on	user	 level	 feedback,	 to	provide	real-time	alerting	of	patients	
with	acute	kidney	 injury	 to	 the	point	of	 care,	 this	will	 allow	early	 intervention	
and	management	 changes	 in	 those	patients	 in	 order	 to	 improve	outcomes	 and	
limit	resultant	complications	and	sequelae	from	AKI.		
		
Following	 a	 clear	 definition	 of	 the	 epidemiology	 of	 AKI	 (Chapter	 2)	 and	 the	
development	of	a	system	to	provide	clinical	alerting	of	the	presence	of	AKI	to	the	
point	of	care,	 the	next	stage	 in	 the	quality	 improvement	process	was	to	go	one	
step	 back	 in	 the	 disease	 process	 and	 focus	 on	 the	 ultimate	 form	 of	 treatment,	
namely	 prevention.	 By	 determining	 a	 patient’s	 risk	 of	 AKI	 it	 should	 then	 be	
possible	 to	 define	 and	 ultimately	 alert	 (using	 the	 described	 “Careflow”	 alert	
system)	to	high-risk	patients,	in	which	simple	interventions	can	be	instigated	to	





models	 focus	 on	 the	 need	 for	 renal	 replacement	 therapy	 (RRT)	 after	 cardiac	
surgery.	One	of	the	first	of	these	was	by	Chertow	et	al	who	produced	a	risk	model	
for	predicting	AKI	after	cardiac	surgery,	based	on	a	population	of	40,000	patients	
who	 underwent	 cardiac	 bypass	 or	 valvular	 surgery	 in	 43	 Veterans	
Administration	 Hospitals	 in	 Virginia.	 211	 A	 risk-stratification	 algorithm	 was	
formulated	on	the	basis	of	interactions	between	potential	risk	factors.	211	There	
were	 inherent	 flaws	 in	 the	 study	 cohort,	 specifically	 a	 lack	 of	 females	 and	
African-American	patients.	Thakar	et	al	produced	a	clinical	risk	score	to	predict	
post–cardiac	 surgery	 AKI	 requiring	 RRT,	 based	 on	 33	 217	 patients	 who	
underwent	cardiac	surgery	at	 the	Cleveland	Clinic	between	1993	and	2002.	 183	
The	 scoring	 system	was	derived	based	on	13	preoperative	 factors	which	were	






prediction	 of	 AKI	 in	 unselected	 emergency	 admissions	 to	 a	 district	 general	
hospital.	Finlay	et	al	published	a	recent	study	of	AKI	risk	factors	associated	with	





The	 aim	 of	 the	 study	 reported	 here	 was	 to	 develop	 risk	 models	 for	 the	
development	of	acute	kidney	injury	in	a	general	hospital	setting,	in	an	unselected	
population.	 While	 risk	 models	 can	 be	 employed	 at	 any	 point	 during	 hospital	
admission,	as	data	becomes	available,	as	was	clear	from	the	qualitative	analysis	
presented	 in	 Chapter	 3	 it	 is	 key	 that	 an	 alert	 of	 risk	 is	 delivered	 to	 the	 right	
person	at	 the	 right	 time	 in	order	 to	 inform	and	 influence	decision	making	and	
add	value	 to	a	patient’s	care.	 It	was	determined	therefore,	 that	 there	were	 two	
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The	 study	 here	 developed	 and	 assessed	 traditional	 methods	 to	 provide	 risk	






(ROC)	 curve	analyses	 suggest	 that	 there	 is	discriminatory	power	of	 the	model,	
and	with	an	Area	Under	the	Curve	(AUC)	value	of	0.75	this	is	acceptable	for	use	
in	clinical	practice.	This	has	been	validated	 in	a	 second	population.	This	model	




A	 risk	 model	 has	 also	 been	 developed	 (risk	 Model	 2,	 Chapter	 5)	 to	 predict	
patients	who	will	develop	new	AKI	in	the	first	72	hours	of	admission	to	hospital.	
The	 ROC	 curve	 analyses	 suggest	 that	 there	 is	 discriminatory	 power	 of	 this	
second	model	but	 this	 is	not	 as	 effective	as	 the	admission	model,	with	an	AUC	
value	of	0.68.	This	has	again	been	validated	in	a	second	population.	This	model	
was	 also	 re-defined	 with	 use	 of	 the	 NHS	 England	 algorithm	 (Appendix	 9)	 to	
define	AKI.	The	ROC	curve	analysis	demonstrated	an	AUC	of	0.67	with	use	of	this	
definition	of	AKI.	The	third	model	to	predict	worsening	AKI	in	the	first	72	hours	
of	 hospital	 admission	 (risk	 Model	 3,	 Chapter	 5)	 did	 not	 prove	 to	 have	 any	
discriminatory	power	and	would	not	provide	clinical	benefit.	This	was	therefore	
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not	validated	 further.	From	the	modelling	 to	predict	worsening	AKI	 in	 the	 first	
72	 hours	 of	 admission,	 these	 results	 suggest	 that	 key	 variables	 have	 not	 been	
included	in	the	model	or	that	the	development	of	AKI	in	hospital	is	subject	to	a	
random	effect,	which	is	not	measured.			The	model	to	predict	new	AKI	in	the	first	






study	 provides	 valuable	 evidence	 of	 the	 relationships	 between	 key	 variables	



















may	require	 infrastructure	changes	 in	some	NHS	hospitals;	however,	 there	has	




NHS	 England	 have	 recently	 made	 considerable	 progress	 in	 improving	 patient	




established	 acute	 kidney	 injury	 it	 does	 not	 address	 the	 issue	 of	 prevention	 of	
harm	 in	 the	 first	 place	 hence	 the	 requirement	 for	 the	 development	 of	 risk	
assessment	 tools	 a	 key	 recommendation	of	 the	NCEPOD	report.	 100	 In	 addition	
the	reporting	of	AKI	will	not	require	a	response	by	the	attending	medical	team	in	
other	words	 there	 is	 currently	 no	 requirement	 for	 a	 standardised	 response	 to	
alerts	to	established	AKI.		
	
The	 work	 reported	 here	 and	 a	 future	 study	 examining	 the	 impact	 of	 an	
automated	 alert	 will	 inform	 further	 national	 strategy	 with	 respect	 to	 AKI	
prevention.	 The	 work	 here	 and	 further	 studies	 examining	 the	 complexities	 of	
implementation	 of	 auditable	 clinical	 alerts	 have	 informed	 these	 workstreams	
and	in	the	future	will	provide	more	clarity	in	a	complex	area.		
	
To	 date	 there	 have	 been	 no	 intervention	 studies	 in	 comparable	 unselected	
populations	which	have	shown	a	reduction	in	episodes	of	acute	kidney	injury.	A	




The	 work	 reported	 here	 has	 demonstrated	 the	 significant	 morbidity	 and	
mortality	 both	 long	 and	 short	 term	 of	 patients	 who	 experience	 acute	 kidney	
injury	managed	in	hospital	and	has	developed	methods	of	alerting	the	presence	
of	AKI	 to	 the	point	of	 care	 in	 real-time	 to	ensure	efficient	 intervention	with	an	
aim	 to	 improve	 these	 outcomes.	 Qualitative	 work	 has	 also	 highlighted	 the	
complexity	regarding	the	implementation	and	delivery	of	alerting	systems	to	the	
clinical	 front	 line.	The	work	 reported	 in	 this	 thesis	has	also	demonstrated	 that	
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routinely	available	data	can	be	used	to	highlight	patients	at	risk	of	acute	kidney	
injury	 both	 at	 the	 point	 of	 admission	 to	 hospital	 and	 following	 admission.	
However,	 the	 methodology	 used	 has	 its	 limitations	 and	 further	 analysis	 and	
testing,	 including	 continuous	 modelling,	 non-linear	 modelling	 and	 interaction	
exploration	 may	 refine	 the	 model	 further.	 The	 work	 here	 provides	 valuable	
evidence	 of	 the	 relationships	 between	 key	 variables	 available	 from	 hospital	
electronic	records,	and	acute	kidney	injury.	Some	of	the	models	may	be	refined	





and	 national	 policy	 in	 the	 detection	 and	 management	 of	 acute	 kidney	 injury	
(AKI),	 and	 provides	 a	 firm	 basis	 for	 future	 work	 in	 both	 the	 fields	 of	 clinical	
alerting	and	risk	assessment.	Chapter	2	(and	published	in	the	academic	literature	
–	 see	 Appendix	 2:	 Paper	 2:	 What	 is	 the	 real	 impact	 of	 acute	 kidney	 injury?),	
brought	 our	 understanding	 closer	 to	 the	 real	 incidence	 and	 outcomes	 of	 AKI	
managed	in-hospital	than	any	study	published	in	the	literature	to	date.	This	work	
highlighted	 to	 both	 healthcare	 professionals	 and	 managers	 the	 importance	 of	
AKI	in	clinical	practice	both	in	terms	of	a	clear	understanding	of	morbidity	and	
mortality	and	subsequent	increased	burden	and	cost	to	the	healthcare	economy,	
(see	 Appendix	 3:	 Paper	 3:	 The	 economic	 impact	 of	 acute	 kidney	 injury	 in	
England).	 These	 results	 have	 provided	 a	 baseline	 for	 quality	 improvement	
projects	aimed	at	early	identification,	improved	management	and	where	possible	
prevention	 of	 AKI.	 The	 publication	 of	 these	 papers	 led	 to	 considerable	 debate	
within	 the	 media,	 the	 medical	 community,	 and	 at	 a	 high	 level	 within	 the	
Department	of	Health.	Following	this	NHS	England	released	a	patient	safety	alert	
(Stage	Three:	Directive)	mandating	 that	 all	Trusts	 in	England	alert	 to	AKI,	 and	




quality	 improvement	 partnership	 to	 raise	 awareness	 of	 and	 improve	 the	
management	of	AKI.	
	
After	 defining	 the	 true	 impact	 of	 AKI,	 and	 stimulating	 the	 debate	 within	 the	
medical	 community,	 the	 work	 here	 then	 progressed	 to	 methods	 of	 aiding	 the	
improvement	 of	management	 in	 clinical	 practice.	 The	work	 reported	 here	 has	
developed	 a	 simple	 reporting	 /	 alerting	 tool	 to	 define	 all	 patients	 within	 a	
hospital	 trust	 who	 have	 acute	 kidney	 injury	 (AKI),	 to	 allow	 focused	 and	
standardised	clinical	intervention	by	Critical	Care	Outreach	Nurses	and	specialist	
Renal	 Consultants.	 Importantly	 the	 use	 of	 Critical	 Care	 Outreach	 Nurses	 to	
support	 the	 management	 of	 AKI	 has	 been	 replicated	 in	 numerous	 other	 NHS	
trusts	throughout	England	following	this	work,	and	is	currently	being	tested	in	a	
project	 supported	 by	 the	 National	 Institute	 for	 Health	 Research	 (NIHR).	 The	
work	here	also	nurtured	the	 idea	of	education	at	the	point	of	care	with	Critical	
Care	Outreach	Nurses	trained	in	the	management	of	AKI	providing	education	to	
healthcare	 professionals	 including	 junior	 doctors	 and	 nursing	 staff,	 while	
reviewing	patients	with	AKI	following	the	alert.	
	
A	 qualitative	 study	 was	 performed	 to	 assess	 the	 integration	 of	 the	 alerting	
system	into	clinical	care.	While	a	small	study	this	provided	valuable	insights	into	
professional	 interactions,	 information	 sharing,	 and	 personal	 and	 professional	
characteristics	on	the	use	of	electronic	clinical	information	and	clinical	decision	
support.	 This	 work	 informed	 further	 developments	 in	 alerting	 to	 the	 point	 of	
care.	The	alerting	development	work	here,	as	part	of	a	development	partnership	
with	a	commercial	company,	developed	a	new	alert	system	to	provide	real-time	
alerting	 of	 patients	 with	 AKI	 to	 the	 point	 of	 care,	 utilising	 mobile	 device	
technology,	 and	 allowing	 collaboration	with	 specialist	 teams	 in	 real-time.	 This	
successful	 system	 has	 now	 been	 implemented	 in	 a	 number	 of	 NHS	 trusts	 in	























The	work	 described	 in	 this	 thesis	 is	 part	 of	 a	 quality	 improvement	 journey	 to	
begin	to	highlight	and	address	the	disease	process	of	acute	kidney	injury	(AKI)	in	
clinical	medicine	within	 the	 secondary	 care	 (hospital)	 environment.	Whilst	 the	
work	here	has	provided	valuable	insights	into	the	epidemiology,	natural	history	
in	 hospital,	 health	 care	 costs	 of	 the	 disease,	methods	 of	 alerting	 clinicians	 and	
healthcare	professionals	 as	 to	 the	presence	of	 the	disease	 and	 finally	 to	define	
key	variables	and	develop	risk	models	to	determine	risk	of	AKI,	this	work	cannot	
purport	to	have	defined	an	entire	quality	improvement	program	for	AKI.	There	is	





Kingdom	during	a	6-month	period.	The	catchment	population	 for	 this	cohort	 is	
from	East	Kent	 in	 the	South	East	Coast	of	England.	 In	comparison	to	 the	wider	
population	 in	 England	 East	 Kent	 has	 an	 older	 population	 (mean	 age	 42	 years	
compared	 to	 the	 national	 mean	 age	 of	 39)	 but	 with	 fewer	 ethnic	 minorities	
(6.3%	 of	 Black	 and	 Ethnic	 minority	 compared	 with	 14.6%	 nationally).	 105	












days	 of	 the	 event	 to	 distinguish	 this	 value	 from	 the	 baseline	 SCr.	 However,	
practically	in	many	cases	there	may	be	either	few	or	no	pre-hospitalisation	SCr	
values	making	distinction	between	baseline	and	reference	SCr	impossible.	This	is	
an	 area	 that	 requires	 further	 guidance	 and	 consensus	 from	 the	 international	
community	 and	 various	 strategies	 have	 been	 suggested	 including	 varying	 the	
baseline/	 reference	 creatinine	 from	 admission	 to	 365	 days	 prior,	 95	 taking	 the	
average	 of	 values	 between	 7–365	 days	 prior	 to	 admission,96	 back	 calculating	
reference	 SCr	 for	missing	 values	 from	an	 assumed	MDRD	glomerular	 filtration	
rate	of	75	ml/min/1.73	m2,	97	and	(most	recently)	a	method	employing	multiple	
imputation	 using	 known	 comorbidity	 strengthened	 by	 factoring	 in	 the	 lowest	
admission	 SCr.	 98	 For	 simplicity	 the	 lowest	 SCr	 in	 the	 12	months	 prior	 to	 the	
acute	rise	was	chosen	to	define	AKI.	 It	may	be	that	by	doing	this	 the	study	has	
included	 patients	 with	 progressive	 CKD	 and	 defined	 them	 as	 AKI	 stage	 1.	
However,	as	LaFrance	et	al.	95	demonstrated	and	the	data	here	confirms,	patients	





to	 categorise	 AKI	 (for	 those	without	 pre-hospitalisation	 creatinine)	 in	 8.2%	 of	
admissions	 with	 AKI.	 It	 is	 acknowledged	 that	 the	 assumption	 that	 AKI	 was	
present	 if	serum	creatinine	 improved	following	admission	by	greater	than	26.4	
μmol/l	 may	 not	 always	 be	 correct	 but	 use	 of	 this	 methodology	 was	 only	
necessary	 in	 8%	 of	 those	 categorised	 as	 having	 AKI.	 The	 incidence	 of	 AKI	 in	





reporting	 of	 AKI	 in	 trusts	 in	 England,	 which	 will	 address	 a	 number	 of	 these	
issues.	By	standardization	this	will	allow	clear	comparison	of	data	reported	from	
across	 England	 and	 the	 work	 conducted	 by	 the	 Renal	 Registry	 in	 partnership	
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any	 degree	 of	 AKI.	 The	 200	 patients	 in	 this	 group	 who	 did	 not	 survive	 the	











While	 the	 statistical	 models	 used	 in	 this	 analysis	 have	 accounted	 for	multiple	








Following	 on	 from	 the	 epidemiology	 to	 define	 the	 problem	 of	 acute	 kidney	
injury,	 the	next	 step	 in	 the	work	here	was	 to	develop	alerting	 systems	 to	alert	
healthcare	 professionals	 to	 the	 presence	 of	 AKI	 as	 soon	 as	 this	 information	 is	
available,	 aiding	 recognition	and	 in	doing	so,	 start	 to	 improve	 its	management.	
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The	 initial	 work	 here	 developed	 and	 implemented	 a	 reporting	 tool	 to	 define	
patients	 in	hospital	with	AKI	and	then	direct	specialist	 intervention	in	terms	of	
both	 critical	 care	 outreach	 and	 renal	 specialist	 services,	 to	 these	 patients.	 The	
qualitative	analysis	reported	here	has	provided	guidance	as	to	the	best	approach	
to	 further	 implementation	 of	 clinical	 alerting	 in	 AKI,	 however,	 this	 is	 a	 small	
scale	analysis	in	one	centre	and	as	such,	may	not	be	generalisable.	The	next	step	
in	development	 involved	a	partnership	with	a	commercial	 company	 to	provide	
real-time	 alerting	 of	 AKI	 to	 the	 point	 of	 care	 on	 mobile	 devices,	 accessible	
anywhere.	Whilst	 this	 aims	 to	 alert	 to	 the	presence	of	AKI	 to	 the	 clinical	 team	
looking	 after	 the	 patient	 the	 instant	 the	 known	 presence	 of	 AKI	 is	 available,	 a	
number	of	issues	do	need	to	be	addressed	in	future	work.		
	
Firstly,	 to	 date	 there	 have	 been	 no	 intervention	 studies	 involving	 alerting	
systems	 for	 AKI	 reported	 in	 the	 literature	 that	 have	 shown	 clear	 clinically	
statistically	 significant	 benefit	 in	 terms	 of	 reducing	 AKI	 progression	 and	
improving	outcomes	 in	 terms	of	morbidity	and	mortality.	Secondly,	 there	 is	no	
standardised	method	used	to	alert	to	AKI.	Over	the	last	5-years	methods	of	alert	
definition	 and	 delivery	 have	 been	 developed,	 often	 governed	 by	 resources	
available	 and	 logistic	 considerations	 at	 each	 hospital	 trust.	 While	 the	 patient	
safety	directive	from	NHS	England	goes	the	first	step	to	ensuring	alerting	occurs,	
it	does	not	define	a	method	of	delivery	of	alerts.	A	 future	multi-centre	study	 is	
required	 to	 test	various	methods	of	alert	delivery	 to	define	 the	best	method	to	
adopt	nationally	to	add	clinical	value	to	the	patient’s	care,	in	terms	of	improving	
outcomes	 in	 AKI.	 One	 other	 issue	 previously	 with	 AKI	 alerting	 nationally	 has	
been	 the	 differing	methods	 of	 defining	 baseline	 kidney	 function,	 however,	 this	
has	 been	 addressed	 with	 the	 NHS	 England	 national	 algorithm	 for	 AKI	 as	
described.		
	
In	 terms	 of	 generalizability	 the	 resources	 of	 each	 NHS	 trust	 must	 be	 a	
determinant	 factor	 in	 AKI	 alerting	 delivery.	 Whilst	 some	 trusts	 may	 have	 full	
coverage	of	wireless	services	with	an	extensive	wireless	network	and	all	 junior	
and	senior	doctors	and	specialist	nurses	having	trust	mobile	devices,	others	may	
be	 technologically	 far	 behind	 this	 position,	 especially	 in	 the	 current	 financial	
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climate.	 This	 does	 suggest,	 however,	 that	 a	 health	 technology	 assessment	 is	
required	 in	 this	 area	 to	 ensure	 such	 systems	 can	 deliver	 clinical	 cost	
effectiveness.	It	also	raises	a	question	of	a	bring	your	own	device	(BYOD)	policy	




The	next	step	 in	 the	work	described	here	moved	one	stage	back	 in	 the	disease	
process	of	AKI	to	the	ultimate	form	of	treatment,	namely	prevention.	In	the	AKI	
risk	modelling	analysis	presented	here	to	develop	risk	models	to	predict	AKI	on	
admission	 to	 hospital	 and	 at	 72	 hours	 into	 the	 hospital	 admission,	 the	
weaknesses	 of	 this	 study	 include	 the	 fact	 that	 this	 was	 a	 retrospective	 cohort	
study	using	hospital	databases	 to	 find	predictors	of	acute	kidney	 injury.	 It	was	
carried	out	 in	 a	 small	 geographical	 area	of	 England	 (Kent)	 and	 covered	 a	 one-











In	 future	 work,	 further	 analysis	 and	 testing,	 including	 continuous	 modelling,	
non-linear	modelling	and	interaction	exploration	may	refine	the	models	further.			




However,	 the	 study	 reported	here	used	 a	 very	 large	unselected	dataset,	which	
represents	 the	 kind	 of	 populations	 presenting	 to	 the	majority	 of	 UK	 hospitals.	
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Whilst	there	was	no	cardiothoracic	surgery	performed	at	either	hospital,	AKI	in	
this	 setting	 has	 been	 extensively	 studied	 and	 represents	 a	 very	 small	 and	
unrepresentative	 group	 of	 people	 with	 AKI.	 The	 study	 was	 carried	 out	 using	
robust	 methodology,	 the	 initial	 dataset	 used	 to	 develop	 the	 models	 was	
randomly	 selected	 from	all	hospital	 admissions	over	a	year	on	a	3:1	 ratio.	The	
model	was	validated	in	the	remainder	of	the	population	and	then	subsequently	
tested	in	a	second	population	from	a	different	hospital	trust	demonstrating	that	
ethnic	 and	 social	 differences	 had	 little	 effect	 on	 the	 models,	 neither	 did	 the	
potential	 difference	 in	 coding	 practices	 between	 organisations.	 The	work	 here	
has	 therefore	 been	 able	 to	 demonstrate	 that	 these	 models	 can	 transfer	 to	
another	hospital	 trust,	 however	 these	models	may	only	provide	 a	platform	 for	
further	analysis	and	refinement	before	they	can	be	employed	more	widely.	This	





alerting	 in	 clinical	 care,	 in	 terms	 of	 clinical	 benefit	 and	 cost	 effectiveness.	 In	
future	 work	 another	 important	 consideration	 is	 the	 use	 of	 AKI	 as	 a	 clinical	




alerting	 systems	 such	 as	 the	 National	 Early	 Warning	 Score	 (NEWS)	 and	
definitions	 of	 SIRS	 (systemic	 inflammatory	 response	 systems)	 and	 more	
importantly	sepsis.		
	
The	 National	 AKI	 program	 is	 aimed	 at	 addressing	 a	 number	 of	 the	 above,	
unanswered	 questions	 and	 providing	 standardisation	 of	 definition	 and	 clinical	



















































































































































































































































































































































































































































































































































































































































Acute Kidney Injury and CKD: Chicken or Egg?
Recent longitudinal cohort studies have suggestedthat episodes of acute kidney injury (AKI) with
only small transient decreases in kidney function are
associated with the subsequent development of chronic
kidney disease (CKD).1-6 Both CKD and, more re-
cently, AKI are well recognized as global public
health issues, associated with significant morbidity
and mortality and resultant health care economic
burden. There is considerable conceptual overlap and
interplay between the underlying pathophysiology
and pathology, definition, risk factors, and outcome of
the 2 conditions. Do silent and unrecognized episodes




Determining the pathophysiology and pathology
underlying acute kidney disease and CKD helps us
understand their conceptual overlap and how to accu-
rately detect and define them. Changes in renal vascu-
lature occur with age, as in other vascular beds, often
due to comorbid conditions, but also in their absence.7
It is suggested that these changes eventually cause
cortical glomerulosclerosis, interstitial fibrosis and
tubular atrophy, and compensatory hypertrophy and
hyperfiltration of glomeruli in the medulla, contribut-
ing to CKD development.8 It also has been suggested
that low birth weight is associated with subsequent
CKD through low nephron number and compensatory
hypertrophy and hyperfiltration of glomeruli.9 With
increasing age and CKD, function in both proximal
and distal tubules is compromised, hampering the
ability to control fluid and electrolyte balance and
affecting tubuloglomerular feedback.7,10 These
changes may exacerbate clinical events such as dehy-
dration and drug toxicity, which carry a high risk of
AKI.8 Given that people with CKD have an increased
burden of vascular disease, they may be more suscep-
tible to ischemic AKI. Supportive data from animal
models suggest AKI as a “vasomotor nephropa-
thy,”11,12 but what happens after AKI? Renal tissue
has the ability to recover from sublethal or lethal
cellular damage.13-17 However, function may not be
fully restored, with the development of CKD.14 Kid-
ney function may be related directly to a cycle of cell
injury and recovery after AKI (Fig 1A).18 Damage to
renal tubular epithelial cells is thought to be extended
by renal vascular endothelial injury and dysfunction.
Endothelial repair is important to overall recovery and
thus may have an impact on long-term function.19
This model describing cellular phases of AKI applies
to acute tubular necrosis, but can be extrapolated to
other causes of AKI. What happens most frequently is
limited to the very early part of this process. In
patients developing CKD (Fig 1B), the initiating in-
sult leading to damage, inflammation, and repair (ini-
tiation) may result in fibrosis (extension) and then
further damage in a self-perpetuating cycle of progres-
sion (maintenance) to end-stage renal disease (ESRD).
Early intervention at the stages of initiation and exten-
sion may prevent CKD and ESRD, whereas later
intervention during the maintenance stage may only
delay progression, with the extent of delay determined
by the success or otherwise of intervention. Patients
with AKI may or may not have pre-existing CKD (Fig
1C). Okusa et al20 (pathophysiologic concepts from
Sutton et al18) suggest that after AKI, there are 4
possible outcomes: (1) full recovery, (2) incomplete
recovery resulting in CKD, (3) exacerbation of pre-
existing CKD accelerating progression to ESRD, and
(4) nonrecovery of function leading to ESRD. AKI
also may recover incompletely, leading to a step down
in glomerular filtration rate (GFR) falling short of
CKD. Patients with AKI are also likely to have risk
factors for CKD; thus, patients without known back-
ground CKD who develop AKI may already have
unrecognized kidney disease and decreased func-
tional reserve, not yet manifest as CKD. These pa-
tients are programmed to develop future CKD, and
the AKI episode simply speeds up the development of
overt CKD. In this respect, renal outcomes of AKI and
CKD are the same, suggesting they are part of the
same pathophysiologic pathway.
A key question is whether the “I” in AKI truly
stands for injury or for impairment and/or injury. Is it
underpinned by histopathologic damage and, if so,
when does this become relevant in terms of future
CKD and/or progression? Do undetected episodes of
AKI in the community lead to CKD? When patients
present with CKD without an obvious cause, is the
pathophysiology related to multiple undetected AKI
events in the community?
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From an ischemia-reperfusion injury model of AKI
in rats, Basile et al19 hypothesized that as long as there
is adequate functional reserve, the single-nephron
GFR of surviving nephrons increases to maintain a
constant total GFR. This suggests that even in patients
in whom creatinine and GFR values return to base-
Figure 1. Conceptual model of glomerular filtration rate (GFR) and cellular pathology over time in acute kidney injury (AKI), chronic
kidney disease (CKD), and AKI and CKD. (A) The cellular phases of AKI leading to repair, highlighting the possibility of initiating a
self-perpetuating cycle of inflammation producing fibrosis leading to CKD. (B) The phases of cellular injury in CKD. After an initial insult,
there is initiation of the inflammatory response with repair. This then may lead to the extension phase with added fibrosis. Past a point of
no return, the disease process embarks on a self-perpetuating cycle of cellular damage and fibrosis (maintenance phase) leading to
deterioration in GFR and progression to end-stage renal disease. The figure also shows the effect of intervention on the disease
process. (C) The effect of episodes of AKI on the progression of CKD with 3 possible outcomes; complete recovery, stepwise
progression, and inexorable decline.





line, there may be underlying permanent damage
masked by compensatory mechanisms. These patients
subsequently may have an increased risk of CKD and
AKI due to underlying “subclinical” damage.
Are AKI and CKD biologically part of the same
pathologic pathway with eventual glomerulosclerosis
and interstitial fibrosis, with AKI leading to fibrosis




The difficulty comes with the necessary time con-
straints. For AKI, there must be an increase in serum
creatinine level over 2 (Acute Kidney Injury Network
[AKIN] criteria21) to 7 (RIFLE classification22) days.
For CKD to exist, GFR must be decreased or there
must be evidence of kidney damage for at least 3
months.23-25 These definitions may not capture all
cases of acute kidney disease. Certain causes may
lead to changes in serum creatinine and GFR values
during a time outside those currently specified, preclud-
ing definition. These cases should not be neglected
because intervention may be required. For this reason,
the new KDIGO (Kidney Disease: Improving Global
Outcomes) AKI guideline proposes an operational
definition for acute kidney diseases and disorders
(AKDs), of which AKI is a part, and provides a
diagnostic algorithm for defining AKD, AKI, and
CKD (Fig 2).26
Accurate definition has important research implica-
tions. Previously, variation in definitions used and
populations studied made determination of epidemiol-
ogy and the interplay between AKI and CKD more
difficult. This has been improved by adoption of the
RIFLE and AKIN classifications of AKI. However,
problems arise when baseline creatinine level is not
known. A retrospective cohort study by LaFrance and
Miller27 assessed 1,126,636 veterans (US Department
of Veterans Affairs health care system) hospitalized at
least once between 2000 and 2005. The highest serum
creatinine level during hospitalization was compared
with the lowest using 4 different baseline periods
(in-hospital only and 3, 6, or 12 months preadmis-
sion). AKI was defined as a greater than 1.5-fold
increase in serum creatinine level or an increase of
0.3-0.5 mg/dL over baseline.27 The cumulative inci-
dence of AKI ranged from 12.5% (in-hospital base-
line) to 18.3% (baseline up to 12 months preadmis-
sion). By extending the baseline period to at least 3
months, they found that discriminative power in-
creased slightly (C statistic increased from 0.846 to
0.855; P ! 0.001). They suggested a need for consen-
sus on defining baseline in database studies. The
KDIGO AKI guideline suggests that an estimated
creatinine level can be used provided there is no
evidence of CKD.26 However, there are cases of CKD
in the community not previously appreciated. Estimat-
ing baseline creatinine level in these cases may lead to
the diagnosis of AKI in patients with previously
unrecognized CKD.
Definitions of both AKI and CKD in the literature
may not be accurate or comparable. For example, the
Figure 1. (Continued)




definition of CKD based on diagnostic coding or
preoperative GFR taken as baseline function can
introduce bias in detection. Singh et al28 suggested
that differences also could reflect greater specificity of
administrative codes for AKI in patients without CKD.
This emphasizes the need for consensus about the
definition of baseline function.
By defining AKI and CKD, we are describing
decreased function, which can lead to complications
including ESRD and mortality. In disease prevention/
detection, we therefore aim for risk modification.
There clearly is a significant overlap in risk factors for
AKI and CKD. Elderly patients have a higher preva-
lence of AKI and CKD related to an increased preva-
lence of comorbid conditions (hypertension, diabetes,
atherosclerotic disease, and cardiac insufficiency).29
This is at least partly due to an increased prevalence
of comorbid conditions with age. With common risk
factors that may be playing a pathophysiologic role,
the entities of AKI and CKD may be a process of
definition of the same pathophysiologic pathway. The
significant overlap in risk factors also makes investi-
gation of CKD as a risk factor for AKI, and the
converse, difficult. Is it possible to accurately correct
for all confounding variables?
AreCKDandAKIRisk Factors for EachOther?
The literature suggests that CKD is a significant
risk factor in the development of AKI.1,30-34 In a
number of studies, after multivariate adjustment for
comorbid conditions, CKD consistently remains an
independent risk factor for AKI after radiocontrast
administration, cardiac surgery, and sepsis.35 Table 1
lists evidence from the literature showing over-
representation of CKD in the population that develops
AKI, suggesting that CKD is a risk factor for AKI.
There also is mounting evidence that AKI is a risk
factor for or, more accurately, “contributes” signifi-
cantly to CKD and CKD progression, leading to
ESRD (Table 1). Hsu et al41 suggested that the growth
of ESRD incidence in the United States could not be
accounted for solely by an increase in CKD incidence
and may be attributable in part to AKI. A population-
based study by Ali et al42 compared patients with
acute on chronic kidney disease with those with AKI
alone. Patients with acute-chronic kidney disease were
older, with less chance of renal recovery.42
Is part of the increased risk of AKI in patients with
background CKD the fact that they are heavily bur-
dened with comorbid conditions, as a result of which
they are more likely to experience nephrotoxic insults
such as radiocontrast nephropathy? The CKD popula-
tion also is more likely to be using angiotensin-
converting enzyme inhibitors, angiotensin receptor
blockers, and diuretics, increasing susceptibility to
AKI. This population is more likely to have kidney
function tested and AKI discovered. Conversely, pa-
tients without pre-existing CKD have fewer comorbid
conditions, are less likely to be using susceptibility
agents, and are less likely to have kidney function
checked; hence, AKI (especially milder stages) may
remain undiscovered. We suggest that these “silent
and discrete” episodes of AKI in the community may
relate to CKD development and progression. How-
ever, data are lacking in the literature and this requires
further investigation.
What Is theEffect ofAKI andCKDonOutcome? Is It
Summative?
In terms of nonrenal outcomes, there is clear evi-
dence that outcome from AKI is poor. From local
data, only 56% of patients who experienced severe
CKDAKIAKD
NKD
Func!onal Criteria Structural Criteria
AKI (acute kidney injury) Increase in SCr by 50% within 7 days, or increase 
in SCr by 0.3 mg/dL within 2 days, or oliguria
No criteria
CKD (chronic kidney 
disease)
GFR <60 for >3 mo Kidney damage for 
>3 mo
AKD (acute kidney 
diseases and disorders)
AKI, or GFR <60 for <3 mo, or decrease in GFR by 
≥35% or increase in SCr by >50% for <3 mo
Kidney damage for 
<3 mo
NKD (no known kidney 
disease)
GFR ≥60, stable SCr No kidney damage
Figure 2. Definitions of kidney dis-
ease and their overlapping relationship.
Estimated glomerular filtration rate (GFR
[mL/min/1.73 m2] assessed from mea-
sured or estimated GFR) does not reflect
measured GFR as accurately in acute
kidney injury (AKI) as in chronic kidney
disease (CKD). Abbreviation: SCr, serum
creatinine. Adapted from the KDIGO (Kid-
ney Disease: Improving Global Out-
comes) AKI guidelines,26 with permission
of KDIGO.




AKI in the hospital survived to discharge; only 28%
survived to 3 years post discharge.43 Most studies of
AKI in the intensive care unit report mortality !50%.
Intensive care unit and in-hospital mortality increase
as the severity of AKI increases.3,34,36,42,44-52 Even
small isolated increases in serum creatinine level have
an associated increase in short-term morbidity and
mortality and longer term outcomes, including 1-year
mortality.3,34,44,53-57 However, could it be that AKI is
not a risk factor for these outcomes, but is a risk
marker of systemic illness? We know that isolated
AKI without other organ involvement has a better
prognosis than AKI in the context of multiorgan
failure.
CKD also has been shown as an independent
predictor of morbidity and mortality.58,59 We there-
fore would assume that AKI in CKD has a summa-
tive effect on outcome. Studies show lower in-
hospital mortality in patients with AKI on a
background of CKD compared with patients without a
background of CKD.35,37,49,60-63 This would seem
counterintuitive. One explanation might be that pa-
tients with CKD require less of an insult to manifest
clinically apparent AKI or are more likely to have
their kidney function tested and AKI discovered; thus,
severity of the AKI episode is less in these patients
with CKD and hence outcomes are better. Conversely,
those with CKD may have more resilience to acute
insults secondary to conditioning or priming and
tolerate AKI better. It is also possible that those with
CKD receive better/different care than non-CKD coun-
terparts when AKI is identified, thus affecting out-
comes. It also has been suggested that results may be
confounded by malnutrition (lower serum creatinine
values from low muscle mass).50
Conclusion
To conclude, both AKI and CKD confer significant
morbidity and mortality. Regardless of which is the
chicken or the egg, the risk factors and pathophysiol-
ogy underlying AKI and CKD are similar. Should we
consider AKI and CKD as part of the same pathologic
pathway and a continuum over time and surmise,
based on a 2-hit theory, that AKI before the diagnosis
of CKD contributes to CKD and that AKI after the
diagnosis of CKD exacerbates it? With an ageing
population and increasing comorbidity burden, AKI
and CKD will continue to have a significant impact on
Table 1. The Association Between CKD and AKI From the Literature
Study Population Conclusions
CKD as a Risk Factor for AKI
Nash et al,36 2002 Consecutive medical and surgical admissions of an
urban tertiary-care hospital; N " 4,622
7.2% developed AKI, of which 45.5% had
baseline SCr !1.2 mg/dL
Chertow et al,37 2006 618 ITU patients with ARF; data from PICARD 32% of patient with ARF had baseline GFR #30
Hsu et al,38 2008 1,746 AKI patients requiring dialysis compared with
600,820 hospitalized patients who did not
develop AKI
ORs for developing AKI, by GFR:





LaFrance et al,39 2010 CKD population with GFR !30 44% had a least one episode of AKI over a
median of 19.4-mo follow-up
James et al,40 2010 920,985 adults with "1 outpatient SCr Risk of admission with AKI increased with
heavier proteinuria and decreased GFR
AKI as a Risk Factor for CKD
Ishani et al,1 2009 233,803 patients hospitalized in 2000, aged "67 y
on discharge; did not have previous ESRD or AKI
Of patients with AKI and no background CKD,
72.1% had CKD documented within 2 y of
AKI
Triverio et al,2 2009 89 patients requiring RRT on ITU After AKI, 50% of patients without background
CKD progressed to CKD within 3 y
Mehta et al,3 2004 618 ITU patients with ARF; data from PICARD In-hospital mortality rate, 37%; rate of mortality
or nonrecovery of kidney function, 50%
Mehta et al,4 2002 552 ITU patients with ARF Of 258 patients who survived (47%), 17 (7%)
were dialysis dependent after discharge
Note: Conversion factor for SCr in mg/mL to #mol/L, $88.4; GFR given in mL/min/1.73 m2 (for conversion to mL/s/1.73 m2,
$0.01667).
Abbreviations: AKI, acute kidney injury; ARF, acute renal failure; CKD, chronic kidney disease; ESRD, end-stage renal disease;
GFR, glomerular filtration rate; ITU; intensive treatment unit; OR, odds ratio; PICARD, Program to Improve Care in Acute Renal
Disease; RRT, renal replacement therapy; SCr, serum creatinine.




health care economies. It is important that further
effort is focused on improving the definition, diagno-
sis, effective prevention, and treatment of both condi-
tions. Better understanding of this complex interplay
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What is the real impact of acute kidney injury?
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Abstract
Background: Acute kidney injury (AKI) is a common clinical problem. Studies have documented the incidence of
AKI in a variety of populations but to date we do not believe the real incidence of AKI has been accurately
documented in a district general hospital setting.
The aim here was to describe the detected incidence of AKI in a typical general hospital setting in an unselected
population, and describe associated short and long-term outcomes.
Methods: A retrospective observational database study from secondary care in East Kent (adult catchment
population of 582,300). All adult patients (18 years or over) admitted between 1st February 2009 and 31st July 2009,
were included. Patients receiving chronic renal replacement therapy (RRT), maternity and day case admissions were
excluded. AKI was defined by the acute kidney injury network (AKIN) criteria. A time dependent risk analysis with
logistic regression and Cox regression was used for the analysis of in-hospital mortality and survival.
Results: The incidence of AKI in the 6 month period was 15,325 pmp/yr (adults) (69% AKIN1, 18% AKIN2 and 13%
AKIN3). In-hospital mortality, length of stay and ITU utilisation all increased with severity of AKI. Patients with AKI
had an increase in care on discharge and an increase in hospital readmission within 30 days.
Conclusions: This data comes closer to the real incidence and outcomes of AKI managed in-hospital than any
study published in the literature to date. Fifteen percent of all admissions sustained an episode of AKI with
increased subsequent short and long term morbidity and mortality, even in those with AKIN1. This confers
an increased burden and cost to the healthcare economy, which can now be quantified. These results will
furnish a baseline for quality improvement projects aimed at early identification, improved management, and
where possible prevention, of AKI.
Keywords: AKI, Incidence, Impact, Outcomes, General hospital
Background
Acute kidney injury (AKI) is a common clinical problem
characterised by an abrupt decline in kidney function,
ranging from a small rise in serum creatinine (SCr) to
anuric kidney failure requiring renal replacement ther-
apy (RRT). AKI may either be present on admission to
hospital, or develop during the course of admission. The
many aetiologies and risk factors for AKI are well de-
scribed [1-4], as are the short and long term conse-
quences [1,2,4-7].
In the last decade the definition of AKI has been stan-
dardised, refined and adopted in clinical research [6,8]
leading to improved understanding of the epidemiology
of AKI and a realisation of its potential health econom-
ics impact [9].
A number of studies have documented the incidence
of AKI in a variety of populations [9-20] but to date we
do not believe that the real incidence of AKI has been
accurately documented in a district general hospital set-
ting. The aims of this study were therefore to (i) use the
acute kidney injury network (AKIN) definition to de-
scribe the real incidence of AKI in a typical general hos-
pital setting in an unselected patient population, (ii)
describe the associated short and long-term outcomes,
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patients (18 years or over) admitted to East Kent Hospitals
University NHS Foundation Trust (EKHUFT) between 1st
February and 31st July 2009 were included. Time of entry
to the cohort was the date of admission for each patient.
EKHUFT comprises 3 general hospitals with a total of
1250 inpatients beds serving a defined population of ap-
proximately 744,400 people (582,300 adults) in the geo-
graphical area of East Kent in the southeast peninsula of
England [21]. Patients were followed up until the 31st
March 2011. Patients receiving chronic renal replacement
therapy (RRT) (including dialysis and renal transplant-
ation), maternity admissions and day case admissions were
excluded from the analyses.
Data extraction
Data were extracted from the EKHUFT data warehouse.
This data warehouse stores patient demographics and all
patient episodes, including primary diagnosis and co-
morbidity for each episode. Unique patient identifiers
were used to link the data warehouse with the pathology
database.
AKI was defined by the AKIN criteria using the lowest
SCr in the 12 months prior to the date of hospital admis-
sion as the reference after the method of Lafrance et al.
[22]. In cases where there were no pre-hospitalisation
values and the follow up SCr (lowest in the 12 months fol-
lowing discharge) was lower than the peak in the study
admission, the follow up creatinine was used as the refer-
ence SCr. The assumption was made that if SCr had
improved following admission by greater than 26.4 μmol/L,
then the admission must have involved an AKI (UK
Renal Association, Acute Kidney Injury Clinical Practice
Guideline) [23].
The peak creatinine during the inpatient stay was used
to define the stage of AKI.
Independent variables
Patient demographics (to determine age and eGFR cal-
culations), postcode (to determine deprivation score),
co-morbidity, and primary diagnosis were extracted.
Both co-morbidity and primary diagnosis were coded for
each hospital episode on the data warehouse using ICD-
10 codes. For primary diagnoses the ICD-10 group was
extracted for each admission (Additional file 1: Table S1).
For co-morbidity (secondary diagnoses), validated coding
algorithms from Quan et al., [24] with further validated al-
gorithms for diabetes [25] and hypertension, were used to
determine a modified Charlson co-morbidity score for
each patient. The number of admissions and outpatient
appointments in the 12 months prior to a patient admis-
sion were also recorded. From the baseline pathology data,
the baseline chronic kidney disease (CKD) stage was de-
fined for each patient, using the baseline creatinine (lowest
creatinine in the 12 months prior to admission), or the
post-discharge nadir creatinine was used for the subset of
patients without a pre-hospitalisation creatinine.
Outcomes
Mortality, hospital length of stay (LOS), intensive care
LOS, and change in residence resulting from admission
were recorded. Date of death and 30 day re-admission
rates were also recorded wherever relevant. The date of
death was obtained from the Patient Master Index (PMI)
on the hospital patient administration system (PAS).
Where a patient died in hospital this field was populated
using the discharge details of the patient’s episode and
was therefore validated at the point the patient was dis-
charged as ‘died in hospital’. Where a patient died fol-
lowing discharge the PAS PMI record was updated via a
weekly report from the Open Exeter national system
which provides the date of death for any patient recently
deceased [26]. Data on LOS, intensive care LOS, re-
admission, and place of discharge were complete, as re-
corded on the hospital PAS.
All admissions during the recruitment and follow up
periods were extracted. AKI stage was calculated for all
admissions until the end of the follow up in order to in-
form the survival analysis.
Data were also extracted from the renal data system
(Renal Plus, CHI) and from the intensive care database
to determine whether patients in this cohort received RRT
during admission, and whether they were still dependent
on RRT 90 days post discharge. Patients who received
RRT (often in ITU) but did not meet the creatinine cri-
teria for AKIN 3, were upgraded to AKIN 3 in line with
the specifications of the AKIN criteria.
Statistical methods
Patient level demographic summaries were performed,
considering a single observation per patient. For patients
with more than one admission with AKI data were sum-
marised at the time of the admission with their highest
AKI stage where there was a valid reference SCr. For pa-
tients who had no valid AKI recordings over the course
of the study, data from the first admission was used in
the analysis.
Normally distributed data were summarised as the mean
and standard deviation. Continuous data not normally dis-
tributed were summarised by median and inter-quartile
range, or the percentage of values in each category for cat-
egorical variables.
Three of the continuous variables, Charlson co-morbidity
score, number of previous admissions in the previous
12 months, and number of outpatient appointments in the
previous 12 months all had a very highly skewed distribu-
tion. So that outlying values were not overly influential,
these three variables were categorised for analysis.




Chosen outcomes of interest were mortality, LOS, in-
tensive therapy unit (ITU) utilisation, and increase in
care following discharge. Regression analyses were per-
formed to determine the impact of AKI on each outcome.
Variables used in the regression model, and thought to be
confounders were age, gender, primary diagnosis, modified
Charlson co-morbidity score, stage of chronic kidney dis-
ease (CKD). We also added admission from residential or
nursing care, deprivation index, hospital admissions and
outpatient appointments in the last 12 months. The ana-
lyses were performed in three stages. In the first analysis,
the effect of AKI upon each outcome was examined (an
unadjusted analysis). The second analysis was age and
gender adjusted and the third analysis was multiply ad-
justed, including the above variables.
For primary diagnosis in the regression model, specif-
ically for elective admissions there were diagnosis groups
with too few events. Therefore elective admissions were
set as the reference and emergency admissions split by
ICD-10 group for primary diagnosis.
Logistic regression was used for the analysis of in-
hospital mortality and Cox regression for survival ana-
lysis. A time dependent risk analysis for survival was
employed to allow adjustment for multiple admissions
during the study and follow up period.
Analysis of LOS, which was highly skewed, was per-
formed using negative binomial regression. The ana-
lysis of LOS was performed at the admission level in
the recruitment period, and hence patients may have
contributed to the analysis several times during the
recruitment period. To allow for the correlation between
repeat LOS values from the same patients a multilevel
approach was employed, equivalent to fitting a random-
effects model for subjects in addition to the fixed effects
model.
In order to assess the social impact of AKI the change
in residence related to the admission was assessed. An
increase in care from home prior to admission to hos-
pital, to residential or nursing care on discharge, was
classified as an increase in care on discharge. This as-
sessment was performed by stage of AKI.
Results
Population characteristics and AKI
During the 6 month recruitment period there were
66,829 admissions in 45,621 adult patients (Figure 1).
After exclusion of maternity and day case admissions
there were 36,015 admissions in 27,436 patients (79.1%
of patients had 1 admission during the 6 month recruit-
ment, 14.6% had 2 admissions, 4.1% had 3 and 2.2% had
4 or more). Overall, there were 10,030 admissions in
7,496 patients with insufficient SCr data to define AKI.
Of these 42.9% were elective admissions and 57.1% were
non-elective, the majority had a LOS of 0–2 days (see
below). There were 20,464 admissions with no AKI and
5,521 admissions with AKI (8.8% of all admissions and
15.3% of non-maternity and non-day case admissions).
Of these, 3,961 admissions had AKIN 1, 927 admissions
AKIN 2, and 633 admissions AKIN 3. Of the 5,521 ad-
missions with AKI, 4064 had AKI on admission (73.6%)
and 531 of 633 admissions with AKIN 3 (83.9%) had
AKI on admission.
Of the 36,015 admissions, baseline creatinine data in the
12 months prior to admission was available in 31,435
(87%). In the remaining 4,580 admissions the lowest cre-
atinine in the 12 months following discharge (in survivors)
Figure 1 Derivation of the study population.




was used as the baseline serum creatinine. In these 4,580
admissions, 7.2% had AKIN 1, 1.4% AKIN 2 and 1.3%
AKIN 3. This is in comparison to admissions in which a
baseline from the 12 months following discharge was not
used, in which 11.5% had AKIN 1, 2.7% AKIN 2 and 1.8%
AKIN 3. In admissions culminating in mortality baseline
creatinine data was obtainable in 1209/1379 (88%).
Overall, only 455/5521 admissions with AKI (8.2%) in-
volved the calculation of a baseline using the lowest cre-
atinine in the 12 months following discharge.
For descriptive statistics patients without sufficient
SCr data (“no AKI info”) are reported in the results but
only those patients with valid SCr data sufficient to de-
fine AKI were included in the regression analyses. Pa-
tients with insufficient data to define AKI were younger,
had less co-morbidity and shorter LOS than other pa-
tients (Tables 1 and 2).
The crude incidence of AKI in the 6 month period was
3,067 patients with AKIN 1, 807 AKIN 2, and 588 AKIN
3. In total, 4,462 patients from a catchment population of
approximately 582,300 adults experienced AKI during the
6 month recruitment period, assuming the same incidence
for the remaining 6 months of the year from a population
of 582,300 this represents an incidence of 15,325 per mil-
lion (adult) population per year (pmp/yr).
Co-morbidity as evidenced by the Charlson co-morbidity
score was over represented in patients with AKI, and in-
creased with AKI stage (Table 1). Deprivation was not re-
lated to AKI stage.
Renal Replacement Therapy (RRT)
Only 77 patients of the 588 patients with AKIN 3 (13.1%)
received RRT. Of these, 16 remained on RRT 90 days fol-
lowing discharge (2.7% of AKIN 3). A further 4 patients
who experienced AKIN 3 in their index admission (admis-
sion with highest AKI stage during the recruitment
period) who did not require RRT during that admission,
subsequently required chronic RRT within 90 days of dis-
charge. There were also 2 patients with AKIN 1, 2 patients
with AKIN 2 and 1 patient with no AKI info who did not
require RRT in the index admission but subsequently re-
quired chronic RRT within 90 days of discharge. In total
25 patients were on chronic RRT at 90 days.
Survival analyses
Throughout follow up survival was related to AKI stage,
(Table 3, Figure 2). In the upgraded risk analysis, after
12 months 92% of patients who had no AKI were still
alive, in comparison to 28% of patients who experienced
AKIN 3 (Figure 2).
Increasing severity of AKI was associated with increased
risk of death and shorter survival even after multiple ad-
justment, AKIN 1 almost doubling the risk of death and
AKIN 2 and 3 increasing the risk of death almost 3.8-fold
and 5.5-fold respectively compared to those with no AKI
(Table 4).
In-hospital mortality
Overall, 1,379 (3.8%) of 36,015 hospital admissions in the
recruitment period resulted in an in-hospital mortality.
Only 2.0% of patients without AKI died in hospital com-
pared with 8.1%, 25.6% and 33.3% of patients with AKIN
1, 2 and 3 respectively. AKI severity was significantly asso-
ciated with in-hospital mortality even after multiple ad-
justment, the likelihood of mortality increasing 2.4 fold
with AKIN 1 and 12 and 26 fold with AKIN 2 and 3 re-
spectively compared to patients with no AKI (Table 4).
Length of stay
In those patients who died in hospital LOS prior to death
averaged 10.0-13.5 days irrespective of AKI (Table 2). In
those surviving to leave hospital LOS was associated with
severity of AKI, ranging from a mean LOS of 4.4 days in
patients without AKI, to 17.2 days in patients with AKIN
3. Compared to those with no AKI after multiple adjust-
ment LOS was 1.5, 1.9 and 2.2-fold greater in those with
AKIN 1, AKIN 2 and AKIN 3 respectively (Table 4).
Intensive Therapy Unit (ITU) utilisation
ITU utilisation increased with increasing AKI severity;
3.9%, 6.8% and 21.6% of patients with AKIN 1, 2 and 3 re-
spectively were admitted to ITU, compared with 1.8% of
patients without AKI. Intensive care LOS also increased
with severity of AKI from a mean of 3.0 (SD 7.0) days in
patients without AKI, to 4.4 (SD 7.8), 4.5 (5.4) and 7.3 (8.0)
days in patients with AKIN stage 1, 2 and 3 respectively.
After multiple adjustment, AKI severity was again associ-
ated with ITU utilisation. Patients were 2.8, 6 and 22
fold more likely to be transferred to ITU with AKIN
stage 1, 2 and 3 respectively compared to patients without
AKI. In patients who went to ITU their length of stay in
ITU was 37%, 35%, and 111% longer in patients with
AKIN stage 1,2 and 3 respectively compared to patients
without AKI.
Increase in care
A greater proportion of patients with AKI (4.5% AKIN 1,
5.7% AKIN 2 and 3.7% AKIN 3) had an increase in care on
discharge in comparison to patients without AKI (1.9%).
Although having an episode of AKI conferred a greater risk
of increase in level of care post-discharge there was no as-
sociation with severity of AKI (Table 4).
Hospital readmission
Having an episode of AKI was also associated with an
increase in hospital readmission within 30 days com-
pared with those without AKI (Table 4), although this
did not associate with severity of AKI.





Summary of main findings
The incidence of AKI in an adult population reported
here, 15,325 pmp/yr (10,534 pmp/yr with AKIN 1, 2,772
pmp/yr with AKIN 2 and 2,020 pmp/yr with AKIN3), is
significantly higher than previous estimates reported in
the literature, [20] and is likely to be closer to the real inci-
dence in the population. The reasons for the higher inci-
dence we report here are several. This is an unselected
in-hospital population; there is increased testing of
creatinine due to heightened awareness; the laboratory
service in East Kent comprehensively covers the catch-
ment population; in general because of the geography of
our catchment area all patients in the area are admitted to
one of our three hospital sites; our population is older in
comparison to the United Kingdom average; and finally,
use of the the La France methodology will also increase
the reported incidence.
Table 1 Summaries of mean age, gender, deprivation and co-morbidity at a patient level, only considering admissions
during the recruitment period, and for multiple admissions per patient during the recruitment period selecting the
patient’s admission with the highest AKI stage
Variable No AKI AKIN 1 AKIN 2 AKIN 3 No AKI info
(n = 15,478) (n = 3,067) (n = 807) (n = 588) (n = 7,496)
Age - Mean (SD) 62.0 (20.3) 74.2 (16.3) 76.1 (14.7) 72.5 (15.7) 54.2 (21.0)
Age: 18-39 17.1% 5.1% 3.6% 4.4% 29.0%
40-59 23.7% 11.3% 8.9% 16.0% 28.3%
60-79 36.9% 38.2% 37.3% 40.7% 29.5%
80+ 22.3% 45.5% 50.2% 39.0% 13.2%
Male Sex - % 45.1% 52.2% 45.0% 49.8% 45.8%
Deprivation - Median (IQR) 17.4 (11.8 27.0) 17.2 (11.8, 25.8) 17.3 (11.8, 25.8) 17.2 (11.9, 26.9) 17.2 (11.7, 26.7)
AIDS - % 0.1% 0.1% 0.1% 0.0% 0.0%
Malignancy - % 6.2% 11.5% 14.0% 16.7% 4.8%
CHF - % 2.6% 10.4% 13.9% 11.6% 1.0%
CPD - % 12.8% 17.0% 16.1% 17.4% 8.5%
Cerebrovascular disease - % 7.3% 13.5% 12.3% 11.2% 3.4%
Dementia - % 3.2% 6.7% 8.2% 7.0% 1.9%
Diabetes - % 10.3% 20.2% 18.7% 23.8% 6.0%
Hemiplegia. - % 1.3% 1.8% 1.4% 1.5% 0.5%
Hypertension - % 27.2% 39.% 39.3% 39.0% 15.5%
MI - % 3.0% 5.0% 6.0% 3.9% 0.7%
Solid tumour - % 2.0% 3.2% 4.8% 4.4% 0.9%
Liver disease - % 0.9% 1.8% 3.0% 6.1% 0.5%
PVD - % 2.1% 5.4% 6.2% 4.6% 1.0%
Peptic ulcer - % 0.6% 1.2% 1.7% 1.9% 0.4%
Renal disease - % 1.7% 11.2% 16.4% 22.3% 1.1%
Rheumatic disease - % 2.3% 3.9% 3.1% 4.1% 1.1%
CKD - no data 0% 0% 0% 0.7% 34.4%
no CKD 84.8% 61.9% 62.1% 68.2% 58.0%
CKD stage 3a 10.0% 19.1% 20.1% 15.0% 5.0%
CKD stage 3b 4.0% 13.1% 12.1% 10.2% 2.0%
CKD stage 4 1.0% 5.3% 5.5% 2.6% 0.5%
CKD stage 5 0.2% 0.5% 0.2% 3.4% 0.1%
Charlson ≤ 0 - % 58.0% 31.9% 25.8% 23.3% 74.5%
1-10 - % 25.9% 29.4% 30.5% 30.1% 17.4%
11 + =% 16.2% 38.8% 43.7% 46.6% 8.2%
Chronic pulmonary disease (CPD), chronic heart failure (CHF), myocardial infarction (MI), peripheral vascular disease (PVD), acquired immunodeficiency
syndrome (AIDS).




In this current study we have clearly demonstrated
that patients with AKI, even after correcting for age,
gender, co-morbidity, and CKD, have an increase in
morbidity and mortality both in the short and long term
in comparison to patients without AKI. These outcomes
also hold true for small changes in SCr (AKIN 1). In
comparison with patients with no AKI those with AKIN
1 had a 52% longer hospital stay, a 2.8-fold increased
risk of admission to ITU, a 39% longer ITU stay (in
those who went to ITU), and a 2.4-fold greater in-
hospital mortality. Furthermore, patients with AKIN 1
had twice the long term risk of death, a 33% higher
likelihood of an increase in care, and a 42% higher
risk of re-admission within 30 days. In those patients
with AKIN 3 (the subject of the NCEPOD report)
[27] hospital LOS doubled, there was a 22 times
higher risk of admission to ITU and ITU LOS was
also doubled, consistent with national data from the
Intensive Care National Audit and Research Centre
[28]. Acute RRT support was required in 13.1% of pa-
tients with AKIN 3. Hospital mortality was 26-fold
greater and in those surviving to leave hospital there
was a 5.5-fold increased risk of subsequent death. Pa-
tients with AKIN 3 had a 7% higher risk of requiring
an increase in care and had a 54% higher risk of re-
admission within 30 days than patients with no AKI.
Overall, 0.45% of patients with AKI and 3.40% of
patients with AKIN 3 subsequently required chronic
RRT.
As the time of entry into the cohort was the date of
admission for each patient there is the possibility of re-
verse causality, for example a patient who has a longer
length of stay may have a greater risk exposure to the
development of AKI. However in this cohort, of the
5521 admissions with AKI, 4064 (73.6%) already had
AKI on admission.
Strengths and weaknesses of study
The population-based analysis reported here considers
all patients admitted in a general hospital setting in the
United Kingdom during a 6 month period. The catch-
ment population for this cohort is from East Kent in the
South East Coast of England. Incomparison to the wider
population in England East Kent has an older population
(mean age 42 years compared to the national mean age
of 39) but with fewer ethnic minorities (6.3% of Black
and Ethnic minority compared with 14.6% nationally)
[21]. Nevertheless, we believe that data linkages between
the pathology, hospital data warehouse and renal sys-
tems have enabled us to come closer to the real inci-
dence and outcomes of AKI managed in-hospital than
any study published in the literature to date.
This study is a retrospective database study and clearly
has limitations. Key to the definition of AKI is knowledge
Table 3 A summary of the survival estimates at 6-month intervals along with corresponding confidence intervals
Variable No AKI AKIN 1 AKIN 2 AKIN 3
6 m survival (95% CI) 0.94 (0.94, 0.94) 0.77 (0.75, 0.78) 0.48 (0.45, 0.52) 0.39 (0.35, 0.43)
12 m survival (95% CI) 0.92 (0.92, 0.93) 0.70 (0.68, 0.71) 0.37 (0.34, 0.40) 0.28 (0.25, 0.31)
18 m survival (95% CI) 0.91 (0.91, 0.92) 0.65 (0.63, 0.66) 0.32 (0.29, 0.35) 0.22 (0.19, 0.25)
24 m survival (95% CI) 0.90 (0.89, 0.90) 0.59 (0.58, 0.61) 0.27 (0.24, 0.29) 0.18 (0.16, 0.20)
Note that the AKI groups are based on ‘upgraded’ AKI risk. If a patient experiences a subsequent admission during follow-up with a higher stage of AKI, they will
be upgraded at that point to the higher group.
Table 2 A summary of the length of stay for: all patients, those who died in hospital, and those who survived to
hospital discharge, split by AKI stage
Statistic No AKI AKIN 1 AKIN 2 AKIN 3 No AKI info
(n = 20,464) (n = 3,961) (n = 927) (n = 633) (n = 10,030)
All patients
Mean (SD) 4.5 (10.5) 9.7 (14.6) 12.3 (16.0) 14.9 (18.5) 2.3 (9.8)
Median (IQR) 2 (0, 5) 5 (1, 12) 7 (3, 15) 9 (4, 20) 1 (0, 2)
Died in hospital
Mean (SD) 11.1 (14.4) 11.8 (16.3) 10.0 (11.9) 10.3 (12.2) 13.5 (29.1)
Median (IQR) 6 (2, 14) 6 (2, 15) 6 (2, 14) 6 (2, 14) 5 (1, 15)
Survived to hospital discharge
Mean (SD) 4.4 (10.4) 9.5 (14.5) 13.0 (17.1) 17.2 (120.5) 2.1 (8.8)
Median (IQR) 1 (0, 5) 5 (1, 11) 8 (3, 15) 11 (5, 22) 1 (0, 2)
Length of stay is summarised as a continuous variable, and then additionally split into categories.




of pre-morbid kidney function (baseline SCr) and the
threshold value of SCr from which change is measured
(reference SCr). The importance of baseline SCr is in the
determination of pre-existing CKD and this value should
be based on SCr values available > 3 months prior to
the index event. The reference SCr should be ideally be
the lowest SCr recorded within 90 days of the event to
distinguish this value from the baseline SCr. However,
practically in many cases there may be either few or
no pre-hospitalisation SCr values making distinction
between baseline and reference SCr impossible. This is
an area that requires further guidance and consensus
from the international community and various strategies
have been suggested including varying the baseline/
reference creatinine from admission to 365 days prior
[22], taking the average of values between 7–365 days
prior to admission [29], back calculating reference SCr
for missing values from an assumed MDRD glomerular
filtration rate of 75 ml/min/1.73 m2 [30], and (most re-
cently) a method employing multiple imputation using
known comorbidity strengthened by factoring in the low-
est admission SCr [31]. For simplicity we chose to use the
lowest SCr in the 12 months prior to the acute rise to de-
fine AKI. It may be that by doing this we have included
patients with progressive CKD and defined them as AKIN
1. However, as Lafrance et al. demonstrated and our data
confirms, patients with AKIN 1 using this methodology
still have a significantly increased likelihood of a specific
adverse outcome occurring compared to patients with no
AKI [22].
The lowest serum creatinine in the 12 months follow-
ing discharge was utilised to categorise AKI (for those
without pre-hospitalisation creatinine) in 8.2% of admis-
sions with AKI. We acknowledge that the assumption
that AKI was present if serum creatinine improved fol-
lowing admission by greater than 26.4 μmol/L may not
always be correct but use of this methodology was only
necessary in 8% of those categorised as having AKI. The
Table 4 Regression analyses examining the association between severity of AKI and survival, in-hospital mortality,
LOS, ITU utilisation, increase in care and readmission
Risk of death In-hospital
mortality






















1 No AKI 1 1 1 1 1 1 1
AKIN 1 4.85 (4.51, 5.21) 4.29 (3.68, 5.01) 2.36 (1.90, 2.93) 2.71 (2.17, 3.38) 1.93 (1.75, 2.13) 1.90 (1.84, 1.97) 1.38 (1.13, 1.68)
AKIN 2 12.0 (11.0, 13.1) 16.8 (13.5, 21.1) 4.72 (3.36, 6.61) 3.71 (2.56, 5.38) 2.25 (1.83, 2.76) 2.58 (2.43, 2.75) 1.54 (1.17, 2.01)
AKIN 3 15.6 (14.2, 17.1) 24.7 (18.8, 32.3) 23.8 (16.4, 34.6) 2.27 (1.36, 3.81) 2.09 (1.61, 2.72) 3.07 (2.85, 3.30) 2.25 (1.85, 2.73)
2 No AKI 1 1 1 1 1 1 1
AKIN 1 3.11 (2.89, 3.35) 2.98 (2.53, 3.52) 2.63 (2.11, 3.28) 1.61 (1.29, 2.01) 1.69 (1.53, 1.87) 1.68 (1.62, 1.74) 1.43 (1.17, 1.74)
AKIN 2 7.54 (6.89, 8.25) 13.5 (10.5, 17.5) 5.43 (3.88, 7.61) 2.07 (1.43, 2.97) 2.00 (1.63, 2.46) 2.22 (2.09, 2.36) 1.56 (1.20, 2.04)
AKIN 3 11.6 (10.6, 12.7) 25.2 (18.6, 34.5) 23.9 (16.6, 34.4) 1.56 (0.93, 2.60) 1.94 (1.49, 2.53) 2.72 (2.53, 2.92) 2.27 (1.88, 2.76)
3 No AKI 1 1 1 1 1 1 1
AKIN 1 1.89 (1.74, 2.04) 2.41 (1.99, 2.91) 2.76 (2.20, 3.46) 1.33 (1.06, 1.67) 1.42 (1.29, 1.57) 1.52 (1.47, 1.58) 1.39 (1.14, 1.69)
AKIN 2 3.81 (3.46, 4.18) 12.1 (8.84, 16.5) 6.03 (4.58, 8.51) 1.49 (1.02, 2.16) 1.50 (1.23, 1.83) 1.88 (1.77, 2.00) 1.42 (1.07, 1.87)
AKIN 3 5.49 (4.97, 6.06) 26.3 (17.8, 38.8) 22.4 (15.5, 32.2) 1.07 (0.64, 1.80) 1.54 (1.20, 1.99) 2.16 (2.01, 3.32) 2.18 (1.77, 2.68)
Model 1. Unadjusted. Model 2. Adjusted for age and gender. Model 3. Adjusted for age, gender, primary diagnosis, modified Charlson co-morbidity score, stage of
chronic kidney disease (CKD), admission from residential or nursing care, deprivation index, hospital admissions and outpatient appointments in the last
12 months. All values are statistically significant, with p values < 0.001. The outcomes are defined as follows: ITU transfer - a patient being transferred to and
spending any time in ITU during their hospital stay; Increase in Care - a patient being admitted from home and being discharged to residential or nursing care;
Hospital Re-admission – a patient being re-admitted to hospital within 30 days following discharge; Relative Length of Stay – the ratio of length of stay in comparison to
the length of stay of a patient without AKI; Relative ITU Length of Stay – the ratio of ITU length of stay (in those patients who went to ITU) in comparison to the length















Patient survival by AKI
Figure 2 Kaplan-Meier survival by stage of AKI. Note that the
AKI groups are based on ‘upgraded’ AKI risk.




incidence of AKI in admissions utilising a post discharge
baseline (9.9%) was less than in those where pre-admission
creatinine data was available (16.1%).
We cannot be certain that none of the patients with
insufficient SCr data experienced AKI. These patients
were significantly younger and had less co-morbidity
than those with sufficient SCr data and either had one
or no SCr result prior to, or following hospital admis-
sion. Survivors (9,830 of 10,030) were also short stay pa-
tients (LOS 0–2 days) and were therefore unlikely to
have sustained any degree of AKI. The 200 patients in
this group who did not survive the hospital admission
had a mean LOS of 13.5 days, lack of baseline SCr data
precluded derivation of AKI status in these patients.
This also raises the issue of possible ascertainment bias,
that sicker patients may have more creatinine tests, in-
creasing the probability of detecting AKI.
Co-morbidity data was extracted from the hospital
data warehouse using validated algorithms, however this
still relies on the accuracy of coding of clinical episodes
which may not necessarily be correct. This also applies
to the analysis of increase in care on discharge which re-
plies on the accurate coding on the PAS at time of
discharge.
While the statistical models used in this analysis have
accounted for multiple confounders identified in the lit-
erature to date there is always the possibility that there
may be other confounders hitherto unknown.
Finally, despite our estimates of the incidence of AKI in
a typical general hospital setting being the highest to date,
EKHUFT does not provide cardiothoracic, liver or burns
services and our reported incidence of AKI may still be an
under-estimation of the total population incidence.
Conclusions
This data comes closer to the real incidence and out-
comes of AKI managed in-hospital than any study pub-
lished in the literature to date. Nine percent of all
admissions and 15 percent of non-maternity and non-
day case admissions to hospital sustained an episode of
AKI with increased subsequent short and long term
morbidity and mortality, even in those with AKIN1.
What this study adds to existing knowledge is data enab-
ling a much more accurate assessment of the overall im-
pact of AKI on the healthcare economy. We provide
data concerning hospital and intensive care mortality,
LOS, readmission and RRT usage. We also detail the
rate of RRT after longer term follow up and the social
care impact in terms of increased level of care in those
surviving an episode of AKI. These increased adverse
outcomes from AKI confer an increased burden and cost
to the healthcare economy. The data we have presented
will enable this cost to be quantified and will furnish a
baseline for quality improvement projects aimed at early
identification, improved management, and where pos-
sible prevention, of AKI.
It has been suggested that milder forms of AKI defined
by creatinine criteria may simply represent a marker of
general system pathology and multi organ dysfunction,
not specifically related to kidney injury per se. Whether
this is true or not, AKI defines a group of patients whose
outcomes are poor, both in the short and long term,
who are sub-optimally managed, and who should repre-
sent a focus for patient safety improvement.
With the international agreement on the definition of
AKI and its validation in clinic research, it has become
clearer how important the effective management and
prevention of AKI is. Agreed definitions have provided a
comparable platform for the audit of AKI and its man-
agement and outcomes, both in hospital and in the
community.
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ABSTRACT
Background. Acute kidney injury (AKI) is one of the most
common complications affecting hospital inpatients around
the world. It is associated with high mortality and adverse
long-term outcomes, but there is uncertainty regarding its
prevalence and cost. We estimate the prevalence of AKI in
hospital inpatients in a universal health-care system, and the
immediate and long-term impacts on survival, quality of life
and health-care costs.
Methods. We examined prevalence of AKI in inpatients using
both routine national data for the National Health Service (NHS)
in England, and laboratory data from East Kent Hospitals. We
used regression analyses to estimate the impact of AKI on mor-
tality and length of hospital stay, and a Markov model to estimate
the impact on quality-adjusted life years and NHS costs.
Results. AKI was recorded in 2.43% of hospital admissions
in Hospital Episode Statistics (HES), but age- and gender-
standardized estimates derived from laboratory data suggest
the true prevalence may be more than ﬁve times as high
(14.15%). We estimate that the annual number of excess in-
patient deaths associated with AKI in England may be above
40 000. The annual cost of AKI-related inpatient care in
England is estimated at £1.02 billion, just over 1% of the NHS
budget. The lifetime cost of post-discharge care for people
who had AKI during hospital admission in 2010–11 is esti-
mated at £179 million.
Conclusions. AKI prevalence in inpatients may be consider-
ably higher than previously thought, and up to four ﬁfths of
cases may not be captured in routine hospital data. AKI is as-
sociated with large numbers of in-hospital deaths and with
high NHS costs. Comparison of HES and East Kent data sug-
gests that most of the cases recorded in HES may be relatively
severe AKI (AKIN 2–3).
Keywords: acute kidney injury, cost, economics, mortality
INTRODUCTION
Acute kidney injury (AKI) is one of the most serious and
common complications affecting hospital inpatients, and inci-
dence is believed to be rising [1–4]. It is associated with
adverse outcomes and high mortality, independent of other
risk factors [5–7]. Even mild cases of AKI are associated with
increased in-hospital mortality risk [8], and patients who
recover kidney function after AKI are at increased risk of
developing chronic kidney disease (CKD) and of death [9].
There is evidence that deﬁciencies in clinical care may contrib-
ute to the development and progression of the condition. In
the UK, a recent report by the National Conﬁdential Enquiry
into Patient Outcome and Death (NCEPOD) [10] found that
30% of AKI cases occurring during hospital admission were
avoidable, and that only 50% of patients with AKI received an
overall standard of care that was considered good.
Measurement of the incidence and prevalence of AKI, and
analysis of outcomes, have in the past been hampered by the
lack of an agreed deﬁnition. Most studies have focused on
relatively severe AKI [11, 12], on AKI in intensive care units
[13–16] or on patients who require renal replacement therapy
(RRT) [17, 18]. A 2002 study found that 7.2% of patients at a
US centre acquired some degree of renal impairment during
hospital admission [19]. Newly developed classiﬁcation
systems in recent years have focused on AKI as a spectrum of
disease, and create the potential for more robust measurement
of prevalence and outcomes [20–22].
This study examines AKI among inpatients, estimating
prevalence, mortality, outcomes and the cost to the National
Health Service (NHS) in England. The analysis is based, in the
© The Author 2014. Published by Oxford University Press












































ﬁrst instance, on Hospital Episode Statistics (HES), which
provide details of patient demographics and health-care activ-
ity, including recorded diagnoses, procedures, length of stay
and in-hospital mortality for all individual hospital
admissions in the English NHS. The national dataset is
derived from patient records at each hospital. HES data do
not, however, provide details of AKI stage, or of pre-admission
or post-discharge kidney function, and it is generally accepted
that AKI is under-recorded on patients’ notes.
We therefore compare the national ﬁndings with data from
East Kent Hospitals University NHS Foundation Trust
(EKHUFT). At East Kent, laboratory records were used to
identify AKI, the condition was classiﬁed using the Acute
Kidney Injury Network (AKIN) system [21], prior CKD status
was ascertained and patients were followed for up to 2 years
after discharge.
We use age- and gender-standardized extrapolation from
the study ﬁndings to provide an indication of the possible level
of under-recording of AKI in patient records and routine data-
sets, of the distribution of AKI by AKIN stage, of prior CKD
status and of post-discharge health status and care needs.
MATERIALS AND METHODS
Our analysis used HES data to measure the recorded preva-
lence of AKI in hospital admissions in England, the age and
gender distribution of people with AKI, survival to discharge
and the impact of AKI on inpatient costs. These ﬁndings were
compared with data from EKHUFT, a group of three inpatient
hospitals in the South of England, which serves a deﬁned
population of ∼720 000 people. In both cases, the analysis was
restricted to adults (aged≥ 18). Elective day case and mater-
nity admissions were excluded. In addition, patients on
chronic RRT were excluded from EKHUFT data, but could
not be discretely identiﬁed in HES.
Data
We examined all ﬁnished hospital admissions during
2010–11 in HES, and identiﬁed those with a recorded diag-
nosis of AKI, using International Classiﬁcation of Diseases
(ICD-10) codes N17 or N280.
The EKHUFT data covered admissions from 1 February to
31 July 2009 inclusive. Patients with AKI during admission
were identiﬁed and classiﬁed by the AKIN criteria using
serum creatinine (SCr) data from pathology records [21]. The
pathology records used covered all SCr tests commissioned in
primary, community and acute sectors from 1 February 2008
to 31 July 2010. Baseline SCr was estimated using the lowest
level recorded in the 12 months prior to hospital admission,
after the method of LaFrance et al. [23], and this was com-
pared with the highest SCr recorded during hospital admission
in the study period. In cases where there were no pre-hospital-
ization values and the follow-up SCr (lowest in the 12 months
following discharge) was lower than the peak in the study ad-
mission, the follow-up value was used as the reference SCr. In
these cases the assumption was made that, if SCr fell by more
than 26.4 µmol/L after discharge, the admission involved an
AKI. Cases where no SCr value was available for either the
12 months preceding or the 12 months following admission
were recorded as ‘AKI status unknown’.
The lowest SCr recorded in the 12 months before admission
was also used to estimate baseline glomerular ﬁltration rate
(eGFR). Patients with baseline eGFR <60 mL/min were iden-
tiﬁed as having prior CKD, and eGFR levels were used to
classify stages 3–5 CKD [24].
For both HES and EKHUFT data, we calculated AKI preva-
lence for four patient age bands (18–39, 40–59, 60–79, 80+)
sub-divided by gender to produce eight sub-groups. We applied
the EKHUFT prevalence ﬁgure for each of the sub-groups to the
admission numbers recorded in HES, to produce an England-
level prevalence estimate standardized for age and gender.
Inpatient analysis
We estimated the impact of AKI on mortality and length of
stay in both datasets, using regression analyses. The impact on
days in critical care was examined in EKHUFT only. The
impact of AKI on mortality (odds ratio) was estimated using
multivariate logistic regression. The impacts on length of hos-
pital stay and on days in critical care were estimated using
multilevel negative binomial regression. Two-level models
were used with individual admissions nested within patients.
Covariates used in the HES analysis were AKI diagnosis,
patient age, gender, index of multiple deprivation score,
admission method (elective or non-elective) and specialty type
(surgical or non-surgical). Covariates used in the EKHUFT re-
gressions were age, gender, index of multiple deprivation
score, admission method (elective or non-elective), admission
source (home or not), admission day (weekend or week day),
CKD diagnosis and stage, number of hospital admissions in
the previous 12 months, number of outpatient appointments
in the previous 12 months, comorbidities and primary diagno-
sis. A complete list of covariates is provided in the Supplemen-
tary Appendix. Analyses were carried out in Stata versions 8
and 12.1.
We report results as means with standard deviations or as
ratios with 95% conﬁdence intervals. Further detail on preva-
lence, mortality, CKD status and AKI status at hospital admis-
sion are provided in the Supplementary Appendix.
Inpatient costs
We estimated acute costs related to AKI for general in-
patient care and critical care. For general inpatient care, separ-
ate cost estimates were derived from HES and EKHUFT
activity data. Cost estimates for critical care were based on
EKHUFT data only, as HES do not provide robust data in this
area.
Most inpatient care in the English NHS is reimbursed
through national tariffs, which are set at Healthcare Resource
Group (HRG)-level. HRGs are groups of health-care activities
that are clinically related and similar in cost. Each admission is
grouped to a single HRG, using ICD-10 and OPCS Classiﬁca-
tion of Interventions and Procedures (OPCS-4) codes. In ad-
missions with multiple diagnoses and/or procedures, the HRG




























































For admissions grouped to AKI-speciﬁc HRGs, we attribu-
ted the entire cost of the admission to AKI, and used the tariff
price to estimate unit cost [25]. Tariff prices vary around
England, depending on local cost differences. A formula known
as the Market Forces Factor (MFF) is used to make these local
adjustments. Prices used here are estimated using the average
MFF for the country.
However, most admissions with recorded AKI are grouped
to non-AKI HRGs, reﬂecting the fact that AKI frequently
occurs in patients who have multiple interventions and/or
diagnoses. For admissions in which the patient had AKI, but
the admission was grouped to a non-AKI HRG, the cost impact
of AKI was estimated using regression analyses on length of
stay. Costs were estimated for excess bed days associated with
AKI, using the mean cost of a hospital bed day for AKI HRGs
(LA07C-G) in NHS Reference Costs for acute hospitals (£311)
as an estimate of unit cost [26].
The cost of excess critical care days associated with AKI
was estimated, based on the critical care regression analysis
outlined above. The average unit cost of a critical care bed day
was estimated from NHS Reference Costs (£1213) [26].
Long-term impacts and costs
We constructed a Markov model to estimate long-term
quality-of-life impacts and costs arising from excess CKD and
RRT in patients who have had AKI, relative to a matched group
without AKI. The model was run for a representative patient
aged 72 at outset (estimated from age distributions in HES and
EKHUFT). Parameters were estimated based on data from
EKHUFT, UK Renal Registry, Ofﬁce for National Statistics, NHS
Blood and Transplant and earlier studies (Table 1). Supplemen-
tary regression analysis on mortality (Poisson with scaled stand-
ard errors to correct for over-dispersion) was conducted to
estimate relative risk for use in the Markov model. Quality-ad-
justed life years (QALYs) were estimated using EQ-5D utilities
derived from a recent meta-analysis [27]. Model structure is
shown in Figure 1. Analysis was carried out in TreeAge Pro.
Sensitivity analysis
In sensitivity analysis, we applied the upper and lower
bound 95% conﬁdence interval estimates for AKI prevalence
in each of the age and gender sub-groups at EKHUFT to HES
Table 1. Markov model parameters and sources
Parameters Estimated value Source
% of patients with CKD
Stage 3 at hospital admission
AKI and
comparator
34.18% East Kent data–AKI group. Same prevalence is applied in model to
comparator.
% of patients who die during
hospital admission
AKI 17.44% East Kent data
Comparator 4.98% East Kent data: % of patients with AKI who die/relative risk of death in AKI
% of patients on RRT 90
days after discharge
AKI 0.26% in base case, 0.11% and
0.42% in sensitivity analysis
East Kent data (excluding patients with CKD Stage 4 or 5)
Comparator 0.00% East Kent data
Annual transition probabilities
Normal kidney function to
CKD
AKI 2.50% Bucaloiu et al. (2012) [9] Baseline risk of de novo CKD × HR with
reversible AKI event
Comparator 1.31% Bucaloiu et al. (2012) [9]
CKD to RRT AKI and
comparator
0.17% Incidence of RRT England (Renal Registry 2011) [28] minus estimated RRT
90 days after AKI (East Kent)/CKD prevalence England (HSE 2010) [29]
Dialysis to transplant AKI and
comparator
7.05% (Transplant incidence 2010–11, England (NHSBT), [30] minus transplant
within 90 days of starting RRT (Renal Registry 2011)) [28]/Prevalent
dialysis England (Renal Registry 2011) [28]
Transplant graft failure AKI and
comparator
2.50% Renal Registry 2011 [28]




ONS Life Tables by year of age, [31] adjusted for CKD and RRT mortality.
CKD prevalence by age band from Health Survey for England 2010, [29] CKD
mortality fromMatsushita et al. (2010), [32] RRT prevalence by age Renal
Registry 2011, [28] RRTmortality rate by age band Renal Registry 2011 [28]
CKD to death AKI and
comparator
RR = 1.28 Normal kidney function risk by age × RR of death by CKD stage from
Matsushita et al. (2010) [32], Distribution of CKD by stage from de
Lusignan et al. (2011) [33]
RRT to death AKI and
comparator
Mortality rate in RRT by age band from Renal Registry report, 2011 [28]
Annual cost
CKD Stages 3–4 £241 Kerr et al. (2012) [34] updated to 2010–11 prices
Dialysis £27 765
Transplant year 1 (including
pre-transplant care)
£34 036
Transplant after year 1 £7520
EQ-5D
Normal kidney function 0.78 UK population norm, age 65–74 from Kind et al. (1999) [35]





























































admission ﬁgures. We summed the lower and upper bound
estimates, respectively, and used the resulting prevalence esti-
mates to derive cost and QALY estimates.
We also re-ran the Markov model using the 95% conﬁdence
interval bounds for the proportion of patients requiring RRT
at 90 days post-discharge from the EKHUFT data.
RESULTS
Prevalence
HES data record 5 881 635 inpatient admissions for
3 792 951 patients in 2010–11. AKI was recorded in 142 705 of
these admissions (2.43%) and 122 928 patients (3.24%) had at
least one admission with recorded AKI during the year. Preva-
lence ranged from 0.32% in patients aged 18–39 to 5.74% in
those aged ≥80 (Figure 2).
During the 6-month study period at EKHUFT, there were
36 015 admissions (27 436 patients). Laboratory data indicate
that AKI was present in 5521 admissions and that 4462 pa-
tients had at least one admission with AKI, a prevalence of
15.33% of admissions and 16.26% of patients. The EKHUFT
inpatient population is older than that in HES (Figure 3). The
age- and gender-standardized prevalence for England is esti-
mated at 14.15% of admissions and 14.65% of patients.
At EKHUFT, 38.10% of patients who had AKI during the
study period had pre-existing CKD stage 3–5. In 73.37% of ad-
missions with AKI, the patient had AKI when admitted to
hospital. Further detail is provided in the Supplementary Ap-
pendix.
Mortality
In 40 109 (28.11%) admissions with recorded AKI in HES,
the patient died before discharge. Mortality rates increased
with age. The odds ratio for death in hospital for patients with
AKI relative to those without AKI was 10.52 (95% conﬁdence
interval 9.93–11.16). The relative risk of death in hospital for
patients with AKI was 4.69 (4.59–4.80) (Table 2).
In 13.93% of admissions with AKI at EKHUFT, the patient
died before discharge. Of all inpatient deaths, 55.77% occurred
in patients with AKI. The odds ratio and relative risk for
in-hospital mortality at EKHUFT increased by AKIN stage
(Table 3).
F IGURE 3 : Age and gender distribution of admissions, HES
and EKHUFT.
F IGURE 1 : Structure of Markov model.
F IGURE 2 : Percentage of admissions with AKI, HES and EKHUFT.
Table 2. Length of stay and mortality, by AKI status, HES data
No AKI AKI P value
Length of stay
Mean (SD) 5.14 (11.56) 16.47 (19.71)
Ratio (95% CI) 1 2.57 (2.54, 2.60) <0.001
In-hospital mortality
% Mortality 1.99% 28.11%
Odds ratio (95% CI) 1 10.52 (9.93, 11.16) <0.001




























































Mean length of stay in HES was 16.47 (SD 19.71) days for
admissions with AKI, and 5.14 (SD 11.56) days for admissions
without recorded AKI. Multivariate regression analysis indi-
cated that AKI diagnosis was associated with a length of stay
2.57 (95% CI 2.54–2.60) times as high as that for admissions
without AKI (Table 2).
At EKHUFT, AKI was associated with hospital stays 1.62
(1.57–1.68) times as long as those for patients without AKI.
The impact on length of stay associated with AKI increased
with AKIN stage (Table 3).
Critical care
At EKHUFT, 59.89% of critical care bed days were for
people with AKI. In multivariate regression analysis, AKI was
associated with critical care bed day usage 4.32 (3.63–5.14)
times the level of patients without AKI (Table 3).
Long-term outcomes
HES data do not provide details of post-discharge out-
comes. Data from EKHUFT indicate that, 90 days after dis-
charge, 0.56% of patients with AKI were on RRT. However,
more than half this group had pre-existing CKD Stages 4–5, so
it is possible that their progression to RRT might have oc-
curred without AKI and, indeed, that their AKI may have been
due to rapidly progressing CKD. Of patients with AKI and
CKD Stages 1–3, or no CKD, 0.26% were on RRT 90 days after
discharge. If this pattern were repeated at national level, and if
the prevalence of CKD, by stage, in inpatients with AKI were
the same as at East Kent, it is estimated that 1369 (95% CI
561–2178) people a year who had AKI during an inpatient ad-
mission, and who did not have pre-existing CKD Stage 4 or 5,
would require RRT 90 days after discharge.
Costs
In HES, 23 145 admissions in 2010–11 were grouped for
payment to HRGs speciﬁc to AKI (LA07A-C), 16.22% of all
admissions with a recorded AKI diagnosis. The total tariff cost
of these LA07 admissions was £75 million (Table 4).
Based on the HES regression analysis ﬁndings, it is esti-
mated that, in 2010–11, there were 977 116 excess bed days as-
sociated with AKI in 119 560 admissions grouped to HRGs
other than LA07. The cost of these excess bed days is estimated
at £304 million.
If the prevalence of AKI identiﬁed in laboratory data at East
Kent is representative, the number of annual admissions with
AKI in England is estimated at 832 235. Based on the
EKHUFT regression analysis, the number of excess bed days
associated with AKI in admissions grouped to HRGs other
than LA07 in England is estimated at 2 565 514. Of these,
163 423 days are estimated to have been in critical care units.
Total inpatient expenditure associated with AKI admissions
recorded in HES (excluding critical care use) is estimated at
£380 million. Extrapolations from EKHUFT produce an esti-
mate of £1.02 billion for inpatient expenditure related to AKI
in England (Table 5).
The Markov model estimates the lifetime cost of post-dis-
charge care for people who have had AKI as inpatients in
2010–11 at £179 million. These costs arise through higher
incidence of CKD and RRT, relative to a matched population
without AKI. The lifetime QALY loss is estimated at 1.4 per
inpatient with AKI.
Sensitivity analysis
Using the lower bounds of the 95% conﬁdence interval for
each sub-group at EKHUFT, and standardizing for the age
and gender of the HES population, we estimate the number
of admissions with AKI in England at 740 964 (494 288 pa-
tients) in 2010–11. Using the upper bounds, we estimate
Table 4. Activity and expenditure, admissions grouped to Healthcare
Resource Groups for Acute Renal Failure, HES 2010–11
HRG Elective Non-elective
Activity Cost Activity Cost
LA07A
Acute renal failure with
major CCa
165 £636 524 10 216 £42 082 937
LA07B
Acute renal failure with
intermediate CCa




45 £33 752 910 £1 627 841
Total 438 £1 029 376 22 707 £74 157 012
aCC, complications or comorbidities.
Table 3. Length of stay, critical care days and in-hospital mortality in admissions, by AKI status, EKHUFT
No AKI All AKI AKIN 1 AKIN 2 AKIN 3 AKI status unknown P value
Length of stay
Mean (SD) 4.5 (10.5) 10.72 (15.44) 9.7 (14.6) 12.3 (16.0) 14.9 (18.5) 2.3 (9.8)
Ratio (95% CI) 1 1.62 (1.57, 1.68) 1.52 (1.46, 1.58) 1.88 (1.77, 2.00) 2.16 (2.00, 3.32) 0.45 (0.43, 0.47) <0.001
Critical care
Mean (SD) 0.05 (1.02) 0.35 (2.35) 0.17 (1.74) 0.31 (1.80) 1.57 (4.78) 0.02 (0.51)
Ratio (95% CI) 1 4.32 (3.63, 5.14) 2.60 (2.10, 3.21) 5.61 (4.15, 7.58) 18.2 (14.4, 23.1) 0.02 (0.01, 0.05) <0.001
In-hospital mortality
% Mortality 2.00% 13.93% 8.10% 25.60% 33.30% 1.97%
Odds ratio (95% CI) 1 5.11 (4.23, 6.17) 2.51 (2.06, 3.05) 13.3 (9.67, 18.3) 30.8 (20.7, 46.0) 1.49 (1.12, 1.99) <0.001



























































admissions at 923 505 and patients at 633 932. In sensitivity
analysis 1, we estimated costs based on these prevalence es-
timates (Table 6).
Another key area of uncertainty is the proportion of pa-
tients who require RRT 90 days after discharge. In sensitivity
analysis 2, the Markov model was re-run using the upper and
lower conﬁdence intervals for post-discharge RRT in patients
who have had AKI, from EKHUFT data. Using these values,
the lifetime cost of post-discharge care for people who have
had AKI during hospital admission is 2010–11 in England is
estimated at £117–£246 million (Table 6).
DISCUSSION
The data presented here provide the most comprehensive esti-
mate to date of AKI prevalence in inpatients in England. The
ﬁgure based on laboratory data and AKIN classiﬁcation is con-
siderably higher than earlier estimates based on sub-sets of the
AKI population. The comparison with HES data suggests that
there may be substantial under-recording and possibly under-
recognition of AKI in English hospitals.
Our study ﬁnds that AKI is associated with high mortality;
the relative-risk estimates from the HES regression analysis
suggest that AKI was associated with ∼15 000 excess deaths
among inpatients in England in 2010–11, while extrapolations
from EKHUFT data suggest the annual number of excess
deaths associated with AKI in England may be above 40 000.
We also ﬁnd that AKI is associated with large QALY losses.
The EKHUFT data suggest that mortality and length of hos-
pital stay increase with AKIN stage. Mortality in admissions
with recorded AKI in HES was higher than that for AKIN 1
and AKIN 2 at EKHUFT, and lower than that for AKIN 3. The
mean length of stay for admissions with recorded AKI in HES
was higher than that for all AKIN stages at EKHUFT. While
there are multiple factors that impact on mortality and length of
stay, these ﬁndings may suggest that relatively severe AKI
(AKIN 2 or 3) is more frequently recorded in HES than AKIN
1. More than 70% of AKI cases at East Kent were AKIN 1.
The ﬁnancial burden of AKI, as estimated here, is substan-
tial, equivalent to just over 1% of the NHS budget for England
in 2010–11.
The EKHUFT population is older and less ethnically
diverse than that of England. While the extrapolated preva-
lence estimates presented here have been standardized for age
and gender, it was not possible to adjust for ethnicity. Further
study is needed to examine AKI prevalence in an ethnically
diverse population in England.
It is also important to note differences between the two da-
tasets and analyses. Patients on RRT were excluded from the
East Kent dataset but not from HES. The East Kent regression
analyses used a wider range of covariates than those available
in HES.
There is uncertainty regarding the incidence of long-term
RRT after AKI. The sample size for 90-day post-discharge
RRT at EKHUFT was small, and the conﬁdence intervals
around the point estimate are correspondingly large. Further
studies are needed to examine the impact of AKI on long-term
RRT need.
This study focuses only on AKI in adult hospital inpatients.
Further research is needed on the incidence and impact of
AKI in primary and community care settings.
The recent NCEPOD report in the UK found that 20% of
fatal post-admission AKI cases were both predictable and
avoidable. Many of the failings identiﬁed in that report related
to basic medical care, such as checking of electrolytes, per-
formance of physiological observations and adequate senior
review. However, at EKHUFT, AKI was present at the point of
admission in nearly three quarters of admissions in which
AKI occurred. It is likely therefore that efforts to prevent AKI
will need to focus on primary and community care as well as
on inpatient care.
If 20% of AKI cases were prevented, the ﬁgures presented
in this report suggest that the gross savings to the NHS could
be in the region of £200 million a year, equivalent to 0.2% of
the NHS budget in England. It is hoped that the estimates pre-
sented here will provide a foundation for future economic
evaluation of prevention and early management interventions
for AKI, and of strategies for the prevention of complications
in AKI survivors.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
Table 6. Estimated expenditure related to AKI, England 2010–11,






Excess length of stay in non-LA07
HRGsa
£653 360 453 £847 728 441
Critical care £165 647 101 £230 817 902
Total inpatient careb £894 193 943 £1 153 732 733
Post-discharge care £159 531 140 £204 601 432
Sensitivity analysis 2
Post-discharge care £116 552 207 £246 325 103
aLA07: Healthcare Resource Groups (HRGs) for Acute Renal Failure.
bIncluding expenditure on admissions to LA07 HRGs.
Table 5. Estimated expenditure related to AKI, England 2010–11, based
on HES data and extrapolations from EKHUFT
HES Extrapolation from
EKHUFT
Admissions to LA07 HRGsa £75 186 389 £75 186 389
Excess length of stay in
other HRGs
£304 364 710 £750 463 603
Critical care No data
available
£198 232 502
Total inpatient care £379 551 099 £1 023 882 494
Post-discharge care No data
available
£179 345 543
Total care £379 551 099 £1 203 228 037
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Acute kidney injury: an acceptable risk of
treatment with renin-angiotensin system
blockade in primary care?
Michael Bedford*, Christopher KT Farmer, Jean Irving and Paul E Stevens
Abstract
Background: Use of renin-angiotensin system (RAS) blockade has become increasingly widespread driven by
evidence-based guidance. There is concern about the role of these agents in the genesis of avoidable acute kidney
injury (AKI).
Objectives: To investigate the association between AKI and use of RAS blockade.
Design: Multilevel hierarchical analysis of a large cohort of patients registered with UK general practitioners.
Setting: Primary care practices in East and West Kent, United Kingdom.
Patients: 244,715 patients from 27 practices.
Measurements: Demographic, clinical, biochemical and prescription data.
Methods: Analyses of data acquired between 02/3/2004 and 17/04/2012 using multilevel logistic regression to
determine the relationship between AKI and use of RAS blockade; further analysed by indication for treatment with
RAS blockade.
Results: Sufficient serum creatinine data were available to define AKI in 63,735 patients with 208,275 blood test
instances. In 95,569 instances the patient was prescribed a RAS antagonist of which 5.4% fulfilled criteria for AKI. The
unadjusted odds ratio (OR) for AKI in those prescribed RAS blockade was 1.93 (1.81-2.06, 95%CI) falling to 1.11
(1.02-1.20, 95%CI) when adjusted for age, gender, co-morbidity, GFR category, proteinuria, systolic blood pressure and
diuretic therapy. In patients with an evidence-based indication there was no difference in absolute risk of AKI. However,
prescription of RAS blockade in the absence of indication appeared to be associated with greater risk of AKI.
When analysis was repeated with AKIN2/AKIN3 as the outcome, although risk of AKI remained significant when
unadjusted (OR 1.73, 95%CI 1.42-2.11, p<0.001), after full adjustment there was no increased risk (OR 0.83, 95%CI
0.63-1.09) in those taking RAS antagonists. However, when analysed by indication AKIN2/AKIN3 was significantly
more likely in those prescribed RAS antagonists without indication (OR 2.04, 95%CI 1.41-2.94, p<0.001).
Limitations: Observational database study. No information concerning hospitalisation. Prescribing assumptions
and potential inaccurate coding. Potential survival bias; patients surviving longer will contribute more data.
Conclusions: Use of RAS antagonists increased the risk of AKI, independent of common confounding variables.
After correction for confounders the risk fell away and became non-significant for moderate and severe AKI.
However, where there was no evidence-based indication for RAS antagonists the risk of AKI, whether mild,
moderate or severe, remained greater.
Keywords: Acute kidney injury, Renin-angiotensin system blockade, System for Early Identification of Kidney
Disease (SEIK)
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Contexte: Vu l’abondance de données probantes en la matière, le recours aux inhibiteurs du système rénine-
angiotensine-aldostérone (SRAA) est de plus en plus répandu. Il existe certaines préoccupations quant au rôle de
ces agents dans la genèse de l’insuffisance rénale aiguë (IRA) évitable.
Objectif de l’étude: Examiner, au sein d’une cohorte en soins de santé primaires, la présence de liens entre l’IRA et
l’utilisation d’inhibiteurs du SRAA.
Type d’étude: Une analyse hiérarchique multiniveaux d’une vaste cohorte de patients suivis par des médecins
généralistes du Royaume-Uni.
Contexte: Cliniques de soins de santé primaires situées dans l’est et l’ouest du comté du Kent, au Royaume-Uni.
Patients: Les données ont été recueillies auprès d’une cohorte de 244 715 patients en soins primaires, provenant
de 27 cliniques de soins primaires dans l’est et l’ouest du comté du Kent.
Mesures: Données démographiques, cliniques, biochimiques et issues d’ordonnances.
Méthodes: L’analyse des données recueillies entre le 2004/03/02 et le 2012/04/17 a été effectuée par régression
logistique multiniveaux afin de déterminer la relation entre l’IRA et l’utilisation d’inhibiteurs du SRAA, et ensuite par
indication de traitement avec des inhibiteurs du SRAA.
Résultats: Une quantité suffisante de données relatives à la créatininémie était disponible pour évaluer l’IRA
chez 63 735 patients, qui avaient eu au total 208 275 prélèvements sanguins. Chez 95 569 sujets, un inhibiteur
du SRAA a été prescrit, et 5,4% (5 194) de ces derniers ont eu un épisode d’IRA. Chez les patientsrecevant un
traitement fondé sur des indications probantes, 5,8% (4473 sur 76 517) ont eu un épisode d’IRA. Le risque relatif
non ajusté (RR) d’IRA associé à l’utilisation d’un inhibiteur du SRAA était de 1,93 (1,81-2,06, 95% IC), diminuant à
1,11 (1,02-1,20, 95% IC) lorsqu’ajusté pour l’ âge, le sexe, la comorbidité, la catégorie de débit de filtration glomérulaire,
la protéinurie, la pression artérielle systolique et le traitement diurétique. Chez les patients recevant un traitement par
inhibiteurs du SRAA fondé sur des indications probantes, il n’y avait aucune différence de risque absolu d’IRA. Par
contre, il semblait y avoir un lien entre la prescription d’inhibiteurs du SRAA en l’absence d’indications probantes et un
risque accru d’IRA. Lorsque l’analyse a été répétée avec l’AKIN2/AKIN3 comme critère de jugement, le risque d’IRA
associé à l’utilisation d’un inhibiteur du SRAA restait significatif dans le modèle non ajusté (RR 1,73, 95% IC
1,42-2,11, p < 0,001), mais aucune augmentation de risque n’a été observée après ajustement (RR 0,83, 95%
IC 0,63-1,09). Par contre, le risque d’AKIN2/AKIN3 lié à l’utilisation d’un inhibiteur du SRAA était significativement
plus élevée chez les patients qui recevaient ces agents sans indications probantes (RR 2,04, 95% IC, 1,41-2,94,
p < 0,001).
Limites de l’étude: Étude par observation de données prises dans des cliniques de soins primaires. Aucune
information d’hospitalisation disponible (base de données de soins primaires). Interprétation des prescriptions et
possibilité de codes erronés. Biais de temps d’immortalité possible : les patients qui vivent plus longtemps
contribuent davantage à l’analyse par les prélèvements sanguins.
Conclusions: Notre analyse montre que l’utilisation d’inhibiteurs du SRAA augmente le risque d’IRA. Le risque
est indépendant de diverses variables de confusion, dont l’âge, la mesure de base de la fonction rénale, la
présence de comorbidité pertinente et la pression artérielle systolique. Après correction pour les variables
confusionnelles, le risque diminuait toujours : il devenait non significatif pour l’IRA modérée et sévère. Par
contre, le risque d’IRA légere, modérée ou sévère demeurait élevé lorsque l’utilisation d’inhibiteurs du SRAA ne
s’appuyait sur aucune indication probante.
Renin angiotensin system blockade is known to be associated with acute kidney injury. This is the first study to
examine this association by evidence-based indication. Although renin angiotensin system blockade increases
the risk of acute kidney injury overall, in those with an evidence-based indication the majority of the effect is
explained by underlying co-morbidity. In people with no evidence-based indication prescription of renin
angiotensin blockade is an independent predictor of acute kidney injury.




The use of renin-angiotensin system (RAS) blockade in
the form of angiotensin converting enzyme inhibitors
(ACEIs), angiotensin receptor blockers (ARBs) and more
recently direct renin inhibitors (DRIs) is now widespread.
These agents are effective in lowering of blood pressure,
reducing proteinuria and amelioration of chronic kidney
disease (CKD) progression [1-3]. Evidence supporting
beneficial effects in proteinuric diabetic and non-diabetic
kidney disease has informed clinical practice guideline rec-
ommendations in both CKD and diabetes [4-6]. Evidence
for their benefit in ischaemic heart disease and heart
failure has also informed guideline recommendations in
the general population [7-10] such that treatment with
RAS antagonists has clearly defined high quality
evidence-based indications (well-designed, well-executed
randomised controlled trials (RCTs) or well-conducted
meta-analyses of such studies) in the following patient
population settings:
1. proteinuria (albumin:creatinine ratio [ACR] >70
mg/mmol)
2. hypertension and proteinuria (ACR > 30 mg/mmol)
3. diabetes and proteinuria (ACR > 3 mg/mmol)
4. chronic heart failure
5. post acute myocardial infarction
In addition hypertension guidance recommends use
of RAS antagonists in those with hypertension and
age <55 years or resistant hypertension at any age [8]
and in those aged ≥18 years of age with hypertension
and CKD [10] (RCTs with minor limitations, well-designed,
well-executed non–randomised controlled studies and
well-designed, well-executed observational studies or well-
conducted meta-analyses of such studies).
Outside these indications there is no evidence to sup-
port the choice of RAS antagonists over other classes of
anti-hypertensive agent in the management of hyperten-
sion, with or without CKD. The majority of patients with
CKD will not progress to ESRD and these patients are
predominantly managed by primary care in the commu-
nity. In England during 2012 prescriptions for ACEIs,
ARBs and DRIs accounted for 6.0 percent of all prescrip-
tion items [11]. Not all of these prescriptions will be for
evidence-based indications and this widespread use of
RAS antagonists has raised questions about possible harm
without additional benefit, particularly in the elderly [12].
Despite these concerns over the safety of RAS antag-
onism, in particular in relation to AKI we do not know
the level of risk of AKI associated with the routine pre-
scription of these agents in primary care.
The aim of this study was to examine the relationship
between prescription of RAS antagonists and develop-
ment of AKI in the community.
Methods
We performed a multilevel hierarchical analysis of a
large cohort of patients registered with UK general
practitioners.
Data were extracted from the System for Early Identifi-
cation of Kidney Disease (SEIK) database. SEIK is a
computerized decision support system developed to as-
sist in the management of CKD. The system extracts
anonymised demographic, clinical, biochemical and pre-
scription data from primary care systems. Reports aiding
and advising on the management of CKD generated
using an automated decision tree matrix and several
computer algorithms based on NICE guidance [4-6,8] are
then returned to participating practices. For this study
data were drawn from 27 GP practices across East and
West Kent in the UK. Patients with GFR < 15 ml/min/
1.73 m2 or on renal replacement therapy were excluded.
In initial analyses it was evident that a large proportion
of patients may switch between treatment with and
without RAS antagonists over time, and therefore com-
paring outcomes in terms of episodes of AKI between
these as 2 distinct groups was not viable. We therefore
chose to analyse the data at the serum creatinine blood
test level. For each patient we extracted all recorded
serum creatinine estimations between 02/3/2004 and 17/
04/2012. Each serum creatinine then became a data
point “blood test instance” at which we extracted and
defined the independent and outcome variables.
In performing the analysis at the blood test level there
was then the inherent risk that several blood tests for an
individual patient could represent the same episode of
AKI. Therefore for a given episode of AKI the analysis
algorithm excluded all blood results 30 days either side
of the peak AKI result, unless a result within the 30 days
no longer defined AKI. In this instance subsequent
results were not thought to be part of that AKI episode,
either prior to the AKI in the 30 days preceding the peak
AKI result or demonstrating recovery in the 30 days post
the peak AKI.
At each data point, “blood test instance”, we extracted
or determined: age, gender, co-morbidity (including
hypertension, diabetes, ischaemic heart disease, and
heart failure), GFR category, proteinuria, blood pressure
readings and prescription data including all anti-
hypertensive agents and RAS antagonists. For the pur-
poses of determining proteinuria indications for RAAS
antagonists the highest proteinuria result for each pa-
tient was used. Proteinuria was categorised as per the
KDIGO CKD Clinical Practice Guideline 2012 into
three categories: “normal to mildly elevated”, ACR (or
equivalent) <3 mg/mmol; “moderately elevated”, ACR
(or equivalent) 3–30 mg/mmol; and “severely ele-
vated”, ACR (or equivalent) >30 mg/mmol [13]. There is
variance in prescription of anti-hypertensives including
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RAS antagonists across primary care in terms of the
length of prescription given to patients, and also in the
coding of these prescriptions. In some practices the dose
prescribed and the number of tablets prescribed is coded,
however in others only the tablet strength is coded. We
therefore made the assumption that if the last prescription
date was within 70 days of the “blood test instance”, then
the patient was still receiving the medication at that time,
this was on the basis that the majority of patients receive a
2 month (60 day) supply of medication. At each “blood
test instance” we also defined whether or not a patient
had an evidence-based indication for treatment with RAS
antagonists as described in the introduction.
In this study the outcome variable of interest was AKI
in primary care. AKI was defined by the acute kidney in-
jury network (AKIN) creatinine criteria [14] but using
the lowest SCr in the 12 months prior to the date of the
peak AKI result as the reference after the method of
Lafrance et al [15]. Finally we analysed the association
between ACE/ARB and AKIN2/3.
This work was supported by the East Kent Hospitals
Charity and approved by East Kent Hospitals University
NHS Foundation Trust R&D Department, R&D ref:
2010/RENAL/09.
Statistical methods
The primary aim of this analysis was to examine the as-
sociation between patients taking RAS antagonists and
experiencing episodes of AKI. In the analyses AKI was
considered primarily as a binary variable, present or
absent (ie AKI or no AKI and AKIN2/AKIN3 or no
AKI/AKIN1). A feature of the data was that there were
multiple measurements from some patients and as a
result of this it was unlikely that the outcome values
were all independent of each other. It was likely that
outcomes for the same patient at different time periods
were more similar than from different patients. There-
fore it was necessary to account for this in the data
analysis. Due to the binary nature of the outcome, and
the lack of independence of the data, the analyses were
performed using multilevel logistic regression. Two-level
multilevel models were used with individual measure-
ments nested within patients.
The relationship between RAS antagonists and AKI
could potentially be confounded by various other parame-
ters. Therefore, the relationships between the two key var-
iables were adjusted for several pre-determined factors.
Variables considered as potentially confounding were: age,
sex, hypertension, diabetes, ischaemic heart disease (IHD),
heart failure, GFR, proteinuria, systolic blood pressure and
diuretic usage. The status of each of these was updated at
the time of every blood test.
GFR category was used in preference to the baseline
GFR value, as there were several particularly large GFR
values, which might have been influential in the analyses.
The GFR categories used followed the KDIGO CKD
Clinical Practice Guideline 2012 classification of CKD
[13]. A series of four models were examined, each con-
sidering the effects of RAS antagonists with different
combinations of adjustments for other variables. Model
1 was unadjusted, model 2 adjusted for age and sex,
model 3 for all variables apart from proteinuria and
model 4 for all variables.
The first analysis assumed a constant effect of RAS
antagonists for all patients. Subsequently all patients
remained in the analysis, but the interaction between
RAS antagonists and an evidence-based indication for
their use was included in the analysis. This allowed the
effects of RAS antagonists to vary for patients with and
without an indication.
Results
There were 345,986 “blood test instances” from 121,933
patients in a practice population of 244,715. In 137,276
(39.7%) of the “blood test instances” no prior creatinine
data were available and the presence or absence of AKI
could not be assessed. The baseline characteristics of
these subjects showed them to be significantly younger,
with very little co-morbidity compared to those with
baseline GFR data (Table 1). Only 5 percent had CKD
and 21 percent hypertension, unsurprisingly they were
prescribed significantly fewer medications and only 13
percent had an evidence-based indication for RAS block-
ade. 435 “blood test instances” from 83 patients were
removed as the patient’s baseline GFR was <15 ml/min/
1.73 m2. This left outcome data for 208,275 “blood test
instances” from 63,722 patients. Table 1 demonstrates
the population demographics of these 63,722 patients at
baseline. In 112,706 of these instances the patient was
not taking a RAS antagonist, 3.1% (3,440) of these in-
stances fulfilled criteria for AKI. In 95,569 blood test
instances the patient was taking a RAS antagonist,
5.4% (5,194) of these instances fulfilled criteria for AKI
(Figure 1). Of the 63,722 patients: 27,970 (44%) also
had proteinuria testing. Of these 22,552 (35%) had
“normal to mildly elevated”, 4,473 (7%) had “Moderately
elevated” and 945 (1.5%) had “Severely elevated” levels of
proteinuria.
The majority of AKI was AKIN stage 1. Of the 3,440
instances where the patient was not taking a RAS antag-
onist, 3,194 had AKIN 1, 193 had AKIN 2, and 53 had
AKIN 3. Of the 5,194 instances where the patient was
taking a RAS antagonist, 4,881 had AKIN 1, 246 had
AKIN 2, and 67 had AKIN 3.
To examine the possibility that a rise in serum creatin-
ine associated with implementation of RAS antagonism
led to a false assumption of AKI we also looked at the
number of instances where a blood test occurred within
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90 days of starting a RAS antagonist and at the percent-
age of those with AKIN1. In the first 90 days after initial
RAS antagonist prescription only 194 instances fulfilled
criteria for AKIN1 (4% of all AKIN1 in the study) repre-
senting only 2.5% of 7,765 blood test instances.
Table 2 shows the multilevel logistic regression results
examining the association between RAS antagonists, and
other variables, with AKI.
The results for all four models suggested that treat-
ment with RAS antagonists was significantly associated
with an increased risk of AKI. The size of the effect
decreased after adjustments for potential confounders
falling from a 93% increased risk in the unadjusted
model to 69% after adjustment for age and gender and
to 11% in the fully adjusted model. All of the confound-
ing variables examined were significantly associated with
AKI. There was an increased risk of AKI for patients
with hypertension, diabetes, ischaemic heart disease
(IHD), heart failure, worsening severity of CKD, protein-
uria and diuretic therapy. Males were at an increased
risk relative to females. There was a non-linear relation-
ship between age and AKI, and thus it is easier to view
the results graphically (Figure 2), the results suggesting
that for patients aged less than 60 years there was no
strong relationship between age and risk of AKI. In those
aged 60 and above the risk increased exponentially. There
Table 1 Population and baseline characteristics
Analysed patients No baseline GFR within the
preceding year
Variable Total population No AKI in follow-up AKI in follow-up
Population
Population in the analysis (%) 63,722 (100) 58,904 (92.44) 4,818 (7.56) 49,695
Average age (years) 62.67 61.79 73.42 48.93
Males (%) 28,583 (44.86) 26,097 (44.30) 2,486 (51.60) 21,118 (42.50)
Females (%) 35,139 (55.14) 32,807 (55.70) 2,332 (48.40) 28,577 (57.50)
GFR >60 ml/min/1.73 m2 (%) 50,283 (78.91) 48,135 (81.72) 2,148 (44.58) 47,175 (94.93)
CKD Stage 3a (%) 9,702 (15.23) 8,402 (14.26) 1,300 (26.98) 2,060 (4.15)
CKD Stage 3b (%) 3,019 (4.74) 2,038 (3.46) 981 (20.36) 399 (0.80)
CKD Stage 4 (%) 718 (1.13) 329 (0.56) 389 (8.07) 61 (0.13)
CKD Total (%) 13,439 (21.09) 10,769 (18.28) 2,670 (55.42) 2520 (5.07)
Hypertension (%) 38,912 (61.07) 34,962 (59.35) 3,950 (81.98) 10,454 (21.03)
Diabetes (%) 10,135 (15.91) 8,815 (14.97) 1,320 (27.40) 904 (1.81)
Ischaemic Heart Disease (%) 8,033 (12.61) 6,767 (11.49) 1,266 (26.28) 1163 (2.34)
Heart Failure (%) 916 (1.48) 628 (1.07) 288 (5.98) 63 (0.13)
Had an indication for an ACEi/ARB (%) 26,078 (40.92) 23,156 (39.31) 2,922 (60.65) 6,268 (12.61)
Were on an ACEi/ARB (%) 18,698 (71.70) 16,455 (71.06) 2,243 (76.76) 3,035 (6.12)
Had no indication for an ACEi/ARB (%) 37,644 (59.08) 35,748 (60.69) 1,896 (39.35) 43,427 (87.39)
Were on an ACEi/ARB (%) 5,236 (13.91) 4,751 (13.29) 485 (25.58) 1,095 (2.20)
On a Thiazide Diuretic (%) 12,628 (19.82) 11,384 (19.33) 1,244 (25.82) 2,796 (5.63)
On another Diuretic (%) 1,724 (2.71) 1,305 (2.22) 419 (8.70) 256 (0.52)
On a Calcium Channel Blocker (%) 17,744 (27.85) 15,785 (26.80) 1,959 (40.66) 2,488 (5.01)
On a Beta Blocker (%) 3,794 (5.95) 3,323 (5.64) 471 (9.78) 862 (1.73)
On an Alpha Blocker (%) 1,004 (1.58) 849 (1.44) 155 (3.22) 58 (0.12)
On a Centrally Acting Agent (%) 83 (0.13) 65 (0.11) 18 (0.37) 14 (0.03)
Proteinuria (at study start):
None recorded (%) 35,752 (56.11) 33,504 (56.88) 2,248 (46.66) 35,014 (70.46)
Normal to Mildly Elevated (%) 22,552 (35.39) 20,945 (35.56) 1,607 (33.35) 13,342 (26.85)
Moderately Elevated (%) 4,473 (7.02) 3,732 (6.34) 741 (15.38) 1,065 (2.14)
Severely Elevated (%) 945 (1.48) 723 (1.23) 222 (4.61) 274 (0.55)
GFR (glomerular filtration rate), AKI (acute kidney injury), CKD (chronic kidney disease), ACEi (angiotensin converting enzyme inhibitor), ARB (angiotensin
receptor blocker).
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was a non-linear relationship between systolic blood pres-
sure and AKI, and thus again it is easier to view the results
graphically (Figure 3). Both hypotension and hypertension
were associated with an increased risk of AKI.
Table 3 shows the multilevel logistic regression results
examining the association between RAS antagonists, and
other variables, this time with AKIN2/AKIN3 or noAKI/
AKIN1. Only the first 2 models (unadjusted 73% increased
risk, age and gender adjusted 62% increased risk) sug-
gested that treatment with RAS antagonists was signifi-
cantly associated AKIN2/AKIN3. After adjusting for the
remaining variables (models 3 and 4), there was no statis-
tically significant difference in the occurrence of AKIN2/3
status between those taking and not taking ACE/ARBs. In
this analysis only hypertension, systolic blood pressure,
use of diuretics and presence of proteinuria of the con-
founding variables were significantly associated with
AKIN2/AKIN3.
By indication
The analysis was then repeated with at each “blood test
instance” an assessment made of whether there was an
evidence-based indication for the prescription of a RAS
antagonist, other than simple hypertension. The excep-
tion was proteinuria where the highest proteinuria result
was used. Table 4 summarises the association between
indication, RAS antagonist prescription and AKI sub-
divided by the two differing scenarios (no AKI versus AKI
and no AKI/AKIN1 versus AKIN2/AKIN3).
This summary suggests a greater effect of RAS antago-
nists on AKI for patients prescribed RAS antagonists
with no evidence-based indication. If there was an indi-
cation for RAS antagonist prescription then there was
no real difference in the risk of AKI. In the patients
prescribed RAS antagonists without an evidence-based
indication there appeared to be an increase in the risk
of AKI.
The multilevel logistic regression was then repeated to
examine the effects of RAS antagonists on AKI in the
groups with and without an evidence-based indication
(Table 5), using only model 1 (unadjusted) and model 2
(adjusted for age and sex) of the previous four models
described above. Model 3 and model 4 were not used as
the presence of co-morbidities such as diabetes, heart
failure etc. and the presence of proteinuria would by def-
inition give the patient an indication for RAS antagonist
prescription and hence both these variables and indica-
tion could not be corrected for in the same model.
Terms for the indication of RAS antagonists and also an
interaction term between this variable and the actual oc-
currence of RAS antagonist prescription were included
in the model.
Analysis of the data in this was way suggested that there
was a significant interaction between evidence-based indi-
cation and RAS antagonist use. In both models the risk of
AKI was significantly higher with RAS antagonist use in
both subgroups. However, the effects appeared greater in
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Figure 1 Study cohort and acute kidney injury (AKI) subdivided by RAS antagonist prescription and proteinuria testing.




Where there is an evidence-based indication for RAS
antagonists over and above simple hypertension the
literature suggests clear benefits in terms of reduction in
all cause and cardiovascular mortality, progression of
CKD and reduction in proteinuria [1-3]. Our study dem-
onstrates an increased risk of AKI occurring in primary
care in all patients prescribed RAS antagonists even after
multiple adjustment for confounding risk factors, im-
portantly including adjustment for systolic blood pres-
sure. However, that risk becomes much lower in the
fully adjusted model and when the analysis was repeated
for moderate and severe AKI there was no increased risk
associated with RAS antagonist prescription in the fully
adjusted model. Furthermore, when analysed by evidence-
based indication for RAS blockade, although there was no
increased risk of AKI in those prescribed RAS antagonists
with an indication, in patients prescribed RAS antagonists
without an evidence-based indication the risk of AKI was
significantly increased. This raises the question of whether
or not risk outweighs benefit where there is no indication
for RAS antagonist prescription over and above simple
hypertension. We know from published data that all
stages of AKI, even AKIN1, confer an increased risk of
adverse outcome [15-23].
In high risk situations such as cardiac surgery the risk
of AKI in those prescribed RAS antagonists preopera-
tively is significantly increased, by 27.6% in one study
[24]. There are surprisingly few studies that have specif-
ically addressed the risk of AKI in all patients prescribed
RAS antagonists, and our study is the first to attempt to
examine this by evidence-based indication. A recent eco-
logical analysis suggested that up to 15% of the increase
in AKI admissions in England over a 4-year time period
was potentially attributable to increased prescribing of
RAS antagonists but these findings were limited by the
lack of patient level data including indication for
Table 2 Multilevel logistic regression examining the
association between renin angiotensin system antagonists
and other variables with acute kidney injury
Variable Category/term Odds ratio (95% CI) P-value
Model 1
ACE/ARB No 1 <0.001
Yes 1.93 (1.81, 2.06)
Model 2
ACE/ARB No 1 <0.001
Yes 1.69 (1.58, 1.81)
Age (*) Linear term 0.41 (0.35, 0.48) <0.001
Quadratic term 1.12 (1.10, 1.13)
Sex Female 1 <0.001
Male 1.70 (1.58, 1.83)
Model 3
ACE/ARB No 1 <0.001
Yes 1.17 (1.09, 1.25)
Age (*) Linear term 0.48 (0.42, 0.56) <0.001
Quadratic term 1.08 (1.07, 1.09)
Sex Female 1 <0.001
Male 1.61 (1.450, 1.72)
Hypertension 1.30 (1.17, 1.44) <0.001
Diabetes 1.47 (1.37, 1.58) <0.001
IHD 1.24 (1.16, 1.35) 0.001
Heart Failure 2.29 (2.04, 2.56) <0.001
Systolic BP < 100 2.32 (2.09, 2.58) <0.001
CKD stage 1 1 <0.001
2 1.90 (1.76, 2.04)
3 3.79 (3.46, 4.14)
4 6.79 (5.93, 7.77)
Diuretic 1.42 (1.34, 1.51) <0.001
Model 4
ACE/ARB No 1 0.01
Yes 1.11 (1.02, 1.20)
Age (*) Linear term 0.69 (0.55, 0.87) <0.001
Quadratic term 1.05 (1.03, 1.06)
Sex Female 1 <0.001
Male 1.51 (1.40, 1.64)
Hypertension 1.36 (1.18, 1.56) <0.001
Diabetes 1.13 (1.04, 1.23) 0.004
IHD 1.28 (1.17, 1.40) <0.001
Heart Failure 2.10 (1.85, 2.38) <0.001
Systolic BP < 100 2.28 (2.01, 2.59) <0.001
CKD stage 1 1 <0.001
2 1.82 (1.67, 1.99)
3 3.40 (3.06, 3.77)
4 5.12 (4.38, 5.99)
Table 2 Multilevel logistic regression examining the
association between renin angiotensin system antagonists
and other variables with acute kidney injury (Continued)
Diuretic 1.45 (1.35, 1.56) <0.001
Proteinuria None 1 <0.001
Moderate 1.83 (1.69, 1.99)
Severe 3.27 (2.87, 3.72)
(*) Odds ratios given for a 10-unit increase in the explanatory variable. Odds
ratios describe the effect of all variables upon the outcome. For variables
measured on a categorical scale, the odds ratios represent the odds of AKI in
each category relative to a baseline category. For the continuous variables, the
odds ratios represent the change in the odds of AKI for one-unit increase in
that variable. A series of four models were examined, each considering the
effects of RAS antagonists with different combinations of adjustments for other
variables. Model 1 was unadjusted, model 2 was adjusted age and gender, model
3 for all variables apart from proteinuria and model 4 for all variables. CKD
(chronic kidney disease), ACE (angiotensin converting enzyme inhibitor), ARB
(angiotensin receptor blocker), IHD (ischaemic heart disease), BP (blood pressure).
Bedford et al. Canadian Journal of Kidney Health and Disease  (2015) 2:14 Page 7 of 12
Michael	Bedford	 11905027	 344	
	
prescribing and patient characteristics [25]. Lapi and
colleagues examined the risk of AKI associated with
the concurrent use of diuretics, RAS antagonists and
non-steroidal anti-inflammatory drugs (NSAIDs) in a
nested case–control study. They reported that the
triple therapy combination consisting of diuretics RAS
antagonists and NSAIDs was associated with an in-
creased risk of AKI but that dual therapy combinations
were not [26]. Harel et al. conducted a systematic re-
view of published and unpublished RCTs that provided
numerical data on adverse event outcomes, including
AKI, when comparing monotherapy or combined treat-
ment with different classes of RAS antagonists. The risk of
AKI (defined as a serum creatinine concentration greater
than 176.8 μmol/L) was no greater with combination ther-
apy versus monotherapy [27].
Why is it that we find an increased risk of AKI in
those prescribed RAS antagonists in the absence of an
evidence-based indication, but not in those with an indi-
cation for prescription? It is likely that this relates to the
relative contribution of confounding variables to risk of
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Figure 3 The relationship between systolic blood pressure and the probability of AKI.
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by prescription of RAS antagonists that risk fell when
adjusted for confounding variables and there was no in-
creased risk of moderate to severe AKI after adjustment.
We conjecture that because significant comorbidities
such as systolic hypotension, heart failure and protein-
uria are absent in those without an evidence-based indi-
cation for RAS antagonists prescription the contribution
of RAS antagonism in such patients is that much more
significant. There may also be a lower level of awareness
and monitoring in those with fewer co-morbidities.
Our study has limitations. The study cohort is derived
from the primary care population with recorded serum
creatinine estimations. Although serum creatinine tests
were recorded in 50 percent of the whole primary care
Table 3 Multilevel logistic regression examining the
association between renin angiotensin system
antagonists and other variables with AKIN2/AKIN3
compared with noAKI/AKIN1
Variable Category/term Odds ratio (95% CI) P-value
Model 1
ACE/ARB No 1 <0.001
Yes 1.73 (1.41, 2.11)
Model 2
ACE/ARB No 1 <0.001
Yes 1.62 (1.31, 1.99)
Age (*) Linear term 0.44 (0.30, 0.67) <0.001
Quadratic term 1.09 (1.06, 1.13)
Sex Female 1 0.21
Male 1.15 (0.92, 1.43)
Model 3
ACE/ARB No 1 0.85
Yes 1.02 (0.81, 1.29)
Age (*) Linear term 0.43 (0.27, 0.68) <0.001
Quadratic term 1.08 (1.04, 1.12)
Sex Female 1 0.34
Male 1.12 (0.89, 1.40)
Hypertension 1.87 (1.27, 2.74) 0.001
Diabetes 1.69 (1.33, 2.15) <0.001
IHD 0.96 (0.73, 1.25) 0.75
Heart Failure 2.09 (1.44, 3.05) <0.001
Systolic BP < 100 4.37 (3.18, 5.99) <0.001
CKD stage 1 1 <0.001
2 1.32 (1.01, 1.71)
3 1.78 (1.29, 2.45)
4 2.39 (1.47, 3.91)
Diuretic 1.66 (1.34, 2.06) <0.001
Model 4
ACE/ARB No 1 0.17
Yes 0.83 (0.63, 1.09)
Age (*) Linear term 0.47 (0.24, 0.93) <0.001
Quadratic term 1.07 (1.02, 1.12)
Sex Female 1 0.79
Male 1.06 (0.81, 1.40)
Hypertension 2.17 (1.29, 3.65) 0.003
Diabetes 1.32 (0.99, 1.74) 0.06
IHD 1.07 (0.78, 1.46) 0.69
Heart Failure 1.66 (1.07, 2.56) 0.02
Systolic BP < 100 4.34 (2.96, 6.36) <0.001
CKD stage 1 1 0.47
2 1.16 (0.85, 1.56)
Table 3 Multilevel logistic regression examining the
association between renin angiotensin system
antagonists and other variables with AKIN2/AKIN3
compared with noAKI/AKIN1 (Continued)
3 1.31 (0.89, 1.92)
4 1.38 (0.76, 2.45)
Diuretic 1.56 (1.20, 2.02) 0.001
Proteinuria None 1 <0.001
Moderate 1.62 (1.21, 2.17)
Severe 3.43 (2.22, 5.29)
AKI (acute kidney injury), AKIN1 (acute kidney injury network stage 1), AKIN2
(acute kidney injury network stage 2), AKIN3 (acute kidney injury network
stage 3), sCKD (chronic kidney disease), ACE (angiotensin converting enzyme
inhibitor), ARB (angiotensin receptor blocker), IHD (ischaemic heart disease),
BP (blood pressure).
(*) Odds ratios given for a 10-unit increase in the explanatory variable.
Table 4 The association between evidence-based indication,
prescription of renin angiotensin system antagonist and
acute kidney injury
Indication for ACE/ARB ACE/ARB No AKI AKI
N (%) N (%)
No No 83,724 (97.8%) 1,846 (2.2%)
Yes 18,331 (96.2%) 721 (3.8%)
Yes No 25,542 (94.1%) 1,594 (5.9%)
Yes 72,044 (94.2%) 4,473 (5.8%)
No AKI/AKIN1 versus AKIN2/AKIN3
Indication for ACE/ARB ACE/ARB No AKI/AKIN1 AKIN2/AKIN3
N (%) N (%)
No No 85,428 (99.83%) 142 (0.17%)
Yes 18,989 (99.67%) 63 (0.33%)
Yes No 27,032 (99.62%) 104 (0.38%)
Yes 76,267 (99.67%) 250 (0.33%)
AKI (acute kidney injury), AKIN1 (acute kidney injury network stage 1), AKIN2
(acute kidney injury network stage 2), AKIN3 (acute kidney injury network
stage 3), CKD (chronic kidney disease), ACE (angiotensin converting enzyme
inhibitor), ARB (angiotensin receptor blocker), IHD (ischaemic heart disease),
BP (blood pressure).
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population serum creatinine testing in primary care is
not random. People with diabetes, hypertension and
cardiovascular disease are over represented within our
serum creatinine sample. In just under half of the popu-
lation with serum creatinine estimations there were no
baseline data to determine the risk of AKI and these
patients could not be considered further. However, in
the data analysed the absolute number of serum creatin-
ine tests in those prescribed RAS antagonists was not
dissimilar to the number in those not prescribed RAS
antagonists. Furthermore those with no baseline data to
determine risk of AKI were significantly younger with
very little co-morbidity and only 5 percent had CKD. In
this analysis we could not determine absolute risk of
AKI and it is also important to note that the analysis
only included blood tests from primary care, and there-
fore there is the possibility that we have not accounted
for episodes of AKI that were managed in hospital and
from which no blood tests were recorded in primary
care. This is however a potential strength, as this
excludes hospital acquired AKI and possible additional
confounders. Another limitation is in the prescribing
assumptions. Although primary care databases record
the prescription of a drug the quantity given is
often not available, and this may range for example
from 1 – 3 months. We therefore made the assumption
that if the last prescription date was within 70 days of the
“blood test instance”, then the patient was still receiving
the medication at that time. Although we were able to in-
clude diuretics in the analysis we were unable to accur-
ately define the impact of non-steroidal anti-inflammatory
combinations with other agents on the risk of AKI and
therefore did not include this in the analysis.
Whilst there may be inaccuracies in database coding
of co-morbidities individual patient level co-morbidity
coding in primary care databases has been shown to be
accurate, allowing correction for a number of known
confounders in our analysis [28]. The introduction of
the Quality Outcomes Framework, a pay for perform-
ance system in primary care in the United Kingdom, is
likely to have further improved co-morbidity recording
as targets for chronic disease management have been
implemented [29].
This data set is also subject to survival bias in that
people who live longer may contribute more tests to the
analysis. Another potential source of bias was a misdiag-
nosis of AKIN1 purely as a result of change in serum
creatinine following introduction of RAS antagonists.
However, only 4% of AKIN1 occurred within 90 days of
starting treatment with a RAS antagonist making this an
unlikely source of significant bias.
This is the first study that identifies the risks associ-
ated with the indiscriminate use of RAS antagonists in a
large general population cohort. For the first time we
present data concerning the potential adverse effects of
RAS antagonists in patients without a clear evidence-
based indication for their use other than simple hyper-
tension. Inclusion of all adults is a particular strength as
older people are largely under-represented in rando-
mised controlled trials of RAS antagonists and the inci-
dence of AKI rises exponentially with age. A further
strength of the study is the access to complete prescrip-
tion data because primary care in England records all
prescription data electronically.
Use of RAS antagonists independently predicted AKI
in the multivariate analysis and it should be noted that
in people with no evidence-based indication for treat-
ment with RAS antagonists the risk of AKI was signifi-
cantly increased. There will always be disease groups
where the benefits of treatment with RAS antagonists
clearly outweigh the risks, however we submit that treat-
ment with these agents should be restricted to people in
Table 5 Multilevel logistic regression examining the association between renin angiotensin system antagonists and
acute kidney injury by evidence-based indication (model 1 shows the effects of renin angiotensin system antagonists
with no adjustment, model 2 is adjusted for age and gender)
Model Interaction p-value Indication Odds ratio (95% CI) P-value
No AKI versus AKI
Model 1 <0.001 No 1.94 (1.72, 2.19) <0.001
Yes 1.14 (1.04, 1.24) 0.004
Model 2 0.003 No 1.52 (1.34, 1.72) <0.001
Yes 1.22 (1.12, 1.33) <0.001
No AKI/AKIN1 versus AKIN2/AKIN3
Model 1 <0.001 No 2.31 (1.61, 3.30) <0.001
Yes 0.98 (0.74, 1.30) 0.90
Model 2 0.005 No 2.04 (1.41, 2.94) <0.001
Yes 1.05 (0.79, 1.39) 0.73
AKI (acute kidney injury), AKIN1 (acute kidney injury network stage 1), AKIN2 (acute kidney injury network stage 2), AKIN3 (acute kidney injury network stage 3).
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whom there is a clear evidence-based indication. Given
the increasing incidence of AKI with increased age this
is especially important in older people.
Strategies to mitigate the risk of AKI in people pre-
scribed RAS antagonists should be encouraged, includ-
ing regular monitoring of kidney function and the use of
tablet holidays during intercurrent illness, especially that
likely to involve intravascular volume depletion.
Conclusion
In conclusion the use of RAS antagonists increased the
risk of mild AKI in the community in this analysis and
was independent of common confounding variables
including age, baseline kidney function, gender, relevant
co morbidities and systolic blood pressure. The risk of
moderate to severe AKI was also increased by prescrip-
tion of RAS antagonists but was no longer significant
when fully adjusted for confounders. However, where
there was no evidence-based indication for use of RAS
antagonists the risk of mild, moderate and severe AKI
remained significantly increased.
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This	 report	 describes	 the	 findings	 of	 the	 individual	 interviews	 with	 renal	
consultants	 and	 the	 focus	 group	 with	 outreach	 nurses	 from	 critical	 care	
conducted	approximately	18	months	following	the	introduction	of	the	SAKI	AKI	
alert	system.	The	purpose	of	this	facet	of	the	study	was	to	ascertain	perceptions	
of	 the	 system,	 interaction	 with	 the	 technology,	 communication	 with	 medical	
teams,	 impacts	 on	 patients	 and	 clinical	 practice,	 and	 recommendations	 for	
improvements.	
	




Quotes	 from	 the	 respondents	 are	 used	 in	 the	 analysis	 to	 justify	 interpretation,	
with	 ‘C’	 referring	 to	 a	 consultant	 response	 and	 ‘ON’	 referring	 to	 an	 outreach	
nurse	response.	Further	numerical	coding	refers	to	the	interviewee	code	for	the	





a	 browser	 based	 reporting	 tool,	 hence	 references	 in	 quotes	 referring	 to	
“Qlikview”	are	referring	to	the	AKI	alert	system.	
	







This	 first	 theme	 focuses	 on	 perceptions	 of	 how	 respondents	 first	 heard	 of	 the	














































I	don’t	 think	there	was	any	formal	training	that	 I	remember,	 just	opened	 it	
and	started	using	it.	(C3:1)	
I	 can’t	 remember	 actually.....	 I	 suppose	 [researchers]	must	 have	 shown	 us,	
shown	me	how	to	use	it	but	I	honestly	can’t	remember.	(C2:1)	
	
The	 outreach	 nurses	 appeared	 to	 have	 had	 more	 formal	 training	 which	 they	



























All	 respondents	 appeared	 keen	 to	 support	 colleagues	 and	 welcomed	 the	 alert	




acute	kidney	 injury	 ...	 it	was	quite	 a	 good	 idea	 and	 I	was	keen	 to	 continue	
with	it	and	help	out	the	research	process.	(C1:1)	
I	think	it’s	great	that	there’s	a	system	in	place	to	pick	people	up.	(ON4:26)	
It’s	 important	 work,	 not	 only	 for	 the	 Trust	 but	 it	 fits	 with	 the	
recommendations	 of	 the	 NCEPOD	 report	 for	 AKI	 ...	 and	 the	 general	
Department	 of	 Health	 research	 and	 innovation	 agenda....yeah,	 so	 good	 for	
patients	and	practice.	(C6:1)	
Following	 from	 the	 last	 quote,	 other	 respondents	 also	 recognised	 how	 the	
system	could	improve	patient	care	and	impact	on	practice,	but	also	visualised	the	
proactive	nature	of	the	alert	system	in	bringing	this	about:	
...	 people	 can	 be	 going	 ‘off’	 without	 anybody	 realising,	 so	 having	 an	 alert	
system	 that	 actually	 picked	 it	 up	 and	 prompted	 the	 doctors	 looking	 after	
them	to	actually	have	a	think	about	what	might	be	going	on	with	this	patient	
seemed	like	a	very	good	idea.	(C5:1)	
	...	 it’s	 our	 only	means	 of	 identifying	 some	 of	 the	 sick	 patients	 ...	 and	 quite	
often	 some	 of	 these	 groups	 of	 patients	 we	 will	 only	 pick	 up	 on	 because	
they’ve	 been	 identified	 through	 the	 alert	 system.	 ...	 Had	 we	 not	 had	 that	
access	 to	 that	 we	 probably	 would	 never	 even	 know	 they’re	 in	 hospital.	
(ON2:5)	
...	well	I	think	it’s	a	very	good	idea	...	I	think	is	very	important	and	using	the	








The	 outreach	 nurses	 also	 collectively	 had	 some	 reservations	 due	 to	 the	 added	
workload	and	goodness	of	fit	with	their	role,	an	aspect	elaborated	upon	later:	
I’m	not	sure	we	were	totally	warm	to	it	because	it	was	just	something	else	to	
add	 to	 our	 job	 ...	 And	 we’ve	 got	 one	 of	 those	 umbrella	 jobs	 where	 we	 ...	








Initial	 responses	 to	 the	 alert	 system	 appeared	 to	 be	 encouraging.	 There	 was	
strength	of	opinion	regarding	the	desire	to	support	colleagues	and	the	research	
endeavour,	and	an	understanding	of	its	potential	contribution	to	renal	medicine.	
Given	 that	 the	 alert	 system	 has	 been	 in	 operation	 for	 nearly	 two	 years,	 these	
sentiments	expressed	by	most	respondents	appeared	to	be	enduring,	evidenced	
by	 their	 use	 of	 the	 present	 tense	when	 describing	 their	 views.	 Alongside	 this,	
there	was	however	a	tendency	for	the	outreach	nurses	to	greet	the	system	with	a	
degree	 of	 uncertainty	 regarding	 their	 roles.	 Outreach	 nurses	 had	more	 formal	
training	which	they	appreciated,	and	although	seemingly	brief	and	informal	for	










General	 comments	 about	 the	 technology	 are	 summarised	 by	 the	 quotes	 below	
and	 included	 opinions	 about	 accessibility	 to	 information	 and	 the	 population	
group:		
I	think	the	accessibility	is	good,	the	fact	that	it’s	web	based	so	you	don’t	have	
to	 have	 software	 installed	 on	 a	 specific	 computer	 and	 the	 fact	 that	 I	 can	
access	 it	 from	my	 ipad	at	home	 ...	 I	don’t	have	a	problem	with	 it,	 it’s	quite	
intuitive,	visual	impact	you	know	that’s	fine	again.	(C2:3)	
I	use	it	really	just	to	identify	the	patients	with	AKI	3	and	those	who	have	not	
had	 intervention	 ...	 I	 only	 deal	 with	 the	 ones	 who	 have	 not	 had	 any	
comments,	so	the	new	ones.	(C4:5)	





I	 appreciate	 that	 there	 are	 a	 lot	 of	 tabs	 along	 the	 top	 that	 I	 just	 haven’t	
explored	really	through	lack	of	time	more	than	anything	else	but	in	terms	of	
the	core	functionality	it’s	very	easy	to	use.	(C2:1)	




More	 detailed	 exploration	 with	 respondents	 highlighted	 a	 number	 of	 issues	
regarding	 the	 ease	 or	 difficulty	 of	 navigating	 the	 system	 and	 accessing	 data.	
These	 following	 quotes	 describe	 the	 main	 difficulties	 experienced.	 Firstly,	 the	
speed	and	responsiveness	of	the	system	appeared	problematic:	







...	 there’s	 a	 way	 you	 can	 add	 comments	 so	 that	 your	 colleagues	 for	 the	
following	day	know	 that	 you’ve	 already	 sort	 of	dealt	with	 that	patient	 and	
that	can	be	a	little	bit	sluggish	to	upload	...	(C6:4)	
The	‘modernity’	of	the	system	was	also	commented	on	by	one	respondent:	
...	 it’s	not	very	pretty	 ...	 because	actually	we’re	used	 to	doing	most	 stuff	on	
webpages	 then	 you	 go	 to	 Amazon	 or	whatever	 else	 you	 know	 that’s	what	















Given	 that	 the	 system	 was	 in	 development,	 the	 research	 team	 appeared	
responsive	to	some	of	the	difficulties	respondents	were	experiencing:	
Things	 that	 [researcher]	 has	 changed	 which	 I	 like	 is	 that	 now	 it	 actually	





While,	 overall,	 respondents	 appeared	 keen	 to	 participate,	 a	 further	 theme	 to	
emanate	 concerned	 the	 amount	 of	 time	 it	 took	 to	 use	 the	 alert	 system.	 These	











AKI	Stage	3.	While	 this	 respondent	appeared	reconciled	 to	accommodating	 the	
work	...		







and	the	phone	 ...	 I	 think	that	it	needs	to	be	accounted	for	 ...	 I	 think	because	
it’s	a	big	chunk	of	work	that	we	have	to	do	...	(C1:5)	
Following	on	from	this,	others	had	difficulty	prioritising	the	work,	particularly	as	
there	 was	 a	 significant	 time	 commitment;	 reasons	 for	 this	 are	 explored	more	
fully	in	a	later	section:		
...	trying	to	fit	it	in	there	was	very	difficult	and	it	didn’t	always	happen	to	be	












patients	were	 located,	 the	 uncertainty	 of	 their	medical	 condition	 and	 the	 time	
that	was	wasted:	
…	sometimes	the	ward	has	changed	...	you	have	to	go	on	some	other	system	
to	 find	where	 exactly	 the	 patient	 is	 and	 sometimes	 you	 have	 to,	when	we	
ring	a	ward	they	say,	well,	they’ve	moved	to	the	other	one.	(C3:4)	
...	a	lot	of	the	time	the	results	will	be	from	A&E	and	they’ll	flag	up	on	Qlikview	
from	A&E	 so	 you	 think	 I’ll	go	into	the	computer	system	and	track	a	patient.		
Oh	where	are	they	now	on	the	site	 you	 know.	 	 You’ll	 trawl	 all	 the	way	 over	
there	to	find	out	they’ve	just	had	their	bloods	done	and	their	result’s	better	
so	you’ve	wasted	like	half	an	hour.		(ON2:18)	




I’m	 not	 sure	 true	 real	 time	 would	 be	 a	 necessary	 advantage	 actually	 ...	
because	I	think	that	twenty-four	hours	of	hindsight	allows	certain	things	to	
sort	 themselves	 out	 …	 the	 patient	 that’s	 admitted	 clearly	 dying	 ...	 and	me	
phoning	up	the	 team	looking	after	 them	and	saying	 this	patient’s	got	acute	
kidney	 injury	…	would	 probably	 not	 serve	 any	 useful	 benefit	 to	 either	 the	
patient	or	the	team.	(C2:3)	
So	 there’s	 somebody	 who’s	 flagged	 up	 as	 [AKI	 stage]	 three,	 but	 the	 team	
have	already	started	treating	and	if	you	can	wait	till	the	results	are	back	you	
might	 see	 that	 their	 results	 are	 already	 improving,	 so	 ...	 it’s	 sort	 of	 a	 good	
thing	…	(C4:4)	
Respondents	described	in	more	detail	how	patients	with	AKI	were	identified	and	
how	 decisions	 were	 made	 to	 formalise	 the	 alert	 and	 contact	 relevant	 teams.	




…	 	 you	 would	 have	 to	 log	 on	 to	 other	 systems	 ...	 the	 i-soft	 system,	 to	
sometimes	look	at	the	past	clinical	history	from	clinic	letters	and	you’d	also	





their	observations	and	 things	 ...	 you	know	you	have	 to	go	and	 find	 it,	 yeah	
you	have	to	open	it	up	...	there’s	no	link	directly	onto	Qlikview.	(C4:5)	











too	complicated	 to	access	 it	 ...	 I	would	say	 it	probably	 takes	me	 five	or	 ten	
minutes	to	look	at	all	the	systems	and	formulate	an	opinion	as	to	what	might	
be	going	on	with	the	patient	before	I	try	to	ring	them	...	(C5:5/7)	
…	the	system	 identifies	 the	patients,	 that’s	 the	crucial	bit	yeah	 I	can	access	
the	other	information,	oh	it’s	on	another,	I	have	to	click	another	box	and	put	













whether	 or	 not	 to	 alert	 the	 medical	 team,	 and	 the	 pros	 and	 cons	 of	 having	 a	
system	that	provided	data	that	was	24	hours	out	of	date.		
3	 Interacting	with	Medical	Teams	
A	 prominent	 issue	 for	 all	 respondents	 was	 accessing	 and	 interacting	 with	
medical	 teams	 to	action	 the	alert.	This	 third	 theme	describes	how	respondents	
tracked	 down	 the	 appropriate	 doctor,	 the	 differing	 experiences	 with	





took	up	valuable	 time,	and	 tried	 their	patience.	The	quotes	below	elaborate	on	
typical	communication	attempts	in	detail,	focusing	on	difficulties	tracking	junior	
doctors	and	the	‘tyranny’	of	bleep	identification:	
...	 the	 main	 problem	 …	 is	 mapping	 junior	 doctor	 or	 junior	 doctor	 team	 to	 an	




the	 right	 bleep	number	 ...	 and	 then	 that	 person	doesn’t	 answer	 that	 bleep	 and	 so	
you	try	a	different	member	of	the	team	and	you	know	it	can	take	half	an	hour	to	get	
hold	of	 the	 right	 junior	doctor	 and	 that’s	not	 an	 exaggeration	 ...	 that	 actually	 gets	









































...	what	 you	need	 to	 do	 is	 get	 the	 best	 person	 that’s	 going	 to	 give	 the	 best	
treatment	 to	 that	patient	and	generally	unfortunately	 that’s	not	always	 the	
orthopaedic	doctor.	(ON2:13)	
One	 respondent	 felt	 that	 the	 European	 directive	 on	working	 time	 contributed	
towards	these	difficulties:	

















...	 it’s	very	difficult	 to	 locate	an	orthopaedic	doctor	so	 I	guess	 that	our	 first	
port	 of	 call	 isn’t	 actually	 the	 orthopaedic	 team,	 it	 would	 be	 the	 on-call	
medical	team	or	ITU.	(ON3:12)	






patient	 in	 their	 care,	 there	 were	 differences	 between	 consultants	 and	 nurses	
experiences	 due	 to	 the	 differing	 intervention	 pathways,	 but	 there	 were	 also	
similarities.	 Firstly,	 these	 respondents	 provide	 a	 general	 overview	 of	 their	
respective	 approaches.	 A	 consultant	 describes	 their	 general	 intervention	
pathway:	
I	 phone	 them	 up	 and	 I	 give	 them	 advice	 and	 make	 sure	 that	 they	 are	
repeating	the	bloods	and	doing	all	the	appropriate	things	I	think	they	need	to	
do	and	it	may	be	a	case	of	just	saying	‘are	you	aware’	and	they	say	‘yes’	and	I	
say	 ‘fine	you’re	doing	all	 the	right	 things’	or	 it	may	be	much	more	detailed	
advice	depending	on	the	situation	…	(C2:5)	
For	outreach	nurses,	there	were	some	pathway	differences	between	the	sites	due	
to	 the	 professional	 judgements	 and	 discretion	 of	 the	 outreach	 team	members.	






we	 feel	 that	 they	need	continued	monitoring	 then	we’ll	 retain	 them	on	our	
list.		If	not,	that	will	be	our	only	contact	with	them.	(ON3:7)	





they’re	 usually	 aware	 that	 the	 patient	 has	 AKI.	 I	 cannot	 really	 recall	 any	
instance,	maybe	one	or	two	instances	in	the	last	year	or	however	long	since	






While	 nurses	 had	 similar	 experiences,	 they	 felt	 that	 the	 stickers	 were	
instrumental	in	bringing	about	an	awareness:		
Quite	 honestly,	 I	 think	 the	 stickers	 have	 been	 quite	 successful	 –	 generally	




mixed	experiences.	This	respondent	 for	example	 felt	 that	consultant	colleagues	
were	supportive	overall:	
I	 have	 spoken	 to	 other	 consultants,	medical	 consultants	 in	 other	 hospitals	
and	 they	 say	 it’s	 a	 good	 thing	 that	 someone	 else	 is	 keeping	 an	 eye	 and	
providing	that	extra	layer	of	advice	to	their	teams.	(C1:4)	
For	outreach	nurses,	despite	the	sticker	often	being	applied	after	the	event,	these	











some	respondents	perceiving	some	 indifference	due	 to	 the	 fact	 that	action	had	
already	been	taken:	
…	 it’s	 a	 mixture	 of	 positive	 and	 indifferent	 but	 not	 negative.	 I’ve	 not	 had	
anyone	 getting	 irritated,	 cross,	 abusive	 or	 obviously	 lacking	 in	 gratitude.	
Indifferences	 maybe	 one	 third	 and	 people	 actually	 sort	 of	 sounding	 quite	
positive’s	probably	 two	thirds	and	that	 is	 irrespective	of	 the	sort	of	 level	 if	
you	like,	of	the	person	I’m	speaking	to	…	(C2:5)	
Michael	Bedford	 11905027	 372	
…	they’ve	got	you	know	other	priorities	 they	are	busy	 ...	 they	 just	give	you	
the	information	and	if	you	say	something	to	them	they	will	just	note	it	down	
but	I	don’t	think	they’re	hugely	interested.	(C3:5)		




perception	 issue	as	 to	 the	 significance	of	 the	problem,	 it’s	how	you	handle	
that	…	(C4:10)	
As	 intimated	 previously,	 some	 of	 the	 respondents	 did	 notice	 a	 difference	
between	the	teams	in	the	Trust	in	how	the	patients	were	dealt	with:	





in	people	with	broken	or	damaged	bones	who	then	have	 -	 this	 is	a	slightly	
sweeping	 statement	 that	 I’m	 going	 to	make,	 -	 the	 inability	 to	 do	 anything	
about	anything	 that’s	not	 to	do	with	an	 injured	bone!	 	 It’s	 just	 like,	 “That’s	
not	my	job.”	(ON3:12)	
This	respondent	had	a	sympathetic	opinion	regarding	these	differences:	
...	 I	 am	 aware	 that	 in	 many	 instances	 ...	 the	 surgeons	 are	 less	 aware	 but	













me	 basic	 questions,	 I	 would	 probably	 get	 a	 bit	 upset	 but	 that’s	me,	 every	
doctor	is	different.	(C1:6)	
...	 it’s	 sort	 of	 stepping	 on	 professional	 toes	 a	 little	 bit	 ...	 there	 is	 perhaps	
sometimes	a	worry	 that	we	almost	 take	a	bit	of	a	holier	 than	thou	attitude	





One	of	 the	 factors	 that	 influenced	 the	response	by	 the	 teams	was	 the	extent	 to	
which	they	were	aware	of	the	alert	system.	Some	felt	that	this	was	an	enduring	
problem	due	to	working	patterns,	especially	among	junior	doctors:	
The	 juniors	 ...	 haven’t	 had	 a	 clue	 about	 them	 at	 all	 but	 once	 you	 get	 to	
registrar	level	and	above	they’re	very	receptive	to	it	...	(ON4:14)	
…	even	now	I	think	a	lot	of	them	are	basically	not	certain	why	we’re	ringing	
them	 …	 it	 happens,	 because	 there	 are	 so	 many	 clinicians	 all	 over	 and	
surgeons,	and	physicians	and	nurses,	junior	doctors.	I	don’t	think	everybody	
knows	about	it.	(C3:2)	
...	 	 teams	are	changing	all	 the	time.	 Junior	doctors	change	every	year	 ...	you	




Sometimes	 they’ll	 go	 ‘ugh,	no!’	 and	don’t	 know	about	 the	 system	 ...	 they’re	






ward	…	and	 then	 they	would	say	 ‘sorry,	who	are	you?	And	what	 system	 is	
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this?’	 …	 So	 it’s	 almost	 like	 sometimes	 I	 felt	 I	 was	 a	 bogus	 caller	 …	 then	
eventually,	eventually	now	it’s	old	hat	they	generally	are	aware.	(C1:4)	




There	 were	 similarities	 between	 how	 consultants	 and	 nurses	 approached	
‘alerting’	 and	 discussing	 cases	 with	 the	 relevant	 medical	 teams,	 however	 for	
outreach	nurses,	 the	extent	of	professional	 involvement	 in	 this	varied	between	
the	 hospital	 sites	which	 could	 cause	 confusion	 among	 doctors.	 The	 difficulties	
respondents	 had	 in	 tracking	 down	 the	 appropriate	 junior	 doctor	 manifested	
themselves	as	a	major	problem	and	it	was	clearly	frustrating	and	costly	in	time.	
Respondents	 highlighted	 the	 many	 intricate	 instances	 of	 how	 communication	
can	 fail	 to	 connect	 them	 to	 the	 right	person	 in	 a	 timely	manner.	This	 included	
failures	with	how	bleeps	are	managed,	the	complexity	of	junior	doctors	working	
patterns,	 how	 their	 responsibilities	 are	 organised,	 the	 instability	 of	 medical	
teams,	 and	 how	 the	 movement	 of	 patients	 is	 monitored.	 All	 respondents	 had	
developed	 strategies	 to	 cope	 with	 this	 frustration,	 which	 mainly	 entailed	
phoning	 the	 nursing	 staff	 on	 the	 wards,	 who	 they	 felt	 had	 more	 immediate	
knowledge	of	who	to	contact,	and	maintaining	good	channels	of	communication.		
In	 the	 face	 of	 these	 difficulties	 with	 contact,	 the	 general	 experience	 of	 the	
respondents	was	that	when	the	appropriate	doctor	was	located	and	cases	were	
discussed,	most	found	that	teams	were	already	aware	and	were	dealing	with	the	
situation.	 Outreach	 nurses	 noted	 the	 success	 of	 the	 stickers	 in	 bringing	 about	
awareness.	Some	respondents	felt	a	degree	of	discomfort	with	ringing	colleagues	
uninvited	 for	 little	 justification,	 noting	 that	 responses	 sometimes	 inferred	
disinterest.	 But	 on	 the	 whole,	 responses	 were	 not	 negative	 and	 there	 was	 a	
recognition	of	the	importance	of	interpersonal	communication	skills.	It	appeared	
that	 there	were	differences	between	specialties;	some	respondents	seemed	not	




When	 it	 came	 to	 colleague’s	 awareness	 of	 the	 alert	 system,	 respondents	were	
mixed	in	their	responses.	Some	felt	uncertain	that	there	was	full	understanding	




While	 the	 function	 of	 the	 alert	 system	 is	 to	 ensure	 that	 AKI	 patients	 are	
identified,	 accountable	 clinicians	 informed	 and	 that	 appropriate	 interventions	
have	or	will	be	actioned,	respondents	were	asked	whether	 they	undertook	any	
monitoring	or	follow-up	of	cases.	The	two	sections	here	focus	on	differing	views	




The	 responses	 were	 varied;	 these	 first	 quotes	 from	 consultants	 for	 example	
describe	 experiences	 where	 respondents	 were	 particularly	 concerned	 about	
inappropriate	management	and	took	action:	
…	we	had	one	last	week	where	I	felt	very	strongly	that	the	patient	had	been	
inappropriately	 managed	 …	 my	 colleague	 went	 and	 saw	 the	 patient,	 you	
know,	absolutely	agreed	that	this	was	an	avoidable	situation	that	really	they	
should	 have	 been	 more	 aware	 of	 the	 risks	 and	 the	 fact	 that	 the	 patient	
already	was	developing	AKI	…	(C2:6/7)	












...	 if	 they’ve	 already	 identified	AKI	 then...	 then	 that’s	 it	 and	we	don’t	 really	
necessarily	go	back.		(ON3:11)	
...	 you’ll	 find	 people	 that	 are	 more	 complex,	 that	 have	 got	 a	 lot	 of	 other	
ongoing	 problems,	 that	 have	 got	 maybe	multiple	 potential	 causes	 of	 their	
AKI	that	are	very	sick	 ...	you	keep	on	the	Outreach	list	because	they’re	sick,	
not	necessarily	just	because	they’ve	got	an	AKI.	(ON2:9/10)	





should	be	 just	 chasing	up	and	 let	us	know	 if	 there	 is	progress	or	 lack	or	 it	
rather	than,	you	know,	we	chasing	them	all	 the	time	which	is	happening	at	
the	moment	…	(C3:5)	
Whether	 they	 followed	up	cases	or	not,	all	 respondents	made	efforts	 to	ensure	
that	a	communication	was	recorded	to	alert	 the	 teams	to	 their	 involvement,	or	
mechanism	was	in	place	should	more	advice	be	needed:	
...	 following	up,	no	 ...	 I	 try	 to	 remember	 ...	 put	 that	 as	 a	 final	 comment	you	
know,	 registrar	 or	 SHO	 informed,	 discussed	blah	blah	 blah,	 team	aware	 to	
contact	renal	if	they	have	any	further	concerns	or	issues.	(C4:8)	
...	if	I	was	going	to	carry	on	monitoring	or	seeing	a	patient	from	a	trigger	...	I	
would	 write	 something	 at	 the	 end	 of	 the	 notes	 along	 the	 lines	 of	we	will	



















back,	 and	 they	never	 did.	 And	 for	whatever	 reason	 they	 probably	 felt	 that	
they’d	 finished	 the	 case	 effectively	 and	 they	 didn’t	 need	 my	 advice,	 I’m	
assuming.	(C1:4)	
Related	 to	 this,	 a	 further	 concern	was	 the	 inability	of	 teams	 to	make	a	written	
note	of	the	discussions	with	respondents,	which	impacted	on	the	audit	trail	and	
clinical	decision-making	process.	This	quote	summarises	consultant	experiences:	
What	 I	 hadn’t	 done	 until	 recently	was	 actually	 ask	 them	 to	 document	 the	
discussion	 that	 had	 been	 had	 with	 them.	 ...	 There’s	 no	 documentation	 of	
these	 discussions	 happening,	 and	 I	 suspect	 that’s	 because	 often	 the	
discussions	happen	when	the	doctor’s	not	in	front	of	the	notes	because	we’re	
ringing	them	and	....	catching	them	wherever	they	are.	(C5:8)	
For	 the	 outreach	 nurses,	 there	 were	 clear	 comparisons	 between	 different	
medical	teams,	with	significant	concerns	being	raised	again	regarding	the	lack	of	
appropriate	trauma	and	orthopaedic	team	responses	and	accountability.	Some	of	
these	 quotes	 highlight	 the	 extremes	 that	 the	 nurses	 felt	 they	 needed	 to	 go	 to	
ensure	the	patients	are	appropriately	managed:	
...	 the	medics	 are	 really	 very	 good	 at	 dealing	with	 the	 acute	 kidney	 injury.	
The	area	that	we	have	a	huge	problem	with	...	is	the	trauma	and	orthopaedic	
areas	 ...	 you	 know,	 they...	 they	 will	 watch	 their	 patient’s	 renal	 function	
deteriorate	 and	 then	 the	 nurses	 will	 call	 the	 Outreach	 team	 to	 say,	 “This	
patient’s	got	a	really	big	problem,”	and	then	we’ll	tip	up	and	start	the	whole	
ball	 rolling	 really	 ...	 in	 extreme	 cases	 they’ve	 already	 contacted	 the	 renal	
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team	and	 they	 completely	 ignore	 the	 advice.	And	 that’s	 really	 an	 area	 that	
needs	a	lot	of	work...	(ON3:11)	
We’ve	 started	 using	words	 like	 ‘life-threatening’	 ‘this	 patient	 will	 die’	 and	











There	 were	 differences	 in	 consultants’	 and	 outreach	 nurses’	 experiences	








some	 concerns	 regarding	 the	 documenting	 of	 the	 advice	 given.	 However,	 all	
agreed,	including	nurses,	that	they	would	ensure	the	availability	of	a	contact	for	
further	advice	if	needed.	Outreach	nurses	focused	on	challenges	with	trauma	and	
orthopaedic	 teams	 and	 highlighted	 the	 difficulties	 with	 passing	 on	 the	
management	responsibility	of	AKI	patients	to	them.	
5		 Impacts	on	Patients	and	Clinical	Practice	
This	 final	 theme	 is	 concerned	with	 gaining	 perceptions	 of	 the	 extent	 to	which	
respondents	 felt	 that	 their	 involvement	 in	 the	 alert	 system	 had	 any	 effects,	
Michael	Bedford	 11905027	 379	














are,	 “Oh	 thank	 goodness	 somebody’s	 going	 to	 come	 and	 do	 something,”	






I	 question	whether	 phoning	 a	 junior	 doctor	 team	 or	 consultant	 ...	 about	 a	
patient	admitted	the	day	before	with	acute	kidney	injury	and	who,	they	must	
be	aware	 if	 they’ve	 looked	at	 the	blood	results,	has	AKI,	 I	wonder	whether	
that	actually	provides	any	added	value	at	all.	(C2:7)	
...	I’d	say	three	quarters	of	the	patients	you	ring	up	...	they’re	either	dying	and	
there	 is	 nothing	 you	 can	 do	 or	 the	 team’s	 got	 it	 in	 hand	 and	 they	 know	
exactly	what	 they’re	doing	and	they’re	doing	 fine.	So	you	know	it	does	 feel	
sometimes	like	quite	a	lot	of	work	for	very	little	benefit.	(C5:11)	
This	 respondent	 indicated	 that	 the	 lack	 of	 perceived	 benefits	 stemmed	 from	
advice	not	being	followed:		






Comments	 were	 also	 made	 that	 suggested	 the	 need	 for	 proper	 comparative	
research	and	larger	samples	to	better	estimate	benefits:	
…	 once	 you’ve,	 you	 know,	 given	 the	 information	 and	 instructions,	 what	
happens	 it’s	 not	 really	 followed	 up	 and	 whether	 it	 would	 have	made	 any	
difference	 you	would	have	 to	 compare	 it	with	 somebody	who	has	not	 had	





The	 following	 respondent	 indicated	 that	 more	 benefits	 could	 potentially	 be	









Most	 respondents	 saw	 both	 positive	 and	 negative	 impacts	 on	 clinical	 practice.	
The	quotes	below	refer	to	cases	where	intervention	can	be	positive	and	serve	an	
educational	purpose:		
I	 think	 that	 there	 are	 certain	 groups	 in	 the	 hospital	 that	 are	 very	 poor	 at	
managing	 the	 sick	 patients	 and	 particularly	 patients	with	AKI	 ...	 so	 I	 think	
that	actually,	I	think	that’s	where	I	see	that	we	have	the	benefit	...	when	I	ring	
up	 some,	 one	 of	 the	 surgeons	 to	 say	 did	 you	 realise	 your	 patient	 has	













“Can	we	have	a	 sticker?”	and	 they	will	have	people	 that	haven’t	even	been	
identified	on	the	database	as	acute	kidney	injury	and	they	want	stickers	for	
those	notes.	(ON3:7)	
...	 whoever’s	 on	 the	 nightshift	 will	 go	 round	 in	 the	 early	 hours	 of	 the	
morning,	 we’d	 go	 into	 Qlikview,	 get	 the	 list	 out,	 go	 and	 identify	 these	
patients	 and	 their	 notes	 so	 that	 when	 they’re	 being	 post-taked	 in	 the	




I	 think	 for	 me	 it’s	 been	 positive	 because	 I’ve...	 it’s	 done	 a	 lot	 for	 my	
knowledge	 and	 maybe...	 maybe	 I	 see	 patients	 in	 a	 different	 way	 now.		
Sharing	skills	which	 is	part	of	our	 job,	people	show	 interest	 in	 the	stickers	
and	you’re	able	to	tell	them	what	you’re	looking	for	and	why	so	they	might	
pick	things	up	about	the	drugs	that	you’re	looking	at	and	so	on.		(ON1:24)	


















if	 a	 patient	 was	 admitted	 on	my	 take,	 I	 would	 assume	 a	 hundred	 percent	
responsibility	for	...	acting	and	looking	into	each	problem	and	dealing	with	it.	
And	when	you	 include	a	system	like	this	 I	 feel	 that	number	one	ownership	
could	be	eroded	and	doctors	...	could	become	more	nonchalant	and	lethargic	
and	say	‘oh	there	is	this	computer	system	that	could	pick	this	patient	up	and	





becomes	 an	 issue.	 	 My	 feeling	 is	 that	 once	 you	 document	 in	 the	 notes	
‘Outreach’,	you	then	become	the	first	point	of	contact	for	anything	that	ever	
goes	 wrong	 or	 problems	 ...	 you	 then	 become	 embroiled	 in	 the	 rest	 of	 the	
unfolding	of	the	events.	(ON2:6/7)	
...		some	doctors	will	see	the	sticker	and	your	signature	and	think	that	every	
day	 you’re	 going	 to	make	 sure	 their	 bloods	 are	 done	 and	 you’re	 going	 to	
check	 the	 results.	 	Other	 teams	won’t.	 	Other	 teams	will	 just	manage	what	
they	do	but	it’s	very	varied.	(ON1:9)	




This	 respondent	made	particular	 reference	 to	 the	 establishment	 of	 a	 specialist	





of	 hours	 -	 oh	 that	 can	 wait,	 the	 ortho-geries	 will	 be	 on	 in	 the	 morning.	
(ON2:15)	
There	were	also	concerns	that	the	alert	system	had	generally	impacted	on	their	
professional	 roles	 in	a	negative	way,	 reducing	 it	 to	an	unsatisfactory	screening	
process	induced	by	‘lists’:	
I	 think	 the	 problem	 for	 us	 is	 that	we	 have	 so	many	 parts	 of	 our	 role	 and	
we’ve...	we’ve	 become	 very	 	much	 a	 list	 and	 screening	 culture,	 so	we...	we	
start	off	every	morning	with	a	list	from	the	alert	system,	we	have	a	list	from	






were	 aware	 that	 there	 were	 numerical	 differences	 in	 patient	 interactions	
brought	 about	 by	 the	 alert	 system	 between	 the	 three	 hospital	 sites.	 This	 was	













It	 was	 generally	 difficult	 for	 respondents	 to	 express	 some	 perceptions	 of	 the	








...	 so	 do	we	 save	money?	Don’t	 know	 ...	 do	we	 improve	 patient	 outcomes?	
One	would	hope	to	think	so	and	actually	you	could	then	say	well	improving	
outcomes	 is	 going	 to	 be	 a	 cost	 saving	 in	 terms	 of	 if	 you	 can	 prevent	
somebody	needing	to	go	onto	dialysis	or	needing	to	go	up	to	ITU	for	haemo-







budget	 of	 the	 hospital	 so	 in	 terms	 of	 everything	 else	 it’s	 probably	 a	 small	
cost,	but	in	terms	of	time	at	the	moment	it’s	quite	costly	on	time.	(C1:7)	
...	 well	 it’s	 highly	 cost	 effective	 at	 the	 moment	 because	 it’s	 not	 included	




Despite	 some	 respondents,	 largely	 outreach	 nurses,	 perceiving	 positive	
proactive,	preventive	and	educational	benefits	for	patient	outcomes	and	clinical	
practice,	some	respondents	were	not	wholly	convinced	of	the	value	of	the	system	





the	 alert	 system	 to	 divert	 perceived	 clinical	 responsibility	 of	 the	 patient	 away	
from	 the	 clinician	 who	 was	 actually	 accountable,	 and	 outreach	 nurses	 in	











...	 perhaps	 if	 they	 would	 have	 maybe	 sat	 down	 with	 everybody	 at	 the	
beginning	and	explained	how	the	system	works	and	what	to	do	and	how	to	
go	through	the	system.	(C1:1)	
I	 think	 that	 it	 would	 have	 probably	 been	 advisable	 to	 have	made	 it	 more	
obvious,	more	visible	to	other	staff	in	the	trust	...	you’d	have	to	kind	of	redo	





it	 includes	 all	 specialities	 surgical,	medical	 and	 the	 juniors	 change	 as	well.	
(C6:4)	
I	have	to	say	the	stickers	are	good.	 	 I	do	think	the	stickers	need	to	be	a	bit	













you	know,	 it’s	a	new	project	and	 I	 think	…	you	might	want	 the	Ferrari	but	
having	the	Ford	Fiesta	is	a	start!	(C4:5)	
...	 if	 it’s	 incorporated	 into	 the	 VitalPac	 system	 where	 you	 know	 you	 are	
highlighting	patients	with	acute	kidney	injury	and	you	can	just	with	the	click	
of	a	button	look	at	their	observations	and	then	the	historic	blood	results	and	
then	 what	 has	 been	 ordered	 and	 what	 is	 awaited	 and	 it’s	 live	 data,	 that	
would	be	...	helpful.	(C1:6)	
...	 if	 the	 system	was	 actually	 –	 represented	what,	 you	 know	was	 real	 time,	
then	...	it	would	save	you	quite	a	lot	of	time	...	(C5.6)	
...	 there	 should	 be	 facility	 to	 copy	 and	 paste	 for	 example	 the	NHS	 number	
because	 that’s	how	 it	 identifies	 it	on	 the	monitoring	 form	but	you	can’t	do	
that	so	you	have	to	write	it	down	first	and	then	put	it	in	there.	(C3:3)	





...	 doctors	 don’t	 record	 the	 discussion	 in	 the	 notes,	 so	 there’s	 no	 evidence	
that	 it	 existed	 or	 how	 it	 was	 acted	 on	 ...	 so	 it	 would	 be	 good	 to	 have	 an	
electronic	form	that	could	be	universally	accessed	...	(C6:5)	
From	 a	 reporting	 point	 of	 view,	 we	 wanted	 to	 know	 last	 year	 how	many	





This	 should	 include	 greater	 organisational	 accountability	 for	 tracking	 the	
whereabouts	 of	 junior	 doctors;	 developing	 a	 ‘response’	 alert;	 improving	
pathways	 to	 clinical	 responsibility	 for	 patient	 management;	 and	 creating	 a	
clearer	understanding	of	the	role	of	outreach	nurses,	as	well	as	reassessing	their	
function	in	the	alert	system.			
I	 suspect	 the	 nursing	 staff	 on	 the	 ground	 probably	 know	 amongst	
themselves	 who	 the	 right	 person	 will	 be	 but	 that	 knowledge	 has	 to	 be	
translated	up	 the	 corporate	 structure	 so	 that	 actually,	 the	 corporation,	 the	
















































































































































































































































































































































































































































































































































































































































































































































































































































































AER	(mg/24	h)	 <30	 30–300	 >300	
PER	(mg/24	h)	 <150	 150–500	 >500	
ACR	 	 	 	
	 (mg/mmol)	 <3	 3–30	 >30	
	 (mg/g)	 <30	 30–300	 >300	
PCR	 	 	 	
	 (mg/mmol)	 <15	 15–50	 >50	































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Development of risk models for the prediction of new or
worsening acute kidney injury on or during hospital
admission: a cohort and nested study
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Background: Acute kidney injury (AKI) is a common clinical problem with significant morbidity and
mortality. All hospitalised patients are at risk. AKI is often preventable and reversible; however, the
2009 National Confidential Enquiry into Patient Outcome and Death [National Confidential Enquiry into
Patient Outcome Death. An Age Old Problem. A review of the Care Received by Elderly Patients
Undergoing Surgery. London: NCEPOD; 2010] highlighted systematic failings of identification and
management, and recommended risk assessment of all emergency admissions [Stewart J, Findlay G,
Smith N, Kelly K, Mason M. Adding Insult to Injury: A Review of the Care of Patients Who Died in Hospital
with a Primary Diagnosis of Acute Kidney Injury (Acute Renal Failure). London: National Confidential
Enquiry into Patient Outcome and Death; 2009].
Objectives: To develop three predictive models to stratify the risk of (1) AKI on arrival in hospital;
(2) developing AKI during admission; and (3) worsening AKI if already present; and also to (4) develop a
clinical algorithm for patients admitted to hospital and explore effective methods of delivery of this
information at the point of care.
Study design: Quantitative methodology (1) to formulate predictive risk models and (2) to validate the
models in both our population and a second population. Qualitative methodology to plan clinical decision
support system (CDSS) development and effective integration into clinical care.
Settings and participants: Quantitative analysis – the study population comprised hospital admissions to
three acute hospitals of East Kent Hospitals University NHS Foundation Trust in 2011, excluding maternity
and elective admissions. For validation in a second population the study included hospital admissions to
Medway NHS Foundation Trust. Qualitative analysis – the sample consisted of six renal consultants
(interviews) and six outreach nurses (focus group), with representation from all sites.
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Data collection: Data (comprising age, sex, comorbidities, hospital admission and outpatient history,
relevant pathology tests, drug history, baseline creatinine and chronic kidney disease stage, proteinuria,
operative procedures and microbiology) were collected from the hospital data warehouse and the
pathology and surgical procedure databases.
Data analysis: Quantitative – both traditional and Bayesian regression methods were used. Traditional
methods were performed using ordinal logistic regression with univariable analyses to inform the
development of multivariable analyses. Backwards selection was used to retain only statistically significant
variables in the final models. The models were validated using actual and predicted probabilities, an area
under the receiver operating characteristic (AUROC) curve analysis and the Hosmer–Lemeshow test.
Qualitative – content analysis was employed.
Main outcome measures: (1) a clinical pratice algorithm to guide clinical alerting and risk modeling for
AKI in emergency hospital admissions; (2) identification of the key variables that are associated with the
risk of AKI; (3) validated risk models for AKI in acute hospital admissions; and (4) a qualitative analysis
providing guidance as to the best approach to the implementation of clinical alerting to highlight patients
at risk of AKI in hospitals.
Findings: Quantitative – we have defined a clinical practice algorithm for risk assessment within the first
24 hours of hospital admission. Bayesian methodology enabled prediction of low risk but could not reliably
identify high-risk patients. Traditional methods identified key variables, which predict AKI both on
admission and at 72 hours post admission. Validation demonstrated an AUROC curve of 0.75 and 0.68,
respectively. Predicting worsening AKI during admission was unsuccessful. Qualitative – analysis of AKI
alerting gave valuable insights in terms of user friendliness, information availability, clinical communication
and clinical responsibility, and has informed CDSS development.
Conclusions: This study provides valuable evidence of relationships between key variables and AKI.
We have developed a clinical algorithm and risk models for risk assessment within the first 24 hours of
hospital admission. However, the study has its limitations, and further analysis and testing, including
continuous modelling, non-linear modelling and interaction exploration, may further refine the models.
The qualitative study has highlighted the complexity regarding the implementation and delivery of alerting
systems in clinical practice.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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early	 identification	 of	 Acute	 Kidney	 Injury	 –	 9th	 June	 2014	
(https://www.england.nhs.uk/wp-content/uploads/2014/06/psa-aki.pdf)  
Patient Safety | Domain 5 
www.england.nhs.uk/patientsafety
National patient safety data tells us that patients are dying and suffering severe harm due 
to a delay in detecting Acute Kidney Injury (AKI). AKI often occurs without causing any 
symptoms or signs and its presence frequently goes unrecognised by patients and doctors 
alike. 
“A patient with a complex physical and mental health background became unwell 
QXGTCYGGMGPF&GURKVGRGTUKUVGPVJ[RQVGPUKQPVJGTGYCUPQTGEQTFQHƃWKF
balance. Bloods were delayed until late Sunday night, indicating acute kidney 
injury. Acute kidney injury not recognised or commented on until mid way through 
the following day. Medications given to the patient over the weekend included 
drugs contraindicated in renal failure. The patient was admitted to ICU and on 
admission was unconscious/shocked. There were multiple systematic failures in the 
management of this patient including a life threatening delay in critical care of >12 
hours and systems failure in the recognition of deteriorating patients.”
Acute Kidney Injury (AKI) is a sudden reduction in kidney function. Complex long term 
medical conditions, medication and intercurrent illness are often complicated by AKI. 
It is estimated that 1 in 5 emergency admissions into hospital are associated with AKI, 
prolonging inpatient care and contributing to 100,000 deaths in secondary care. National 
%QPƂFGPVKCN'PSWKT[KPVQ2CVKGPV1WVEQOGCPF&GCVJ
0%'21&GUVKOCVGFVJCVQPG
quarter to one third of cases have the potential to be prevented.
#PCVKQPCNCNIQTKVJOUVCPFCTFKUKPIVJGFGƂPKVKQPQH#-+JCUPQYDGGPCITGGF6JKU
provides the ability to ensure that a timely and consistent approach to the detection and 
diagnosis of patients with AKI is taken across the NHS. 
6JKUCNIQTKVJOJCUDGGPGPFQTUGFD[0*5'PINCPFCPFKVKUTGEQOOGPFGFVJCV
the algorithm is implemented across the NHS.  When integrated into a Laboratory 




Prevention Programme which will include the development of tools and interventions. A 
priority for the Programme is the development and adoption of e-alert systems, based on 
the test result, which will proactively notify clinicians when a patient has AKI, supporting 
implementation of #-+0+%'IWKFCPEG
%). 
Although primary care is an important focus for detection and prevention of AKI, it 
is anticipated that AKI results will be sent to primary care in a second phase of the 
RTQITCOOG/GCPYJKNG6TWUVUCTGGZRGEVGFVQFKUEWUUYKVJRTKOCT[ECTGTGRTGUGPVCVKXGU
the management of AKI test results, particularly at times when deputizing services are 
providing medical cover.
Further support will be provided by the National Programme as exemplar e-alerting 












Who:   NHS acute trusts      
            and foundation 
            trusts providing  
            pathology services
When: $[/CTEJ




Sign up for regular updates: www.england.nhs.uk/patientsafety
2WDNKECVKQPU)CVGYC[4GHGTGPEG
Bring this alert to the 
&KTGEVQTQH2CVJQNQI[+6YKVJ
responsibility for the upgrading 
of LIMS systems
Work with local LIMS supplier 
to integrate AKI algorithm into 
LIMS system
Work with local LIMS supplier 
to ensure the test result goes 
to local Patient management 
systems and into a data 
message sent to a central 
point for national monitoring 
purposes
Communicate with appropriate 
primary care providers to 
ensure they seek advice if test 
results are received
4GIWNCTN[CEEGUU0*5'PINCPF
AKI website where additional 
resources and information will 
be provided as developed
Supporting information 
For further information to support 















Previous result  
Within 0 ± 365 days? 
Index creatinine value 
Defined as 
C1 
If Result within 
0 ± 7 days 
Then: 
If Result within 






Calculate RV ratio 





Calculate RV ratio 
C1 / RV2 
Is higher RV ratio 
" 
Is higher RV ratio 
DQG" 








Is higher RV ratio 
" 
Has change occurred 
Within 48hrs? 
,V'!ȝPRO/" Report without 
alert 
Report without alert. 
Send to authorisation Q 
If creatinine has  
,QFUHDVHG!ȝPRO/ 
In < 7 days. 
Consider requesting 
 repeat If CKD 
 unlikely. 
< RI? Flag low 





Algorithm for detecting Acute 
Kidney Injury (AKI) based on 
serum creatinine changes with 
time  
 
This algorithm relates to the 





(Age and sex 
related if available) 
RV = Reference value. Defined as:  
the creatinine value with which an index 
creatinine value is compared 
D = difference between 
current and lowest 




















Is age < 18 years? 
Serum creatinine 
> x3 ULRI? 
Serum creatinine 
!ȝPRO/" 
YES 
YES 
YES 
YES 
NO 
NO 
NO 
